<%BANNER%>

Role of Brain Soluble Epoxide Hydrolase in Cardiovascular Function

xml version 1.0 encoding UTF-8
REPORT xmlns http:www.fcla.edudlsmddaitss xmlns:xsi http:www.w3.org2001XMLSchema-instance xsi:schemaLocation http:www.fcla.edudlsmddaitssdaitssReport.xsd
INGEST IEID E20110115_AAAAAT INGEST_TIME 2011-01-15T08:16:43Z PACKAGE UFE0008356_00001
AGREEMENT_INFO ACCOUNT UF PROJECT UFDC
FILES
FILE SIZE 1053954 DFID F20110115_AAAOLK ORIGIN DEPOSITOR PATH sellers_k_Page_034.tif GLOBAL false PRESERVATION BIT MESSAGE_DIGEST ALGORITHM MD5
651c0ad10f275b35446a390c3985d4dc
SHA-1
0d23747602f14700352f0471e721c19d92db54fe
F20110115_AAAOKW sellers_k_Page_019.tif
95ecc2031165982a5e83a238fbad3f72
c14ea066b3aba048e81ad938301d2c54c10a19f0
F20110115_AAAOLL sellers_k_Page_035.tif
b4c23071512cf7652e44bd11c2fe1a82
d1e22110adbee6ac857dcc462f358eeaf94825b0
F20110115_AAAOKX sellers_k_Page_020.tif
bff6b3d963430727d40a626af237d06d
65f884890df32e7440b9592ca99f0ddce822efb8
F20110115_AAAOMA sellers_k_Page_051.tif
dce2ac6fe1487c25c1a1d237a4373546
407d35ec4bf5024869c31488eab83f3e137d1fa6
F20110115_AAAOLM sellers_k_Page_036.tif
5f804fe10711bee5f155f63805188894
d1b43951bb7437c1771820e4a60e672a75600e6c
F20110115_AAAOKY sellers_k_Page_021.tif
d522ed5d59490cfc086259ad4bde9c4d
f2c54c29f5a179154a2b3e17b9cf02bf3d493f6c
F20110115_AAAOMB sellers_k_Page_052.tif
23b3136613f8ce6c2afe53b1cf7ee21d
0cdc7798812e0e324f0da6503ba168d48d4e2a14
F20110115_AAAOKZ sellers_k_Page_022.tif
7cedd1cdea47f5f69b902cf39c3b0573
c01efdca6bc32e5206400e36020888dc32cb2ab0
F20110115_AAAOMC sellers_k_Page_053.tif
b590ba1c4ace4a15bb92b4c23dcb3fbb
28d4c98c5e0051b9f8e08473fd84fc1848e4c179
F20110115_AAAOLN sellers_k_Page_037.tif
d6e55f6d85abe4963c61ef2a777b09b9
3831a28e36501fe2d34dbac26b1ab84c1e9dbbbc
F20110115_AAAOMD sellers_k_Page_054.tif
863b5eccc45aab516c401fb16b180cd7
0b974116f5cc0fd7ffd25f35b9984ea3abc42406
25271604 F20110115_AAAOLO sellers_k_Page_038.tif
bc2e8b6e44d5f968876d0bc6f7d176a6
7585f98af5b2696ce4afe59b22f2ebffdde5bc4c
F20110115_AAAOME sellers_k_Page_055.tif
3347452b0dc519215ba2a04b91e0a839
edad05cc13f978ef12857a4edbcbc1fcfb59f39a
F20110115_AAAOLP sellers_k_Page_039.tif
c594b3d0a016dd0f1e820399c34e6862
402e0ae2c8d521080f6222c8a80729b87de149d8
F20110115_AAAOMF sellers_k_Page_057.tif
ff0be3bb8a7b3d89262d763cb2fe1ee1
04c0107b97fe398874673305b5be2565de60d0dc
F20110115_AAAOLQ sellers_k_Page_040.tif
1ffba918d8bbe6005cf485dc59131b7d
e6a8683bc5a117411818e08cfb63228874e2ebee
F20110115_AAAOMG sellers_k_Page_058.tif
4d397c9f20ab746852b13776f2154417
6d9109b6014a5c8169a17b45da0b458220e794b2
F20110115_AAAOLR sellers_k_Page_041.tif
21cc7a7ab91206d113f901e339757fd9
8093a950d8713ebb7bcb6833b802bd4818c43089
F20110115_AAAOMH sellers_k_Page_059.tif
07d0c349fd7f4ad080a486a5aa5c273e
08e3f2304054320005a813b0c0b2e82679b55aa6
F20110115_AAAOLS sellers_k_Page_042.tif
21abd46f190206a74ae415237f051abd
00285f2429e3e9d8006e5efe74c1fda6fee35ec6
F20110115_AAAOLT sellers_k_Page_043.tif
91182faeb052b860d7ac902079ea6e93
a26d2773dbc44a07f0a25890ac031ea0b4fa0e9d
F20110115_AAAOMI sellers_k_Page_060.tif
755bed58813615e911623de4659ecb28
7c7cd270bfdb0189d24a7e00e5769a070cc42d80
F20110115_AAAOLU sellers_k_Page_044.tif
211190eae8b2896a85a9a21b1f3747c2
91c3509394357ec6205bdec50b9211d37c0e51fc
F20110115_AAAOMJ sellers_k_Page_061.tif
99a247c807def35a1f81555b15f9ffc0
70ba5b2a99351a10edb2e336d5c41e713b84f011
F20110115_AAAOLV sellers_k_Page_045.tif
a9163d795cfdc5c951e17639e547399b
d2e5283c2c694ca4c1a264cd57634a35b65c6a5b
F20110115_AAAOMK sellers_k_Page_062.tif
6af78515de6bca44c8f610d48572f372
85475e0913c6f402da575a0505b82ba2e72d804c
F20110115_AAAOLW sellers_k_Page_046.tif
67649c73fda0b6fc5d0612078a897784
26c9689b6b747629912b37b90e41892db6099ab9
F20110115_AAAONA sellers_k_Page_079.tif
2e817d47d1157be818f5f5ef02c8a78d
683faa376f1a3197fc65c23b15c23ad0a01232f3
F20110115_AAAOML sellers_k_Page_063.tif
ae653e4da893cc460d9360d47d647060
e5e8c3808a1165335b8e2b21085b067fe8d6a6e1
F20110115_AAAOLX sellers_k_Page_048.tif
73a3047130c76460c1e9d455133b0b39
e933ad8eebf3bf1ebca47bc349342793450b9d6c
F20110115_AAAONB sellers_k_Page_080.tif
ad6a6dd19a78bd277f947fe7c23d7cfb
51e3f37a7fc397549f2c2eb1d589f93592d67790
F20110115_AAAOMM sellers_k_Page_065.tif
985a97c8f9e83595faf415ea985009a8
0d72ad0c6a362dfb32af2888fbaf2686f3b0df39
F20110115_AAAOLY sellers_k_Page_049.tif
3b09baa0399f85e4dec60da1f8cbacfe
1559562971796f5fb64b1035c0819e4f7e8978d1
F20110115_AAAONC sellers_k_Page_081.tif
6d9918828dfc6a75f9f06df32017b9ac
5bfd57ff5d1661c89aa012e5a3b120c54978cc5e
F20110115_AAAOMN sellers_k_Page_066.tif
f0b86e1d8e001b5a1932b19d46c068f0
d2e88f2cb4405811aa1195c981947c9bd5794ccb
F20110115_AAAOLZ sellers_k_Page_050.tif
a1870e77ecaf8d4f482d259fc5f862bc
ad318e4a5e816ca7b6b202caed0a1cb249c8a098
F20110115_AAAOND sellers_k_Page_082.tif
0e2ac79ceb7dca816ba8d9987dbf6c74
c859be2f2c06e60d3508e69dcfc9bb97d7b4747e
F20110115_AAAOMO sellers_k_Page_067.tif
89e5e0362e6610aad5d53c92f78b9c8d
c7a2e9d0d58aa7684f34ff1f34707424fbca0494
F20110115_AAAONE sellers_k_Page_083.tif
848ca0ed259eda8b2ebebdc4a1526403
232216ed3b684aca90660000719ecf7b4d75f0c2
F20110115_AAAOMP sellers_k_Page_068.tif
9e7e6214534643f25e55b7749dbe4ac7
75d87aa3cf8d4958530ad12262cd06f2639def9c
F20110115_AAAONF sellers_k_Page_084.tif
110e07f9565f87919ce2d77653dee86f
74661541f57c7d7c313a3ac28ae6566aa4dc3ac3
F20110115_AAAOMQ sellers_k_Page_069.tif
7cfcc2fa1f740c962138a2b1ded45167
c5db43b6a46131811371855e1a1ff7995145ccff
F20110115_AAAONG sellers_k_Page_085.tif
21ad592f1ff11a067173c0920b02a1dd
78b860e6a29dfcccecddff1b6abfaf363a14cfb4
F20110115_AAAOMR sellers_k_Page_070.tif
7430038087d29d386c4074ab0e24efb4
9b3c0c137d326207b6f842420a309f851198580d
F20110115_AAAONH sellers_k_Page_086.tif
bb45606880a585a2fbc8617ac529b7c6
5b57014196018e33215f7ecf119d0540e2dda4fb
F20110115_AAAOMS sellers_k_Page_071.tif
024edacd04126b99603455afcd66b4b6
1573ebc732f751aa0eae1c84c9334a3ef72a99b6
F20110115_AAAONI sellers_k_Page_088.tif
c0053a96095b73e40ac87e66255c4887
964e75557b2d5d3db66f6c3db0d002604f47c05b
F20110115_AAAOMT sellers_k_Page_072.tif
a39897238ead0152a47d7c018be6a735
354bbf0eec973f45ba213ff5770c659ef4f1b5dd
F20110115_AAAOMU sellers_k_Page_073.tif
868f3dcfc4c292b667d2bbe5e96ac244
10a151bb62c9cf3642a0b3096d5be9ef7a522808
F20110115_AAAONJ sellers_k_Page_089.tif
b0584f9784259ee97315e71afcad0045
b766b5dfe053d1d9b1c8caf0d971cb2bb2b3f7d1
F20110115_AAAOMV sellers_k_Page_074.tif
121725ce3b1e8db7a4b411b568fae434
d5112d83a41f5e5aabfaec0d2fd3b485f6032001
F20110115_AAAONK sellers_k_Page_090.tif
c11e8724eb73c8e6a7ac04772570189b
d5ea8db1dcced86ce3d82d9c036b86af681e7d92
F20110115_AAAOMW sellers_k_Page_075.tif
3422b1f9199cce4c42fc2389d1f01483
04ca1290a54b670fcf22342314a780afc254a49f
F20110115_AAAONL sellers_k_Page_091.tif
2df02f0094d859890bf08a79b5024984
d6d5443ffac4801028256c85ca4048cfdc2c68a7
F20110115_AAAOMX sellers_k_Page_076.tif
2113784d1d5f2b8c1882269b6d1d7081
b64931a419624d91867e9aac70f2ec25b453c920
F20110115_AAAOOA sellers_k_Page_106.tif
03e03325cb0e865c412de12ad3bdddbe
6f79830a612379a36f05ffb35b8d51267f03256a
F20110115_AAAONM sellers_k_Page_092.tif
37c23603f53370542b90ac233a1b9b38
1833f39c26167469fda5d255dc07c7f56cf3437d
F20110115_AAAOMY sellers_k_Page_077.tif
f837725b9c84551efc13404a573f1153
e9cfd77b3db76f6ec9c8a256439a0868ef071175
F20110115_AAAOOB sellers_k_Page_107.tif
522a5fd5a2f1e0b29dfc34306138b05a
2b7734ec7bcba9c55a81ed79655d2cc4cfc3b23b
F20110115_AAAONN sellers_k_Page_093.tif
6464b1f5013f811fa952ec4b129f03c6
edd199178409302b34f7332e42b0ce484251ea3f
F20110115_AAAOMZ sellers_k_Page_078.tif
7b21c7abbdb3423cf515b66511f2fa46
80fc59bfaf01b604465fcfa836df59e7986caec2
F20110115_AAAOOC sellers_k_Page_108.tif
c0ee4649c3bf8174758052fbc3ac404a
fb21e8fa1c18671826b34f08c9d1b6c1a2e88d60
F20110115_AAAONO sellers_k_Page_094.tif
13f9fdba98f61e1fb6960c9e7e8f53ca
f2630dd46abc965ed87eec815b3379b01cfd7297
F20110115_AAAOOD sellers_k_Page_110.tif
a098914dda6f1e18c8b15f409ba44c41
2669783b320b5abfd5b4c85b82553987fa3ce944
F20110115_AAAONP sellers_k_Page_095.tif
1ae30141b1a78ea2e8784e9d8f7c2b15
b71ecc3b586a459ed1b9721f7cdd014e31037fe7
F20110115_AAAOOE sellers_k_Page_111.tif
3e98fb67ef0fe589b83697bf043a0e43
08e0c2431921dba02195166c3b41cd3c1be6823a
F20110115_AAAONQ sellers_k_Page_096.tif
067c5644a078c15c6cdf83b4993247d9
7e7bd70818dcfa8dc6d4737589f85ab299f3d031
F20110115_AAAOOF sellers_k_Page_112.tif
b4447d9a7af2919faa2c2a1f22ba5c69
78d2e8a6cd685d159997554141967ad1f5237fb8
F20110115_AAAONR sellers_k_Page_097.tif
09cc39d9ed3eaedff539735158568694
0c8c053e92fef7f231f96d4b6930055a7a75c0d9
F20110115_AAAOOG sellers_k_Page_113.tif
2c56171751cc3ccc58ab8ca208c50416
6002fc09f55b85fce2bf4a67a0b9411aeb871cae
F20110115_AAAONS sellers_k_Page_098.tif
7d8095e77a7265ff6cd3bee2e490e352
491d1bea28de1e843b74dea3e74ff31731922167
F20110115_AAAOOH sellers_k_Page_114.tif
5c17696edbb1c2a950d40a4776640855
693276e5bd322cd450a8840ce1179f067332d52d
F20110115_AAAONT sellers_k_Page_099.tif
62503c876a7d6577bc2cbecfd7e9beb3
041def7329a70c69433ce664c1348dff9224d8b0
F20110115_AAAOOI sellers_k_Page_115.tif
a16cad824bb821c40a21aca5c1aedce5
58c5564e70015344426b20ac0fd44577927e8762
F20110115_AAAONU sellers_k_Page_100.tif
e2acd4905d88d87da8b42f353afa1aad
8fff237962a8e90bc9e614cc68c512db438151f9
F20110115_AAAOOJ sellers_k_Page_116.tif
fb460d8e359853e101bdd66a6f96d892
50da547cc7b643e45e0ed8f942b99d6d0ef24c5e
F20110115_AAAONV sellers_k_Page_101.tif
173f7960067f6dfbf042e8468248b6cb
3a647c27561895e234f728b26c535fc760be7cde
F20110115_AAAONW sellers_k_Page_102.tif
a6f2db8e0a9624440aaf12da9d6a6d9b
f1501f7f1225d37f3fd9e43ce704adb4754eb727
F20110115_AAAOOK sellers_k_Page_117.tif
7ed2e7d58bf86d1570e0570a07781485
312f766b6bbd1da330fbc307308ac71e840a7c7e
F20110115_AAAONX sellers_k_Page_103.tif
67f2d83413c3e811be7a4d4fd430a062
52eb42299163a68cd290444bfd61c3466ba401e1
F20110115_AAAOPA sellers_k_Page_135.tif
80b61c358f6a02740cc4fa4152e9c33e
f15294d46f913b8ba1f0efd7a8d426e43163db0b
F20110115_AAAOOL sellers_k_Page_118.tif
77a23c4d25fbd4a9bc7e703cfce1301a
9c0b004a4b391a2c1a7269222f39839eb248c70e
F20110115_AAAONY sellers_k_Page_104.tif
a380075020e3b7e71ddc9262188f8ff0
33d965ec252fc87d92b5ae46cacf858ca631a73f
F20110115_AAAOPB sellers_k_Page_136.tif
71ae5f684d10896d914306a18890aad6
4848878a1e93be88183564810fb14ff5a84642d4
F20110115_AAAOOM sellers_k_Page_120.tif
120e3e1bb5b2e292aa80a85a81795940
2d01b82590a21294e03efb1e897d6d21e2e8a528
F20110115_AAAONZ sellers_k_Page_105.tif
5092851b78a9f65f7e16bbb17966f429
382e4c05735b8a7c29732529d5654743119a464b
F20110115_AAAOPC sellers_k_Page_137.tif
34dd9c414c008ff5c1f461ec738babb7
86ea431bf3691f325b495fff8226c3d214f4bc4a
F20110115_AAAOON sellers_k_Page_121.tif
575c8680bb14e0a04a9f36314177bcdc
9d6cf62d18724cffce008e708b6b5037570a81b9
F20110115_AAAOPD sellers_k_Page_138.tif
505173f2154db0b59faefdc6fc5e46f8
b3580c144d444bafa56cbf85091cf8dcae459d81
F20110115_AAAOOO sellers_k_Page_122.tif
bb1efa52009ac9ed81ad35c7f34591b0
2abdc59203600f4e4b1f97fff2f6c6f7b96dcd55
F20110115_AAAOPE sellers_k_Page_139.tif
d2cb3f235280f94f9cef15b643d383b9
18d79c52d48c7470b94728d7235775cffdd43e47
F20110115_AAAOOP sellers_k_Page_123.tif
bcaa5f9498f9b45981699968090c4123
72ac18573fbf239d0ae6877a56fa3b0601d13545
F20110115_AAAOPF sellers_k_Page_141.tif
f0f98bcc13b47285994962f7d155c4d9
c25bf61829a1f1cf7780a2b9941a4f3a553345fd
F20110115_AAAOOQ sellers_k_Page_124.tif
271d74c65c5ed85de438a39c2d93e744
ead597afb11fda6be04e2d2dcca4c9e77f10664e
F20110115_AAAOPG sellers_k_Page_142.tif
ddf57cc74cdc471afb88da58c8c6574d
9060be49cc35b656a01d25f04e2493a7b8abf1d1
F20110115_AAAOOR sellers_k_Page_125.tif
071aaa28b12637b2ef3a4641636fe00e
d7e511fb193721c18b630d21754f0693d70eb080
F20110115_AAAOPH sellers_k_Page_143.tif
a60427f30e61b17c7ba029bc25edf76e
ddb4f8c5266d2cea22da9ed06067e771ce2a2e59
F20110115_AAAOOS sellers_k_Page_126.tif
a1ddd0569e974b1fa6abbcd8c1bb6c0d
72e5d67feab5344473cbf4cf159c5cdf7aa53011
F20110115_AAAOPI sellers_k_Page_145.tif
956d8811cee9fd6a5f08f2ed4c4186cd
f3baa0d87a2b15e9192f71f2458a1a74a000b4b4
F20110115_AAAOOT sellers_k_Page_127.tif
f2a47849c9314052b1a9941a15ec68d4
83a7bd51c016d98b645cbe2087364a07e165cb20
F20110115_AAAOPJ sellers_k_Page_147.tif
a45bb3f9a54385bf08ed7c99fffa805e
1e849ae2a9ef6aa550cd12349d2377a7e0a81fc1
F20110115_AAAOOU sellers_k_Page_128.tif
ebcf1006c1126db83d130d5d229aad71
b242e789543e633fe7c8036e602679a51b8b3310
F20110115_AAAOPK sellers_k_Page_148.tif
8d797477cb38f3095ae12d2bc85a9d0a
388f12443ff791dff0bc8fad2be7f8da9dabc9e9
F20110115_AAAOOV sellers_k_Page_129.tif
6b8bef7ca24a6632f7da8ff48cf7cb22
600532b0b561e60f51be815caba62f339e48c205
F20110115_AAAOOW sellers_k_Page_130.tif
ad94e9dabb2cc498cb88b27e9a2c1ffd
738c46b3ef91f09d3284319ec65277d729ecc413
34559 F20110115_AAAOQA sellers_k_Page_012.pro
dcfa1d70fe1d5c01f1136886aa1da47f
a97ebb3c828e4dbea9e2739af1640a196e94d456
F20110115_AAAOPL sellers_k_Page_149.tif
4fb4c6b7e918dd2771cd47e612efd9a7
9f7df133ef11d880b79d61d498222b58644a2a23
F20110115_AAAOOX sellers_k_Page_131.tif
f085e6334d5f862579c769aa325cec27
dc5b9d65443d3d951c13d2eb7a0589d9a1aa1d59
29760 F20110115_AAAOQB sellers_k_Page_013.pro
05f7da946250f5d8f809986064f6d123
731a7fcdfaa1154ff6801d042d70faeab470fbe2
F20110115_AAAOPM sellers_k_Page_150.tif
55feaa263cdfc3e573ab4d488972fd14
edb98a2af349023e98e88e11d46d45b35b8e2789
F20110115_AAAOOY sellers_k_Page_132.tif
498e4cd905f0c83945c87744f73fbc9a
b883fb4ea56037dac64301d7b8b7eb394617489e
44517 F20110115_AAAOQC sellers_k_Page_014.pro
7a74b73859e3dd8b1c80c3eb9c058ab5
1f7a51cbadd5eca1b9b34a8c583f7a486ee319e8
F20110115_AAAOPN sellers_k_Page_151.tif
dc4939af2a24b9bbf4b18ae6f3a702e5
e8ff6b9541ca8ff6286f828d516fc0684c835cf0
F20110115_AAAOOZ sellers_k_Page_133.tif
085fea23c333a5c93ba6d9a4394dfb01
d89d5f5124fa9c49d0c373089d55ad428095d37d
50975 F20110115_AAAOQD sellers_k_Page_015.pro
5626230b8aa0503922c0d6f1e99064f8
d77c8391699f3cce6d711986ab0cf9130ac5dacd
F20110115_AAAOPO sellers_k_Page_152.tif
aedcbed21a081c838ce71f4603e52e7d
65d25031ea6a10802afe77f7136dc61a92e781f0
47139 F20110115_AAAOQE sellers_k_Page_016.pro
0419d2560a4eedb0554c3eb952e87af5
2bc6068ee40ac85a4711e7ef1d19544d69527ebc
F20110115_AAAOPP sellers_k_Page_153.tif
71b0bb0b7e066d9ee58db1bce0769946
b5aaf53e0d7106a316994d42daa7157ebb649db3
48227 F20110115_AAAOQF sellers_k_Page_017.pro
59d110baee0f4a27ce4481478cac4345
5ab6b2a5219b433358710c397180eb838f479378
F20110115_AAAOPQ sellers_k_Page_154.tif
d3aab0869740ff66a320c0d1fddf56bf
3cc3a56fa1b922e85c3e63d0a485c486f1a2184a
48780 F20110115_AAAOQG sellers_k_Page_018.pro
25a01aec1634000d5f1e241924bef110
356f37fbab566bc401b2eb2ed233e9881096d8a0
F20110115_AAAOPR sellers_k_Page_155.tif
657e1fcd1d4e7b397426255951f17562
01c40bbf0840cfb50ed272f19102ff3d39cd4d83
49920 F20110115_AAAOQH sellers_k_Page_019.pro
e4885e912706a2503780fb8d5e4fb1a4
759fe39f0c5d0a50c4e9c2d07642bed15a1d8060
F20110115_AAAOPS sellers_k_Page_156.tif
3d1d4b6b700ee4ab3790175ff92ae177
b28722976b33f2bb8ca71b65f4008a2b44c0173f
50042 F20110115_AAAOQI sellers_k_Page_021.pro
e5ee53de93f572657f34dc0ca4a8e567
2710d8b6b9b4f0ec06daccadd491a4216e9d0542
7993 F20110115_AAAOPT sellers_k_Page_001.pro
12cd148d3f031b0982a3cdef489e9cd5
77b6866e53e8d680932f6a78d5a994e69a61133f
45946 F20110115_AAAOQJ sellers_k_Page_022.pro
c7437ea0eb6214a8c150c4b1a20f4d18
fcca55b99cdf701fde54cebf2e8bde63e15b776f
3059 F20110115_AAAOPU sellers_k_Page_003.pro
d33751992a570f429cc93cc5a6777b8e
9ce7a992863ffcebb6d628da84e2e22ecb22f28f
48773 F20110115_AAAOQK sellers_k_Page_023.pro
e982ffb79ca0592fd6788bf7adbe04bc
3e9ad3775734a01745b7890e97ae1af2e2ae0908
37094 F20110115_AAAOPV sellers_k_Page_004.pro
2166bac2d5edce5f7003bd61986d75da
a1a96ceae4a6324e2fa0bd33311e72168ad1d8d9
110785 F20110115_AAAOPW sellers_k_Page_007.pro
139549e9f2a7c23e4cdc69473c123cbf
c58cc12352b65df8cf8d8449812187a22eeac32b
47012 F20110115_AAAOQL sellers_k_Page_024.pro
ab083dc36c2f67a2d6c1c4fefb493de6
37d5a7910703482d6c128f336438c5cc48b4ceb9
114388 F20110115_AAAOPX sellers_k_Page_008.pro
20e7969ff6def64f2a79369a3b282127
e2d17a85c2f104f9938e4240acefd280c7e80db0
14729 F20110115_AAAORA sellers_k_Page_042.pro
70721ee549010e6b22c6f05f3d038d86
099c8324b635857d2440e76ea0e115cc68c452a4
54577 F20110115_AAAOPY sellers_k_Page_010.pro
a9543205b7742d293f5b3637a6cf13dc
5b35bf839f11b4766302576a039b0a226aefbcfe
4248 F20110115_AAAORB sellers_k_Page_043.pro
9e498327d1e0ecabfb799aa8882755bd
0b6cb8b93dd4f226c7c63deeaef38381c40f776f
46490 F20110115_AAAOQM sellers_k_Page_027.pro
dfc7d7cf12092a17f50216fa46ea0817
7f4d14f696ce11624356324f05665c5d26e76558
46534 F20110115_AAAOPZ sellers_k_Page_011.pro
37ccfb3fcd60f0f63dd9ef3d874a8590
d7a931642f00496a57491dc2c6d8d66756d3d88b
42559 F20110115_AAAORC sellers_k_Page_044.pro
2c7dd6fafc26d3b52427dfa78305ea17
53af9afa2946a585ed30e6bf6677d834e4d6527d
46334 F20110115_AAAOQN sellers_k_Page_028.pro
0721af14ed0c38bc7713ceed87fb0c51
31a6051c99598c5a302143b9f2207df98ab74a2a
44967 F20110115_AAAORD sellers_k_Page_046.pro
caeb87381fdfb2d5cf2510b031f9d41f
a4bcb15eb12cb4e6147f6742251324bc315e6b07
45180 F20110115_AAAOQO sellers_k_Page_029.pro
3d64c63ddbd4d4e12d2c3444afed3326
80dedd30edd2513d83fbccb4429031cec9e04171
45684 F20110115_AAAORE sellers_k_Page_047.pro
34415c54a6541410717394638695a15f
84fc50836ce2b457b794e0a6c6370acd9b963f6c
48133 F20110115_AAAOQP sellers_k_Page_030.pro
bf7897ac2aa865c92d93f66b58ffffeb
85a8e29111e6cc5f3ecb7f63f29cc01c72fe5a28
47169 F20110115_AAAORF sellers_k_Page_048.pro
b0b0d72f677f9e6bb7ec34ae1ffecd0a
9549a7865e59e850803a85d13ef7a5ebaaffa04f
46880 F20110115_AAAOQQ sellers_k_Page_031.pro
2bcee4fed7595d40add0d02015c6a54a
60c317635af5b031fdfba14ca74190c3f2f51b9d
44625 F20110115_AAAORG sellers_k_Page_049.pro
2078db7e2d134f960676bc17052259f3
77e8485923ebf11a8eaddc80f83f2617027c8511
48352 F20110115_AAAOQR sellers_k_Page_032.pro
cdd12845dcb158ea9d7adb3a78da4613
d054a3cfd85cb6b976faa04a419228cac83b8a79
48356 F20110115_AAAORH sellers_k_Page_050.pro
29f58099825bd738fcbc28feabdd2fa7
e807fe460fb97fe4137d27548452b7a285caff6c
48618 F20110115_AAAOQS sellers_k_Page_033.pro
b0c4d0d951566d85514081bead9e0845
ddf5cee19790f88f478293d91cebc29bd6473fb9
48502 F20110115_AAAORI sellers_k_Page_051.pro
b87375eb45145dc746437b3058371360
33e5a0afc7ed8321625bcf9cdcbaa99047082b50
48105 F20110115_AAAOQT sellers_k_Page_034.pro
48f733f2d617bd0ff6db43824e2a258e
3721850c55f938b15d42e3a017d78bc5f1a97a25
47447 F20110115_AAAORJ sellers_k_Page_052.pro
cc7a91a23361c003e9400862e8756135
b77cc2b4ea785462d522e78de32d21ac222e4be4
52517 F20110115_AAAOQU sellers_k_Page_035.pro
6f4d8da7f9f5505f7b22a48568b4e8d4
0a67c560434f48886eb5dc0510639fa98b47ea83
46773 F20110115_AAAORK sellers_k_Page_053.pro
cf8e41bf2ac9291bd7e06c935e43d442
9b2f56e375e1b0c28df8481cc659c2bc9ac8694d
48444 F20110115_AAAOQV sellers_k_Page_036.pro
165d67c5c9ffc9f7fcd6088cdfaa6eb8
85c5ec85c82d7caedce8e35302f2bc4b44c27419
16552 F20110115_AAAORL sellers_k_Page_056.pro
4c037caa0db13c1098c0150359ea3c7e
1c2ca2a4b92a93acc41278609a2f00e6e5692cb6
56739 F20110115_AAAOQW sellers_k_Page_037.pro
f013125313dbc7405771aa95d84f386d
38b5e0e6c78d6d3a9ad0b04d4e8e0933e32101f7
51377 F20110115_AAAOSA sellers_k_Page_071.pro
499f3bbabe5bccc01690ade6981cad78
6cadc6cad2855786385a47a7b827a908fd56bae4
15843 F20110115_AAAORM sellers_k_Page_057.pro
586ff125c6fcc72cc8bd47f41e60a210
00cfb6fbe2bb1138ea7483d2f80d1fa46fed236d
6310 F20110115_AAAOQX sellers_k_Page_038.pro
4b3d553e251e80181d1ecf3588d4a833
64440fd9e43d880313b71841a04c976a8f2365b9
21387 F20110115_AAAOSB sellers_k_Page_073.pro
1d9d57888d6e4ae69700f068f393a1bd
0112a5ce3192bd7433860c6a21d1b7d0932e444b
4991 F20110115_AAAOQY sellers_k_Page_039.pro
5121ec4d3eda2cd58e82478089e1fbdf
da82b87a9b4daa4439195ca7bcae300feeb807ba
11584 F20110115_AAAOSC sellers_k_Page_074.pro
6a9e75eb6d84c3a1508f2a4ffff7afe5
e2e70f9111f0a7da7dae2a19a3cd17e34cda93d3
21723 F20110115_AAAORN sellers_k_Page_058.pro
917c431d3e10ffd79782beb5a9814367
5e41df9e6d44747d9c533e63483f4d57ac70b38f
12046 F20110115_AAAOQZ sellers_k_Page_040.pro
d41101dc11f3b6b40a473d264cbf2214
8adc7e6d732175eae332abc8ac94ef4ae7e50e3a
26198 F20110115_AAAOSD sellers_k_Page_075.pro
3cf383f653921ce9e328ba465a06aa5a
53275496f2ab8753dc78beaf84296a1c990a56d5
14951 F20110115_AAAORO sellers_k_Page_059.pro
e71a87d742bca91e9ff97ab277284073
0eb3c4a03accd577992852b2c606cf1f154622bb
42921 F20110115_AAAOSE sellers_k_Page_076.pro
3e85507df467c39bac70330d93ef66bb
07936792036e9734dd698512938bfd9a39174275
11676 F20110115_AAAORP sellers_k_Page_060.pro
e762d96da7e097af4ba670265ebc1a86
df445bd3e6fcac367a8441ca7404073aebbf3c8e
49280 F20110115_AAAOSF sellers_k_Page_077.pro
f318b4ef58fbd398c7b410be6766e517
055e31304c7c2fb1314ad3f39f977fa3fa5faf88
13503 F20110115_AAAORQ sellers_k_Page_061.pro
c93cd4d6ad887fa2190aad173afed23a
037641d2179e4f6ebb2c3fac50fd1654194fe23c
36568 F20110115_AAAOSG sellers_k_Page_078.pro
71bbe374ccfba14a691b4b46914404f4
a341e44c61ec697d2932e344f87a1dcccbc0ad4a
39472 F20110115_AAAORR sellers_k_Page_062.pro
ec8007b39214fdb6003ee70a8966516e
b625feddcbc600bbcab314f921feb1e63b7cfcfe
F20110115_AAAOSH sellers_k_Page_079.pro
699b4950d5645be697c2041a5aeca12d
6d167c0671b100427ddd66bc75cfacb040fbc84a
47158 F20110115_AAAORS sellers_k_Page_063.pro
a7cee81b2432ca1f802715d6170c860f
8b961f4e4c5bde820a8dc20ef2b4c1e64f651570
43535 F20110115_AAAOSI sellers_k_Page_080.pro
7af1981b55efccdf4f08efedf1231e12
87459ab899e9cf7ebaf59c5df7f7503a1320f63a
42421 F20110115_AAAORT sellers_k_Page_064.pro
9addac01404db925a1577a1f79d8a07f
78ffd1dce3e2f993e5ec19d7f57465aaf5426c9c
46385 F20110115_AAAOSJ sellers_k_Page_081.pro
0c22d044107ad54aba97050e78dd6338
f85b66ecf93b6b337fb3b57f72d545f613db11a4
45382 F20110115_AAAORU sellers_k_Page_065.pro
aa9c1a899c25c57968d31df918b49fda
77b24d991c0c5d57d803642577b910c1d547d296
50779 F20110115_AAAOSK sellers_k_Page_082.pro
98c02bbf2acccd5a15e57331fd4bdfcf
7ff6a25867557f3bfbc29d3298c5ed1b185e7dab
40371 F20110115_AAAORV sellers_k_Page_066.pro
efde61216f66fd5c8c8db9fec12ae92a
ce12bd3b7028c1ddc43cea3f5aaf41491fa6aa2b
50504 F20110115_AAAOSL sellers_k_Page_083.pro
297c7d4163715c91e23388a38a8fa243
4c048d9ad78f6cae9bf7912176aa34085fd8e7b3
44276 F20110115_AAAORW sellers_k_Page_067.pro
7ff1b17e763bd828dc86447176d58829
8e0d84a3835b5c31e56f93561ed8e9d828fe7cd2
49817 F20110115_AAAOSM sellers_k_Page_084.pro
15d8b74b9744628d9e381917db4ee19f
d77b7bdb06c25a72842c73b6b55b36131cba96cc
44719 F20110115_AAAORX sellers_k_Page_068.pro
e756b24a82ff2cff8a8b3f41e4d13898
5bc5e8c2dbc8d6880c6e9765e37b7b2b39a839f2
50150 F20110115_AAAOTA sellers_k_Page_098.pro
b5f4b5c67541fbdedce1427abb709ac1
86c309d2b5bff13b0be6a46fde14bd12af14d063
36762 F20110115_AAAOSN sellers_k_Page_085.pro
1375fdebe850f8a5a3e4677f0728deb2
fb5f2244f9612449ce2aefbe5e22e2446f9a8fc3
49362 F20110115_AAAORY sellers_k_Page_069.pro
2a382a7c1e8a63e706a84150f3d3fa2a
78adb2a4d8f82fda765fbbb1af918f92c1995b90
51111 F20110115_AAAOTB sellers_k_Page_099.pro
f7c82ffc248fe83f6265bb830a98eb19
f13aab79fe25829d06515f107e9b5f6144186767
48862 F20110115_AAAORZ sellers_k_Page_070.pro
387b73bc8ad7fd4e0e7c6937c002f467
ef3abbfa84d2d0b03425853238e3b84048017818
49108 F20110115_AAAOTC sellers_k_Page_100.pro
d8c57cbdca7ee85d4171b1c7d5024e86
cf5333d90a525000ccd661be9d15ccdd319c99d3
25064 F20110115_AAAOSO sellers_k_Page_086.pro
2f4105d7c359309e57d69e96a246f23e
ced92f7ca09cbe1297ef0cf92bf454e7b0f036c1
48030 F20110115_AAAOTD sellers_k_Page_102.pro
d93956241ee13e7fd3a49a4f2c80a9dd
c3bee6276d72b57a30c8eb117d53822a86051c4e
15356 F20110115_AAAOSP sellers_k_Page_087.pro
893e9169a48c7f11cdc6fb197515dd76
8a310d49f9feacdc53f63faa0540ed281260fea2
16001 F20110115_AAAOTE sellers_k_Page_104.pro
78f7b0968fca5b6f9ed4223304bb0c71
9eb1c933beb6c0693c084fe2297bc10902fdd3be
17847 F20110115_AAAOSQ sellers_k_Page_088.pro
f34e87521d7c88ddd4f5232d41c24233
1d9e4cd1af10bd0ffa5e21735fb391fa5ce09621
8704 F20110115_AAAOTF sellers_k_Page_105.pro
658685e33c0e2188924982b7361d8adf
3053182faf64757be26445e685b73f7550af768c
8191 F20110115_AAAOSR sellers_k_Page_089.pro
88776b988a7dd4ff7cbd04f3dcbcbe4b
c4ef7e615cfa6e22d3f61b4f2250553cd0e91959
16754 F20110115_AAAOTG sellers_k_Page_108.pro
0057c8b38357da010ccc56b45e9c0e14
567d24294c34f5aa96d64a3e5785a3ae78c667b8
40972 F20110115_AAAOSS sellers_k_Page_090.pro
b70567ae8cb15f607f8227566d354151
00aaa501aa265105a24bbaedb8c73fc91934068a
16759 F20110115_AAAOTH sellers_k_Page_109.pro
a40c8cf979ca655927f12fe0de46995a
0ef8f24f5d20fa2ddb600a4757f911310987dcb3
48565 F20110115_AAAOST sellers_k_Page_091.pro
5ea85fbedd31e61074e6f329319af212
e370f9954db21c8160bc2a95c1a69599b183d75e
43637 F20110115_AAAOTI sellers_k_Page_110.pro
90869971e9adfcba0889510ff2500320
6ea9abd13cade3dde69559446e8c28c291b0e58f
48320 F20110115_AAAOSU sellers_k_Page_092.pro
f818c50a61984edb8086d03f40bb8e07
be5d98196780e7d0a10e1d9175ad30c845f0d348
53434 F20110115_AAAOTJ sellers_k_Page_112.pro
db5eea8906b51008c361977f9dedf3f8
5633cb95503d41028f908e638432049ba1f8c735
40191 F20110115_AAAOSV sellers_k_Page_093.pro
4609fb33e1fe338d27a7955656c1f920
164cdde74951322f922d89504e4bad8ab6155188
39429 F20110115_AAAOTK sellers_k_Page_114.pro
e28625135141213f1eb1a343d502cf40
5801dfd706ac90d6b078f9296305ba838f5c74c0
48886 F20110115_AAAOSW sellers_k_Page_094.pro
e7d086feeb5eaeee5b6147422a81c0de
64f6fc76061b8880472451715f7608a3236421af
39717 F20110115_AAAOTL sellers_k_Page_115.pro
e416fb41c29b28387bfb9b603ae69418
070821e014b7cdb314313697158624966b142cbe
46704 F20110115_AAAOSX sellers_k_Page_095.pro
b50519c13074b827c740713c2eb3733b
01d89634ca369ef846a369b379d9fcb7c7a6eaa5
16868 F20110115_AAAOUA sellers_k_Page_132.pro
c6ff20b31d6d1ce424b007fd944ba4b1
ccb18ce4aa8805daba190c1537ca3a3360a1b872
34052 F20110115_AAAOTM sellers_k_Page_116.pro
fbd511e694562eec0474e9248256c0ac
9e69f4797d6c17ec3b7af2443f60cb90f54e7c45
49664 F20110115_AAAOSY sellers_k_Page_096.pro
87a006116b6e1cc3c9798d5a7061bea5
2aa92f7a775fc69c41baf1dc13d78238f2df69bb
10032 F20110115_AAAOUB sellers_k_Page_133.pro
0bcf674e838d810fc337e02712de747d
a8b6eabd577775a080907127ec14a4d39550eed3
47098 F20110115_AAAOTN sellers_k_Page_117.pro
e1c9a2f678d13e48d491381f82d7e5fd
35cfbe71d257a63a8cd3ee94c72c864ce274d79c
45098 F20110115_AAAOSZ sellers_k_Page_097.pro
1fa199df384c2cb9d7745d419f04c73a
f15b26b3d7df2290517c2f2957ddd1a5e12ac5d4
22109 F20110115_AAAOUC sellers_k_Page_134.pro
6a47d4332d4188117e8dbb086f1601de
11a12aeb27ebbf650a99471cf4801aa0a5149de3
43655 F20110115_AAAOTO sellers_k_Page_118.pro
722362f0d22aff1a806188437d0686a1
239b0acf904445a7a999d1bd8d0db160267ec641
3109 F20110115_AAAOUD sellers_k_Page_135.pro
2af95e4fc5562dac9fd8327ef08621ae
9f908635525d84243df124dade10043aba194496
18928 F20110115_AAAOUE sellers_k_Page_136.pro
82d22406c15a088eaf4682e9cf9fd0ca
0eb1c1acccf23c89cf7f0bd68e3270e106a72ea0
49384 F20110115_AAAOTP sellers_k_Page_119.pro
75137e72b83f304e1f3b0649f8a935c7
31992685f2c6c6d21ebe6a7688a4a48cedac50d0
52237 F20110115_AAAOUF sellers_k_Page_138.pro
7b55edbae7db87511b5dc0be92aefdf2
ba4aa8e0f64c8ab8364a2cc4f5d298b959912e54
46043 F20110115_AAAOTQ sellers_k_Page_120.pro
7054cb72bdb0dfc5b7f22ff144d19019
62267b4ba2df94554652d4057a18625fcd1805c2
5638 F20110115_AAAPAA sellers_k_Page_144.QC.jpg
6d3e722456604bc7f9efcd1e50f2afa6
6e5e38e7775050b85c4c434761aecab1318da5a8
49215 F20110115_AAAOUG sellers_k_Page_139.pro
dde321f535fcaa8e4d602ebb9f497b85
f5b1ec28471da75ec4d2b04e30ecd75b68af881c
43328 F20110115_AAAOTR sellers_k_Page_121.pro
eb9c38086adc4c4b5a07a09d8039d2e0
b4ee4cb4d8728b938788cd2fa11cbcb4ea34ac0e
23778 F20110115_AAAPAB sellers_k_Page_021.QC.jpg
46b244910b0402a183a1c6f2f84a4e54
484d5c630dce1285f7228aafc1cc09d792ef76f3
44666 F20110115_AAAOUH sellers_k_Page_140.pro
802b4315afdab711870f7bd24759d609
dc932c3475f32d6a0dea4ca2e81b097d08ed8bf3
44671 F20110115_AAAOTS sellers_k_Page_122.pro
b0834dc2147797dda7258882e3782aca
ae2f0b1b2ab25c403ccf39b841d5b634ccbd6368
17488 F20110115_AAAPAC sellers_k_Page_106.QC.jpg
04549730ce3c09407b8a5e49a3930fbc
43021e43ce0e53c99383484f4229917de529b7a3
49961 F20110115_AAAOUI sellers_k_Page_141.pro
bdf3691df286a5130de2fd22159fb901
3ba07c854ade5dfc1d02c4520ac78fba03b74adb
44342 F20110115_AAAOTT sellers_k_Page_123.pro
813aa09c192d3d3e5133b8eb51aa841a
a0715ac72cc1e80e97c24af7dc24bcde799e6779
4450 F20110115_AAAPAD sellers_k_Page_058thm.jpg
c560c32e7c571cb3821c88b49e0dbaec
93951afe5954af3fb6b2b8b8dea0b67fabe16627
38868 F20110115_AAAOUJ sellers_k_Page_143.pro
6dd6dcdbfaf7e09682cbd32d69ddf872
91ccbe02701c309b3e8d8d59465aacff7779ad8b
47511 F20110115_AAAOTU sellers_k_Page_125.pro
7b655aa5698403b098acfa29a5633e2a
6b3ac67388167f8156b61628a00b9c1873b51666
24223 F20110115_AAAPAE sellers_k_Page_142.QC.jpg
430c3999e18c13d5c0de200f367fa478
064346a50209b9aca449a61cbf5499affef60ef8
4777 F20110115_AAAOUK sellers_k_Page_144.pro
01840f067630058000ab20039d757cd0
6512dba26d582240f3967720710c2f8db6ab2139
51257 F20110115_AAAOTV sellers_k_Page_127.pro
597ebf29f58ce5858755ab8159546273
679530f60cac802e5649eb535746c6be1d4a3376
10740 F20110115_AAAPAF sellers_k_Page_057.QC.jpg
50b47f0befc58ee0fee5c8d71934f973
4ba2ac73e0369c12b686e713c405d96bd226f0c8
52909 F20110115_AAAOUL sellers_k_Page_145.pro
6c36a0dbbf97983e8901c0598bb5b91f
3a0fe632fc31e0fd047f1694b75e34bb254c5278
52404 F20110115_AAAOTW sellers_k_Page_128.pro
ddc39c7734ae2c49395884890fe0b1b7
1f6b4e716ce72a2e6d91032e77c69d8ed87b8a02
5322 F20110115_AAAPAG sellers_k_Page_114thm.jpg
aa9358f52ce710998dbb1aa7b3d07f43
cd95345a5b362c37aa974d64da524bf181184517
1519 F20110115_AAAOVA sellers_k_Page_004.txt
d070866952dafbb3b6a34fd8c4d956b5
bdcbb55a3c1a18365e650a09ea97c0e82f720b6c
60051 F20110115_AAAOUM sellers_k_Page_146.pro
a9db8845373c47e493ab23e54f2c5b98
7e2e86484f72e6a972e15a9970f1f7e600e83b0d
3078 F20110115_AAAOTX sellers_k_Page_129.pro
f07f125dfca47b205b70009cafe079b8
2f3640745bf2459c4ee54892ac4dc7d47cee5588
6699 F20110115_AAAPAH sellers_k_Page_138thm.jpg
cbb2b9e23b33bd292431931093d176cb
5f38b39fd6d9221a4e48ab29bbd6c02b04f6650b
259 F20110115_AAAOVB sellers_k_Page_005.txt
7e9c3643137a9697696cd39665787f64
ef3fed178825157ce9ed1f7f6b3ed8630eeddf9e
66047 F20110115_AAAOUN sellers_k_Page_147.pro
42772d52eda654750640e8a3308fa191
7ded2a9c0a9ae4f6e59a6c30ba5348ca4f716abf
14940 F20110115_AAAOTY sellers_k_Page_130.pro
3c0c630cc4f2838c7b0957d8421242af
67db74610fbc9fa4efb34fd3c7ceb0e52e866dd0
20543 F20110115_AAAPAI sellers_k_Page_066.QC.jpg
8e76813cb7728d0a098014189e6727e1
473f960a4f98246ac3d9d884ba84fc556bde1e78
3422 F20110115_AAAOVC sellers_k_Page_006.txt
1509b8cc18ba8ca2e97b60e85414a5af
79d6a1b8b3a9a0cfb5816d9d483041893e704090
59692 F20110115_AAAOUO sellers_k_Page_148.pro
008913643a19fe62d1ff1b97442d59f6
f66faa5d616eafd6251b9d69d6dc52a65bed4a64
8689 F20110115_AAAOTZ sellers_k_Page_131.pro
bd9c03eea06ebd3bea9951996e60a853
989b99b48b81bf0e985d64cea62963799e7e21d8
24068 F20110115_AAAPAJ sellers_k_Page_083.QC.jpg
972c4b51997f8d558c0f62d9b116ba51
a75b0932469b04264987cfccd825bf896c14937d
4523 F20110115_AAAOVD sellers_k_Page_007.txt
f045d928b5920f1fa73376e68ed4556e
14a82f3b952e3332063824de43ddda0cc9564049
63374 F20110115_AAAOUP sellers_k_Page_149.pro
f40b513fda519ab41dad598a018bf39a
3a4bab45781d2c8cf95507e6ee509ba66ea37c10
6451 F20110115_AAAPAK sellers_k_Page_051thm.jpg
af7ce216defdc5d9130dd8b0d8016742
8aaacdde78226c21f835c2357dc8f16bbfca6c8a
4722 F20110115_AAAOVE sellers_k_Page_008.txt
dd45b882692d487c3d30e54428ee2675
18609c334c53d3884d004494cd1e48256ed50c80
5502 F20110115_AAAPAL sellers_k_Page_086thm.jpg
eba2567a96b0eaa8480173cf9199c09d
13838f80da31e773423a4f80559b90729a449af0
3080 F20110115_AAAOVF sellers_k_Page_009.txt
bbf3c01b25e365cb7721ae4215901152
d0b68655404d3dcd06965a3fbaf693a2794815aa
66137 F20110115_AAAOUQ sellers_k_Page_150.pro
e4f92b002fa63eb123e4b5e60ca18b2f
5880d82e94857948ee0939f6a8efb7b047e8eadd
4825 F20110115_AAAPBA sellers_k_Page_156thm.jpg
92b6770d6ce1f7d5504933813e3e428c
7c1bd0275870b43902b14ffa381cf543d07ada04
14858 F20110115_AAAPAM sellers_k_Page_107.QC.jpg
c3e3ae183feb375065f0a2d8c9ff1d90
1c337e877f95e8888f8ba13a036e09a5a03af880
2183 F20110115_AAAOVG sellers_k_Page_010.txt
6d852143d53869e2fcebe5509c3cbd6c
b0695c63d09005b5496c36835b43e399659fe99d
60107 F20110115_AAAOUR sellers_k_Page_151.pro
c350e533edf0839035091d3314efe02f
e038193ae7583593c2af0b97d3d00035da5b8c82
3146 F20110115_AAAPBB sellers_k_Page_039thm.jpg
6cfbf4d69700f9dac116130c75523a75
356f3e3c57062c73fbc2834579ee51c792c16da9
9080 F20110115_AAAPAN sellers_k_Page_043.QC.jpg
f4e9529cc709835feed0621081fed37a
61cb12a8b5f1f035495048194d707fd74e2c1f09
1848 F20110115_AAAOVH sellers_k_Page_011.txt
28ebd17aa74e9012bb4878a898883a7f
adee998d869a1a48988330c874cd7097b6ed2321
64065 F20110115_AAAOUS sellers_k_Page_152.pro
e3b47e1ce72e14c763809ebc8211ab2b
5b44350a408da83c5b975457f6c4179976824bee
12909 F20110115_AAAPBC sellers_k_Page_088.QC.jpg
b855f2a10dd32a4a2dbe8785024607fc
e921effed0c555d0cfc98827f0a410dbeb8911a3
3275 F20110115_AAAPAO sellers_k_Page_060thm.jpg
a2a7ffe7368a35c2fe7b87ecf145d566
bb25f6e630037603257aa0f5efced49b94b091ce
56876 F20110115_AAAOUT sellers_k_Page_153.pro
f40706262a87c0840cb3975d4ea82854
ea98afefd11df600afbe5f4c187f328fb74e2fb1
1194 F20110115_AAAOVI sellers_k_Page_013.txt
9f74e112e186e8c2e42424d4df92736c
b5974f854dce3abb49d177623c20d352aaaa32e0
21555 F20110115_AAAPBD sellers_k_Page_093.QC.jpg
adec8c0eb0a6cb867917ea95698667cd
5e75c37fc2369240f6f04f96da27a570abdd3e0b
7997 F20110115_AAAPAP sellers_k_Page_133.QC.jpg
435c0916f3903f88003c71ca9a6f622d
de71161c9dcf51cd9f438184d1029ff49af0dc55
62223 F20110115_AAAOUU sellers_k_Page_154.pro
284a0078053241d504da0dd520e25529
d4c9a01d67a7c641b9893d5714ab0f8bf5ed70f0
1855 F20110115_AAAOVJ sellers_k_Page_014.txt
0de3b8f50cf5d9b394ef533318594683
df3cfc964e20687a4a404e96df3c456ad236c47d
6232 F20110115_AAAPBE sellers_k_Page_125thm.jpg
6d9b1172facfa8a08e287f49beedd4b8
3bb8008ae9a87f86139f2e5cb28f70dcaeb7b85a
1405 F20110115_AAAPAQ sellers_k_Page_002thm.jpg
ed0c1ff1b9b8b31f6160be260bc2e92b
77d4ce8eb82cdf9ac152b29dd2915b2af1096f9f
17798 F20110115_AAAOUV sellers_k_Page_155.pro
1bcbebf2b0875828a8ea8d3df3b7afe9
0cb7927ccfa3dd20c6874ad52046cd7c88aaaa8b
1858 F20110115_AAAOVK sellers_k_Page_016.txt
375ed83282a1df8f36f0bd0bef150ab3
7a0341bfbed9239b13d7919ba10bd5f990ab52ba
20951 F20110115_AAAPBF sellers_k_Page_014.QC.jpg
b425d72a7353bf8821da6022a91b82aa
900b18cad8f71329957e8fb273dfc1e715187588
6344 F20110115_AAAPAR sellers_k_Page_095thm.jpg
82a930fccb39054b1f666fd4b447c389
51bf7fdab34b28bb7afe0d7477eb85d1ace63d99
32077 F20110115_AAAOUW sellers_k_Page_156.pro
7b71042f3822a01706943659ed2b9189
8bd93af36ccae986d515835f5b40dcba9b913f77
1913 F20110115_AAAOVL sellers_k_Page_017.txt
d1c7fde9b0354b57e34f9e3b5d63a29e
f5c90f1ee3bbfdc1e97da1cc0e6f69b836f02b68
3379 F20110115_AAAPBG sellers_k_Page_059thm.jpg
6bdef38c6f7f99c68dabe697d7fc7aae
6d233ebc44ea4d662a9de116d9e6f01ec2b79792
2401 F20110115_AAAPAS sellers_k_Page_072thm.jpg
4f50b6f3bb4652290298a507082b2b13
a924129d18fe422cf67b39d4754c39412781d902
460 F20110115_AAAOUX sellers_k_Page_001.txt
4741bb5f916731f4e6f8ffe10d759fc0
b1366c7af7f5a093e5f9ee947340240626b2906c
1954 F20110115_AAAOWA sellers_k_Page_036.txt
501a2b73e9c076b5ab5ba99d474ca322
a774b05be589f8929ccd182cf11898eaaecd0632
1926 F20110115_AAAOVM sellers_k_Page_018.txt
5a25b2ccda866501c924aa4d7384b00d
a13e9583c38e63a127ce15143236afbc3ebab1d7
6388 F20110115_AAAPBH sellers_k_Page_026thm.jpg
7b8e1643f18d07a72ceac9fc46b754e1
787ab92fd75538871e4ec03aa6aa7d4b55c1f9c8
6100 F20110115_AAAPAT sellers_k_Page_007thm.jpg
3f1baffee8887e68fd79d67e0a8d0794
1dbb9de3e21cb777c9cef96f1d22048a3d24f970
130 F20110115_AAAOUY sellers_k_Page_002.txt
27351868d22893318654133a727cf1f9
fd4c806d901ee2fd971ef3adacfc2605b9428ca1
2334 F20110115_AAAOWB sellers_k_Page_037.txt
718edf3bda4bffa76fbff881d79efe50
72ff080780fd5fbc165c96ae039a7d5c9a3d1abe
1965 F20110115_AAAOVN sellers_k_Page_019.txt
2cbf5e6ee0505032e68da0e22dfb6d4a
b1e873665738a652d2138e15dbc7fb6cbc1105ac
6669 F20110115_AAAPBI sellers_k_Page_082thm.jpg
06eef338ad32b4d335fc736780355d51
b505b3d0fd53b429b68c866eaac534b72b6b5f97
9510 F20110115_AAAPAU sellers_k_Page_042.QC.jpg
4156981be23f9fada754ba0da5bf7cbe
7a20cf24eec6c03a87347a68f25d8e042c70c0a7
140 F20110115_AAAOUZ sellers_k_Page_003.txt
76482a74c81da61d326b235ec852b541
4c08ea17cbb096fb0418a6cf88d5d822aaeab3ba
322 F20110115_AAAOWC sellers_k_Page_039.txt
7ccba69b7768a96448a807d7a218950c
cbf4f4abd701df0d23ab7051fdfb3e0ea5a32820
1970 F20110115_AAAOVO sellers_k_Page_021.txt
3e97194f0b8f4e9d2477453df015f492
3aa679ee75b0b18be6351c2a4f485d688d429b1a
2355 F20110115_AAAPBJ sellers_k_Page_001thm.jpg
2ec78cff680958b356e73affc7362bbc
83371cdaeb73e9b3b15632ae946d28ebd11d0f1a
6092 F20110115_AAAPAV sellers_k_Page_053thm.jpg
4b9245c97eef9833e481fcdaff413512
79876aab07c98622392ab99ca63c7f8caefb3351
836 F20110115_AAAOWD sellers_k_Page_040.txt
8b7011be2aa3a759c73d38bbe17a479b
283ef5b13c32a67b2abafba42a88c7984731023d
1924 F20110115_AAAOVP sellers_k_Page_023.txt
bb2129f716d242e0065615e30bf9af83
ae06c73fba5540974ff5ec3ac45fdd6f6eb9dd50
21112 F20110115_AAAPBK sellers_k_Page_110.QC.jpg
08ce2ae07dbcfc3979858e5a5bb5dda9
26174fe7d6a7b80ca166570cbafec350bdc97716
6671 F20110115_AAAPAW sellers_k_Page_079thm.jpg
58c0b28afb9156bf784df81564bcfe14
d2d40ccb3688bcda7a0032bc9c2ec35eb06c7c0c
566 F20110115_AAAOWE sellers_k_Page_041.txt
d22df4cd64ffde6ab037a7a32e83ed34
2c0c079ecccaeb98947a2c1a881c55d77878c77b
1890 F20110115_AAAOVQ sellers_k_Page_024.txt
3583b42ad9cb464769f01d01290b9adb
13ca01a1840b823e63b40c7b02e2437672700423
5290 F20110115_AAAPBL sellers_k_Page_078thm.jpg
609d2b6c77d36c6e6e48b8818d1126de
3ff69eae23e80d48ac922dd1801e5ed5fefcd6de
4266 F20110115_AAAPAX sellers_k_Page_087thm.jpg
a35338a28d8b51a63ed572f4486564c1
23797670a1b16877445eab5c0017f11c3bb6469b
940 F20110115_AAAOWF sellers_k_Page_042.txt
31056f9e6b1d0b65b8d2c334409bc974
67a512b66901e48a8342818d24e1f1b9b83f6042
3093 F20110115_AAAPCA sellers_k_Page_057thm.jpg
4c9f1f0e33026cc2fc1ceed744b47d2a
9b765cb8802fd9559f14e1511c32b476f912c330
21286 F20110115_AAAPBM sellers_k_Page_140.QC.jpg
6bcf7f2cd5ff7e3947d5612c240b147d
8a6ccb14be44d520a76b781b459bcdf9172167eb
6015 F20110115_AAAPAY sellers_k_Page_118thm.jpg
d12acfc9e0146c922bfd6a27e1a2991f
922205e49d2bc703df2a83e22648b338f21f378b
202 F20110115_AAAOWG sellers_k_Page_043.txt
2d805a15c2afde93c8ff90339cebaed3
8528db236231a9b89032022ba2d171ec17cec282
1879 F20110115_AAAOVR sellers_k_Page_025.txt
1b6138004346965eb5d986dccc635593
fc0cf29419103be40df3f2844ffbf9f559936dab
6444 F20110115_AAAPCB sellers_k_Page_054thm.jpg
0ea32865c0a492e4c801869ac81da698
20e618b124da3ab69909c1962dd337df0ee9c85d
19697 F20110115_AAAPBN sellers_k_Page_062.QC.jpg
8a9e7ec8bbffb920a70bb341aee1ee5f
5bfb29eec99759ad1586db8d0affe3b7c21cb07b
24357 F20110115_AAAPAZ sellers_k_Page_127.QC.jpg
3a6dec2291ecf9a4cc8efea73057fbd1
a19931eb10ffba1a6f228d3135307a1d6b19aaa2
1788 F20110115_AAAOWH sellers_k_Page_044.txt
a47d031916a2ccb9751b93effceb162e
ddf7c7480a7cc69a4f6bf2ecbda4f3c2ae674bc9
1892 F20110115_AAAOVS sellers_k_Page_026.txt
57c704c86f1b1d1d482cfca792f0419a
0f90e6b735e85a138230904ff5e9f590ece3cf04
6378 F20110115_AAAPCC sellers_k_Page_102thm.jpg
2f2d73388138a55aee57fd04a12910fa
6765b1c9490bea05976c7b50cf1c7b2c44a28638
23573 F20110115_AAAPBO sellers_k_Page_084.QC.jpg
969c884c00c66e15842eff36e5a8196a
b690dd5e3bd0fb58a9f692687194424e7b1d28a3
1834 F20110115_AAAOWI sellers_k_Page_045.txt
9b7cfd172790daf8f9f678c6ba981cda
9eeb8651f74a35543557919b20e62e16520d0706
1838 F20110115_AAAOVT sellers_k_Page_027.txt
3c2a9de2e02991f3f423a1cf1ddb994f
2a048685cb50967794eba5570e985c3e0b8c1906
4514 F20110115_AAAPCD sellers_k_Page_006thm.jpg
15c9b1a6e0f7a7ebadc172b92cf3a047
ab0dba4dd93b320feeb383b617e94cfb54b9bd18
6480 F20110115_AAAPBP sellers_k_Page_094thm.jpg
a9a043459d76221ddefd7cbf6eedd631
85157eec7eb318f437d8fed366d2aa5205044dd1
1806 F20110115_AAAOWJ sellers_k_Page_046.txt
826c0fe4e38c3606068a83c2e9459d44
1875b687ae90cdf3820521c32dbc6820ab520895
1832 F20110115_AAAOVU sellers_k_Page_028.txt
06a539d7b6036dd6e750feaaeb381db7
cd708af40f698efe3420f071b1e6bc8bf8c081ea
23278 F20110115_AAAPCE sellers_k_Page_094.QC.jpg
d98a797175c6011feeb2f31280b4fecf
298ccc158c8b40068c07cced48a72b0b36b4a462
22902 F20110115_AAAPBQ sellers_k_Page_018.QC.jpg
ed59cce08311218d35216592caee36a1
351470460ade46dfe357b7bea5d94db41ab8f476
1857 F20110115_AAAOWK sellers_k_Page_048.txt
c54719ab5cfbcc79aa445ed5c3ba9bb4
53267378022440b5d9be62d46a5f5c2b44769009
1791 F20110115_AAAOVV sellers_k_Page_029.txt
d6e1d55f210dcbd128014a6c90c0c0c9
9eb78550e7641c66b2918128d9f4e1f3ccf73a41
5918 F20110115_AAAPCF sellers_k_Page_037thm.jpg
1bd1ccc459dd0e0db926e890f4f1f4f5
37777bc5b7dd30d0d2f7cb1972e5d91f8833b97c
23531 F20110115_AAAPBR sellers_k_Page_015.QC.jpg
eeca0f07f7938fc9aa05d5eb1812a765
94cfba53b9bda298263ff0e846427f33532ba7af
1801 F20110115_AAAOWL sellers_k_Page_049.txt
8fa6c9240226337b165421e673b2b61e
380db1ece01d16a9c935ce0be5b8fb3d7c9a45ec
1856 F20110115_AAAOVW sellers_k_Page_031.txt
ad8f7b3abfa6b2378652f0c83d08412d
449cabf5bcb1014e3f5765a8f590aed887a62f2a
6325 F20110115_AAAPCG sellers_k_Page_063thm.jpg
1cb5ab5080b993d95e5bd5efc8771969
0a9baddc9b8d4422b5dae3a4dee0e11caa65428c
9579 F20110115_AAAPBS sellers_k_Page_155.QC.jpg
c42073a07f7a22cf4244027f122779c3
b0a8003ad952cbbab28c49aba8e988dbdacd9581
1716 F20110115_AAAOXA sellers_k_Page_064.txt
540b205745f1e6af309bb6372a84b70c
022009f3db6bf65b7fe9813900aeaa84bda49d4b
1916 F20110115_AAAOWM sellers_k_Page_050.txt
de6ae9b7f91096d3c8d799ac89997549
faa489b2d2046af8a2c30a6b1d081ecab57af9d0
1904 F20110115_AAAOVX sellers_k_Page_032.txt
561380dde2ed5a6514a6aa516b328a14
9073b482e0b255b4295b71464db9604b45b86ad4
16635 F20110115_AAAPCH sellers_k_Page_006.QC.jpg
39e4168ae90d3249a982bd65ffdc1f36
ded05711ae7cf50349a689622c90abcfd553b98a
6251 F20110115_AAAPBT sellers_k_Page_029thm.jpg
05019a9b3ae69a737ea0fc4b1b856811
59f8c55cd26a9147ca9585465af48d2aaa05a68b
1796 F20110115_AAAOXB sellers_k_Page_065.txt
432b35daa59484ea68d86c02e21c4a13
cc7b2e461c3058c2a30257a743d03e2bd1b4a260
1910 F20110115_AAAOWN sellers_k_Page_051.txt
13ad16cdf0513e8d10ca3401607b353b
5ce0c42006fae6510dd30c21efb9c3601b1b2379
1919 F20110115_AAAOVY sellers_k_Page_033.txt
d6d3ac26bd4cac3507b97b84dd7cef79
6ee2d3b3156d184a52045ccd165eb550f6c59c33
19005 F20110115_AAAPCI sellers_k_Page_143.QC.jpg
c46f983da6d9a4bcb782d32d86e93253
14855cc3c943c832ba77d801b28fad6ea73a8f6b
6219 F20110115_AAAPBU sellers_k_Page_068thm.jpg
b1292a485305e8efd825acc29b2c85a8
ede6b60f7a935d8a7f9c62a196e405842ebd3e46
1755 F20110115_AAAOXC sellers_k_Page_067.txt
80e3137b8cb0c5fcb194fcb1133daab3
bb754361c9a6180c897ab148ddca3a85f57a3430
1907 F20110115_AAAOWO sellers_k_Page_052.txt
aefc777db32e40b7f1fcd59b249d3d46
2da6b5bec1061157926136d7ed11d6781356efa4
F20110115_AAAOVZ sellers_k_Page_034.txt
0e446160c20b6311ef0295977c528b1d
58a96d5c6542c4bbd1c5a23abc9f300496084429
4498 F20110115_AAAPCJ sellers_k_Page_013thm.jpg
e15d2834b5e907a9761d003ad2cb568b
a0aae81aca9115ae2dc3c21162ca403902891df8
23525 F20110115_AAAPBV sellers_k_Page_077.QC.jpg
15eaeeb3d02e60ac716adb8e25959061
8bf6ae5d9caafdaed0a616e1e5b4dad0903797f2
1808 F20110115_AAAOXD sellers_k_Page_068.txt
17734d6f0a24a20c08a4e655d2bc34ed
9c79429238ea4ac0ea3c5f6bea29d3f627162f93
1850 F20110115_AAAOWP sellers_k_Page_053.txt
69e38dc3b656a7bb7caa89ffabad940a
272a3c315f99143a928c29077e2b0c964f658fb9
6200 F20110115_AAAPCK sellers_k_Page_067thm.jpg
25a0a40cbdf4cb87eadbe67cce0eb73e
d563a8e4b097455302f98ff32e7814c5e6933881
26491 F20110115_AAAPBW sellers_k_Page_147.QC.jpg
f1fc8fed015e592196bb517f07a83f49
16b79d42f8075338267226a5e5aaaf3d99d738a7
1945 F20110115_AAAOXE sellers_k_Page_069.txt
d1b2c6a6332081a0ad234265f9011079
5225152d503a088f405a5a1a6a229151f33ce8d0
1979 F20110115_AAAOWQ sellers_k_Page_054.txt
638fd3105f6e4f4e6c40fddf7691a220
04bce8c42ac61be25241f8f33e75f77111d699de
20853 F20110115_AAAPCL sellers_k_Page_118.QC.jpg
7ab602f771885f4e81af93dc1b165187
04e3d35ffea1e69d94417aa5b3f30c14b19f0240
6181 F20110115_AAAPBX sellers_k_Page_049thm.jpg
0fc70b66b3e4711542ed7ee7033ff614
334e2aa01c3045d1a8cea1a201ec1b1db7d67d49
1923 F20110115_AAAOXF sellers_k_Page_070.txt
a499cf1ee9f66c62b95a268e4bf01c26
04d617ceb86a0bdf6c9b4ea5b1b7b27d64a855d1
1635 F20110115_AAAOWR sellers_k_Page_055.txt
7bbfb48183b7e592822bb39a5de90734
e277deec554384275f12330a12ac9e8635f689d5
21434 F20110115_AAAPDA sellers_k_Page_067.QC.jpg
8026090541f8986bf316bdc59bb76531
cb459b9532ac5a31da5927f23fb56a347608f584
21528 F20110115_AAAPCM sellers_k_Page_053.QC.jpg
15679d18ec2b2237df160fc635165b53
d747f8130ffc724ee2c69c8c05c73bed16a3441d
24002 F20110115_AAAPBY sellers_k_Page_098.QC.jpg
555cd641d7a0f45077f4f42223bd4463
01170264dea6147e6a8175b353c952e376e7a62a
2023 F20110115_AAAOXG sellers_k_Page_071.txt
221c72958961ca81b63d14c65f92f4d0
84098bce0f18dd8994ccbbb90e7ead17be02a607
22707 F20110115_AAAPDB sellers_k_Page_016.QC.jpg
65a172ec560a7e7a784dee943576aa67
fe72935f30e0439181bf8e59e018342afa5ba231
4470 F20110115_AAAPCN sellers_k_Page_009thm.jpg
66e09428e226f62a3e69cc5469cc38e6
49d0b1c9313e27009a8e595d92c34216ba9627f0
6349 F20110115_AAAPBZ sellers_k_Page_024thm.jpg
a131686962f3b5dd1af1e0ca7424cb66
d73ff56d8c37a5cc9e559f87c8cad9c413030ffd
512 F20110115_AAAOXH sellers_k_Page_072.txt
9225b9413d333aece62eea0af3a0603f
c2df0869014a9b25f7f282c37e18cba493f003fa
721 F20110115_AAAOWS sellers_k_Page_056.txt
43f808bf10ed7468ef1e5762d547d437
2f0dcfb42c8e603fb02304182965f0f35b438cdb
23226 F20110115_AAAPDC sellers_k_Page_036.QC.jpg
18f79e206bec90308c4897ff02770187
300961c0ba51b6de2f8a2afa9d8f8ca8a931c12c
6157 F20110115_AAAPCO sellers_k_Page_075thm.jpg
c8f0d152c86ebc6a9c3e3e01c6f38d48
7324c9f3fa2a5c9c14d3f44ae77f47d1cf831899
1143 F20110115_AAAOXI sellers_k_Page_073.txt
cda90bce54f2c12954d7de422e857c01
bbf04c72e01c34ea74f1fe8384c41738f11a6409
729 F20110115_AAAOWT sellers_k_Page_057.txt
b72bc143bab6a0bbcf0788a102832aeb
402a31e62f5f78c78a9635f9ec3587dc3a9b70d4
71929 F20110115_AAAOAA sellers_k_Page_020.jpg
7280952c7693f8942a339f2388b82861
5f254440a1008453a5db3b4bc11623ad7f8b66c1
6528 F20110115_AAAPDD sellers_k_Page_034thm.jpg
13d02bfbb1caea7cd6490b2bdad82a0f
c82d1a9af64e5eff7a62efb8cc23ef7bff19e505
F20110115_AAAPCP sellers_k_Page_032thm.jpg
5323dd0fb2ad579361f174aac36570ba
f933d658ff3d00fcfb001aa79d866bf075a265b6
576 F20110115_AAAOXJ sellers_k_Page_074.txt
144c61d3db00eff7e354ef936609f31d
93a34bd179efcce7e171349d4aa364d54a24ea6d
1202 F20110115_AAAOWU sellers_k_Page_058.txt
f25e65e458f6c644e32227c7d36b027b
fbfb8385dbc4f55245be8fb33577b2f7c15e77ae
73216 F20110115_AAAOAB sellers_k_Page_021.jpg
b0d5cc2e78ed0df4511d563e1dbb53e8
fddef464a7438d8485ed5aad0d0157747559aa2d
2843 F20110115_AAAPDE sellers_k_Page_041thm.jpg
4d6085077d32ff492f4eef554f0a05dd
81d8c9d5127d1cd288d1a788ad34eb9b1e271df4
5925 F20110115_AAAPCQ sellers_k_Page_076thm.jpg
d51db0f111d901b4705674460a6e0db5
53bb329deecbbba5527dc71142e0576f89bc888f
1778 F20110115_AAAOXK sellers_k_Page_076.txt
d9831d4cbfa8349a3bf26f1f39ef8f6c
7f83dbb5b75c5eb99e223259aeb0b0f04ad56d38
673 F20110115_AAAOWV sellers_k_Page_059.txt
ce60c22ca1c93eb385a4d0fb5c05183f
fc880f939d4afce7f6b55a48072b7a7604447788
67887 F20110115_AAAOAC sellers_k_Page_022.jpg
155fc7b84e946754ab18b3ffed50a603
55df3f4b7f80f94fb7e3de5e774e77fb965e550a
6246 F20110115_AAAPDF sellers_k_Page_052thm.jpg
ffcf753d9964d548460f950d27ee7265
c3dfbed349417a95c6d81d8cdd35942792bd33d9
26291 F20110115_AAAPCR sellers_k_Page_152.QC.jpg
9033d6d4704a3bef6c6d087892b68431
24d136ce2c477569a6d58d11e4ec41d921d0e168
94346 F20110115_AAANUJ sellers_k_Page_147.jpg
52b371709961f81ca5b0f5bff80aebfe
6431e65b7e9e73696fbb8cc0d864b307e8602bc9
1941 F20110115_AAAOXL sellers_k_Page_077.txt
e24f222facb919e1c5618dc4d9716fdb
231657920eeec5d8718260659935f922adba5914
593 F20110115_AAAOWW sellers_k_Page_060.txt
58d40d4f6f5380caa234f541c8018ba8
43141f4c8153ffb0abded7dc7f13cce4af5eefe7
68456 F20110115_AAAOAD sellers_k_Page_024.jpg
d42d3d598600750543b4627bc7511232
ec69209e543a2b3362026cba952088717a3dcd11
22552 F20110115_AAAPDG sellers_k_Page_120.QC.jpg
2c2a49413544f49398d7a8dff5acc5be
9d2fe6e796061ed484f6d90786a7865d0d1649bd
5009 F20110115_AAAPCS sellers_k_Page_116thm.jpg
ed23d900bbbd593215ac261fb167a91b
a413625702f1c5aafe215d7bcffff7a91cfe97ee
886 F20110115_AAANUK sellers_k_Page_132.txt
d7ac1f55da0ad445b0da2ce587066573
685478f638bb25cd8e7715e955e2549a077013a7
1493 F20110115_AAAOXM sellers_k_Page_078.txt
16ebf326c44ae20e5bd1a3cae556930c
6cf5acde32e3e9255fea1ac54ea5f529b3002466
605 F20110115_AAAOWX sellers_k_Page_061.txt
e9c42a5dd5a5c58ee01ef6070ff5db4d
e00e82a8f4729216c548d7bb1e2811dfc0a09c78
69193 F20110115_AAAOAE sellers_k_Page_025.jpg
717d72d901cce05b64766e5da1950954
8a2adff52b7e0e464b6c11dec621fe925e10b168
1918 F20110115_AAAOYA sellers_k_Page_094.txt
98cbe08fa6382b68c793b970d6432c5f
533e43f238811d24229d93ddf2fadf1e2e55e826
14493 F20110115_AAAPDH sellers_k_Page_132.QC.jpg
d610162f25784ae7c1c1b5dfdeda3d68
21c475e5ec52c74802281d17c0bad0e2d576a94c
23287 F20110115_AAAPCT sellers_k_Page_023.QC.jpg
d3d08b4fb83987af86facbb77be8937e
f3fd864aaa983cdb5346ad76f848ba353d157994
19846 F20110115_AAANUL sellers_k_Page_106.pro
7412da5303a7d6026b1523d4f44670d2
f453e1972166ea7047edb5d73ac2136d9247fe5c
1736 F20110115_AAAOXN sellers_k_Page_080.txt
9a6cdbefa90b62a31594fcb9b015fd76
f92beed5f265b1ee6fbc80ba9358c63bf1a5bc00
1679 F20110115_AAAOWY sellers_k_Page_062.txt
527d21bad75ffdde69a098e20c7663e7
cccd230ebb68a3dcee6160b09ce4e4c257bf4e9b
66533 F20110115_AAAOAF sellers_k_Page_027.jpg
ce42c52944188dbeec4c4d76c142230a
dbf64fa43d9e04b380c96d9f94ef08e7eb3d7ef2
1883 F20110115_AAAOYB sellers_k_Page_095.txt
9834d61490852ce2102f7232fbe8524b
2e09509075090b597bb5c2c6cad2f20e678e8fc9
6717 F20110115_AAAPDI sellers_k_Page_038.QC.jpg
b66f926374f17224be1233ba400c8b90
db9753d37a5645beb2e876af5ce1686712e7a51c
22494 F20110115_AAAPCU sellers_k_Page_125.QC.jpg
c2675c514e69e400096b19441bc32322
a2751627cf700b9c60f1addde32554f5d2082bfc
1944 F20110115_AAANUM sellers_k_Page_119.txt
fd325a4f77099e5c76ac17d549f1da0b
d2e7de687f7b603be3092fa114604b17205efcbe
1835 F20110115_AAAOXO sellers_k_Page_081.txt
ac97ec95aa5070f3ea54775b9440c593
04a23b2a33875e2d810dc2ecc956cdc82434a2c4
1865 F20110115_AAAOWZ sellers_k_Page_063.txt
d774354cf1e425ef324c8025547242b2
efca46d9a7474e5765ab2be1ef6f079cfaa91d58
67219 F20110115_AAAOAG sellers_k_Page_028.jpg
1c624c72d631aeeaa7de0265e896e18b
d39d1844bcc21fee41599a1a36c849aecd840ddf
5920 F20110115_AAANVA sellers_k_Page_064thm.jpg
4a121fea85887be285cda96b3fecd972
1ee51a6317f8dcea66e4ea199311122ba5454e4a
1955 F20110115_AAAOYC sellers_k_Page_096.txt
35657de8e4cc1cf043fd7e6a45d6aeb9
af2ed85478ef4a26399942adcbf2566ca8858e4a
22120 F20110115_AAAPDJ sellers_k_Page_122.QC.jpg
59e12860509b1bc03049a6638a4dc42a
91c5de696b526558185b2fc898944bba2690070d
12905 F20110115_AAAPCV sellers_k_Page_056.QC.jpg
aa9f4313825eedd31598f4510c1aeb64
844ece744ae4ca63c14d2020f7794fae48ba9c09
47567 F20110115_AAANUN sellers_k_Page_101.pro
f2ba1da1880807e7acf9bbb2b53c21a5
f10a3789ab796d397c42e5b8c128bf2116f80030
2037 F20110115_AAAOXP sellers_k_Page_082.txt
e1044019947a03c86bf9e9dac3b417ed
f835c9c1bfcb5595e32d5cdf6525a5a4d866acc1
67301 F20110115_AAAOAH sellers_k_Page_029.jpg
6597fb2966dc55039b9204e43e8e20d0
85cc78d6d071af819f12be4555510407cb082015
23010 F20110115_AAANVB sellers_k_Page_030.QC.jpg
bde0acbb5c8edb3a3b687e68bc554cae
207b11beddb2437c4c91c158ffbb855b80c197be
1787 F20110115_AAAOYD sellers_k_Page_097.txt
4eddd256768921557961db2e424a34fb
a92db39cd337ba02e32034c70ffade59fe313745
6436 F20110115_AAAPDK sellers_k_Page_033thm.jpg
d70bf4bf4185b0e459c8a7a6a2aec11a
2f46c3313e52669d5fda408ca44a243bcd77c37d
2992 F20110115_AAAPCW sellers_k_Page_061thm.jpg
b64d0a892a884c747c1973c354e3f2b5
eec3bf65c4c1089def85b5fb8b724cda76035f60
25584 F20110115_AAANUO sellers_k_Page_149.QC.jpg
fa4eb25e695f06ec32e3815400fe4917
7217b7695851075578b51d6eac0f559abe7b60e6
1991 F20110115_AAAOXQ sellers_k_Page_083.txt
49051f378c75d956bc60e7a97bb55c8f
e93ac86cc8164f2cc9cb81f9cc426f2fe7813148
70808 F20110115_AAAOAI sellers_k_Page_030.jpg
4314b3325f4d9686e2640a0767d3aa97
840bef6d195f92f198b676340bd8859179549847
F20110115_AAANVC sellers_k_Page_023.tif
53ad210533abf5cfe768bc9c640b8121
ed2c09eae7834b805a47d861aa05311c45b33a35
2044 F20110115_AAAOYE sellers_k_Page_099.txt
746d2129fa012c0a19e571e401e2a4ce
202dd6ba745caead23b0122794f0b3e01b601943
6185 F20110115_AAAPDL sellers_k_Page_045thm.jpg
b50181bf3171b5c99a74c2cbf44d3203
f15ea81ab7e642cbb4debaabd19c6cfdaf1861aa
15278 F20110115_AAAPCX sellers_k_Page_135.QC.jpg
f728f597361742a2c13a5100358553b6
2f81edfb12cc10567825906145ea664675861f1e
1963 F20110115_AAANUP sellers_k_Page_005thm.jpg
cbc6a4352cea1f5211b4006c06e5716b
40db21fe6a021006443602510dbeed0b4b5f8e8c
1962 F20110115_AAAOXR sellers_k_Page_084.txt
ea1860ddf2eb74d53dc86c329a13fd51
f6da5788261baa23aa2784b763c01646c3f14d7a
69380 F20110115_AAAOAJ sellers_k_Page_031.jpg
7c1002520df566125ab472fe572b3bc2
e26569f65ce91ed1a6ef7629706d85c7c17d4c48
5875 F20110115_AAANVD sellers_k_Page_115thm.jpg
5a8bfd27fb9bf76b89e4223d583c552d
be70aa2eaacc55e66d341b692551dd465ad2fa5f
1940 F20110115_AAAOYF sellers_k_Page_100.txt
2aff3d046dd90423c8969512ef155a4c
12cccc1d67eb9efa9de44cd529ddde5bc1b7be81
7640 F20110115_AAAPEA sellers_k_Page_105.QC.jpg
4719669305a339ce1c96372c83049a18
80f8bcce7a99c2b5d4da435b65b49d6559c92d06
23540 F20110115_AAAPDM sellers_k_Page_033.QC.jpg
7ca63049f7bcb6eec3a4a6d6717fe567
53ecd132bd7203e229546709ee1cc48b94a1f778
6560 F20110115_AAAPCY sellers_k_Page_021thm.jpg
b9dbd0bdb7626d6018564b54c0606375
ee914dc3c0dfc59e42eb39648fafe8388088c37e
50525 F20110115_AAANUQ sellers_k_Page_111.pro
6ce1f3ecd33ab44cb17d72ff65e967f5
bc3a1a82aa4ab6dfc59b0f50a660a37914bc4384
1473 F20110115_AAAOXS sellers_k_Page_085.txt
fce6079e46e946527d40a0a06744f732
5eaaba73b3bc02261afeb91477bd7d77b2c1c806
70332 F20110115_AAAOAK sellers_k_Page_032.jpg
c6320f4348ceb2d16f32029ac6af9592
d0bf26e168726a9455ef9681983aca3360be569d
F20110115_AAANVE sellers_k_Page_140thm.jpg
31d923c492b0074f4f4c3fad149fc145
d74c0b8eb422dc932ef2f426aa0fa917c1102755
1874 F20110115_AAAOYG sellers_k_Page_101.txt
26fb2226a59c3e1ced432d3c4efaa9cc
14037f3bce4f1715d07b491e76db1f51a4fb5376
5236 F20110115_AAAPEB sellers_k_Page_085thm.jpg
6c322c715855b638ede15f1458faca88
3a0e8895340e49b0a3a1999878697c5198cbf430
25955 F20110115_AAAPDN sellers_k_Page_154.QC.jpg
8d37631b07b8a7896874c4e6db271b66
480f6fb6628907d7eec90d66cb3f7cd41b47d0e8
6512 F20110115_AAAPCZ sellers_k_Page_071thm.jpg
ebd14e87e04dd99ce41ad8d89636bfbc
7709bc262e995dbf60279126d5db7ebffc8c2cd8
70055 F20110115_AAAOAL sellers_k_Page_033.jpg
737876110e7a8566ef02ca82ca1fec19
5262e1bfc21f44ecbcfb2ca00bad2bbb15226045
2056 F20110115_AAANVF sellers_k_Page_035.txt
d456a4c808731291174f53458627ecf9
321bcca28f5f5cca16c0b91ecf4f513e251374cf
1900 F20110115_AAAOYH sellers_k_Page_102.txt
dd95a18e68c8e95d7c485cb66b84dd7a
b7d38f5555d8cf747c39b94bb11e8b39cabd638c
6356 F20110115_AAAPEC sellers_k_Page_025thm.jpg
286e7e9f38bbe7263f9d6b6e2b1d16c7
20c55a14f332fac16c380108dfcadb609b258699
2608 F20110115_AAAPDO sellers_k_Page_038thm.jpg
94cd80c1a216773709e810850689c54c
17edd23bcd870156f6cf2d2b6389cffb1e777d5f
75010 F20110115_AAANUR sellers_k_Page_009.pro
ceeb1ea792f584fe0e63d0c43b7a1d2b
3980f4f12fbc31319daa832f4cc2a90e0d207794
1370 F20110115_AAAOXT sellers_k_Page_086.txt
938cc497c815dc6b1f7d9c26d294703c
f7d00d365e3d9fafb60d7a1ce25b42d0018a8a3a
65954 F20110115_AAAOBA sellers_k_Page_049.jpg
86b6c9f33be7cbaa69150a1f6fc3378a
3e4c06b6e8d202cf92f3be1eee35c8686022ade5
71230 F20110115_AAAOAM sellers_k_Page_034.jpg
4e5c07d964e9883802232c029ae4fe86
ca5903af10336e16108d69ff800d04773e6cc8ae
108705 F20110115_AAANVG sellers_k_Page_126.jp2
643ede4b5274cfdf16dde19147511b9c
357134e24fd0c8185f8f006313523066b58c4895
716 F20110115_AAAOYI sellers_k_Page_104.txt
f27c14ca84d5f00b6e13122ead4f6d8f
47928dc2949d8121f646d54f2ddd962cae0160ad
20084 F20110115_AAAPED sellers_k_Page_010.QC.jpg
2e1849e8e859ad0826cccf9b68335a85
b5789c96929555a703f0ebf3e990784bfa7613ed
22834 F20110115_AAAPDP sellers_k_Page_047.QC.jpg
8412dbe937a9888a182c70ce93c2bad4
387bb8bde630939e1a80635a068868a52784f7b5
47977 F20110115_AAANUS sellers_k_Page_026.pro
41f6eaf355af79cb23448b62b44b38f7
364efd375735748342ca4b337ea45fd271e54968
908 F20110115_AAAOXU sellers_k_Page_087.txt
e24e4256fca6b887e0e07c70f47e5e3b
d7e5c10de9a050ec8064af894ba394e86106046a
73330 F20110115_AAAOBB sellers_k_Page_050.jpg
651439f0615b040df3d5e4ba39163376
485efd9eb05a2887972652705130170748797849
69864 F20110115_AAAOAN sellers_k_Page_036.jpg
ec05f459f0a643d351c4f51ff00e7988
e592fa7dc9b66efa0f269ffaae633d0fcd26431f
309 F20110115_AAANVH sellers_k_Page_038.txt
276614454f87df40098829c5015f3c54
b2e776904a53a7cd6a4dfbfc20e8770fc5f60212
410 F20110115_AAAOYJ sellers_k_Page_105.txt
b707e3383784814a0928ca804e9e770a
745555997ae204544961c19e14584f401cc2670c
24726 F20110115_AAAPEE sellers_k_Page_035.QC.jpg
26f441dc196df83253d5bb7dd4feb86c
da9809fc8b5c63c6cf5931938f4be368f5944ac5
6500 F20110115_AAAPDQ sellers_k_Page_083thm.jpg
b9c61058ccb15ff68b753385d1009de6
1147c729113292cf5032a059c8e9fd36e8716e2d
1188 F20110115_AAANUT sellers_k_Page_075.txt
b4afb6671c6bc659588f2def8abd340e
db0f6340910377ddd7eec6a6424c57af1561759a
857 F20110115_AAAOXV sellers_k_Page_088.txt
d7267e0bc102e2c5048ff09ef2687129
2c7300432ea7db66840dd665903ef23abbc2e3fb
70194 F20110115_AAAOBC sellers_k_Page_051.jpg
ccfd1b4ec476197ab38ca9d67b93944f
9ff1fd52ac4630fa10bf46ab34d33caa7be5e617
79103 F20110115_AAAOAO sellers_k_Page_037.jpg
cecfabd078912d6ea2427d8a574245df
a0dbaeef3da4c4d9051abe6ba84ab94933d0e600
F20110115_AAANVI sellers_k_Page_144.tif
bdaf97af882923657ade97173cbd50a8
0c63fbe32bf4509d3d3997b0f30662d6082d0a79
887 F20110115_AAAOYK sellers_k_Page_106.txt
8bea89f43bc35875e3a99f3c8fc724b7
747c162597d63443598af991d75250a792b6b057
4270 F20110115_AAAPEF sellers_k_Page_132thm.jpg
4309ab07313b4ecabf65b1a10c12dbd3
ebe8415c81ab452ece339efc9360aad0aa217371
6574 F20110115_AAAPDR sellers_k_Page_142thm.jpg
9ba1c086988c5b115c20728c980eabad
df395b996a1047ddaf25a4069020d306778abb5b
7802 F20110115_AAANUU sellers_k_Page_089.QC.jpg
2b81f3e7c056d70e973104323b6d4333
28f28512c927b7b130d2bc36f99099b1b1adc23d
352 F20110115_AAAOXW sellers_k_Page_089.txt
d684f3db215d47ef4273d457a078d403
4802efba75989eacb2465b285f05bde4fb23f5e0
68414 F20110115_AAAOBD sellers_k_Page_052.jpg
b62cd172306172486eb84fc24d98f50a
d902538fd9c836c61c133337d71a79d9f923c575
19785 F20110115_AAAOAP sellers_k_Page_038.jpg
5747a7c88ee2718a48ca24feb8394327
9a59c31a4d4a7cd02cb080137343ecec1661233b
466065 F20110115_AAANVJ sellers_k_Page_109.jp2
b27356324fdecefb8196a59078bfba30
0388ea2405a425b0a8cdd5ef89957fb9432b9a4d
1368 F20110115_AAAOYL sellers_k_Page_107.txt
8a100b45e13aef3a60f43a3a075e03f3
619d841fe9ef3d06a1755a5dfbbb318617053da4
13853 F20110115_AAAPEG sellers_k_Page_058.QC.jpg
6793723e121439a53c023ca3ffb55fb6
23eb822b46193902ca0e85cb3263610e24cc7a0d
22576 F20110115_AAAPDS sellers_k_Page_070.QC.jpg
1fcb8835b557f8d22cdbd8621ea938ac
c485bd48cfc3c7c5c57a8fe7d61f9fe6048c9fd4
1760 F20110115_AAAOZA sellers_k_Page_123.txt
052c23ee5e194c87d522f862cba61d11
dd2a6562d82388c3e8745a92251912a2ab43f89f
1740 F20110115_AAAOXX sellers_k_Page_090.txt
0c4d00df1765ed946c773634b06935b8
a9fc0c889e06ef83b95f01fb409d188fa7d9fcbe
67112 F20110115_AAAOBE sellers_k_Page_053.jpg
0ac5096e54014e5be0a44975067269c3
163224d15c147103b01f465f65112837236d306e
25117 F20110115_AAAOAQ sellers_k_Page_039.jpg
39704a4828aae2fe1703e6e39153aa9b
c9089a189263fab1a457122c0902b96561160164
80285 F20110115_AAANVK sellers_k_Page_006.pro
8e6ce34755302d05ebd120a919b7f706
6bcb6c3e8f2077ae5aa9584d3bd571e38a4c733b
933 F20110115_AAAOYM sellers_k_Page_108.txt
ff2bdc400293e746cad46efd993e4ca6
199dc19bf0b2f6ff769dc6aa6f60394cc5cde1cc
F20110115_AAANUV sellers_k_Page_056.tif
3e091bb16b8556f9a5dc7bae98d46438
ef0fe3667b6faebbe347a4f240ab236db5d49ea1
6632 F20110115_AAAPEH sellers_k_Page_050thm.jpg
11b0ccbb0a1042242de42821d001cd0f
23611a533eec08ab5719ce21b3e7e8544f2c8055
5625 F20110115_AAAPDT sellers_k_Page_090thm.jpg
495d774977a3901fb00b7193864b3335
2211a949492e5673a17f4f3c5df55b97aaf2f1e2
1880 F20110115_AAAOZB sellers_k_Page_124.txt
6b9baa8903d1e271d501cd67069e6658
6ead980c6f29cf6badd49bec150723d4b13155cb
1917 F20110115_AAAOXY sellers_k_Page_091.txt
bb26cf999df9809b21999d62bcf90d78
e796ffb7b29015c508edeef2199de7bc5618e5b7
72032 F20110115_AAAOBF sellers_k_Page_054.jpg
4252f6cc94fb109ef6dd89d19d48eb57
f157a706c6b9e890ec59ac3867fe26f63d7b186f
35297 F20110115_AAAOAR sellers_k_Page_040.jpg
d96c98fcc9fbd5d984c985b51ef0adef
6949b01c94a2b351a214c9a6872865a8b9a9c822
2990 F20110115_AAANVL sellers_k_Page_130thm.jpg
6342b1d41a0445beaca3991cc1183ffd
52acf16c35f00f98b01e86015f3f01036c445978
845 F20110115_AAAOYN sellers_k_Page_109.txt
86156e2429664a1fa5368ba618dc1d5c
e47b09b3add297cbe90259df486edfa8c4ee4b0e
2788 F20110115_AAANUW sellers_k_Page_105thm.jpg
0661117ff99703536186c1291675ec6a
6453ab0efc7dc12ad4007f5330f52a35b586360a
19193 F20110115_AAAPEI sellers_k_Page_078.QC.jpg
2da383a785d876c87fa5e4ff8a6c491b
99723cce6952dba2df6ca431cc97c7542c2b72cf
4179 F20110115_AAAPDU sellers_k_Page_104thm.jpg
4616711306f30d84af2b8ac1960f2e2b
88502695c3fdc167b93bb4afd1ad085a96b55960
F20110115_AAAOZC sellers_k_Page_125.txt
1e16f675d0c1a986ae3dcbfff7517875
9c924e4eb61931bc541f5470fd0d4173431e1dae
1908 F20110115_AAAOXZ sellers_k_Page_092.txt
e01108f43d8af4c46ccb639decccb296
7b78c1350e7f6c7b0c20b99a68279e8577dace8e
60878 F20110115_AAAOBG sellers_k_Page_055.jpg
7fbd2395fe94067804b216fb00625695
0df9295bf18400aab8c24f31cb289998d50cc5e8
943991 F20110115_AAANWA sellers_k_Page_135.jp2
f0d3d579075d1e9da0117784eb218957
f4fe44cf9a70708c98ccc209c1e8db6ad5f7dd84
24743 F20110115_AAAOAS sellers_k_Page_041.jpg
27031ed4669e01ff81c3b0ad5159c440
0278d7a2f2f657a688c539cbb93934b336ed1076
22480 F20110115_AAANVM sellers_k_Page_107.pro
1eabdadb7dbf0883dbad9a395caa08c2
0acd53608280e90fc69a94390e960354cb9cbd18
1812 F20110115_AAAOYO sellers_k_Page_110.txt
3110c168463b89abcfb34ff401f805ff
91bbd85957159949d74e01592f2ea98e80ff842e
96495 F20110115_AAANUX sellers_k_Page_007.jpg
d6c99bb335c4bc961ecfbf335c54c47f
3f94cbbd6891096bf22df86583ebed23377e7658
5986 F20110115_AAAPEJ sellers_k_Page_145thm.jpg
c1481b62e9144fe97e064b369ead520e
5ad6d80b6d6eec3b02501e059aa8f67277fd9fbe
23427 F20110115_AAAPDV sellers_k_Page_096.QC.jpg
79ab49861b0e8390378dc48cc1fe190d
e5cfc7035d92c6b5761f566937316fdc0202d87e
2010 F20110115_AAAOZD sellers_k_Page_127.txt
1023a2e8b352172756887af41afe6ad8
5ae2bff930f557e63d7e2c85f914f66941bab904
1988 F20110115_AAAOYP sellers_k_Page_111.txt
39e1fe32c64f0c7e0fb5757ddcc7868f
c672f1dfd0122b12f6214bdc83cf490a8c4a5143
44474 F20110115_AAAOBH sellers_k_Page_056.jpg
03fab9e53d79a7a196dc8b089fc0651a
1c1f497492c1675623323f2d63d5eee35fcaf9ff
2713 F20110115_AAANWB sellers_k_Page_150.txt
791cc1d83659d544bdc0ab0551878c91
6dbe916c33a415d8f644af17180de2d7e5f9daae
31945 F20110115_AAAOAT sellers_k_Page_042.jpg
237a587c119d13b0a2fb9d21d91b4b17
a53685ade3cc16c58b96c0bd02ade5c70dc1e65d
F20110115_AAANVN sellers_k_Page_047.tif
4c98418742eb022049512f04d72efee1
fba06aabab205108d452fc13379e067f2c24a9cd
102541 F20110115_AAANUY sellers_k_Page_024.jp2
c9c4be5807b506e5d15a10ea7be0b2b7
d4de08d2dd11441602107c3d0255f08d074a2280
2994 F20110115_AAAPEK sellers_k_Page_131thm.jpg
c4a09a8c63a62a01a0139d405bdf57cb
efb4f5a2f9fc9b7c6b1e908cde7fd0e985fe255a
4740 F20110115_AAAPDW sellers_k_Page_129.QC.jpg
48de6a6a79bb4e8fd3d44396a660ee0c
6c6accb88744f56a3dd640724e6de0e957141fa4
136 F20110115_AAAOZE sellers_k_Page_129.txt
7a5ec8bd017e06113814ebb3a31aeee0
dab8df1f98c27041ffbf5a72bcf568882931b0c4
2095 F20110115_AAAOYQ sellers_k_Page_112.txt
197ea040ab1b2d0289db4b0ec6516ff6
1871957f8443b8b20a9cc73b38e455129c195e87
34530 F20110115_AAAOBI sellers_k_Page_057.jpg
3cfd691b2f73fbd131e3ca25ee8e7496
46fad6b83bce0ec3fabefa26716b2b0f4e1caf9e
F20110115_AAANWC sellers_k_Page_140.tif
8184b7c2b9567f41bd112f4fb980cc23
e34c95221239be7ef0f499f187483e2173ca8be8
26318 F20110115_AAAOAU sellers_k_Page_043.jpg
a08b839c21ce3380aef8532d98034e13
b24db67595bf1f9fff661e5ccc91322657997b4d
6160 F20110115_AAANVO sellers_k_Page_123thm.jpg
1644aeac81514fd4c7ceb58ae5c30aaa
4a8d4e757b443d12129e2c1d469a5c97798108dd
23766 F20110115_AAANUZ sellers_k_Page_054.QC.jpg
84dd89240650e22a457c1c2643c094ae
d218e148199217e596744be0b3d7bb9f3dcd6e6e
F20110115_AAAPEL sellers_k_Page_121thm.jpg
c3ecdb1998e63616851e4983dc949c11
e2829daa2631fc9de1ce411d6d435a6dc8b7e1d2
10559 F20110115_AAAPDX sellers_k_Page_040.QC.jpg
9aa818a8573a436d0907d28535bbb1e8
b2d4f2d451a0afe3cb2f24db51e2d0940193081f
711 F20110115_AAAOZF sellers_k_Page_130.txt
e32d9bc0289c6634e8327dbc43e71747
3f9dc1209c7d06ab7f6c34f304f9a0d0c9784d5f
2011 F20110115_AAAOYR sellers_k_Page_113.txt
4ecf8d7b5780cf9cf1afddb7189b31b9
b01f915b119e2d53289e7494e33053ccb0acbe85
45759 F20110115_AAAOBJ sellers_k_Page_058.jpg
ef771fbae7956d0eca1e993668f0db5b
e5c31ce212a084c7aad6bbdc2b5b3a3638500201
23256 F20110115_AAANWD sellers_k_Page_001.jpg
0a17cedd0ed16e7c8f2563932bfe7ce5
088f15753c42bd1ab42b7485463b6ea91f013a44
63871 F20110115_AAAOAV sellers_k_Page_044.jpg
3b0724ef9d77ccb293230d08e4f0a993
58712c401d02ae487923219403360c6c94073f08
50051 F20110115_AAANVP sellers_k_Page_054.pro
60d6c7a9fcee1e9770a316a5c8b8ed5a
8ccbe902b0e4d4b7c966d68bf105440f06015c12
9087 F20110115_AAAPFA sellers_k_Page_061.QC.jpg
08aa6fee92f9454c5002454c0410e8ed
98c066a796fb3bb05fc59c89900aec90520732b0
6497 F20110115_AAAPEM sellers_k_Page_141thm.jpg
68f9ac790cf90d4cd65c0ea26dfbd2fa
1e2da15c605f73b4458b8fbb7af5a7ee0688bd6f
7181 F20110115_AAAPDY sellers_k_Page_150thm.jpg
fd53a0a7eac9c5f3d13767a898bfbd95
9f16792ac1eb242b8ed563fa6172c1a3719ad0bb
490 F20110115_AAAOZG sellers_k_Page_131.txt
c4df3551f05ebc03945a19c06afd3cf2
792e824982f315bdf23a6760dcae152bb8c1236c
1572 F20110115_AAAOYS sellers_k_Page_114.txt
594c96dba0cf0e35acb6e5edb4baf4c8
4ebb2b2a00b3c6f09b333c0f1920780c6490508f
34787 F20110115_AAAOBK sellers_k_Page_059.jpg
18c4a4283cc9c1d15a6b3223c6c4bca9
4f563c174d346187e3c04024bf8c35cd0302ae2b
67891 F20110115_AAANWE sellers_k_Page_125.jpg
8aeaf65ba72e99240b9dfd043f217793
01244a764c5ae37321ce619f3bc3bb7ee568b3b7
67456 F20110115_AAAOAW sellers_k_Page_045.jpg
da872adec6d0d071715fd5cee29935a7
006bcb13ed9cb754871cb69b1da2a3387d4f3a9f
22375 F20110115_AAANVQ sellers_k_Page_145.QC.jpg
265a15621252c2fd2a42971d5c311dc3
9f350c29ecb65ee97b2d9eb3ac37e812cb7643fc
21568 F20110115_AAAPFB sellers_k_Page_027.QC.jpg
c0261f71e14a85b5a0d0d5f41bcb03f9
cc817964bf2c4eb55e3f4fba017e2cd12917264c
6626 F20110115_AAAPEN sellers_k_Page_153thm.jpg
ee1bf54543b401c4ac0338dece9d13ec
255641f6ffbb61284d2d174951e348e8effdbfc3
6525 F20110115_AAAPDZ sellers_k_Page_017thm.jpg
e91f4c6f5d3d2c0b66b1cc5e150114e2
c113c6ce0a39e9af1a1f83dc195f41d98b897eab
467 F20110115_AAAOZH sellers_k_Page_133.txt
f97ecbff7d9aafdaba764a38e474e201
af24cfa9753720965ec8fb68ae85abc1c2140f8b
1608 F20110115_AAAOYT sellers_k_Page_115.txt
b67d3bcc56597425a0b4a5bfc9a85d28
df4ca97064c6a36fd396cf965a63e3ab19fb98d4
31291 F20110115_AAAOBL sellers_k_Page_060.jpg
96af1a28b378bf95998bb1635fea4032
5ded402c6cc8375a331d42fa095970056303fdc0
108725 F20110115_AAANWF sellers_k_Page_119.jp2
f13bda0458322af49f3b9e1deacb5c47
d6296cbc5b71701ef2f87af3ed9b31577361c1b8
65416 F20110115_AAAOAX sellers_k_Page_046.jpg
a166e6e8d9a379db0f0aee42a5ad2dfa
d3a5d55eddfef3fc8803826ea9dd6a5667598cae
41067 F20110115_AAANVR sellers_k_Page_055.pro
391f3e7512ed175a54dd20130bd96b7a
154e06cf151c479624c6e9fff1899e1e8a02934a
23291 F20110115_AAAPFC sellers_k_Page_034.QC.jpg
ca3910ccba23548c5aa8c212152d6cc7
a9e63b204fb52d482a357edf4775ace637a7fe31
24418 F20110115_AAAPEO sellers_k_Page_153.QC.jpg
d9bd2d119ba952301c7d51b57cb27dd3
353c688da5a7160a8a697bdf8e3573b9cba35375
991 F20110115_AAAOZI sellers_k_Page_134.txt
ca8e5d25a74e5f76b7e775dfde572681
51964a3b59749cb8b1822a5128869e691e2fe98b
30854 F20110115_AAAOBM sellers_k_Page_061.jpg
9ff3d5a19db064a85e46a9dcd1274027
dcecdd2ab11980e33ad07f7c36580b65c3e5c3b9
1948 F20110115_AAANWG sellers_k_Page_079.txt
b11723accaa60600465b600d63c59f34
fcbeb51b382a73aae81a904706ef570477dc1699
70745 F20110115_AAAOAY sellers_k_Page_047.jpg
6e01d5db7601e3068c310fea46db1033
7a61963ac8760f3f69623d4777c7cb20e8e433fa
65133 F20110115_AAAOCA sellers_k_Page_076.jpg
9cc3e927f3b83d5dee63aed48b061586
331704898c2dcb4d3b6e382f8ce856864f40634f
5898 F20110115_AAAPFD sellers_k_Page_110thm.jpg
49f068895d02e8ad466d1ebd06c5d829
942f6771df82b5e76c7b33dcea5c25558f18cb83
5281 F20110115_AAAPEP sellers_k_Page_143thm.jpg
5e90f80b80bf9191a093d2895fd8086c
1883e1bfbc96cac47da2cf2f16560fcb708a3b2d
901 F20110115_AAAOZJ sellers_k_Page_136.txt
f3f357b85d61d9f6b031c06b4d7bf27c
b30630747abb38e6786c28d7a97f2efe96fce538
1471 F20110115_AAAOYU sellers_k_Page_116.txt
5fa8604f634ec6094a0a64c17277c214
1bdd7de38efe370b31990c4830ff7529ab8e7654
59243 F20110115_AAAOBN sellers_k_Page_062.jpg
ffb9aacca37975f0e18e319ae8700dbf
46c068b8baedebe0765e0c12094444689b8ded93
51123 F20110115_AAANWH sellers_k_Page_113.pro
6a68bde6c8c424ac3fdbaa2eb93420aa
29da3cd240b18d8a4f8a57f92a22913ccb46beeb
69132 F20110115_AAAOAZ sellers_k_Page_048.jpg
6a7f45687cbad7e9129c4facb005a52e
94b49a3e6f0c490a41328e9928061e5efec57d5c
138337 F20110115_AAANVS sellers_k_Page_152.jp2
94f855d6ff8842988845a76703168488
600713c5a84647d296108b19c4d120449227428c
72366 F20110115_AAAOCB sellers_k_Page_077.jpg
71a4eb794f552d819b8da35ee4efe6f9
34f2b4c6145b5cf5a683962a4317558aecc59cba
1831 F20110115_AAAPFE sellers_k_Page_129thm.jpg
8137aefccf608aca7a375258ff878b48
87222b00c11fdd2c01079f71babb76cd49e746c6
4291 F20110115_AAAPEQ sellers_k_Page_056thm.jpg
70faf59236d7dbc48b01e4463f0a3007
f534c103179a4c9945926c3aec796c45751f1c4b
1873 F20110115_AAAOZK sellers_k_Page_137.txt
29e0b48c06c3507299a812cd4ba8110d
7e4eafc878c628468dc29bd97f9eb147b70b205a
1861 F20110115_AAAOYV sellers_k_Page_117.txt
82d0ba5a79fe7db5b0b64e97e2b220e6
881b47b3acd32807838dbff439680ec6541ed0a6
69668 F20110115_AAAOBO sellers_k_Page_063.jpg
cb3a414b24aa25dcf65a171b92f62855
43f79a19f59fb077cdfe04cd909d263d392f6abb
23508 F20110115_AAANWI sellers_k_Page_113.QC.jpg
99876f6c168033bac2333bcb922097b5
2c2a256a3b1c8ae1965e95b1b358c0ed28bc8189
6507 F20110115_AAANVT sellers_k_Page_119thm.jpg
8952ecff9b7656832612ce2246b8db83
e2663de8cce42e38f8009d241fd0f0482b63a06f
56052 F20110115_AAAOCC sellers_k_Page_078.jpg
3f877a0f3debdd92411e049ec556d680
541e5b374036c3409206d15784df9e607b79659a
4094 F20110115_AAAPFF sellers_k_Page_136thm.jpg
2c12e64089129cdf91fbf20083d1f9cd
113eca054fb7cc417eb7fd9a9ea1ce82e35c9575
6393 F20110115_AAAPER sellers_k_Page_031thm.jpg
83bce4df35bfafedbd98c254cb828239
73f86acabebd33d20cf68e0eaa640e3696fb81ec
2079 F20110115_AAAOZL sellers_k_Page_138.txt
0c00cbbaace62fa435183fbcd106038c
daad817543fe73517b50e7b85a8c47a64bea57ff
1735 F20110115_AAAOYW sellers_k_Page_118.txt
7e67756d211f5f01e1d74996de5a0eb9
56d0c32f8960b6bed24cad8d5c093ae9db417fa1
62540 F20110115_AAAOBP sellers_k_Page_064.jpg
1571308c40b230185ceb1939d893cd30
1398d94ba2cd0cafb4fefec36122223513652e4a
97907 F20110115_AAANWJ sellers_k_Page_080.jp2
00961f4c576b151f431d8f9fbc3597ff
aeba1705997ed988ca62ed089eb741b15d79cdcb
23650 F20110115_AAANVU sellers_k_Page_139.QC.jpg
a9676eb5ebf42005e1fd591beea720d8
b56c17c52f81b4b94ce17792bd99401333ac7aa0
71672 F20110115_AAAOCD sellers_k_Page_079.jpg
271904188728727de7d5f56aeb99de43
87c580c5586883f9d2e6bc75e1e91e5abed14636
5456 F20110115_AAAPFG sellers_k_Page_062thm.jpg
46d0799915a488ae34ab4173cf1cf3f3
b6b5289da747c3e8fff5c36008d794fd82f47f5e
23882 F20110115_AAAPES sellers_k_Page_020.QC.jpg
a3a2582f876505b0ddc6ad70eb72902f
ba085807fb4a7cef06940b0ee1083d941b728313
1983 F20110115_AAAOZM sellers_k_Page_139.txt
54393e7c665cbfff0693173a8ab4cddb
95c1f7aaa7c74a33a9a436a94490702c2c138bd0
1813 F20110115_AAAOYX sellers_k_Page_120.txt
a710d8e2402ebe35ac60b15f56e275db
2d9756e3389b5614c409d8238616e44d113fe75c
66778 F20110115_AAAOBQ sellers_k_Page_065.jpg
45656d368e3af7118f2382d67cc40efc
2cae1532a21a25c64a46d5177208b9672df13b6e
F20110115_AAANWK sellers_k_Page_015.txt
827eb041947e5b0ef70ef1658cf2066c
ee316deabd34c422120654a67b073c4c1b6ef113
71758 F20110115_AAANVV sellers_k_Page_009.jpg
ad30fa244c182c01b06e22b18dc5d44a
0d58953e3e6a1588672b95ebc97aa8f7e9beee49
66021 F20110115_AAAOCE sellers_k_Page_080.jpg
4483a3b3513b214b0ba034f49b9973a2
d38095b3c7d30eea7e161a0fa940db1d8cf1aed6
19001 F20110115_AAAPFH sellers_k_Page_114.QC.jpg
1e35a1b7c5651652ca14d683ba1f032e
d4abe4f06e4d5bd655db75fa8c26a71e315a2352
9858 F20110115_AAAPET sellers_k_Page_060.QC.jpg
54f193ba74e69e538c8c6b5e2a1cd442
687d7bd16c8826d0e1f3f900e3faa348d5c6f650
F20110115_AAAOZN sellers_k_Page_140.txt
2eaed122b67e647ebd4626a5f926f8da
de9cbb99e7a8ea867f5c9ff6687a7506a515f485
1723 F20110115_AAAOYY sellers_k_Page_121.txt
35a7fabb73c73d13a0e5b77db8c093bd
b3ea2fd19c143d257c3fc3ad0bc1451be9b80233
62222 F20110115_AAAOBR sellers_k_Page_066.jpg
5cd735426486775d36633be043e8193e
0b00503b4d8aea7734a4ab24d0b594abe5e1b168
48997 F20110115_AAANWL sellers_k_Page_020.pro
0bcdbe6947caf7825d0c63eb46b2462c
0e67f9ae1026a2df78865da29144557219185c9f
22959 F20110115_AAANVW sellers_k_Page_069.QC.jpg
8674c30765bd6d7209bda521d930c81f
775588530eda9cdf5bd79d43101ce71e7b36dcab
69096 F20110115_AAAOCF sellers_k_Page_081.jpg
0aa9a630e6eb5d85ed3ea0ea2931b572
0b6a6880c39f8c2cf712be16bb6b337083806b92
2836 F20110115_AAAPFI sellers_k_Page_155thm.jpg
36e4e9ea5f4f3f839b2e9b92931943c7
4e6fb21b71e4a810fb8d202647b718ed127a9be2
4370 F20110115_AAAPEU sellers_k_Page_088thm.jpg
402cb7f76701ec7d23fc14860e4eb463
dc72e344f964dec6e6e74c42db81a2dbfa0f8150
2019 F20110115_AAAOZO sellers_k_Page_141.txt
1e5d26eb0f28c0d5997ad0b294355907
d75ce27571eea18a9b43ae2e656d0a90f097cea1
1802 F20110115_AAAOYZ sellers_k_Page_122.txt
a89e71c8d2f4211c3d20cf65d17e6d61
c4f6df9481199652ab214b96376b7820c5e7fb3d
66717 F20110115_AAAOBS sellers_k_Page_068.jpg
77529ddfc20c49ba5ba6dc91f7530722
28697632691ca49a8df30cae746e957a47de6a27
2061 F20110115_AAANWM sellers_k_Page_128.txt
32a8ceb92bdf7c6b516218f9e0a27fde
8d79571f1ecd9ee267fc2843140725f3a6ac2e70
779 F20110115_AAANVX sellers_k_Page_155.txt
410ff17e1e5ce256065efd19bf3bc5ea
5c6645595c6148fa179f1ccf079c1bbf75c4976f
74471 F20110115_AAAOCG sellers_k_Page_082.jpg
76929e2271fb5a01c8b7f53b171812cd
74f1bea2a2cac4bc7c24b956f3d65620d2a44f26
1895 F20110115_AAANXA sellers_k_Page_030.txt
f0b70c1a41f1b9e8cccc7b478397bc6a
ffc0c0e70669ce5bade9d7f75bd693e5e6f81802
6255 F20110115_AAAPFJ sellers_k_Page_101thm.jpg
fa90e1e9be7858171be1a602610ea349
9ac619ce079acc65946c39b9b640e4d7a1c8e077
24469 F20110115_AAAPEV sellers_k_Page_008.QC.jpg
d44fed060f3128924b132c9d6a353958
be15275af6f218e22f1071d0a963d431afe6c82e
2026 F20110115_AAAOZP sellers_k_Page_142.txt
a8db137b31c1ae806bb17b8c1068e320
11f9934f40420b46794738bdd32cae46da45d54e
98905 F20110115_AAANWN sellers_k_Page_068.jp2
b8447f0501ae418def17fc1c399689a1
5584e7741b420a72587e56073cab8f1680d59fd5
243488 F20110115_AAANVY sellers_k_Page_105.jp2
3fc98f7c3523775f87154848f842571b
fc50c6546f38584a3f5ca2df02b3b4e4eb6b7210
73474 F20110115_AAAOCH sellers_k_Page_083.jpg
0a1158406fd4295c00a27a3864bf0d2f
12437085381a76ec9856d8e60bc85d573334a2ee
26099 F20110115_AAANXB sellers_k_Page_131.jpg
953aebdf33fd24b33eb20ee02cf112af
0db19df2292794974bd7b1c02ce430ebf95bfdea
70767 F20110115_AAAOBT sellers_k_Page_069.jpg
5e340d1fe63f36a56e79d7ea714c3fcf
54b0f93420afca36ee38a65f88da9dc0a20abdfb
4790 F20110115_AAAPFK sellers_k_Page_108thm.jpg
c556ed973fa07e7619cb3754a337e649
70b262edab7e224f1e9d76c8852be71aacd76316
22880 F20110115_AAAPEW sellers_k_Page_037.QC.jpg
5e00b6e25e93594b85c86c2989a032f4
a99eff18019b50ae0bb3777081ff4a4a84060719
274 F20110115_AAAOZQ sellers_k_Page_144.txt
5fcbeef9b858295c821974bf2ceed944
74cf6f7220e9116f42eee09e23b453b53099835b
22409 F20110115_AAANWO sellers_k_Page_063.QC.jpg
832342c3054e4e2c23e7ba8e3684e21b
99a749c8309bca8d9d3afa4df708a0ba49caab1e
21956 F20110115_AAANVZ sellers_k_Page_029.QC.jpg
b8f62e1ad4a7e6ba386b372010dfe8bd
900a901406cf913186e3a9bbd8fb178e6bc75ee8
72243 F20110115_AAAOCI sellers_k_Page_084.jpg
716471bdfe98413512647c1ea59df6ea
b2918228b1c0b22db914352945c374d31358ce36
1566 F20110115_AAANXC sellers_k_Page_012.txt
94a83d144cbdc52504bd7a33b7467769
400c74c8b399ee1dc69ec9169ecab9bddf3cacdc
70937 F20110115_AAAOBU sellers_k_Page_070.jpg
b373bfd9fcb6576322faa1868d772358
bea320e28f5905124f147bbd758c2961677557e0
4913 F20110115_AAAPGA sellers_k_Page_107thm.jpg
63101c7a04e9be8a916d44e79118f0b3
98bfd18cad833dd3f9a93b92740d07ac92136e2a
F20110115_AAAPFL sellers_k_Page_065thm.jpg
437c03a44735075e47680f1342f1fd62
c18e82bd1090dd8277515833f9191b55ffec25e5
3398 F20110115_AAAPEX sellers_k_Page_040thm.jpg
81173a7d6b91d9bfddd59465c1f742dc
09ac96ede5753fbca3ff4c0aedecbb78229729a9
2180 F20110115_AAAOZR sellers_k_Page_145.txt
b0f151c16ca28dfd84da4547df724bbc
7cbe896fb7b9ca1198eae852f7d662a554b53f34
F20110115_AAANWP sellers_k_Page_087.tif
a63058a74f2a96e6eb4a85c5a5e69703
51c0a3ecb5a89b2ea5ba7202d2101dcfbe1a20db
57366 F20110115_AAAOCJ sellers_k_Page_086.jpg
941461aa539293f7ec6984e17b987671
3c25ba824551d7000c53448611e365f1f11694c5
23861 F20110115_AAANXD sellers_k_Page_071.QC.jpg
7a244c8b06ef173d55633242cd5d9af6
8def858ce991d6b1128daeb28e86eba9e5f680e4
72779 F20110115_AAAOBV sellers_k_Page_071.jpg
e5fbbf96f79ac8d94e88ea875def4bb1
c6818d20ee6d0f760bb4f560e6a32e781f9b9499
24861 F20110115_AAAPFM sellers_k_Page_146.QC.jpg
13fe88abb8a08e67cef179840a6f2663
f6eaefbbb0b4d2165471042460ca9c536ddcced7
22290 F20110115_AAAPEY sellers_k_Page_091.QC.jpg
704cc67a6ffab5db86e1aef33b7b031b
eccf896446f03d2137cded95c6b87fef273a0f19
2475 F20110115_AAAOZS sellers_k_Page_146.txt
0d2bf146084b1c6b438f4aab9c5de235
6c60e087fa67860050cbe748be180f521c64aa0f
6476 F20110115_AAANWQ sellers_k_Page_023thm.jpg
9adf8856e3929c50d7b8e4578fbb5442
debdc9d130ddd50a6f97562ea2e2a3b23a4d2645
40848 F20110115_AAAOCK sellers_k_Page_087.jpg
7c17c34baf2c35247b3dbf3ccbde7c08
bf3511bab46397851872fd8c02e289326ea95242
6335 F20110115_AAANXE sellers_k_Page_069thm.jpg
9cd015ca08675bd7d6b72ece108d1c27
2f94c8c8649a15e07dcbd33ec607ce90b470a9ec
22927 F20110115_AAAOBW sellers_k_Page_072.jpg
69c00ac8ba0708e8c7342b6788b85774
a2352a56a1c69ce471cf730017ab0920755b08fc
7584 F20110115_AAAPGB sellers_k_Page_001.QC.jpg
267618beb626e1f036ce24a7b58ac12e
66e8e189f451ca7bd21696e770ff88b9aaa76ee1
6270 F20110115_AAAPFN sellers_k_Page_100thm.jpg
a599799595af9595979c6ec7f2ae1187
b826f28e073b3a12997df150ae7a9f6b59e894cf
4906 F20110115_AAAPEZ sellers_k_Page_012thm.jpg
318627c978a86118789a0a621fd7e83f
21f3a70e54a6ff8d7650229427af182c94237bde
2474 F20110115_AAAOZT sellers_k_Page_148.txt
b0fdc44740a08047f902e71ab0728623
b5643027d8b4467b7d48f9c3a8cfb92ae3bf1677
F20110115_AAANWR sellers_k_Page_047.txt
2edff54848bf8c0769023b51c0b3116b
92e1a59abe148d9b6498f08fc1d2707851807157
40931 F20110115_AAAOCL sellers_k_Page_088.jpg
9c1030cde7ed3597b4df980e1e009057
9a43b5930802a6f480cfd51ac839584aa8859a99
2498 F20110115_AAANXF sellers_k_Page_151.txt
55ba0371b8346ba8e57a0a6da7a8e232
5e5cc4491e6706869354f2650850f1537198079f
56248 F20110115_AAAOBX sellers_k_Page_073.jpg
8046632534f78e8e2b95049bc9d0a0a2
390d2f78ca06089626f0055e29c1e4b320e59bf5
21250 F20110115_AAAPGC sellers_k_Page_123.QC.jpg
fda33cd9d471ec38e8a3690b940b8da8
d3d55e62000b439d718f430706fb8e66da22ba4a
6221 F20110115_AAAPFO sellers_k_Page_120thm.jpg
79d28f87ae0d7dd7642904ca5a2a1819
d66d6e1d2f936c5fcdb8c37e4d41d56f57616200
2626 F20110115_AAAOZU sellers_k_Page_149.txt
cfcc65ce85d5fdd8b62f6d550de00b08
8501162677de92771831c5ae1cee25c0f212436b
5617 F20110115_AAANWS sellers_k_Page_005.QC.jpg
3fe32d72179eb93b8440695244f24777
27b9d40d0d5efcb7c2f0dbf7020198fec686f3bf
40074 F20110115_AAAODA sellers_k_Page_104.jpg
a6132608d1dd4ccf768be6b30e4704ca
2388798620e07b0cbf0a9dd6d5e259d5f43d58dc
23737 F20110115_AAAOCM sellers_k_Page_089.jpg
0f92007d3aaee491e2ac46c8b8b031c3
37c12eacf19fbd0df89562e9d71e38f5cd42cd7e
75239 F20110115_AAANXG sellers_k_Page_035.jpg
98c3484ad8372b139c2d4f8bd675f6aa
b08e1078e949d7ca8aed2e354b1ff713586e66db
30032 F20110115_AAAOBY sellers_k_Page_074.jpg
c493e8fb2b946b2fe986790c8cec9176
938f06c34479376d9b81168ed22dac044b5ee40f
6403 F20110115_AAAPGD sellers_k_Page_084thm.jpg
7579b0f3504bcdbb288f90776a350f69
4bc212269d23dd0fcf67c5a2ac559dcdd6ef5695
6091 F20110115_AAAPFP sellers_k_Page_097thm.jpg
8db1689cc54e8b2d7f24996268832a9d
774aee2b6ed79f310fb8654142d578aa1dee9444
25469 F20110115_AAAODB sellers_k_Page_105.jpg
1b6a451ede2498ba65b83ea00ac0bf39
70b287162549d47bf16db1453cab5d5fa6736a4a
60351 F20110115_AAAOCN sellers_k_Page_090.jpg
ac9561b96237b21be1127ea2de20a140
b95d1adb9ddaaf7adc47e41525dbbad6e6ec5880
73209 F20110115_AAANXH sellers_k_Page_126.jpg
f5ef47c44c22f3a7f3a8b25aa9ad0188
8cbebeb518cdec7c41f7fd353a7aa82971dc6666
59866 F20110115_AAAOBZ sellers_k_Page_075.jpg
fb60647071261b583308b8c6528f3f79
9e529ed8ed1f5768327101dd99c868d6bf2931db
24123 F20110115_AAAPGE sellers_k_Page_112.QC.jpg
47e64f0f78e4618d9b4eed11cd821a63
97306704dbfde7ff5ca3df6cad9153429aeb6b6a
19921 F20110115_AAAPFQ sellers_k_Page_090.QC.jpg
dcc6cc035ec115f8868e849e5e86ed34
b93811a067c76cae6aba16c20a95076f63a64dea
2646 F20110115_AAAOZV sellers_k_Page_152.txt
5478729a74a418144f3f4855a3fa4a55
1b47e4bd138a4a2f83372a20e4b04162d27d2f5e
17822 F20110115_AAANWT sellers_k_Page_085.QC.jpg
b9edbc302dc55d22a4f4901587fa21d6
ca81764f3992a0ef68fcdea600b462b41abb0a59
54840 F20110115_AAAODC sellers_k_Page_106.jpg
483d6e640874af2942554985ff1a2678
588f272366bb84421d5776636a25424ccfe8fbc8
70024 F20110115_AAAOCO sellers_k_Page_091.jpg
e9c5fd1e58031c3442c5ac4070e98363
4bb6fd55f2b1b2ed0e19f3ebcd050387463c4e4c
109131 F20110115_AAANXI sellers_k_Page_084.jp2
a8d5e41c8c18e10d4aed6e9845d8278b
74012feb87a9681131c65d9feeed591484825f04
23176 F20110115_AAAPGF sellers_k_Page_032.QC.jpg
247685425b3c1be0eb4604923ea6e2a5
e0140a57a361c5fd84d009927850fd0a4afc043b
22611 F20110115_AAAPFR sellers_k_Page_081.QC.jpg
18157b5b48a86d588cf22483483dc0bf
e9d0081904f6b84d308b0b76c0f7ca15004f9ad6
2354 F20110115_AAAOZW sellers_k_Page_153.txt
82891d86444516b26aad4cb60c281f8b
51bc5e0d23f0bb50bcc4dc2fcd1e0138adfc62c2
105358 F20110115_AAANWU sellers_k_Page_033.jp2
d5296af2363762c3cfa182bb3bcce8aa
e6b89fa2c4bec157a01ea170e29ddf0123570b91
46516 F20110115_AAAODD sellers_k_Page_107.jpg
2a400f4a9b311b299aeb73fb2e926b3a
31b5867c27dc8f5bd318624e99254a94f3a7b959
67860 F20110115_AAAOCP sellers_k_Page_093.jpg
e0b5023744fb5eb121ca85f2216fbb3d
1ba81480023b825d534077eb95dcae47f9192166
6289 F20110115_AAANXJ sellers_k_Page_117thm.jpg
b73bead659546731209471ee3e48dcc6
49ea42ba2681b4557693869c434c6700a11b6101
21926 F20110115_AAAPGG sellers_k_Page_045.QC.jpg
d55649c47de9af3efa98e5b0e255f7ef
89eddc499208f9f782a95ff37cd30bf229b0e2f0
6298 F20110115_AAAPFS sellers_k_Page_111thm.jpg
8f43127574a36898d55c21c81683c4b7
c4db7296ccab2047a6859464b591eb664c7303e5
2572 F20110115_AAAOZX sellers_k_Page_154.txt
652b673baa33105ae36c894a78e12b30
73a3f29f88402573b41df677a8219c2314bede0b
65883 F20110115_AAANWV sellers_k_Page_067.jpg
bf906c552ac0b37e49af6f015d31442e
adfc7cdbfb2dd24cedc82a4a017593a8c6ff2e75
51096 F20110115_AAAODE sellers_k_Page_108.jpg
2f260652ca77833481487a0d04fab758
7ca0e97c1c4eb86fb964adff9df784acd7e26d0b
69826 F20110115_AAAOCQ sellers_k_Page_094.jpg
1cae1d8210d660397283ba4a5199ee4c
eddd3ead644213a3aac2aa13b7458ae301574c00
16205 F20110115_AAANXK sellers_k_Page_005.jpg
f427663dfc7e592e3e15878a8bec3580
4777598ef2bafc176fa2ca96309286193a9cc0d1
24871 F20110115_AAAPGH sellers_k_Page_148.QC.jpg
5318fcd366b42c56738283290ad8ea19
bb1f8b5103029c2a436f0c74c38d85ca40a98955
20680 F20110115_AAAPFT sellers_k_Page_115.QC.jpg
33ecabef61f50a1f8f1344d7cdfb728a
c11ddf509bb4b4184524d44ee341fe49a8264679
1322 F20110115_AAAOZY sellers_k_Page_156.txt
2714543a7d2ad3c1de1002d79d871948
1685ddad49fe93c2208d26c27c7df506777831fc
23881 F20110115_AAANWW sellers_k_Page_128.QC.jpg
8bf2219e784ff39b618b386316ad584a
c77c1ef09950772beedfcefa1d8e994dfd048097
40047 F20110115_AAAODF sellers_k_Page_109.jpg
9c0bed16e937834b2157393b45f1a385
842650c9b2a9394847fb6044d4436923d0a44534
70135 F20110115_AAAOCR sellers_k_Page_095.jpg
f813840233e8517e71aefc7d48e837f3
b9406ecbd63384bd0cc8cd5081621b3ce00b643b
10167 F20110115_AAANXL sellers_k_Page_041.pro
3ef5f8fd39ca84eeb4e07f2cd229c9e4
980b3562002be3725767a861eea602354f3b3db6
5507 F20110115_AAAPGI sellers_k_Page_073thm.jpg
39e3845662d0bac026c5fbf64b7ac858
4eeb2580a6b02d45f5ac4cb3ac02e53aeeded2dc
5966 F20110115_AAAPFU sellers_k_Page_014thm.jpg
f757d7b4b8121e30aacbe5459003ba5e
76805379143b2ca34b283f92d0985a8b97c75329
1840137 F20110115_AAAOZZ sellers_k.pdf
1fbca8dd260f941acf070f0d856be988
3040a5799cf63d6f0cc7773c04dee07590c98bcd
2721 F20110115_AAANWX sellers_k_Page_147.txt
32f15cd16acb3383d837319f99d2848c
ebbca0a9b3d7522010f4b317a6c573113d4ba978
65477 F20110115_AAAODG sellers_k_Page_110.jpg
4db1e408dcdcc6264a2bd57d75197b71
e49352e19795f090110028e4a499ab4ed017d510
89447 F20110115_AAANYA sellers_k_Page_066.jp2
3b63ed6faa9544f128d08664af42499a
387c6c72c40a474abc282d0dc881c41b5023958c
71562 F20110115_AAAOCS sellers_k_Page_096.jpg
c30a253ee674f84f46c026e0b06c5142
f112b5b23a3904d0a36719f75fc996cf325103cb
179 F20110115_AAANXM sellers_k_Page_135.txt
63e0e7086bef01fa5c7b0fc0b4dece1b
28c46dd9f639fd15edd4dfc3ec7408112312ed19
6532 F20110115_AAAPGJ sellers_k_Page_018thm.jpg
6249a62672a8d3d3c5f0e6c4a6399846
410c632259b105275a13c2b510647d254095ab2a
22394 F20110115_AAAPFV sellers_k_Page_102.QC.jpg
f6f7ac5d28eb62919c75429285825fc8
188f8facc7932d253ccb3a1a4461495b66987a31
6974 F20110115_AAANWY sellers_k_Page_147thm.jpg
d70694c9672565810c1286c64bc544c3
d96f1279ca14dd95f5547b734933fea1d4c68ea4
71905 F20110115_AAAODH sellers_k_Page_111.jpg
3eb98a33e26545b9a5d0a33ae2cc7ba0
31a8d9357cca332edb7a2411abed61da5f997884
23842 F20110115_AAANYB sellers_k_Page_141.QC.jpg
489c2b818dd0a8512d39a4cd9b40c388
ab2443e89ee934b5a99cf2d8a51b4aad56c9d937
67734 F20110115_AAAOCT sellers_k_Page_097.jpg
2683d30f5e879f1513e69592bd89eafa
a041da166eb54d280cf03d0fcb57b191b15916ce
115446 F20110115_AAANXN sellers_k_Page_145.jp2
f66ea72ef8ade5346c9bc9e05294a520
d93507669ced3d295d4412daf562b69eea10a1a6
8537 F20110115_AAAPGK sellers_k_Page_131.QC.jpg
17b5da6c6d18de2cd6ee349db5adabbe
eddeb3cbe41cce9e64afeef915fa912b9b822114
6674 F20110115_AAAPFW sellers_k_Page_112thm.jpg
b0d2ba628f88a4af2b9bd6fddc9a18a4
0a936c265307356d9c381b77f9555601574b6633
F20110115_AAANWZ sellers_k_Page_005.pro
9761167567e2a2460e28e23a81e0ca25
ad74d529b27911d46ab298bbff28ee7f20f278a3
74000 F20110115_AAAODI sellers_k_Page_112.jpg
87ff5af7e7a008aa301daba16fefc6a2
03cc539d38d82f5b52a13a6b75e6984cda580a13
5634 F20110115_AAANYC sellers_k_Page_055thm.jpg
a59e38d79e306117f9f95c0b8cf3bb0e
99f7677f42bbf4f2efe9d76973f18cba6fcd8eba
73342 F20110115_AAAOCU sellers_k_Page_098.jpg
a551fdc834cb4da0074db9d7e399b8df
4fd96e5ccc591e80a4856acf40c3fc0765ce562d
712014 F20110115_AAANXO sellers_k_Page_132.jp2
6965b23e4c09876b0cd042e41b06a3de
b04dc1338f65dbf4cd9731b7bc270b176a39428c
6731 F20110115_AAAPHA sellers_k_Page_015thm.jpg
ce3ad275dddfafbfb802b50ea4906831
3bb03b330c9fdbba3948791b26cb682eb212f8b5
10261 F20110115_AAAPGL sellers_k_Page_059.QC.jpg
8f131d07e83ef0dfffcd623192e7d154
3109de61ac2cd9178cea673ef05ade914888ad47
6496 F20110115_AAAPFX sellers_k_Page_139thm.jpg
d6dab0c9163cf5fcf4622afe97a9ac80
86ddf30ca08855f6568f672637092bedf82b0704
71997 F20110115_AAAODJ sellers_k_Page_113.jpg
d3f30e8d3f8491616e58a9ad241d6012
daaa74e7868c318a4ff2bee1d1bacf17a7b7b43a
F20110115_AAANYD sellers_k_Page_146.tif
a432c11b3e05e784fcf3f61368f71df3
346b7da658600f824e0306cd6074b9d1907212be
73671 F20110115_AAAOCV sellers_k_Page_099.jpg
2b8a3a2031a291fd90349857dbfc48ab
e36d01a3034a79973078a9359ceebd55c8a21c2d
22874 F20110115_AAANXP sellers_k_Page_124.QC.jpg
519d5974569767c39fa08c4c86ad59ca
630eddb44c21423f8e6e6f59544b65478ec25fef
22968 F20110115_AAAPHB sellers_k_Page_017.QC.jpg
58992a1ea718cfd102d64a10db614caa
55094c6d488391fc1dd1227afdce637bafa9168f
17303 F20110115_AAAPGM sellers_k_Page_134.QC.jpg
24f28c5d349dfc776d1f1f83a08bef5c
2c25e7633eb9fdcff6eac967cc7a493add528434
22472 F20110115_AAAPFY sellers_k_Page_022.QC.jpg
86c36f570b67a776486927f15bd4e381
454295f903bb8dc4153c683779ab4ca9c8fd063f
58253 F20110115_AAAODK sellers_k_Page_114.jpg
394d5cc048f4d9140a41cb4e1f0c7257
938d99a01aa1cc75e8524c151fb9bf390d0311ef
1971 F20110115_AAANYE sellers_k_Page_098.txt
56e3dcf0a185a9cee5f445bc90c03f5f
114196aca779d22ac7acb9aab22c83d2fb4ac132
69575 F20110115_AAAOCW sellers_k_Page_100.jpg
94a506485127765c656f462b8bdf8559
294238858c0c444e8e48dab92b4b5c688be287ca
1816 F20110115_AAANXQ sellers_k_Page_022.txt
fe53608dfef55abb6135ec88a945b4c4
20eff2a9caf088b74137ec605aa242970bcb9aab
6095 F20110115_AAAPGN sellers_k_Page_122thm.jpg
eb8d524e1a4aaaf1e2fa71b593d86459
610edba6f1bf6863396577c54adbddfedae356b0
6319 F20110115_AAAPFZ sellers_k_Page_080thm.jpg
84b5106cc690a53f73d2760bbcbfd69f
1b9c801008f870024304b3f3231d76b8b221d57c
60364 F20110115_AAAODL sellers_k_Page_115.jpg
8d66d7c031c8fced1fa23172da5ef958
4acb3a7ec7a997fde7be8d1f785690eee9ba6894
1554 F20110115_AAANYF sellers_k_Page_143.txt
e6d99715f892dc8130066c655c2d15fb
50b0f85eaf3721d1e158b228a0942a9108bae278
69360 F20110115_AAAOCX sellers_k_Page_101.jpg
647ef51655438687490d50949760f124
65acfec8597841336bf325e529c7c1abc7cefb6f
21540 F20110115_AAANXR sellers_k_Page_068.QC.jpg
c2d8f901ce9a4086fbf19fff635a547a
2cfa9304c1546e2f436a205314c9709584ec688d
23543 F20110115_AAAPHC sellers_k_Page_019.QC.jpg
5ed78c4927682bbc3e169d52f94014e9
6053ae2f110f491559a0ab16c02101f15938070c
F20110115_AAAPGO sellers_k_Page_003.QC.jpg
ffcca8c62eec0105082655c83079f269
90e43e94845f666bac9e28daf2332ef0b7638f07
50845 F20110115_AAAODM sellers_k_Page_116.jpg
b69295e47353dccf68624ba702effddc
f2f98318b8dfcfc1ed0e6fa1673b812bd86794dc
1436 F20110115_AAANYG sellers_k_Page_002.pro
0abd7ca8e76069f4df25796e47039823
25863a1840b3bdd7b05131b9a4ba2bb8a05c5790
69682 F20110115_AAAOCY sellers_k_Page_102.jpg
f61d6c7861c3d07d02c64f33f117ade6
4665feadb763d004bc2675678a5589ab13eab41e
71719 F20110115_AAANXS sellers_k_Page_023.jpg
359a852773b2a4d0ca685d0a51cfd6c7
985f7226b7fa159b989ede830280770eeae0ba53
25063 F20110115_AAAOEA sellers_k_Page_133.jpg
ec4b6977e837a86aed9626e304c38002
c973b6f41c5359dcb583771e7fc329a1ef64a1ff
6647 F20110115_AAAPHD sellers_k_Page_019thm.jpg
1bd87a4f7f2198951489492457d94115
56a3147d6624e67a5556e06f7eeeeffb9fbf761a
5327 F20110115_AAAPGP sellers_k_Page_004thm.jpg
8e3d5d551e6d9e7bec9a3f3de98d0546
1e0998d253c197689120b15d3a2a7a72cf48cd3a
68646 F20110115_AAAODN sellers_k_Page_117.jpg
9e9c7aa2e7688f44059ec28c27514a0b
dc41063aeb0b6dac63d17bdac4691ccd690f461a
103044 F20110115_AAANYH sellers_k_Page_095.jp2
447e672e1fdfe07113ed6008937613d1
aa7ab568a6366d07acb134a106e76a7fcea8ac54
52074 F20110115_AAAOCZ sellers_k_Page_103.jpg
76c14917703eec5ad74595342911d931
fc46d334da3a04d98c3fe689e44f9239a63d960c
12736 F20110115_AAANXT sellers_k_Page_003.jpg
9114ab8e781d46f6e997e6812408c998
fb2f022da159596b54a56d9d570ec9221f9c606f
54357 F20110115_AAAOEB sellers_k_Page_134.jpg
bbbe01d73809bf34accff3f7f88999b9
f7cb9514eb17e1398ba50646bc22c1bd9fab0c0e
6445 F20110115_AAAPHE sellers_k_Page_020thm.jpg
76721c6af76339a4322a7ed9115e1927
a2c42a0946833016974ee784faee1358ccd16c07
6470 F20110115_AAAPGQ sellers_k_Page_016thm.jpg
65b59c333677de8734340e35ecd29993
cbfaf7bead029e64242cd1a49fb051154436dcc3
64675 F20110115_AAAODO sellers_k_Page_118.jpg
335a10f09047c86b720db09c0534e871
b1fa1a61cd10c5e8cf5431da0b2fdec71385e2fc
21588 F20110115_AAANYI sellers_k_Page_049.QC.jpg
d03886f22339110eb0289d3839d347d9
81f1deea5db22de29bb1648e3e35f2c8c98dbae1
48202 F20110115_AAAOEC sellers_k_Page_135.jpg
c64f99d1ef99182b709ca0e1173d53a3
ca75492690a3d3d180c0aca14d97ce79f24dd6c9
F20110115_AAAPHF sellers_k_Page_022thm.jpg
44c738ec3f276a423bce88a241fb9263
d498845896e6ef8f9ab67f6a72c00a472e68b7fe
234015 F20110115_AAAPGR UFE0008356_00001.xml FULL
47000174cecb0a749fad53800037e6a6
0b4c605017ec4f06d2fa0e180eb4272c0353942f
71087 F20110115_AAAODP sellers_k_Page_119.jpg
2801c7427accb6471af7d70ad1fbb70e
4ae5aeaa660982fa9b31d8cca18e8e895ce50969
246498 F20110115_AAANYJ sellers_k_Page_133.jp2
cad10ca4c9831b4a0ce3ad3f7cb641b2
52c975e7ec2e06a04bd430156461adb71a2ff239
F20110115_AAANXU sellers_k_Page_134.tif
a06c9a55a8ddcc6ffe0a6b85f954a911
e1874d7bc684135f4addefd1f9e350dc6bf6ae7f
41626 F20110115_AAAOED sellers_k_Page_136.jpg
fad83e19183079c4316cf5797c4fc243
767a7b4bfb6ca1ec837d309d83e822dd5741f3b2
22985 F20110115_AAAPHG sellers_k_Page_024.QC.jpg
cc64479bbafd16b7d2eab9c2cc79c81d
fc2f9b1869400678a4576dacfcdc2d30ec7866e5
3430 F20110115_AAAPGS sellers_k_Page_002.QC.jpg
1350ecbabeeb868e9f0ff04deedfc372
d71937a50789090dc64c4763158423a9e44b6097
69353 F20110115_AAAODQ sellers_k_Page_120.jpg
b915972d45841b0eeda159bb09a1fb89
eaef699c115ab75c7cdfaa70c83aafaf51f23539
11811 F20110115_AAANYK sellers_k_Page_072.pro
9ff2c9f7984c305420fec16c08936987
23738a1a2829801d726675b9598d20f599ce9f4e
47734 F20110115_AAANXV sellers_k_Page_025.pro
e90a7366feb6a1a52d7e6006dd029e0a
12b61eb21ce6bd7a914c0547047d9dff9d17557e
68235 F20110115_AAAOEE sellers_k_Page_137.jpg
a39294c1eeeee712ba351a8f97ff7a52
fdd0d8ea716566e5d3e0a78eb5397a2cc48faaa9
22827 F20110115_AAAPHH sellers_k_Page_025.QC.jpg
3fbc46589b394dc0b580d50e11d4279a
dc86907701dc2da9e18edbeae1d5589dfe743acf
1503 F20110115_AAAPGT sellers_k_Page_003thm.jpg
c40bd434941c248b407fc406ac5eed30
02dd1d5af9046ec8017f5ec3d2f68433a26c2d6a
64364 F20110115_AAAODR sellers_k_Page_121.jpg
d9292863f591ca788debd7e075d98c40
51203baebca18b6d1a8ecc89d300dbddae33df69
59363 F20110115_AAANYL sellers_k_Page_011.jpg
6c480934b9215ef9925a688f4bc9b1c9
2bad39f7abd6cd6c28e5797d243e34c28196a2ba
2009 F20110115_AAANXW sellers_k_Page_126.txt
afc07345f9c843303ecd1b2f1fcdb75b
e306c5c16597bcfe58d9134f346b08938b4f8b96
73383 F20110115_AAAOEF sellers_k_Page_138.jpg
ca98af2d0db4c41ab1125589049dae79
1dba6b31ea6805f8760eca33ebe09254348aa7cf
22532 F20110115_AAAPHI sellers_k_Page_026.QC.jpg
fbf4896253682e7f3361b5ffdd8c7c94
022226c4eb21710e047f909f113b035cf4633cac
18696 F20110115_AAAPGU sellers_k_Page_004.QC.jpg
feac5cd1b1bdb8902211a7e544cc3d05
5774eb06c26c2ebaf865e1673cb23dd16500b966
77058 F20110115_AAANZA sellers_k_Page_103.jp2
8abdcd1ab55201a47a536612c62f98ec
c7c21f2e7601de97acf7d0b5d35ff1d3c14ee139
65981 F20110115_AAAODS sellers_k_Page_122.jpg
97c21f8f620d0129c6c05a5de2542e66
7c621e10189c6d5062011f031ac6511bf3258be2
85148 F20110115_AAANYM sellers_k_Page_146.jpg
6f0062720f3896f1d82d499d4da22a79
55aeaa326b0dd03408320ee17c6a9784e7410919
34953 F20110115_AAANXX sellers_k_Page_103.pro
6d1960382a1a7c7fec87c25e2c38d771
81e9ac909fb135efb024c5891fb8b0329e2018fc
71762 F20110115_AAAOEG sellers_k_Page_139.jpg
fb5397bf3a55e2588a66f9f180d67131
a8170eb4abc7e7dd3fe6df9591a049177602cb67
6280 F20110115_AAAPHJ sellers_k_Page_027thm.jpg
9cfc33a929f74ba0e4dc3f1ead94c562
459cd7742b1d7d6cb10a94abcbc896582415faed
24457 F20110115_AAAPGV sellers_k_Page_007.QC.jpg
2e8c6a0b7fe84b8dd1c2f00e291b7dea
343530bde8953df649858debe704537e2e149255
4882 F20110115_AAANZB sellers_k_Page_011thm.jpg
fd35ce364b9e90af902c4b2d456fb746
c18c18b5244d705bc4311f10c7e73e71a4f606b1
65985 F20110115_AAAODT sellers_k_Page_123.jpg
99cc760852a0ef8ebc3cb5b95454be85
b888577ff12f141c881e98ae9fb993a93f59501c
6847 F20110115_AAANYN sellers_k_Page_152thm.jpg
3257232ecb43456d67a3c46eff671af5
f980bcb04012e745c7fedf71569a11100f959ce5
1401 F20110115_AAANXY sellers_k_Page_103.txt
c2c66e1b4cdfb9be575e18339abb3600
b39920ec708a43789bbc831debd4a48491f7f2b7
65702 F20110115_AAAOEH sellers_k_Page_140.jpg
02ba01d078ebb95c45529987da6b3c1d
060ddab08b5c8018ab382d99920d73b766bad5c1
21734 F20110115_AAAPHK sellers_k_Page_028.QC.jpg
29834ca205b6fb2c950c5b588ac168c0
01b0c1bf62a112197d1d852b17bda90ec74d75c6
6010 F20110115_AAAPGW sellers_k_Page_008thm.jpg
3deb6decba590ff2274c1857512f65f1
ef6764552c3b2004bdaf0e2439b9e5159bdf68c4
F20110115_AAANZC sellers_k_Page_013.jp2
397b58d3760a9429c1cd33636e37847c
42369820814314fbc48549dfc18c930a93130dc3
70333 F20110115_AAAODU sellers_k_Page_124.jpg
25310e485e578d0a4a50fd58276abe68
bfdb9f1b32b66d4858018144958e7098cfc2a76e
47470 F20110115_AAANYO sellers_k_Page_124.pro
0634a6ca6694f59d78d50bf3dac19df2
9d969fdc2a58b8fe803202ad7cbaa0083f2c3d19
1643 F20110115_AAANXZ sellers_k_Page_066.txt
4aeba5bfaec833068bc98d57242a7a48
737fd942ef24f881c442f8cc0da846834ecafd03
71983 F20110115_AAAOEI sellers_k_Page_141.jpg
7622e071f15ec696db0c1fac3d5742b9
a46e9a6b1f2514d42df4b3a773898fa2616655e2
23667 F20110115_AAAPIA sellers_k_Page_050.QC.jpg
dc36bc7274e3e5ab03f13b13171f3a4c
e62f9b1038cb434c25574de95eb57d24dd069224
6142 F20110115_AAAPHL sellers_k_Page_028thm.jpg
c3282db833a3b905414f1fe9378d275c
c0af9952065897eb0d53986e2d2137099f4e01f7
17982 F20110115_AAAPGX sellers_k_Page_009.QC.jpg
e37e1ae0a80f2adb8ca9bec34b3ad592
3c6d5e8f5f7b725f6a5f4c08712a575eaae8d430
45541 F20110115_AAANZD sellers_k_Page_137.pro
e74b88cd39e0f04d17b88c1fad9569c8
146993a0401285e6d7d3d314e601aafa7aa09c1d
74133 F20110115_AAAODV sellers_k_Page_127.jpg
4e4c82f1149f99e11327909531761ca1
69cb8e7b9b2eb65ae681c689bce92412121521e1
F20110115_AAANYP sellers_k_Page_109.tif
b1cd0715bb65d7e8f84c9cd0f0e4608b
f14cf7512d050cf321449242eaf4d28ec5df249b
73377 F20110115_AAAOEJ sellers_k_Page_142.jpg
0b8c901c60649faac119c65f189c5e39
da42d918bb7c51a1faf83e67ef74787c5ed06cd2
22524 F20110115_AAAPIB sellers_k_Page_052.QC.jpg
dbffbc5c4047cc61042ca7b5656431d0
8310a1269a8a498ca63aa8f9c32ad0a1b0f87b81
6519 F20110115_AAAPHM sellers_k_Page_030thm.jpg
d60d16c1ccc4637547e532f84e7e9a63
70c2a60eacf3ec7c8a432417bde197e1b44767a8
16874 F20110115_AAAPGY sellers_k_Page_012.QC.jpg
60389a453b4794c7186c308e3992906e
9e8452d0edfd76db997e317f60ba010b8bcb20ef
1628 F20110115_AAANZE sellers_k_Page_093.txt
a1dcc037344e09606c86f0db80416ff1
35ea48b5f6eb38a8b273c7b957566c2b09e2507b
73111 F20110115_AAAODW sellers_k_Page_128.jpg
8f67aee5b1e5705f444b182d9e4138c0
c613dd0da98e405faecc7ae5d0ced87389dbed79
23750 F20110115_AAANYQ sellers_k_Page_079.QC.jpg
e4cfbee6b4f3d09b7dd86a460304161e
53040c7e3affd65af269dd4bd6d290570b2037cc
57589 F20110115_AAAOEK sellers_k_Page_143.jpg
a83bad055bf8d5c36936946bbe363f5d
fb69c06feaf66a16741b4ba08aa3d8a17b17deac
19958 F20110115_AAAPIC sellers_k_Page_055.QC.jpg
114de8da3d942689407b12b5cc06bb47
06b8b95bd4d8e42aca5bc87b8c08256bbf1721f1
22437 F20110115_AAAPHN sellers_k_Page_031.QC.jpg
b714e6addca736b055c893829c8619e8
378d4d09b7bc07df6f6a8a4fe06bdb9fba8f2a3c
15180 F20110115_AAAPGZ sellers_k_Page_013.QC.jpg
f0df13cac4872580cf66d0bb3c759b4a
447c84ceb643b62631a1de823edd9806c8700cf2
5373 F20110115_AAANZF sellers_k_Page_010thm.jpg
18ec1145c8dbee8a8be12f0703f5d377
6c1437b3d55a1ac94f0649b96af29d00c66c6a5a
14142 F20110115_AAAODX sellers_k_Page_129.jpg
bf55e4109aacea79a4f0fb707e1d477a
5d040188ae5e0571474d6f2bdb210ca45d53f1f5
6460 F20110115_AAANYR sellers_k_Page_096thm.jpg
7450ff8a6e3c5be5a06f83aa5e15de1a
6e96105145ee73567e9d7b648e242e508530d8c8
16572 F20110115_AAAOFA sellers_k_Page_005.jp2
7259adc0839c80d817b56293d41eeb04
2f763dbd9f4ac4db7b32f307fc2cf8b41ae48358
17758 F20110115_AAAOEL sellers_k_Page_144.jpg
c2803c12f6666f5b791884a1ea11576f
b1e991c54643e33140def1c57cfd95b3381e4c4c
6687 F20110115_AAAPHO sellers_k_Page_035thm.jpg
799bdc7f3a8603d32b78dac5812ba236
21fcba73020e9bbdd8d32334f37e8949eeac5cae
55326 F20110115_AAANZG sellers_k_Page_085.jpg
0f12d8accaef536bad6780aae4d7b114
ddf0357ffeb9e790514f93bcd7ee306a84835ecc
31919 F20110115_AAAODY sellers_k_Page_130.jpg
86045dd6d90ba9f954d74cb7cf32e4f9
34a4bafa66374a6b481de44d252b8d175cfdf99c
46231 F20110115_AAANYS sellers_k_Page_045.pro
95c510d3be95d00125c3977e9fb4cdf0
f76ffbc270a4ee3270d120065f0ec17ea4cef191
78103 F20110115_AAAOEM sellers_k_Page_145.jpg
dd0762cff955508999dcc7377ee8ea13
639f7be607b302ed1879d8ab46aeec90b0d9b21a
20480 F20110115_AAAPID sellers_k_Page_064.QC.jpg
62a1da7bb1fc0b13852ccf1a508c5556
47e50be620c1551a5e8576bccdadf90d7a1b39fa
6477 F20110115_AAAPHP sellers_k_Page_036thm.jpg
75d8da52d073c731d3de350795d7c775
6d9a2add8beb63b2f0630214b729d74cb7e1b711
17185 F20110115_AAANZH sellers_k_Page_011.QC.jpg
8bb4c6239a53d105ea79f58d32ce26bb
cb9244aaf0e1d3d8a55c67804784d7716c8d8d73
48558 F20110115_AAAODZ sellers_k_Page_132.jpg
f4faf557b87f3e42ba59644d3144b5b6
79125469410488bb8760ca767a056a2864a9178a
64786 F20110115_AAANYT sellers_k_Page_014.jpg
d78e3043720315f6f91caa7f869ea6b2
1dfc6c7cfaa0418cd3722c95ce44de726a99e804
1051962 F20110115_AAAOFB sellers_k_Page_006.jp2
96a034ac72ecd5248dcbbd8964a527b5
7038ca47e83b01efb6b15811ca0e50f0f2a433f3
88488 F20110115_AAAOEN sellers_k_Page_148.jpg
e6e19ffed49633d2728e1eca54241ddf
6247f6848c328c4e3a965a3b057c13c9d6acc12d
21907 F20110115_AAAPIE sellers_k_Page_065.QC.jpg
efb20ccd10a618d32e838165ba0657b0
bd080f9221a05fc2ec56c0ef471571ff75341447
8397 F20110115_AAAPHQ sellers_k_Page_039.QC.jpg
2b779b94d1e53cba9058d0f9e374b8b9
7ec3c456b80c9d5fe28d6c282ff8d4fb7111fa0e
50815 F20110115_AAANZI sellers_k_Page_126.pro
75f86e930aa22d093a51a3ba6bef044e
1352e2d6d3feed6332809b4370da33741ac1b2ed
68066 F20110115_AAANYU sellers_k_Page_010.jpg
3ac97ec1a4f357464d5b27ebe646d600
84550aeabe619b215a3adce264be8745f2966413
1051975 F20110115_AAAOFC sellers_k_Page_007.jp2
958f5b22a80dd4fe1b051d1358162d56
1f5f83419a420930de51d732938faa06f05fc1ba
89787 F20110115_AAAOEO sellers_k_Page_149.jpg
67accdbd225901d67fa9143902552d24
fbcf4b612c2b967d582d30605f3109deac8f2c9b
5679 F20110115_AAAPIF sellers_k_Page_066thm.jpg
0511cfbc34bb99071e83ed73f781c6d9
38f60537ef35f7804099b727ff5d79c4f0d9113b
F20110115_AAAPHR sellers_k_Page_042thm.jpg
50589e99dc159f0885fe4eec826bf495
3192d49832f597cd7f6a0ce6c1ee6a7d8156f685
51209 F20110115_AAANZJ sellers_k_Page_142.pro
8c1e7fba4fe0be6c1ac861dd6d20ba82
02d142c326b9476e31ef3a0893175fcb65f6f0ce
1051986 F20110115_AAAOFD sellers_k_Page_008.jp2
7eeee503d31636a1473d57a5e44a9a21
e48f3136186ef49360b917792298bc22d842535b
94479 F20110115_AAAOEP sellers_k_Page_150.jpg
6bbba2c379deab73779257538a27a49a
b475e189bf2af634c2640324116ae6f2f190274c
6472 F20110115_AAAPIG sellers_k_Page_070thm.jpg
3b1d226260658de40bb468de48c1e7b6
b01ef1ac73c55a65971d42bbeb3d3a50606507f8
3410 F20110115_AAAPHS sellers_k_Page_043thm.jpg
50c45d4d2e906ba40201bec44e795414
bb332b8010693e3ce2eb85646e5f09a11803a4db
F20110115_AAANZK sellers_k_Page_064.tif
6ec37091d57f801aa99920e322b53415
f60619f05b3e071b66bcfc923b9d93fdeb81442f
70555 F20110115_AAANYV sellers_k_Page_092.jpg
cc8eb2cb4f5a4aae2483f9ef4ddaabbd
7208fd1190d7267a964003bc29b310731e0225ac
1051983 F20110115_AAAOFE sellers_k_Page_009.jp2
e59e26677e24ae6d2c301fcc8a66c9d0
1d833dafe826f62b8d94a6e842beb83219760cd0
85964 F20110115_AAAOEQ sellers_k_Page_151.jpg
029b81839b974bc47c07a59cc5db5558
b099820fdcb82b497df47043ec7d34e983cda617
7593 F20110115_AAAPIH sellers_k_Page_072.QC.jpg
2bb3fbde5107ba0fb9f75adf96a2e8e2
40dc64df548fec6b3b8fbaa5c53298ce1837fa84
20714 F20110115_AAAPHT sellers_k_Page_044.QC.jpg
35b6f79ee77db7a4a2bf31cf86e7f103
635f826cf80113b36dcb632648002da1aee9ee74
F20110115_AAANZL sellers_k_Page_119.tif
e5d18a463363218095a1f3639d79cbc3
e2be7ef2509954aa4deb511742e06a91191d51e7
1929 F20110115_AAANYW sellers_k_Page_020.txt
f970755d37d0877e1b5ac3bb1fb93bd8
b449b0361633c60c0a0bf67270138a76c6145417
F20110115_AAAOFF sellers_k_Page_010.jp2
d70f8044abfe03efc8e2f0be9642ca11
a98a67112a359374c868f4e28fc48fbab0f162a8
94717 F20110115_AAAOER sellers_k_Page_152.jpg
e06b61fa41d9321ee9b3139e50e46029
3b7b275f487a5f9ed5b8cb67a05517c9d4f69465
17509 F20110115_AAAPII sellers_k_Page_073.QC.jpg
137a6036ca3c847c1fe0bf9cd5ee3754
17b2100a1d656d5b57ad1a3db088a03680ecdd1d
5799 F20110115_AAAPHU sellers_k_Page_044thm.jpg
44c54e3055f1f6456ed7591984be2464
492f7e0bb11b4453c0629b677e96cd57d4d9f3da
180451 F20110115_AAANZM UFE0008356_00001.mets
13e4d71b74ff48850f460f7064f86bcd
95fdc0251f87b2138589f0fa61a167cdf1e9873d
69685 F20110115_AAANYX sellers_k_Page_026.jpg
59ae5c502ce6987eae304a5b942fc06e
562a726fe5a87c28d99904b3595458a0fbe44c7b
1051980 F20110115_AAAOFG sellers_k_Page_011.jp2
074c1156df00c7fe4a2b43030c23dc04
ea43d68d01db22b640cff964398e2505efeaef4e
81994 F20110115_AAAOES sellers_k_Page_153.jpg
f2b45d36e216a277d760e37c185d2ef7
22d44607a210c7dab0562e64881af8fe8b9a5075
9885 F20110115_AAAPIJ sellers_k_Page_074.QC.jpg
a90896fb456e9808c5aa87fd895af5f2
1a80951bf77c7946e9de3a4e319b4d385b21cf37
22108 F20110115_AAAPHV sellers_k_Page_046.QC.jpg
7b8c22de05f598f617111a3769f1b23e
eb5ea2f18f46fd81d6b83a2b5e7377789d2d706d
7954 F20110115_AAANYY sellers_k_Page_041.QC.jpg
59a58c26d1ae6f78cde80451254a2eb7
f7a7c385e6af92fd2eb7789cabbe65d08dc2b392
78751 F20110115_AAAOFH sellers_k_Page_012.jp2
b32bf477f6f1e5580554e2d4cae58ac6
4181a422090fa0158f0b6c266596412eb18924bd
93383 F20110115_AAAOET sellers_k_Page_154.jpg
0a63bd4ec94313ec83fc0e92506c64eb
0b0e1979d2315c81391da79ce99eaaa8c1afe7a4
3432 F20110115_AAAPIK sellers_k_Page_074thm.jpg
352ecd352d63f6cc709c790d643d6266
cc3934f2c2c2df6173f11b00064be87075daac6c
6330 F20110115_AAAPHW sellers_k_Page_046thm.jpg
f52d6bb50c9795973e6965c606ae68a0
437827a52aa3083b8ee0a9cf8d93782318aaac2a
22733 F20110115_AAANYZ sellers_k_Page_051.QC.jpg
f1aee3d1fd112e4708039c7e62dfe930
70640eda14842e093065a61b9b7c3388c71e8f45
96420 F20110115_AAAOFI sellers_k_Page_014.jp2
1694025d23740623e5dfd73288d0ab69
be48193f956877944f48e61440cdc6058fed05ab
33413 F20110115_AAAOEU sellers_k_Page_155.jpg
f01f2c882231c8ef9a4481bb97ac400b
48f6b6809931a35afa3d24013feff23f317db5cb
6524 F20110115_AAAPJA sellers_k_Page_098thm.jpg
75e993d0def3370475106fbd86f8da49
5c4033ab62f97abe6969315b254620018e104ab4
19692 F20110115_AAAPIL sellers_k_Page_075.QC.jpg
634223e1b73a35f8434bb45538fe59b8
4414e9645ea13daa1074e5f124bbbe45f2af375d
F20110115_AAAPHX sellers_k_Page_047thm.jpg
cb4ccd7fafe4b79e09685a874b7baa7a
014d47aa1832e941572f8c8ebf9f3439ffc2ebea
10685 F20110115_AAANZP sellers_k_Page_002.jpg
b80551478a1e0d42dc91cbe22a9cd03d
62198a89f7b2da09e68cf14961ee80875c280685
109784 F20110115_AAAOFJ sellers_k_Page_015.jp2
dddad2be4baf70ef82d5c66b5326e22a
b794cf0de17bd12b77fe2701955e5a3c8582136a
51530 F20110115_AAAOEV sellers_k_Page_156.jpg
eefac6523c4e2d353c15c13123a079ac
a47f435fa0d745350efd26896a28ad40c3057ffe
24517 F20110115_AAAPJB sellers_k_Page_099.QC.jpg
4a5ec38f6f2f47ad49f5fde0ee0378d4
d7858f3f29ed15812ffbf8356bf595319084b276
21245 F20110115_AAAPIM sellers_k_Page_076.QC.jpg
6415e73f31396f090631724ba4797544
e216ceaa6adc564472ea8b399c1864c26eddd18d
22977 F20110115_AAAPHY sellers_k_Page_048.QC.jpg
c33646db4e6a2d491c1c2770c8badc91
604c231c73d2ce57046fc76a8269ee5ee1dd30cc
56263 F20110115_AAANZQ sellers_k_Page_004.jpg
464117db9c8a6b6c37f4d98b0dad741b
354829f332cc3891f306eedc674e5220a56eb827
103583 F20110115_AAAOFK sellers_k_Page_016.jp2
9410c9a21f9f556c07dd70a66e81fd3f
a59835a217f9a8e7b811d14112402910079c4b49
24343 F20110115_AAAOEW sellers_k_Page_001.jp2
407015c4d9ac7f50a757bba92417db6c
d4b9b944b5f6e08649275640783cf6720dc66b24
6566 F20110115_AAAPJC sellers_k_Page_099thm.jpg
f2c498766ad81d2e66dc73a9d3dcdc09
cab8ca49073552ac53ba82122107a7da7e4abfa0
6548 F20110115_AAAPIN sellers_k_Page_077thm.jpg
2721f0875bef006caa666b36be1d9373
701ec2292b4fd39aa0beed3ed4d8acd3e1d8f7ff
6275 F20110115_AAAPHZ sellers_k_Page_048thm.jpg
1ea40da07c8d30ccb421f7470375eebf
bfb32ff37b9c344279669597cc09293358c378c5
65352 F20110115_AAANZR sellers_k_Page_006.jpg
0954494e940865c9dc7ce47a01fff761
b994b32b82802544f451ae6e2b6f223553e2f09b
106696 F20110115_AAAOGA sellers_k_Page_034.jp2
6ffb609e025b841bae128e3467c99d8a
56154d776dc4acfd911f959a92fc2ff0837a4f23
104363 F20110115_AAAOFL sellers_k_Page_017.jp2
70a900b43e821296b95290e83e0968de
28e54e623d524871ec0f1b437893193b08821ce0
6271 F20110115_AAAOEX sellers_k_Page_002.jp2
bd3aab72dc7660d2c012dcc3c05d6a75
2799a9b8f1af52897a97cf4e6f01f55d26092154
22615 F20110115_AAAPJD sellers_k_Page_100.QC.jpg
a1d83b062bbfd1aeb651e9478a5124b0
988eac899cde0b1d8338e5b6e98f3eb26365a66a
21358 F20110115_AAAPIO sellers_k_Page_080.QC.jpg
48be96f8b80405ff00eadbf56feefbff
7c975549078f70e0ddf2d25b94a15f021af74886
97706 F20110115_AAANZS sellers_k_Page_008.jpg
c90ffe9bc242a645199fe4779bee1bec
380eecfb0bcb0468c790a74ed794d3d8d9f60c5a
113426 F20110115_AAAOGB sellers_k_Page_035.jp2
b6a317cab6679bb4098e3ed12a1eeeda
343b176d2ce67c3ba237deee6750bc30833a0b4d
105127 F20110115_AAAOFM sellers_k_Page_018.jp2
3351758c4677cdf87d700bc8b32aa6f5
3fa3b2db8dca1417abbd4223c863128c6469a1f8
9902 F20110115_AAAOEY sellers_k_Page_003.jp2
702b43b1d2ae98571820b9f5daf94c1c
217f1bc38834b75709a00b57372b1cf6f896334e
6308 F20110115_AAAPIP sellers_k_Page_081thm.jpg
476aec8c3af4d1b16704db5cb431a292
82229b4f37b9a88d4f14625f6a05974077becc95
106746 F20110115_AAAOFN sellers_k_Page_019.jp2
3233d48a322f99e89052394ca78f8fe5
2ca4697a1d2b7e774b956167561285318a81b415
83048 F20110115_AAAOEZ sellers_k_Page_004.jp2
efd62c2734d2d0d7e9c8c48a42512d2b
a60eb8fedf8c81b64b4603b82430ce5f4c6fe5ce
54683 F20110115_AAANZT sellers_k_Page_012.jpg
aac2ef0ce0ca32c8074e69ad7f65f0a1
fc29048e736163661c190eb3ec52d3aad1db2999
22589 F20110115_AAAPJE sellers_k_Page_101.QC.jpg
9bbe10800dd48ccb5c3b95143a28e72a
d31e684f81a31ee213eff8d6ad16678874219e84
23925 F20110115_AAAPIQ sellers_k_Page_082.QC.jpg
46c971d83db86c6aacb6669fd4ddf086
57b5d7ef3cc165ab5524e188ff2c5538b699d183
105432 F20110115_AAAOGC sellers_k_Page_036.jp2
178e4e5162942b6f816965364cc14601
c5b716481ef194f9fcce4b065b8cd280139298c8
109048 F20110115_AAAOFO sellers_k_Page_020.jp2
dfc0c84d1470430aad1bcb2e4a033529
0a98fceff895a75cd962c69619cf2306dba1a85a
45981 F20110115_AAANZU sellers_k_Page_013.jpg
060e0299b508f87060276239d6df482e
b4bfdec2a9a81aed8237bc3d9134c52eea134406
17353 F20110115_AAAPJF sellers_k_Page_103.QC.jpg
29c5d314ac887660f5779d69b2f60d8f
452b71b52140dd50c5918366da2f627817ea571a
17994 F20110115_AAAPIR sellers_k_Page_086.QC.jpg
eb4905c83ff0987cbc5a07bccc5366ae
f6ac51448310cb44622f8e150a7f9889961296f5
117209 F20110115_AAAOGD sellers_k_Page_037.jp2
1b6215744f94a2323fa8d97ad866a418
b6a4343bf8b7b49136f4e063f3530071956e9872
110283 F20110115_AAAOFP sellers_k_Page_021.jp2
9f5c9dfed5c50158bd052f5998942b39
964e3d96913d19dc4aceb20ddfa2347b8d824a44
72138 F20110115_AAANZV sellers_k_Page_015.jpg
4c48c8f0d31ceaa716c8564c98acb5e0
33adb59690cfd697c9d6299f895ee6902b7807df
5015 F20110115_AAAPJG sellers_k_Page_103thm.jpg
d3aa243da4818208cc238107356a9cc2
425588117fde37b7ac41343ff75aa2b2c0824a1e
13022 F20110115_AAAPIS sellers_k_Page_087.QC.jpg
ac856cfbefd230faca6daf426839e39f
dd21b807ba0f84ae9bca2cf9f694e2e5771da3fd
208813 F20110115_AAAOGE sellers_k_Page_038.jp2
d91c9c457428a29a16409de24092a4d4
16fa364db1849734db45f391c155a1fdcbe7943b
101369 F20110115_AAAOFQ sellers_k_Page_022.jp2
b9b2f99749279912d63ec06586cf53c3
046af05282f1fa294baccd950e26a0770410a973
12834 F20110115_AAAPJH sellers_k_Page_104.QC.jpg
44fa0b9cd3e4cfed96550718613771bf
1e400f7dabba78b4db42f9cac8fb1ed220c2e274
2680 F20110115_AAAPIT sellers_k_Page_089thm.jpg
3b723d5b44cf41a7b09bb1a7dc6efdaa
4c59b32665578633117f502fafe5dcdcd26c84f4
279177 F20110115_AAAOGF sellers_k_Page_039.jp2
1667c66c0d556f627cc2b124d5fde04d
e3f0779dad53da928d9b7ca137d10dd49b204290
108282 F20110115_AAAOFR sellers_k_Page_023.jp2
1d99348bb5d81008935e35623f7bd4d8
3e43dc189eea29f49f945d7705c3854c94ebad39
70027 F20110115_AAANZW sellers_k_Page_016.jpg
c9d6d6821346b7efe545823b9481730b
8da7e5992fd954e04916e5024d5eaf054b3f1a63
5376 F20110115_AAAPJI sellers_k_Page_106thm.jpg
7e767bcf4082d4c545b9790d20777116
44d9a31f8ef0a750c16c8fd6c9f5eb9e5bc4c541
6352 F20110115_AAAPIU sellers_k_Page_091thm.jpg
1762776ee6e29cef9c8db51c6ceab09a
68b2315133a5b49d1b3e875feb6fd09439e39269
502269 F20110115_AAAOGG sellers_k_Page_040.jp2
268e232243487d7264f3acf750c37cb2
97b0d4c2c2c525e7eac383686b409b7460ae2565
104086 F20110115_AAAOFS sellers_k_Page_025.jp2
190cd8da43c01e9aec8849a48e62bc5c
f3b35cc2897e77b4669252aab0bdc7923c4ff888
69422 F20110115_AAANZX sellers_k_Page_017.jpg
b6316fdb23246afd6fdece20ad73d512
076a5b5e50e53e5ff6a928e1704585aba079fa6f
16058 F20110115_AAAPJJ sellers_k_Page_108.QC.jpg
e9f20e66c7c385d32ffc0e4ab038f9a3
09a6d2e105e10f3354dfdc7bf33ea4fc8fec1e28
22613 F20110115_AAAPIV sellers_k_Page_092.QC.jpg
31a9e75be77ec0d1efa7f23523b5b7a7
5acb166434111d814c6368636ce089d776b177f1
352795 F20110115_AAAOGH sellers_k_Page_041.jp2
4c7fc154bd93478b1db40794cb9d6acd
95ea630bb4cb649a601766f573919e5cd3999180
103608 F20110115_AAAOFT sellers_k_Page_026.jp2
9c6ee4cf8dcf872794dde8efbe82d876
0c1caf01c8da9ae9eb44ee3a7827b5e4e84900e9
69883 F20110115_AAANZY sellers_k_Page_018.jpg
454f06785dde5600662c61ac25993b3b
8bc1b61d774191e0d87fb40db3605977d9106b90
11976 F20110115_AAAPJK sellers_k_Page_109.QC.jpg
b462722f36fd9fd5203adcf1bbdb23b7
1a0e13fed6ee71a5f09e4db56f66e3429b5491f1
F20110115_AAAPIW sellers_k_Page_092thm.jpg
6e11f4be9c8a2f02565fec9d809c4b88
60eb8a5a8a995ea26cf9ef77782bb44a4214371e
427895 F20110115_AAAOGI sellers_k_Page_042.jp2
d894942839a6c209f37ff441b85a106d
9cf3624a83a41d2bb2cbe21544c4f0d814cbf809
99567 F20110115_AAAOFU sellers_k_Page_027.jp2
2458a57a8555ba56a72f71dddc21446a
e5b37edbb53780f9597482959f08802a7b6d4849
70978 F20110115_AAANZZ sellers_k_Page_019.jpg
a8d3306ca1213d704acc595c607d180f
afce8b72c5358c93384bc13e04187ab8356c2b27
4846 F20110115_AAAPKA sellers_k_Page_135thm.jpg
bea370d7db6a83286f8ec7163d371bdd
5d1911677b08eb1339eb7f1715997b6683e47643
3744 F20110115_AAAPJL sellers_k_Page_109thm.jpg
2712ae75ad669d9ebc58d1ff9e41e1b7
993a2939feee1c2c08c973e20369c33e6d00854e
6176 F20110115_AAAPIX sellers_k_Page_093thm.jpg
fe801d815a4b44a7c13f573e95a645a8
8c32c8daaa404d738f40736c11961d3eeff156ba
321269 F20110115_AAAOGJ sellers_k_Page_043.jp2
c2d05fefa62230d4ae622fd9ee01d3e5
5c79889dc5073f07e8f166d8090311be83c8401a
100272 F20110115_AAAOFV sellers_k_Page_028.jp2
676f8b027d3d81cb6956491d5efdbb22
4d3f5624e80cd82d98cf908659e36bd8787ddd42
12898 F20110115_AAAPKB sellers_k_Page_136.QC.jpg
603b0ada6ac4f9903f19944248d78dc4
052434625c085d9114261b3328c9d73bf7fbfa36
23182 F20110115_AAAPJM sellers_k_Page_111.QC.jpg
926b228fe4b1ae85b9c5470921ccaf32
0d3b088e947476f539c086ae67d2ee261bfc74dd
22742 F20110115_AAAPIY sellers_k_Page_095.QC.jpg
dd2f5a46c64d93f56c474e2aac65bc25
1c56bca8ef5cd97140719943dfbb9a5c4d650810
93874 F20110115_AAAOGK sellers_k_Page_044.jp2
b6cdc3024deb5dcdd5ab11027104b5da
627c7a07a0348479c754d315823fa015503428b4
100514 F20110115_AAAOFW sellers_k_Page_029.jp2
4d658e0c68275e8878bebcc572acbd22
bd81135bf569ea4012747edfd802fdb63876b348
21774 F20110115_AAAPKC sellers_k_Page_137.QC.jpg
d5b2920e4e82de132b5142c4a8d619db
90603921d173b2918831e47c3957ee04899e7dcb
6611 F20110115_AAAPJN sellers_k_Page_113thm.jpg
c1708c433803b21a6ce2c1bab9a142ef
3d2f8c06910bb674e9ed2850d341009247205b3b
22536 F20110115_AAAPIZ sellers_k_Page_097.QC.jpg
8be0b44ad514ebad11614e9dab63b8b0
aaed66e16e48631183cd57f74866219f2e00f0a4
101432 F20110115_AAAOGL sellers_k_Page_045.jp2
f2f5abd74b0856729fc30865e7149440
ffc882993cd73f78fcd54af88a797d0416e8baf2
105257 F20110115_AAAOFX sellers_k_Page_030.jp2
a849f0e9c8315204175346586cb7e1e0
e99073153d58c4a39f967117ee3ee9d5fbb7008f
308327 F20110115_AAAOHA sellers_k_Page_060.jp2
99f56e95ad64e9b2556009e2ca808e20
3587d806c2d1c5ff30818271f0d845c017b59866
6140 F20110115_AAAPKD sellers_k_Page_137thm.jpg
52c68273eeed6f2b4d5d1a816c3ac11a
770d187aacb8053dc161dfdf22006af067e61972
17095 F20110115_AAAPJO sellers_k_Page_116.QC.jpg
66a0b96412dfd67de800f485594ba35d
57a71be965968c83054706f195ace08089627e6f
100159 F20110115_AAAOGM sellers_k_Page_046.jp2
8ab92b5a75ed6f65fa87bdf3fcc1d8e3
69b9cb90da6ea069759f93d81b6da36b6d2df2ed
102684 F20110115_AAAOFY sellers_k_Page_031.jp2
fdfbbb5f1738e86fe54aad4ea187bb7d
2ce33b0707729a7aaf52cdc6e594f92cdedd1e1f
330553 F20110115_AAAOHB sellers_k_Page_061.jp2
83d4be73400a3e56dcc0b240264bc508
e32c2b21eee04d92392831354d1573ab270a04e9
24100 F20110115_AAAPKE sellers_k_Page_138.QC.jpg
ee08e2aef7a2277c45adc263d1ba8541
fef16483b25fbbcad9a05d768e4d0dbfb7a68881
22928 F20110115_AAAPJP sellers_k_Page_117.QC.jpg
701b74537f694f409ae08848a1fa3530
8896790214849c9f3b14f1647a5bd975fdfd41bb
103979 F20110115_AAAOGN sellers_k_Page_047.jp2
28fc24be1884a981d30b1d688af03440
d5b66cad0645787e81f259261fc0e941ea9ce898
105535 F20110115_AAAOFZ sellers_k_Page_032.jp2
0081ccb6200f3197f38ccf2c8ab741fa
563ea00e4f3cb20f77fb2b1a6badcc5e5d3dc140
85938 F20110115_AAAOHC sellers_k_Page_062.jp2
4e2c9c3a9bc7969f6e8f7cbe2a5c48f0
658655c548d0eb5b6b3d2ad4dbc8011ed854e649
23225 F20110115_AAAPJQ sellers_k_Page_119.QC.jpg
51acd91efaa759f3ea26b90c13fff527
e32f0d2b790a9b1ade14f355c6f8bf94359bf480
104532 F20110115_AAAOGO sellers_k_Page_048.jp2
6f32b5f9232e395848b8352ea9562d41
643e7085629590015fbea84461dbdb9407dc2b7d
2105 F20110115_AAAPKF sellers_k_Page_144thm.jpg
ea7322f917ab905b157452eff7ca3968
ba38e80f6bd6cb538fbba1c3a2b45e6fb394b7de
20945 F20110115_AAAPJR sellers_k_Page_121.QC.jpg
760141ea90665c71c1ab48f245933e57
5fc142076db218421491b7f7248090c94e227481
98368 F20110115_AAAOGP sellers_k_Page_049.jp2
441a5d13a4ded6dd7d540971b53c7267
5ee9e0025e3affea5b358f160c9716e7e1edf1c0
102198 F20110115_AAAOHD sellers_k_Page_063.jp2
f87cb822bd8e7eaef5ce01bec4ab4e58
fc7e7fc0af8808e259f360934a1af377724e58df
6652 F20110115_AAAPKG sellers_k_Page_146thm.jpg
7984515824356f20517da6faa079e4b8
15f8d9a362838b3d2a67e4b2b5d5472da67690de
6392 F20110115_AAAPJS sellers_k_Page_124thm.jpg
50d3b7c6a9c42bacf25fbac19c42bb07
d81b4de71e6b21440404cf165f6f823349d3d84f
93500 F20110115_AAAOHE sellers_k_Page_064.jp2
36243923074464daf54e970c11d2eaa4
546cc7ad97465dee84ccd8d599da9c84084e8b06
106282 F20110115_AAAOGQ sellers_k_Page_050.jp2
bce96e499aa46af6da93715a1ffeb373
47f0894c75de77ac3de9838ccfa97b5169ee70d5
6831 F20110115_AAAPKH sellers_k_Page_148thm.jpg
d7590b194a77bbb7f510d609b9ef9919
419768d379ad2fc6953806b51928e0a370bb8cce
24162 F20110115_AAAPJT sellers_k_Page_126.QC.jpg
b54e849b15875484d9c9bfd7ab67495c
59ca7240d84753497560c7a3e0050839671e7d8e
100980 F20110115_AAAOHF sellers_k_Page_065.jp2
4df6a0a5420c4e28eff9af4e025b000e
09464ad6cbc681f6ef3a9a9fb6b9c06072989caa
104988 F20110115_AAAOGR sellers_k_Page_051.jp2
cc4e4cb1f5f69055ef00ef74c5a33c7a
eb717ca48f2ce8f6226bd52c610471f7f79a6af3
6873 F20110115_AAAPKI sellers_k_Page_149thm.jpg
d994ba9efc4c3da2aca6c6786664a2e6
42ff75fdb82db8e7e2e962bb245dd1bf4f382cad
6538 F20110115_AAAPJU sellers_k_Page_126thm.jpg
c44f9a2b40f4f7acb43e4bf67b6e3e8b
e83989d6a5881e4149c89ee0eea2c9654d430577
98129 F20110115_AAAOHG sellers_k_Page_067.jp2
a207245d7f55d7af4a211ad416c96039
c39d0be1303a4dd69ea8fe3f9e5478785a4d9dd2
103902 F20110115_AAAOGS sellers_k_Page_052.jp2
e1cc879e72e168b61189fdee3a8901c4
34a2d5bbfb7b3e6b9271342f979c10aa6e0bf2e1
26979 F20110115_AAAPKJ sellers_k_Page_150.QC.jpg
938f115ad45499270296ba47c0379c21
6ec297f8b31782f08f8bc1ac956aea751293783c
6579 F20110115_AAAPJV sellers_k_Page_127thm.jpg
cc2b040e104d78b6f460e0d1fe07560a
c8b558d771d3bd4457521fa997acf99a88fee03c
105966 F20110115_AAAOHH sellers_k_Page_069.jp2
bf9f1dc67e9b792d6f5f052645c6667d
b5c2f1a48f6c680441f42f69d7928b54faa1c2a5
100493 F20110115_AAAOGT sellers_k_Page_053.jp2
fffc05b546816a734c7a960badd91ba8
d00aada49957be8dfa03dc9c017e0f07a243ccd5
23641 F20110115_AAAPKK sellers_k_Page_151.QC.jpg
20273d2dd4e44c6e5aee48e642939784
e22613fb11dcd336f8594e36ef650440998ce51d
6617 F20110115_AAAPJW sellers_k_Page_128thm.jpg
b18cff84e527bf32ca97148cfb74ac3e
f58595e3c6d82383a98e61d41b0d90ea3721d1d5
105118 F20110115_AAAOHI sellers_k_Page_070.jp2
cd973c14a542a8d1f48b90a26c18d1ca
e76738a7ac5b80478c001561cbec7f26dac4e589
108944 F20110115_AAAOGU sellers_k_Page_054.jp2
11d0958b95a210af26cabe4f3aacb06f
ab00318d1daaa6f05fceb4e0aaae22a686132cc0
F20110115_AAAPKL sellers_k_Page_151thm.jpg
52d5ca935eb52fb2b7aa2646439203ac
a4fcc6dd0af1bb8a00d48350de411821ab4190cc
9833 F20110115_AAAPJX sellers_k_Page_130.QC.jpg
ac616c7234e2f1e5ce13a5428d669994
4dbb55b8dfe1e84e34c1420ebd5aeba54654e411
109321 F20110115_AAAOHJ sellers_k_Page_071.jp2
5e8cbe097524864ddaffb1fefa203646
fc4b14eb3a9507c43c68fffbbab71f0f79e9ad68
90419 F20110115_AAAOGV sellers_k_Page_055.jp2
69cd3cad2e4f993fe802f5ae7ec768f5
b178d0d37ffe0a5436073eca9299e406ba42018c
7122 F20110115_AAAPKM sellers_k_Page_154thm.jpg
dbf5c37dc32b7e8faa483aa870dac49b
77941e785a1f759a5136907fb95032ce1917af02
2940 F20110115_AAAPJY sellers_k_Page_133thm.jpg
c876c821734c3199b58640edfdf2e766
ecc0f91c1b4f53a1417428596ed72ab67ac57574
28480 F20110115_AAAOHK sellers_k_Page_072.jp2
99db806ff034d833bcc8a94db90639bd
03be8d11909039eec9879fde7f76b746688dedbf
1051804 F20110115_AAAOGW sellers_k_Page_056.jp2
e15804d7fb3985717b2ab3088ccc6148
1b9f140d7e870f2aabb4f432c6fa25c20c9fd7f6
17057 F20110115_AAAPKN sellers_k_Page_156.QC.jpg
c8178c2ecac622f1dbccc95f412fb271
8c341c133846e36489c1a83a4b0ddf118cdfe813
5356 F20110115_AAAPJZ sellers_k_Page_134thm.jpg
559d3b00f777f2ff89946d12408cf372
db7ed47d1c9d8835cc024c2cd1021819a69a8baf
87854 F20110115_AAAOIA sellers_k_Page_090.jp2
66ee0af9bf8e1473ba01504ca85d1084
d6aa5bd9d94f37226e1c38f11b97e65e61e5728a
874972 F20110115_AAAOHL sellers_k_Page_073.jp2
62c377e86e62139f0d8e5e04b7575013
3e47639be1b1eb1ef8587087ac4ed7874702f3ed
387152 F20110115_AAAOGX sellers_k_Page_057.jp2
ddebf9266077a3db54fd0e38d621051c
806d3079e3ea9dece252694d980b17ead2a6e37a
105468 F20110115_AAAOIB sellers_k_Page_091.jp2
1b54f7411ff685c69a77ba52b10bf74e
ab4008099697fc9f0f64e4d96b27bf3ff4f4b03e
324728 F20110115_AAAOHM sellers_k_Page_074.jp2
2f962c1c84112f81ce3abc8c309272f8
3e8cc346fb51cd1434fa0ff92c5103b9c5b746d2
562723 F20110115_AAAOGY sellers_k_Page_058.jp2
e5f1968357f031153f69e4f1950c451e
8bef860d4db4ccaad5254314cf0d73b6fe6aa343
104879 F20110115_AAAOIC sellers_k_Page_092.jp2
0b56fba3524f7fc6ebb4e1fed989b73e
729749ef861722136b9a532608a42ea8f08d5160
930160 F20110115_AAAOHN sellers_k_Page_075.jp2
f253291e49aaff79902c9031e80db5a3
5ec1501263da62f560bfabf77371048aeb8e5f48
383160 F20110115_AAAOGZ sellers_k_Page_059.jp2
5f68dd05dde6cb8e615f688edfb85880
7d250e925c5fd4d012b510912052af445e9db63d
918136 F20110115_AAAOID sellers_k_Page_093.jp2
1ad259ef32c6a48995800d1002c9d90a
952f93c347c0c61e9b79c8e5385eeef2bd90789c
94219 F20110115_AAAOHO sellers_k_Page_076.jp2
7cc3177e66705d7c576f6a7696c4972b
5cf4ff4106b4a0a1ba1d02cbb4f7aa6947ef1e01
109201 F20110115_AAAOHP sellers_k_Page_077.jp2
7eb444cab0ca33a43eae6f0b9276fce0
92d312dd689a399275f9ca88b225208ec07a41f5
107584 F20110115_AAAOIE sellers_k_Page_094.jp2
114ebd35a01c37a075a3d659302d30b7
e2fea3bacb4269a96b0db60348097189803f7d1d
82226 F20110115_AAAOHQ sellers_k_Page_078.jp2
093a2dfe727a1b650fbe9ab2088a8108
d61f126367a7e7ce01682e5ba6314492eeb0a9eb
107439 F20110115_AAAOIF sellers_k_Page_096.jp2
0663306451cc57e5e6beacff4abeafb7
daf4e530577e20b72733a3d4ea6a5a83d5ae672f
104707 F20110115_AAAOHR sellers_k_Page_079.jp2
9fdb7fcee5ee031eaa52429c1205b3ef
8ae526c056e24d139b7161799417c1d3e1fa1fbe
99746 F20110115_AAAOIG sellers_k_Page_097.jp2
cd44665904afbecbe62923cb2ddcade8
b31ee65d1084108c761b5cbe55ea2900eca21ab4
102356 F20110115_AAAOHS sellers_k_Page_081.jp2
f5366d756b572d7dd3aed8f153f6f935
4a815714644b296f62c73ba1cd52b98d55aec53e
109509 F20110115_AAAOIH sellers_k_Page_098.jp2
5c72e1ac57b0a33872f3731238ad9794
ab32c6202784a8e5be6c3670431a9fdab82d5c18
111602 F20110115_AAAOHT sellers_k_Page_082.jp2
b05a03eff93225ea2d748312d75d459f
470922cc30c6e07b0ac9d3dccd5881c977352f3e
111093 F20110115_AAAOII sellers_k_Page_099.jp2
a277c6874b124144891e7243566c22a4
0bd383c7fca5f1782f4512227270ac558e321916
109078 F20110115_AAAOHU sellers_k_Page_083.jp2
301f91fab1da78e7cf5e4f649be991ef
6e6f85857eb570718a72839f56bf2f6e458e1b60
105453 F20110115_AAAOIJ sellers_k_Page_100.jp2
6c56c42fd2e3225b63b69e3eaad985ec
2e65627caca32836c51da2721b9fe62d5c0d3906
81788 F20110115_AAAOHV sellers_k_Page_085.jp2
e49bdc088bc93453681210ce02bdc1ba
be2be6646b6e348d77eae545c9e4c0af8152267c
103152 F20110115_AAAOIK sellers_k_Page_101.jp2
bc7cce0e9904b701d79d7e26e8167e9b
6e7c2b4064d1da05030e30c690951227481c46ec
837481 F20110115_AAAOHW sellers_k_Page_086.jp2
8e65b7e5b0da3ba015ada7e69df4f496
ccf7a801534f0d0eede43da5d6f7d89377e58da9
104309 F20110115_AAAOIL sellers_k_Page_102.jp2
e57ad8805772b26627e406beab7f9170
063cade24ec4dd49c8c068ba515250e2e4f680e5
550016 F20110115_AAAOHX sellers_k_Page_087.jp2
74dcc1291e0fa0aa4bfa4bb30b515af4
ae23ce6a425ddab3db4a6d954ae676025dc4024a
95488 F20110115_AAAOJA sellers_k_Page_121.jp2
891b22cb0e0ba4db580fd9afacb3a7d1
6cf54d014f78cf376b7a9495e97ff382ad0d8f65
418702 F20110115_AAAOIM sellers_k_Page_104.jp2
6a0cb1a7b5ef5379d0dbc24a022e0779
c6abb14ca4aa7f7112fa4179901eda76373b209d
543155 F20110115_AAAOHY sellers_k_Page_088.jp2
273e8e2d7516eb62874b0cab53d0d275
41e19a3b51f0d15ab27428425727f48b3b9f3b50
98487 F20110115_AAAOJB sellers_k_Page_122.jp2
80e948bc95ae86b55e74d4c0aace7456
520548ecddb468176a29ba2eb70af88917b2ff88
762601 F20110115_AAAOIN sellers_k_Page_106.jp2
68363ee123e7800f8b0480a11dbedd37
ccd030bbaf5232b61d8b4b4a351994da2f1a8d03
225577 F20110115_AAAOHZ sellers_k_Page_089.jp2
b1bd2280681593769235834a5988a377
993700b90fc7afe64ae4319d08ed4f96e9c1f48b
97017 F20110115_AAAOJC sellers_k_Page_123.jp2
b0636f2c4ac4e6d59dbb0923d6d168fe
d14bba04b87de336586e4f1e5a5277fa5c2b0c67
638923 F20110115_AAAOIO sellers_k_Page_107.jp2
de12493c37c3a141b1538fd0b8a2650b
ecf95681396ca19d8067b968990e750e47dbe5ee
102885 F20110115_AAAOJD sellers_k_Page_124.jp2
03cb0a69a247c0a8fd036457d61e9105
5c60136d30327da16baf6a2641bdf9c3e6719a3a
820146 F20110115_AAAOIP sellers_k_Page_108.jp2
2aeeedecb3b9211c571d32f3baad86b6
28568d443ba728c334b87020d229a45f8dcfe4b3
101867 F20110115_AAAOJE sellers_k_Page_125.jp2
2492bea1274be9fdd2a0cb296362830d
04b4d6248bc169869343641e891e56964af33c14
93812 F20110115_AAAOIQ sellers_k_Page_110.jp2
4c9484215bb660398492070d8ed043ab
ad89ae354f859dada5b3755a3b7550b856d6e430
108842 F20110115_AAAOIR sellers_k_Page_111.jp2
1f7952e30f2e2552a9f4e674f05a91c9
e0273df6351a06377781b6c46e6b3a9298461aea
109200 F20110115_AAAOJF sellers_k_Page_127.jp2
e8ae140136b4ad08343e28c0ae440386
32461b80dc662d07383e3ca10079b1584f054ec1
113146 F20110115_AAAOIS sellers_k_Page_112.jp2
dcdd7e6762584e41e2fd4629010c219a
9d038cb746b3abf7eff7b8835b39db73e0ff4949
110087 F20110115_AAAOJG sellers_k_Page_128.jp2
28a5b3038d5f53041be0539d57883b9e
8b35a85b96235f0bb5d43bc67a1336bae8a4a602
108317 F20110115_AAAOIT sellers_k_Page_113.jp2
2a18f6ce68e839b392d4570e222b9d1b
08435f572eb651397fa5525e22fc9d46b038be86
94673 F20110115_AAAOJH sellers_k_Page_129.jp2
e8b1bd823466fdfd9a360689d6cd3810
87bf004382f186b7475785d8815842dda448c24f
85723 F20110115_AAAOIU sellers_k_Page_114.jp2
d3b769b6850ce4baa83ad3df81099fbc
12ecfecf3b48e403607eaadb91523a2291ab6334
385276 F20110115_AAAOJI sellers_k_Page_130.jp2
75715e1ef1d2679d04fc3c036f631bc1
19a5ebfc646f6f2a32d37ec473f37cc2430f29af
88975 F20110115_AAAOIV sellers_k_Page_115.jp2
639ab32b889e250088566b086ea0d007
a21efbc96f486d86d545892c2d790da1346cae4a
257775 F20110115_AAAOJJ sellers_k_Page_131.jp2
c6147c1e3b209a19887e09507341e0f3
8a4096624f4d78b85289a530ba3cacc4a01afd24
73583 F20110115_AAAOIW sellers_k_Page_116.jp2
a75ef133e14b0d81bd05b3112949c193
2feffc661b6e772960964cb7ae3407282ca53da3
793208 F20110115_AAAOJK sellers_k_Page_134.jp2
42f65716211b046e688793950fe3f0a9
8c35e6570c5f4ddb44413a9a9333472770dbf374
103815 F20110115_AAAOIX sellers_k_Page_117.jp2
4f959ad9b980f1b7bf3221ddbbb6eb9d
d669574c390f8dc303f938d7cdf14d49dc2e52fa
125473 F20110115_AAAOKA sellers_k_Page_153.jp2
fa42dc61b7e46113fc99cdb77af27229
7ad1222efc786caa6f62a21196fc914e73b88df9
575339 F20110115_AAAOJL sellers_k_Page_136.jp2
9af306b7ac86ec049d6f75de1810cb5b
c68bd2b6c066109a3c8f1972dd13b9278d22a9e6
94998 F20110115_AAAOIY sellers_k_Page_118.jp2
316ce5507fb00006afc0bb39c90747d3
1ee3dad4552e732fd96f0076e177abff1b68ef4a
135876 F20110115_AAAOKB sellers_k_Page_154.jp2
b308fd9718980342698493244f0dec76
93429924cbcab0b51702b2e7a67b198461865b54
97670 F20110115_AAAOJM sellers_k_Page_137.jp2
f042eaa2a3ba128129660718c192bfd9
35f3205c4e85ad8ff940b622138c8442d47b2f7a
103008 F20110115_AAAOIZ sellers_k_Page_120.jp2
78d00107e7e9d692991271c110d591b8
3990d3cc6bf1cc9e79a681800656a0dd9b865c71
41253 F20110115_AAAOKC sellers_k_Page_155.jp2
d1642ae32e929ae1c00b071fafa8d421
f17c375b21366e442dd161a63e91abb28e5df737
110167 F20110115_AAAOJN sellers_k_Page_138.jp2
33a72559c545764e03eedbb8945b42cb
4a0a8ea725e99f08870e25496745ca24c337bf70
73575 F20110115_AAAOKD sellers_k_Page_156.jp2
ca9e67aeae1a7c8c3e3a973714575153
344dc90e338d0799ac4193630a4a07e476a598c1
106428 F20110115_AAAOJO sellers_k_Page_139.jp2
e06de8d3397135f7645535c1c00a35a4
972e0d49b5e30d472c884b947a01870d40c983ce
F20110115_AAAOKE sellers_k_Page_001.tif
ea31d888421a89167d971a1b96c8db6b
17692ae88d9cb1b21a5d076f442d9dedaf98b4e6
95205 F20110115_AAAOJP sellers_k_Page_140.jp2
b76e4e946ec89ca7179585c2ef408b66
5f987e1ecc8e3d6359c8bdbe2780b05db1d1e8e3
F20110115_AAAOKF sellers_k_Page_002.tif
035e2903ff9ed1cda661d71b8d88e8c4
9a8f0fd4217fe505d32129c403f1387f7c92d246
108006 F20110115_AAAOJQ sellers_k_Page_141.jp2
e2b47510f3307fa9df34770dceb6f6b0
69b949dcfb68176bcc1160d088cb29f469f41a2f
109942 F20110115_AAAOJR sellers_k_Page_142.jp2
672d79cca5e8d1324bf1453e65bc25fe
6cf3e1c00f23587170b0db41b500d90b41d132c0
F20110115_AAAOKG sellers_k_Page_003.tif
5d01bec19252ce31045d3bf86857296e
f2fe87aab5e1f8d1f7122eb68cef0efef53112ab
85933 F20110115_AAAOJS sellers_k_Page_143.jp2
726ef62e8f0d83c87703e38726f60341
f7157f2be422825786cf57ece393dd14e646680e
F20110115_AAAOKH sellers_k_Page_004.tif
9b8b75b8c910523ac612aeac34ec959e
a938767169abebee5c49a951f7b0fe496d30ecb2
176157 F20110115_AAAOJT sellers_k_Page_144.jp2
130605ada8574351fb732b125afb2543
6daaec9b84c30d1c4e64be1a4e2472573150ead7
F20110115_AAAOKI sellers_k_Page_005.tif
44c1cb3156bcb89ff1a4fcff1e58540b
87f71bb86a9ddb97440bbfe4261e302945bd6e23
129984 F20110115_AAAOJU sellers_k_Page_146.jp2
1f36471ba618ee149648da867b4fdf67
c397f09109c680819b64e722d1527a8c1a80467f
F20110115_AAAOKJ sellers_k_Page_006.tif
75b988b1a282b85a86e7653e5fa01981
8080f2bb12010f5f2094a6c0291dccd46ffc1222
141391 F20110115_AAAOJV sellers_k_Page_147.jp2
2fc021d0bd5c26a03e9c3e3ba4fb9777
72a52f841d7b5c000810094deaff5a0d378373d7
F20110115_AAAOKK sellers_k_Page_007.tif
08b32135f59588ba040d49f7cfe68de7
f0e9a66930cd7178840396b7dd0fddbec498eeb3
130248 F20110115_AAAOJW sellers_k_Page_148.jp2
cf632c75cf79bc46b85a22e7609b4001
d7d3a0837ea55252cfa7800da1a44137dcad7545
F20110115_AAAOLA sellers_k_Page_024.tif
b71b3db2d308e0b6b3cbdcdd5c9ecaec
f66d1ee8ca432f3c5b014ad2ba31468a5b305ff4
F20110115_AAAOKL sellers_k_Page_008.tif
428675298f671dbfb074eadbcd54fe9b
97e891cd86f3af71984013895cbe945504cadbf4
134182 F20110115_AAAOJX sellers_k_Page_149.jp2
9e247e99bed87d3faea3402c13f12c70
ca7f35aa0a35f195c1d6799476b1c79a669a3f95
F20110115_AAAOLB sellers_k_Page_025.tif
deeddc173595b89f62a22300951a47ac
7bb34ee530869f9e767c91e5812299182639ff82
F20110115_AAAOKM sellers_k_Page_009.tif
3aabfa2747c15f8549c255b3effc8ab9
01a4cd664bbc0cf12e27087d76ca1b2ca557a03c
142594 F20110115_AAAOJY sellers_k_Page_150.jp2
645161a3896125e3b4b975b08ddf5afb
454905aef462bb863db595194770c179d7a08af5
F20110115_AAAOLC sellers_k_Page_026.tif
ed52010a9a599980da57a3a1d1088746
d381722ba6a70382b2893272e2a6a0e008115107
F20110115_AAAOKN sellers_k_Page_010.tif
dffab9630922c76773d2cc4b15483122
7eb7d43f6a342811b015f79af05c68a8ff660c96
129372 F20110115_AAAOJZ sellers_k_Page_151.jp2
e24074f5f3c9fb329c5fb749f74d7cda
1ee4719f5b270180b94612de025d386244b244a1
F20110115_AAAOLD sellers_k_Page_027.tif
8ed192d7f3ce45a7dee67d2c3718baa3
cd13ac22bfa79877edaa6eab9187ee2a3cdb0923
F20110115_AAAOKO sellers_k_Page_011.tif
6172480fa965fbba98aa3dd207b04583
67c883e14bd416b71e3c46020b592c69d227c492
F20110115_AAAOLE sellers_k_Page_028.tif
1df05408d0073147607f2172b844ef17
285bcace42aea31ea4e7efe5c406071174aeb41b
F20110115_AAAOKP sellers_k_Page_012.tif
4dce9d50fdf535e0972926754e0da4c7
972ecd994e5610c5ab786f9655878edea2a46cb7
F20110115_AAAOLF sellers_k_Page_029.tif
7b974ce6a0c9cd27d9b8c7450c638fb8
7c1509c492b03c78e858c21a0bc25eb83db5fd3d
F20110115_AAAOKQ sellers_k_Page_013.tif
bc6862db170664a452b00e11d1829624
f8836bc06c9e797a76422772af6439b159031922
F20110115_AAAOLG sellers_k_Page_030.tif
6b536bbd4a9a9845a87656c90aac71e9
32c64f768b81d17cf5bb7197c1db701b94d4106e
F20110115_AAAOKR sellers_k_Page_014.tif
cb0098b4ca6beb270a57008a001d5de6
267f35854d3883d3e6587b7a28670ca140150584
F20110115_AAAOKS sellers_k_Page_015.tif
91d433c1e307b89695dc4043f9dfbfe3
67cc19451756f25e18740f76523c87e57ebc034d
F20110115_AAAOLH sellers_k_Page_031.tif
54420075e20b71a77cd960610d92820f
dd065e364c59e2bd27d7fd020c1ab36e70f64b17
F20110115_AAAOKT sellers_k_Page_016.tif
12496f4345ede522e1db993784235aa8
fd4f4a3a569a9e0b2c9fdc78c1772fb24071b739
F20110115_AAAOLI sellers_k_Page_032.tif
21439b4380e6a528c3f8f21ca4010cea
5ca853756e0c6ba0cdce8d4cf2732041e0511405
F20110115_AAAOKU sellers_k_Page_017.tif
c0c11c6b8b14e78ed7421f1e8547a02b
b83106e774a7684c09096f7b4ede85a6104bc341
F20110115_AAAOLJ sellers_k_Page_033.tif
8714df200c908c3c01cbcb8a93f101f1
916e51887bc02099800fa9dda339ec04af4286c7
F20110115_AAAOKV sellers_k_Page_018.tif
bd19fadb06d79818441713d8fdded13e
21eb132a22211f7a5c508e82c3674ce363a6d282



PAGE 1

ROLE OF BRAIN SOLUBLE EPOXIDE HYDROLASE IN CARDIOVASCULAR FUNCTION By KATHLEEN WALWORTH SELLERS A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLOR IDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 2004

PAGE 2

Copyright 2004 by Kathleen Walworth Sellers

PAGE 3

This work is dedicated to my family, w ho has taught me to embrace life with love, perseverance, and grace.

PAGE 4

ACKNOWLEDGMENTS I could not have completed this work without the assistance from many colleagues and friends. First and foremost, I would like to thank my mentor, Dr. Mohan Raizada, who has consistently supported and encouraged me these last several years. It was by chance that I worked in his research group before starting my graduate program, and I could not have found a better group with which to work. Dr. Raizadas excitement and fervor for new ideas have helped shape my appreciation for scientific research and the pursuit of knowledge. I also want to acknowledge all of the members of the Raizada research group, past and present. I am fortunate to work in such a friendly and intellectually-stimulating environment. Specifically, I want to thank Drs. Beverly Falcon and Matthew Huentelman, the two graduate students in our research group who both helped me tremendously. In addition, I would like to thank Drs. Carlos Diez, Cheng-wen Sun, Jorge Vazquez, Shereeni Veerasingham and Hong Yang for all of their intellectual guidance. I greatly acknowledge the members of my committee, Drs. Michael Katovich, Gerard Shaw, Colin Sumners and Charles Wood. Each has provided me with unique experience and expertise to further my research and career. In addition, I want to thank all of my teachers throughout my education. Without a solid learning base, I would not have reached this goal. iv

PAGE 5

Finally, I want to thank all my family and friends who have supported me over the years. It is they who lift my spirits and keep my sights set high. Each of my loved ones has a purpose in my life for which I am eternally grateful. v

PAGE 6

TABLE OF CONTENTS page ACKNOWLEDGMENTS.................................................................................................iv LIST OF FIGURES.............................................................................................................x ABSTRACT......................................................................................................................xii CHAPTER 1 INTRODUCTION........................................................................................................1 Central Regulation of Hypertension.............................................................................1 Brainstem...............................................................................................................2 Hypothalamus........................................................................................................4 Baroreceptor Reflex...............................................................................................4 Mechanisms Underlying SNA...............................................................................5 Renin-angiotensin system..............................................................................5 Reactive oxygen species.................................................................................7 Implications.........................................................................................................10 Soluble Epoxide Hydrolase........................................................................................11 History.................................................................................................................11 Epoxyeicosatrenoic Acids...................................................................................12 Vasodilatory properties................................................................................12 EETs in the brain..........................................................................................14 Alternate actions of EETs............................................................................14 Dihydroxyeicosatrenoic Acids.....................................................................15 Cytochrome P-450...............................................................................................16 Epoxygenases in the brain............................................................................16 20-HETE......................................................................................................17 sEH and Hypertension.........................................................................................17 sEH Polymorphisms............................................................................................19 Rodent..........................................................................................................19 Human..........................................................................................................20 sEH polymorphisms in cardiovascular disease............................................21 sEH polymorphisms in other disorders........................................................21 Phosphatase Studies.............................................................................................22 Summary.....................................................................................................................23 vi

PAGE 7

2 INCREASED SEH EXPRESSION IN SHR VS. WKY RAT BRAIN: IN VITRO AND IN VIVO ANALYSIS........................................................................................31 Introduction.................................................................................................................31 Materials and Methods...............................................................................................33 Animals................................................................................................................33 Immunohistochemistry........................................................................................33 Real-Time RT-PCR.............................................................................................34 Western Blot Analysis.........................................................................................34 Neuronal Cells in Primary Culture......................................................................35 Losartan Treatment of SHRs to Normalize Blood Pressure................................35 Statistical Analysis..............................................................................................36 Results.........................................................................................................................36 Cellular Localization of sEH...............................................................................36 sEH Expression in the SHR.................................................................................37 In vitro Validation with Neuronal Cells in Primary Culture...............................37 sEH Expression Following Blood Pressure Normalization.................................38 Discussion...................................................................................................................39 3 CENTRAL SEH INHIBITION INCREASES BLOOD PRESSURE AND HEART RATE IN THE SHR...................................................................................................49 Introduction.................................................................................................................49 Materials and Methods...............................................................................................51 Animals................................................................................................................51 Statistical Analysis..............................................................................................51 ICV Cannulation..................................................................................................51 Abdominal Aorta Cannulation............................................................................51 Blood Pressure and Heart Rate Recordings.........................................................52 In vivo Drug Delivery..........................................................................................52 Results.........................................................................................................................53 Effect of sEH Inhibitor DCU on Blood Pressure and Heart Rate.......................53 WKY rat.......................................................................................................53 SHR..............................................................................................................53 Effect of sEH Inhibitor AUDA on Blood Pressure and Heart Rate....................54 Dose response...............................................................................................54 WKY rat..............................................................................................................55 SHR.....................................................................................................................55 Discussion...................................................................................................................55 4 ROLE OF ROS IN ANG II-INDUCED REGULATION OF BLOOD PRESSURE.63 Introduction.................................................................................................................63 Methods......................................................................................................................65 Animals................................................................................................................65 ICV Cannulation..................................................................................................65 Abdominal Aorta Cannulation............................................................................65 vii

PAGE 8

Statistical Analysis..............................................................................................65 In vivo Drug Delivery.........................................................................................65 Dipsogenic Response...........................................................................................66 Results.........................................................................................................................66 Angiotensin II Pressor Response.........................................................................66 gp91ds-tat Prevents Ang II-Induced Blood Pressure..........................................67 WKY rat..............................................................................................................67 SHR..............................................................................................................67 gp91ds-tat Prevents Ang II-Induced Drinking....................................................68 Discussion...................................................................................................................69 5 MECHANISM OF CENTRAL SEH INHIBITION ON BLOOD PRESSURE REGULATION...........................................................................................................77 Introduction.................................................................................................................77 Methods......................................................................................................................80 Animals................................................................................................................80 ICV Cannulation..................................................................................................80 Abdominal Aorta Cannulation............................................................................80 Blood Pressure and Heart Rate Recordings.........................................................80 Statistical Analysis..............................................................................................80 In vivo Drug Delivery.........................................................................................80 Evaluation of Spontaneous Baroreceptor Reflex Gain........................................80 Analysis of Heart Rate Variability......................................................................81 Neuronal Firing Recording..................................................................................82 Results.........................................................................................................................82 Waveform Analysis of Baroreceptor Parameters................................................82 Index of spontaneous baroreceptor reflex gain............................................82 High frequency analysis of pulse interval....................................................83 AUDA Regulation of Sympathetic Nerve Activity.............................................83 Increased EETs Linked to Increase in BP and HR..............................................84 MS-PPOH.....................................................................................................84 11-NODA.....................................................................................................85 Effects of sEH Inhibition Function through ROS...............................................85 Discussion...................................................................................................................86 6 EFFECT OF SEH OVEREXPRESSION IN THE PVN OF SHR AND WKY RATS97 Introduction.................................................................................................................97 Methods....................................................................................................................102 Animals..............................................................................................................102 ICV Cannulation................................................................................................102 Abdominal Aorta Cannulation..........................................................................102 Western Blot Analysis.......................................................................................102 Transformation of pCR 2.1 sEH cDNA into competent cells....................102 DNA miniprep............................................................................................102 Large-scale Lentiviral Production.....................................................................103 viii

PAGE 9

Infection of COS-7 cells with lenti-sEH...........................................................105 Cytoplasmic Isolation for HPLC Analysis........................................................105 Radiotelemetry Recordings...............................................................................106 PVN Coordinate Determination........................................................................106 Immunohistochemistry......................................................................................107 PVN Injection of lenti-sEH...............................................................................108 In vivo Drug Delivery.......................................................................................108 Statistical Analysis............................................................................................108 Results.......................................................................................................................109 Infection of COS-7 cells with lenti-sEH...........................................................109 Functionality of Lenti-sEH................................................................................109 sEH Overexpression in WKY PVN..................................................................110 AUDA delivery..........................................................................................110 EET agonist delivery..................................................................................111 Localization of viral delivery.....................................................................111 sEH Overexpression in SHR PVN....................................................................111 Discussion.................................................................................................................112 7 CONCLUSIONS AND FUTURE DIRECTIONS...................................................124 sEH Overexpression in Alternate Brain Nuclei........................................................124 sEH Expression.........................................................................................................125 ROS-Mediated Pathway of EET Function...............................................................126 Validation of Baroreceptor Reflex Findings.............................................................126 Role of sEH in Glial and Endothelial Cells..............................................................127 Role of Central Epoxygenases..................................................................................128 Effect of sEH Manipulation in Female Rats.............................................................128 Implications of Central sEH in Human Hypertension..............................................129 LIST OF REFERENCES.................................................................................................132 BIOGRAPHICAL SKETCH...........................................................................................143 ix

PAGE 10

LIST OF FIGURES Figure page 1-1 Major pathways of the RAS....................................................................................25 1-2 Major pathways of ROS production and metabolism.............................................26 1-3 Scatter plot of gene expression in the SHR and WKY hypothalamus and brainstem ..................................................................................................................................27 1-4 Arachidonic acid metabolism..................................................................................28 1-5 Tissue-specific functions of EETs...........................................................................29 1-6 Cellular membrane actions of EETs........................................................................30 2-1 Cellular localization of sEH in the brain .................................................................43 2-2 sEH mRNA levels in SHR and WKY brain regions ..............................................44 2-3 sEH protein expression in SHR and WKY brain regions ......................................45 2-4 sEH protein expression in neuronal cultures ..........................................................46 2-5 Effect of chronic losartan delivery on SBP in the SHR...........................................47 2-6 Effect of chronic losartan delivery on central sEH expression ..............................48 3-1 Effect of ICV DCU delivery on blood pressure and heart rate ..............................60 3-2 Dose response of ICV delivery of AUDA to SHR and WKY rats..........................61 3-3 Effect of central AUDA on blood pressure and heart rate .....................................62 4-1 Effect of central Ang II on blood pressure and heart rate. .....................................73 4-2 Effect of gp91ds-tat on Ang II-induced BP response in the WKY rat ..................74 4-3 Effect of gp91ds-tat on Ang II-induced BP response in the SHR ........................75 4-4 Dipsogenic responses of ICV gp91ds-tat and Ang II ............................................76 x

PAGE 11

5-1 Effect of central AUDA delivery on baroreceptor parameters.................................91 5-2 Effect of atenolol on AUDA-induced blood pressure..............................................92 5-3 Effect of MS-PPOH on AUDA-induced blood pressure.........................................93 5-4 Effect of EET agonist on BP and HR in the WKY rat.............................................94 5-5 Effect of ROS inhibition on AUDA-induced BP and HR response in the SHR......95 5-6 Effect of AUDA and gp91ds-tat on neuronal firing rate..........................................96 6-1 Lentiviral vector.....................................................................................................116 6-2 sEH protein expression in lenti-sEH-infected COS-7 cells...................................117 6-3 DHET measurements using HPLC analysis...........................................................118 6-4 Blood pressure and heart rate recordings following lenti-sEH and lenti-neo delivery to the WKY rat PVN..............................................................................................119 6-5 Blood pressure and heart rate recordings following AUDA delivery in the lenti-sEH-infected WKY rat...........................................................................................120 6-6 Blood pressure and heart rate recordings following EET agonist delivery in the lenti-sEH-infected WKY rat...................................................................................121 6-7 Localization of lenti-sEH delivered to the PVN of WKY rats...............................122 6-8 Blood pressure and heart rate recordings following lenti-sEH and lenti-neo delivery to the SHR PVN.....................................................................................................123 xi

PAGE 12

Abstract of Dissertation Presented to the Graduate School of the University of Florida in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy ROLE OF BRAIN SOLUBLE EPOXIDE HYDROLASE IN CARDIOVASCULAR FUNCTION By Kathleen Walworth Sellers December 2004 Chair: Mohan K. Raizada Major Department: Physiology and Functional Genomics Recent studies have linked peripheral soluble epoxide hydrolase (sEH) to hypertensive animal models. However, the role of this enzyme in the central control of blood pressure has not been elucidated. Thus, the objective was to investigate the involvement of brain sEH in blood pressure control through expression studies, pharmacological inhibition, and overexpression of sEH in the brain. First, sEH expression in the hypothalamus and brainstem, two cardioregulatory brain areas, was increased in the spontaneously hypertensive rat (SHR) compared to the Wistar Kyoto (WKY) rat. Second, inhibition of the enzyme by intracerebroventricular (ICV) delivery of pharmacological agents increased both blood pressure and heart rate in the SHR, an effect opposite to that following intraperitoneal delivery. This concomitant increase in blood pressure and heart rate in the SHR was accompanied by a depression of the baroreceptor reflex gain. xii

PAGE 13

The pathway by which sEH inhibition resulted in an increase in blood pressure and heart rate functioned through an accumulation of its substrate, epoxyeicosatrienoic acid (EET). Central delivery of the EETs resulted in an increase in pressor response in the WKY rat. In addition, -adrenergic receptor antagonist atenolol blocked the effect of sEH inhibition, indicating the pathway involves sympathetic activation. Furthermore, the effects of sEH inhibition were regulated by reactive oxygen species member NAD(P)H oxidase. This generator of toxic free radicals also mediated the central pressor response of angiotensin II. These observations suggest that central EETs and sEH inhibition are involved in increasing blood pressure. Finally, gene transfer using the lentiviral vector was used to overexpress sEH in cardiovascular-relevant nuclei. In the WKY rat, heart rate decreased six beats per minute following sEH overexpression and blood pressure remained unchanged. These studies, taken together, suggest that an increased expression of sEH is a futile central nervous system response in protection against hypertension. xiii

PAGE 14

CHAPTER 1 INTRODUCTION Hypertension has long been regarded as a silent killer, a disease that presents few symptoms but can generate devastating health problems and eventual death. Beginning as a sustained increase in blood pressure, this disease can lead to end-organ damage including heart failure. Cardiac output and total peripheral resistance determine blood pressure. Each component of this equation is influenced by a number of physiological factors in several organs including the kidney, heart and brain. For example, the heart regulates its contractility through input from baroreceptors in the carotid sinus and aortic arch that react to pressure changes (Zanchetti and Mancia 1991). An increased cardiac contractility results in an increased cardiac output, thereby increasing blood pressure. Similarly, increasing sodium intake leads to an increase in the bodys fluid volume, thus increasing cardiac output. Total peripheral resistance is ultimately controlled by the levels of hypertrophy and constriction present in smooth muscle cells that shape how the blood flows through the vasculature. While these factors define the major influences of blood pressure, it is necessary to understand the mechanisms underlying these factors in order to prevent and even reverse this disease. Central Regulation of Hypertension The brain continues to emerge as essential in the bodys regulation of blood pressure. For example, when an animal senses a predator, the sympathetic nervous system increases blood pressure and activates other defense mechanisms to prepare the animal for a fight or flight response. This response begins when the body senses danger 1

PAGE 15

2 and transmits this input to the brain to activate the sympathetic nerves that send projections to the brainstem and spinal column. Preganglionic neurons from these areas project to postganglionic neurons that in turn project to the heart or blood vessels (Dampney 1994). Two forms of preganglionic neurons are important in cardiovascular function, sympathetic preganglionic neurons (SPN) and vagal preganglionic neurons. Activation of SPN result in an increase in pressor response, while vagal preganglionic neurons regulate the baroreceptor reflex response that controls heart rate and blood pressure (Dampney 1994). Thus, signaling from these neurons regulates or controls cardiac contraction and blood vessel constriction. This autonomic nervous system signaling therefore regulates both blood pressure and heart rate from information initially processed from areas in the brain. In order to elucidate the involvement of the brain in blood pressure regulation via sympathetic control, it is necessary to identify regions that signal to the SPN. Retrograde tracers injected into the intermediolateral cell column (IML) have been used to map afferent neuronal projections. Specifically, transneuronal retrograde tracers incorporating either herpes or pseudorabies virus have been used recently to push the retrograde tracer into the cell body, thereby allowing the identification of specific nuclei that signal to the SPN (Strack et al. 1989). These techniques have identified nuclei in the brainstem, hypothalamus, caudal ventrolateral pons, and the A5 noradrenergic cell group. Based on a plethora of data underlying their influence on sympathetic activation, our research group has chosen to focus on the brainstem and hypothalamus. Brainstem The brainstem functions to regulate essential physiological functions including blood pressure, heart rate and respiration. This brain region houses several specific

PAGE 16

3 nuclei involved with cardiovascular function, including the rostral ventrolateral medulla (RVLM). The RVLM signals to the SPN, and bilateral denervation of the RVLM results in a decrease in blood pressure (Guertzenstein and Silver 1974). The RVLM therefore has influence over the pressor response. The excitatory response of the RVLM is regulated by several known factors. Excitatory inputs include acetylcholine, angiotensin II (Ang II), vasopressin, and excitatory amino acids (Andreatta et al. 1988; Dampney 1994; Gomez et al. 1993; Maeda et al. 1991; Willette et al. 1984b). Inhibitory factors include GABA and opiate receptor activation (Kishi et al. 2002; Punnen et al. 1984; Willette et al. 1984a). The important transmission ability of the RVLM is highlighted in work done with nitric oxide synthase (NOS), a known depressor. First, the inducible form of NOS, iNOS, is higher in the RVLM of normotensive Wistar Kyoto (WKY) versus spontaneously hypertensive rats (SHR), indicating a reason for the increased sympathetic activity in the SHR (Chan et al. 2001). Second, injection of eNOS, the endothelial form, increased GABAs inhibitory action on RVLM neurons (Kishi et al. 2002). Third, injections of Ang II into the RVLM increased both sympathetic vasomotor activity as well as blood pressure (Dampney et al. 2002; Kishi et al. 2002). Finally, gene therapy using adenovirus encoding eNOS delivered to the RVLM resulted in a decrease in blood pressure, heart rate and SNA in the WKY rat (Hirooka PBMP 2003). Thus, the RVLM functions to increase SNA and hence blood pressure through its neuronal projections. While some of these regulators have been identified, the complete mechanism of the RVLM in blood pressure control is not yet understood. In order to develop

PAGE 17

4 comprehensive treatments and preventative measures towards the development of hypertension, it is necessary to elucidate and define this role. Hypothalamus The hypothalamus is known for its regulation of body homeostasis and contains several specific nuclei that are linked to blood pressure regulation. The paraventricular nucleus (PVN) of the hypothalamus contains both magnocellular and parvocellular subdivisions, surrounding the third ventricle in an inverted triangular shape. The PVN has neuronal projections to the IML in the spinal column and also receives and transmits signals to the RVLM and the nucleus tractus solitarius (NTS) in the brainstem (de Wardener 2001). In relation to sympathetic control, the PVN can directly innervate the SPN or send projections to another excitatory nucleus such as the RVLM (Allen 2002). In fact, the PVN has a large number of catecholaminergic fibers ascending from the RVLM that release norepinephrine (de Wardener 2001; Palkovits et al. 1992). Norepinephrine delivery to the PVN increased blood pressure by 30 mmHg, suggesting that the PVN has direct role on the central control of blood pressure (Harland et al. 1989). The PVN has a diverse collection of neurons with distinct projections; therefore, its relation to SPN control is complicated. For example, electrical stimulation of the PVN has both stimulated and depressed blood pressure (Dampney 1994). Hence, while the PVN serves as a control unit for SPN action, its overall role is difficult to elucidate. Research of this key hypothalamic nucleus continues to define its control in brain-mediated blood pressure. Baroreceptor Reflex Apart from the influence of SPN on the pressor response, the baroreceptor reflex response is also an important component in cardiovascular regulation. Long believed to

PAGE 18

5 function only in the short-term regulation of blood pressure, recent evidence points to the baroreceptor reflex response as an important regulator of the long-term control of blood pressure (Malpas 2004). Baroreceptors are found in the aortic arch and the carotid sinus where they transmit and receive cardiac impulses to the IML and finally the brain. These impulses stimulate vagal preganglionic neurons that in turn affect heart rate, sympathetic vasomotor activity and the rate of secretion of vasopressin (Dampney 1994; Sved et al. 2001). Thus, the baroreceptor reflex response functions to control the balance of blood pressure and heart rate stimulation. The RVLM is a major mediator of the baroreceptor reflex response (Dampney 1994). For example, baroreceptor activation leads to an inhibitory effect in the RVLM (Colombari et al. 2001). The PVN has not been extensively studied in baroreceptor activation control, but studies do suggest it modulates this action through signaling with the NTS (Kannan and Yamashita 1985). The baroreceptor reflex response plays an important role in cardiovascular regulation and is influenced by brain nuclei also involved in SPN control. Mechanisms Underlying SNA Renin-angiotensin system As discussed, firing of neurons from specific nuclei including the PVN and RVLM to the IML result in an increase in SNA and hence an increase in blood pressure. Mechanisms controlling these oscillations in firing rate involve a number of hormones, neurotransmitters and other gene products, many still unknown. One major example of how these factors in the brain regulate hypertension is the renin-angiotensin system (RAS). The brain RAS continues to emerge as a vital regulator of hypertension since its discovery and characterization more than thirty years ago. Figure 1-1 illustrates the main

PAGE 19

6 pathways and members of the RAS. Classically, angiotensinogen is made in the liver and then cleaved by renal renin into angiotensin I. Angiotensin I is then converted to Ang II by angiotensin I converting enzyme (ACE) produced in the lung. Ang II, an eight-membered peptide, then binds to the Ang II type 1 receptor (AT 1 R), a G-protein coupled receptor (Sasaki et al. 1991). This binding results in an increase in blood pressure through vasoconstriction, increased sympathetic activity and fluid/salt volume regulation. Ang II functions as both a hormone and as a neurotransmitter in the brain and is also present in cardiovascular-relevant tissues including the kidney, heart and vasculature. (Allen et al. 2000). The initial understanding of the RAS has advanced and become more complex with new findings. First, the RAS has been identified both systemically and in individual tissues. Second, novel components have been identified that increase the complexity of this system. For example, ACE2 converts either Angiotensin I to Angiotensin (1-9) or Ang II to Angiotensin (1-7) (Turner et al. 2004). In most tissues, Angiotensin (1-7) acts opposite to that of Ang II (Chappell et al. 2004). These contradictory effects are also seen when Ang II binds to the AT 2 R. With each new discovery of the RAS, the pathway is further elucidated and better understood. Ang II is a major player in the central regulation of hypertension. Intracerebroventricular (ICV) delivery of Ang II results in a dramatic increase in both blood pressure and drinking (Di Nicolantonio et al. 1982). This response begins within minutes and is only a short-term effect following bolus delivery. Ang II has also been extensively studied in specific brain nuclei that function in blood pressure and dipsogenic responses (Pan 2004). For example, Ang II injection to the subfornical organ results in a

PAGE 20

7 profound dipsogenic response, while injection into the PVN, NTS or RVLM leads to a dramatic increase in blood pressure (Bastos et al. 1997; Mangiapane and Simpson 1980; Muratani et al. 1993; Tanaka et al. 2001). Taken together, central Ang II binding to the AT 1 R in several brain nuclei induces a pressor response. One ongoing area of study involves the mechanisms underlying this blood pressure control. Ang II through AT 1 R stimulation is known to increase neuronal firing rate and norepinephrine release from sympathoexcitatory neurons, therefore resulting in sympathetic nerve activation (Sumners et al. 2002; Zimmerman et al. 1984). One question that remains is what are the steps involved after AT 1 R stimulation and prior to sympathetic nerve activation? Recent evidence points to the involvement of reactive oxygen species (ROS) as a second messenger in the central mediation of RAS. Reactive oxygen species ROS has emerged as a major player in a number of disease states, including cardiovascular disease. ROS members include superoxide (O 2 ), hydrogen peroxide (H 2 O 2 ), and the hydroxyl radicals. ROS are formed from oxygen converted to superoxide by enzymes including NAD(P)H oxidase and xanthine oxidase (Figure 1-2). Superoxide is converted to the hydrogen peroxide using superoxide dismutase (SOD) and then normally converted to water via either catalase or glutathione peroxidase (Becker 2004). This pathway is not destructive to cellular function and is the normal progression of oxygen processing. Oxygen is processed through the mitochondria in order to provide energy for metabolic functions. During certain disease states and times of physiological stress, however, hydrogen peroxide can instead be converted to hydroxyl radicals that lead to cellular injury. Thus, when the ROS outnumbers the available antioxidants,

PAGE 21

8 oxidative stress results (Touyz 2004). This damaging progression is thought to be a significant factor in a growing number of disease states. NAD(P)H oxidase, one of the key enzymes in the generation of ROS, was originally localized in phagocytes (Hanna et al. 2002). It is able to convert oxygen to its superoxide form by converting NAD(P)H to NAD(P) and donating the released electron. This conversion rendered it able to defend the host cell against microorganisms. More recently, though, focus has shifted to the role of NAD(P)H oxidase in other tissues. This enzyme was found to be a major source of ROS in cardiovascular tissue, and it has also been localized to both neurons and glia in the brain (Hanna et al. 2002; Zimmerman and Davisson 2004). One key difference between NAD(P)H oxidase sources from phagocytotic or non-phagocytotic cells is that the NAD(P)H oxidase in non-phagocytotic sources is constitutively active, thus increasing the probability for oxidative stress. NAD(P)H oxidase is a multimeric enzyme consisting of membranous subunits Gp91ds and p22 and cytoplasmic subunits p67, p47, p40 and Rac (Hanna et al. 2002). The active form the enzyme is initiated when p47 is phosphorylated and transports to the membrane along with the other cytoplasmic subunits and binds with Gp91. Phosphorylation of p47 is driven by protein kinase C (Rey et al. 2001b). Due to the importance of ROS in a wide array of systems, several inhibitors and activators have emerged in the field of study. Tempol is a SOD mimetic used in a variety of studies as an antioxidant, though its specificity is low. Recent studies used an adenoviral vector to deliver SOD to the brain (Zimmerman et al. 2002). In addition to SOD manipulation, NAD(P)H oxidase has also been used in therapeutic approaches. A peptide that competes with the docking portion of gp91 was sequenced to block the

PAGE 22

9 effects of NAD(P)H oxidase. The tat peptide derived from HIV was included upstream of the docking sequence in order to facilitate delivery in vivo (Rey et al. 2001b). This peptide, gp91ds-tat, is a specific, effective blocker of NAD(P)H oxidase both in vitro and in vivo. Several studies have implicated ROS in the central Ang II-mediated pathway. ICV delivery of SOD using adenovirus prevented Ang II-induced increases in blood pressure and drinking (Zimmerman et al. 2002). In addition, the Ang II-induced decrease in heart rate was abolished. These results were reproducible using both the mitochondrial and cytoplasmic forms of SOD. Given the wide range of impact from ICV delivery, studies were undertaken to elucidate the importance of specific brain nuclei in the ROS-Ang II connection. Adenovirus encoding a dominant-negative inhibitor of NAD(P)H oxidase activator Rac1 was injected into the circumventricular organs (CVOs) (Zimmerman and Davisson 2004). CVOs are distinct brain regions in that they lack a blood-brain barrier; therefore, they are influenced by both the brain and the periphery and serve to pass information across the two. RAS members are present in several CVOs, and previous research highlighted the cardiovascular regulatory role of RAS in the CVOs (Muratani et al. 1996). This adenoviral delivery resulted in preventing the pressor and drinking responses of Ang II (Zimmerman and Davisson 2004). Thus, ROS involvement in the Ang II pathway is localized to distinct neurons as well. As a complement to the in vivo experiments, Ang II treatment of primary lamina terminalis cultures led to an increase in superoxide, indicating the importance of Ang II on ROS production in vitro (Zimmerman et al. 2002).

PAGE 23

10 Implications The central control of blood pressure is regulated by neurotransmitters, hormones and genetic factors that act to control SNA. While we understand the importance of specific nuclei in both the hypothalamus and brainstem, the mechanisms underlying this control have not been fully elucidated. Hypertension is indeed a complex disease whose establishment and progression cannot be pinpointed to one genetic malfunction. Thus, in order to understand the genetic basis of hypertension, it is necessary to identify multiple genes underlying the basis of this disease. Our research group began the task of identifying genes novel to central blood pressure regulation by analyzing differences in brain gene mRNA levels between the SHR and WKY rat, using microarray technology. The SHR was chosen because of similarities between this genetic strain and human forms of genetic hypertension (Lindpaintner 1994; Louis and Howes 1990; Trippodo and Frohlich 1981). The hypothesis was that genes involved in the central regulation of hypertension would have different gene expression levels between the hypertensive and normotensive state. However, this genetic profiling cannot in itself distinguish genes whose expression alters as a consequence of hypertension. In order to analyze 7000 genes and 1500 ESTs, the Affymetrix U34A Rat GeneChip was used. Isolated mRNA from the hypothalamus and brainstem was amplified, fluorescently-labeled, hybridized to the chip, and scanned in order to be analyzed using GeneSpring software. Figure 1-3 highlights gene expression expressed as log values in four SHR compared to four WKY samples. Each point represents the average measurement for an individual gene between the rats in each group. Dotted lines segregate genes with a two-fold expression change between SHR and WKY rats.

PAGE 24

11 EPHX2, the gene that encodes the soluble epoxide hydrolase (sEH) protein, had the highest expression discrepancy between the two models. The sEH gene, indicated by the arrow, was significantly upregulated in the SHR and virtually undetectable in the WKY rat. This result incited a review of sEH and how it may be related to hypertension. The following section discusses the history, pathways and actions of sEH and how these factors may function to regulate blood pressure. Soluble Epoxide Hydrolase History The family of epoxide hydrolases (EH) includes sEH, microsomal EH (mEH), leukotriene A4 hydrolase, and cholesterol 5,6-oxide hydrolase (Spector et al. 2004). sEH was first identified as a cohort to mEH, a detoxifying agent to many foreign ingested agents. The sEH gene was first cloned in 1985, and its dimer structure (two 62-kDa subunits) was deduced in 1996 (Arand et al. 1996; Grant et al. 1993). A ubiquitous enzyme, sEH converts arachidonic acid metabolites and linoleic acid epoxides to less active forms through the addition of water (Zeldin 2001). Figure 1-4 outlines the placement of sEH in the major pathways of arachidonic acid conversion. The sEH enzyme can act on several substrates, and initial evidence suggested 1,2-disubstituted aliphatic epoxides were the ideal substrates for this enzyme. In fact, radiolabeled forms of this type of compound are used in activity studies of sEH (Borhan et al. 1995). The active site of sEH has been identified by crystal structure analysis to be a catalytic triad (Arand et al. 1996). Recently, more research has focused on the structure-function relationship in sEH. Crystal structure analysis revealed that sEH is a homodimer made up of two 62.5 kDa units. The two C-terminal domains interact with

PAGE 25

12 each other, while the N-terminal domains have no calculated or observed interactions with each other (Newman et al. 2003). Epoxyeicosatrenoic Acids The most well-studied role of sEH involves its enzymatic conversion of vasoactive epoxyeicosatrenoic acids (EETs) to dihydroxyeicosatrenoic acids (DHETs). The EETs are formed from arachidonic acid (AA) through the enzymatic action of cytochrome P-450 (CYP) epoxygenases (Zeldin 2001). The EETs are divided into four different regioisomer forms (5,6-, 8,9-, 11,12-, and 14,15-EETs) and are found in a variety of tissues including brain, kidney, and vasculature (Fang et al. 2001; Spector et al. 2004). Figure 1-5 outlines the main pathways and tissue locations of EET regioisomers. Most forms of EETs promote vasodilation, while their DHET metabolites are relatively inactive. Vasodilatory properties EETs in the vasculature have been implicated in blood pressure control due to their ability to dilate arteries. While EETs are found in a variety of tissue including the brain and kidney, plasma levels of these epoxygenase products predominate over all other known sources (Rosolowsky and Campbell 1996). EETs are produced from arachidonic acid in the endothelium; however, they are secreted from the cells to act on vascular smooth muscle cells. Evidence suggest that EETs bind to and activate the G-protein coupled receptor subunit Gs within the smooth muscle cell which then stimulates the large conductance calcium-activated potassium (BK(Ca)) channel (Harder et al. 1995; Li and Campbell 1997). Potassium influx into the cell results in hyperpolarization and therefore dilation of the vascular smooth muscle cell. Thus, increasing EET plasma levels decreases blood pressure by decreasing total peripheral resistance via vascular

PAGE 26

13 smooth muscle dilation. Figure 1-6 illustrates this vasodilatory action from a cellular level. Evidence for this dilation is as follows. First, all regioisomer forms of EETs have been found to activate BK(Ca) channels in vascular smooth muscle cells (Harder et al. 1995). Second, 11,12and 14,15-EETs increase the open-state probability of Ca 2+ -activated K + channels in coronary smooth muscle cells (Campbell et al. 1996). Third, all the regioisomers relax coronary vessels following contraction with thromboxane mimetic U46619 (Campbell et al. 1996). Fourth, EETs can transiently increase Ca 2+ release from intracellular stores, which also functions to activate BK(Ca) channels (Li and Campbell 1997). While this pathway results in the overall hyperpolarization of the membrane, it is not necessary for the EET-modulated activation of BK(Ca) channels. Finally, an increased EET production is associated with hypertensive models, presumably as a feedback mechanism that cannot overcome the increase in blood pressure (Omata et al. 1992; Pomposiello et al. 2001). Taken together, these studies provide comprehensive evidence that EETs function to relax the vasculature and thus lead to a decrease in blood pressure. This evidence of membrane hyperpolarization has led to high speculation that EETs function as the elusive endothelial-derived hyperpolarizing factor (EDHF) in the vasculature. While enormous evidence has implicated nitric oxide as a major player in relaxing arteries, complete abolition of relaxation cannot be achieved with inhibitors to NO action alone. The remaining action is termed EDHF, and its identity remains unknown. While EDHF is likely to be a combination of several factors, the hyperpolarizing nature of EETs coupled with their high expression in the vasculature has

PAGE 27

14 led to the hypothesis that EETs function as EDHF (Campbell et al. 1996; Fisslthaler et al. 1999). EETs in the brain EETs are expressed in astrocytes and endothelial cells in the brain, and evidence suggests their vasodilatory roles found in the periphery are translated to cerebral blood flow control in the brain (Medhora et al. 2001). All regioisomer forms of EETs are expressed in the brain, though astrocytes preferentially intake 8,9-EETs over 14,15-EETs (Shivachar et al. 1995). In addition, 8,9-EETs were not converted to DHETs in astrocytes. Whether this result was due to sEH regulation or other conversion mechanisms is unclear. EETs from both astrocytes and endothelial cells dilate smooth muscle cells through activation of the BK(Ca) channels (Gebremedhin et al. 1992). The central result of this dilation is an increase in cerebral blood flow. While all regioisomers act to dilate the cerebral arteries, 8,9-EETs and 11,12-EETs are the most potent forms in the brain (Gebremedhin et al. 1992). Studies that inhibited the CYP-450 epoxygenases in the brain and thereby prevented the formation of EETs resulted in the reduction of basal cerebral blood flow by 30% (Alkayed et al. 1997). Thus, central EETs play an integral role in the maintenance of cerebral blood flow. Alternate actions of EETs These four regioisomers of EETs exert different functions dependent on their tissue location. Vasodilation in the vascular smooth muscle leads to a decrease in blood pressure via the enlargement of arteries and thus an increase in blood flow, thereby decreasing total peripheral resistance. A second organ potentially involved in the sEH regulation of blood pressure is the kidney. Vasodilatory properties of EETs in the renal

PAGE 28

15 vasculature result in changes in renal blood flow and hence changes in water and electrolyte balance. All regioisomers modulate calcium influx in the vascular smooth muscle, while 11,12-EET is the predominant form regulating calcium as well as other studied functions in the endothelium (Spector et al. 2004). In the myocardium, all the regioisomers inhibit the sodium ion channel, while only the 8,9and 11,12-EETs activate the K(ATP) ion channel (Lee et al. 1999; Lu et al. 2001). EETs can also be converted to different metabolites using enzymes ranging from COX to CYP -oxidase (Zeldin 2001). These actions are dependent on the tissue type and likely the availability of sEH, since treatment with sEH inhibitor N,N-dicyclohexyurea (DCU) augments the conversion by these alternate enzymes (Spector et al. 2004). EETs can also be effectively stored in phospholipids if not immediately converted by enzymes. Dihydroxyeicosatrenoic Acids Studies on the function of DHETs have produced inconsistent results compared to the role of the EETs. For example, DHETs is generally less potent than the EETs. Evidence in support of this includes decreases in Ca2+ uptake and relaxation of the bovine coronary artery compared to the EETs (Campbell et al. 2002). However, DHETs do activate the BK(Ca) channel of coronary artery myocytes and serve to dilate coronary arterioles following constriction with endothelin (Spector et al. 2004). While the general consensus is that the EETs overshadow the DHETs in their action, DHET function cannot be discounted due to lack of sufficient studies done on these metabolites. Overall, however, by converting EETs to DHETs, sEH acts to attenuate EET action and promotes the relative inactivity of DHETs.

PAGE 29

16 Cytochrome P-450 EETs are only one branch of products generated from arachidonic acid. Figure 1-4 illustrates an overview of the pathways stemming from arachidonic acid. Cyclooxygenase converts AA into a variety of prostaglandins that have been well characterized in their inflammatory activation role. Prostaglandins have also been implicated in labor induction and metabolic regulation. The second conversion pathway uses lipoxygenases that generate hydroxyeicosatrenoic acids (HETEs). HETEs are well studied in their roles in vascular tissue. HETEs are known to be potent vasoconstrictors in the kidney and vasculature. The cyclooxygenase and lipoxygenase branches of arachidonic acid conversion are therefore stimulating in their roles both in blood pressure control and other essential physiological regulation. This section will focus, however, on the CYP conversion of arachidonic acid and what is known and hypothesized about its role in the brain. 20-HETE, an alternate product of CYP action, is discussed regarding its vasoactive effects opposite to that of EETs. Epoxygenases in the brain Most isoforms are able to convert AA to all regioisomer forms of EETs. Isoforms in the brain include CYP 2C11, 2C12, 2D18, 2D19, 2C29, 2C38, and 2C39, though more may be identified in the future (Roman 2002). Interestingly, the studies done to localize epoxygenase expression in the brain have pinpointed the enzymes to astrocytes. These studies hypothesize that central epoxygenases have a role in microvascular control. In contrast, though, CYP 2D19 has been localized to dopaminergic neurons, suggesting that CYP members are not found exclusively in the glia (Thompson et al. 2000). More

PAGE 30

17 research is needed to elucidate this pathway in conjunction with EET-mediated effects on cardiovascular control. 20-HETE Regioisomers of HETEs can also be generated by CYP, specifically -hydroxylase of the CYP 4A family. -hydroxylase converts arachidonic acid to 19-HETE and 20-HETE. 20-HETE acts as a vasoconstrictor in vessels ranging from the kidney to the brain. While EETs activate BK(Ca) channels, 20-HETE inhibits these channels, thus inducing contraction (Croft et al. 2000). Inhibiting 20-HETE results in a decrease in blood pressure due to the decrease in total peripheral resistance. Levels of both 20-HETE and CYP 4A are increased in the SHR (Omata et al. 1992). In addition, this vasoconstrictor is activated by Ang II, further elucidating its role in hypertension (Croft et al. 2000). Thus, 20-HETE functions are opposite to the vasodilator role reported for EETs and its overexpression is linked to hypertension. In summary, these arachidonic acid metabolites from the epoxygenase and -hydroxylase pathways serve a variety of functions throughout the body, and these functions are dependent on the converting enzymes that regulate the activity of these metabolites. sEH and Hypertension sEH has been implicated in cardiovascular, renal, and inflammatory biology functions. Recently, studies have linked sEH to hypertension through both a transgenic model overexpressing the gene and sEH inhibitor studies in the SHR. sEH-null mice were generated from offspring of chimeric mice with the disrupted sEH gene (Sinal et al. 2000b). Homologous recombination was used to disrupt the sEH gene in embryonic stem cells. High performance liquid chromatography (HPLC) revealed that the sEH-null mice had elevated levels of EETs and decreased levels of DHETs as compared to the wild-type

PAGE 31

18 mice. Blood pressure was measured using tail-cuff and compared between groups. Male sEH-null mice had decreased systolic blood pressure and did not have an increased blood pressure in response to salt loading. Female sEH-null mice had no significant change in systolic blood pressure. Thus, deletion of the sEH gene lowered systolic blood pressure to that of the female mice. An important subsequent finding was relative sEH expression in the SHR and WKY rat from Charles River Laboratories. As previously mentioned, the SHR is a good animal model to use for hypertension studies based on similarities to the human form of the disease (Lindpaintner 1994; Louis and Howes 1990; Trippodo and Frohlich 1981). Using an sEH-specific antibody, researchers found a significant elevation of sEH protein in the SHR kidney and liver; in fact, it was hardly detectable in the WKY rat (Yu et al. 2000a). Given the overexpression of sEH in the hypertensive model, researchers sought to determine whether the activity of this enzyme was linked to blood pressure. The second major paper addressing the sEH control in blood pressure involved the intraperitoneal (IP) delivery of sEH inhibitor N,Ndicyclohexylurea (DCU). Treatment with 3 mg/kg DCU resulted in a 65% decrease in 14,15-DHET and a 30% increase in 14,15-EET (Yu et al. 2000a). As a result, systolic blood pressure decreased by 22 mmHg in the SHR and had no significant effect in the WKY rat. Thus, pharmacological inhibition of sEH also results in a decrease of systolic blood pressure in hypertensive male rats. In summary, both a genetic and a non-genetic method for decreasing sEH in the periphery led to a decrease in systolic blood pressure and were accompanied by a decrease in the conversion of EETs to DHETs.

PAGE 32

19 Expression studies for sEH have also included alternate models of high blood pressure aside from the Charles River source of SHRs (Imig et al. 2002). Peripheral or central delivery of Ang II results in an increase in blood pressure and consequently hypertension (Allen et al. 2000; Di Nicolantonio et al. 1982). Ang II was chronically infused (60 ng/min) using an osmotic minipump, and blood pressure was recorded using tail cuff (Imig et al. 2002). Following IP injection of the sEH inhibitor N-cyclohexyl-N-dodecyl urea, systolic blood pressure decreased 30 mmHg in the Sprague-Dawley (SD) rat. Following sEH inhibition, sEH expression increased two-fold in the kidney. However, sEH overexpression is not present in all SHR sources. As discussed below, the Heidelberg (Heid) SHR has a lower sEH expression compared to its normotensive control. Thus, the importance of sEH overexpression in the peripheral tissues remains to be established. sEH Polymorphisms Rodent It is important to note that in the Ang II-infusion study, the basal sEH expression in the SD rats was highly variable, ranging from present to not present. This variable expression is typical of sEH in SD rats. SD rats are outbred, which increases the probability of new gene patterns with each new breeding source. Interestingly, sEH has known polymorphisms found in both rodent models and in humans. As previously described, the SHR from Charles River has increased sEH expression in both kidney and liver (Yu et al. 2000a). However, sEH expression in Heid SHR and WKY rats was oppositeWKY rats have increased sEH expression in the liver and kidney (Fornage et al. 2002). This finding was accompanied by the identification of a separate sEH allele in the Heid rat source. The two alleles differ by four single nucleotide polymorphisms

PAGE 33

20 (SNPs). Consequently, the polymorphism identified in the Heid source results in a blunted sEH activity. Thus, presence of these polymorphisms and reduced activity can explain the strain source difference in the Western blot analysis results. Human Polymorphisms in sEH have also been identified in humans; in fact, most of the research involving the sEH role in the human focuses on polymorphism and its effects ranging from sEH activity itself to coronary artery calcification. The human form of sEH is 73% identical to the mouse form, with 100% similarity in the catalytic triad (Przybyla-Zawislak et al. 2003). This highly conserved region underlies the importance of the sEH active site across species. The human sEH gene has been localized to the p arm of chromosome 8, specifically, 8p21-p12. The sEH gene is not without differences in its sequence, however, as highlighted by three separate studies. Initially, seven SNPs were identified in liver samples from twenty-five human subjects. Two of these SNPs resulted in amino acid substitutions, while the remaining five were silent mutations (Sandberg et al. 2000). In the second study, a total of thirty-six SNPs were identified in forty-eight members of the Japanese population. Five of these SNPs were found in exons of the gene (Saito et al. 2001; Sato et al. 2004). A third study resulted in the identification of six SNPs of the gene in a population size of seventy-two. Three of these polymorphisms had an increased level of epoxide hydrolase activity while one had decreased activity. The one with decreased activity also had significant reduction in 14,15-EET hydrolysis. Interestingly, the incidence of sEH polymorphisms in the sample group studies was higher in the Black population as compared to White or Asian population (Przybyla-Zawislak et al. 2003).

PAGE 34

21 sEH polymorphisms in cardiovascular disease This variation in sEH polymorphisms as related to race and disease was further examined in a recent correlation study. The sEH gene was mapped in 1201 African American and 1506 White subjects, and groups were separated based on the presence or absence of the genotypes Gln287/Gln287, Arg287/Gln287, Arg287/Arg287 (Fornage et al. 2004). The Gln287 polymorphism has been shown to result in a decrease in sEH activity. The presence of the Gln287 polymorphism was associated with a two-fold increase in coronary artery calcification in an African American subset of the Black population (Fornage et al. 2004). This finding suggests that a decrease in sEH activity and thus an increase in EETs may lead to an increase in coronary artery calcification in the African American population. In a separate study involving a family afflicted with familial hypercholesterolemia, the sEH polymorphism Glu287/Arg was identified (Sato et al. 2004). Results indicated that patients with one Arg287 allele as well as defects in the LDL receptor gene had elevated total cholesterol levels as well as plasma triglyceride levels. No positive correlation was identified in subjects not having defects in the LDL receptor gene. Thus, it is interesting that these different polymorphisms at the same locus elicit different effects on sEH activity. More research is needed to elucidate possible mechanisms underlying this hypothesis and other associations between sEH and cardiovascular disease. sEH polymorphisms in other disorders The Arg287/Gln287 polymorphism was further studied to identify any correlation between this sEH SNP and Parkinsons disease (Farin et al. 2001). The rationale behind the study was that a decrease in sEH activity leads to an increase in active epoxide

PAGE 35

22 intermediates, which may generate an increase in oxidative stress, leading to Parkinsons disease. No significant correlation was measured in Parkinsons patients, indicating a decrease in sEH activity was not related to Parkinsons disease. However, this study cannot rule out other sEH roles that may be related to CNS disorders or general oxidative stress in general. In addition, the general study size could mask a subset of Parkinsons disease development that may in fact stem from sEH dysregulation. Finally, SNP allele frequencies were measured in a subset of the Japanese population for future studies on cancer. The sEH gene was included in this study based on its involvement in conversion of toxins (Yoshimura et al. 2003). Thus, sEH is being examined in a variety of disorders and diseases based on its widespread activity and implications. In addition, its ubiquitous expression and polymorphisms resulting in changes in activity target this as a candidate gene for regulation of a number of genetic-based problems. Phosphatase Studies Two recent PNAS publications focused on the role of sEH as a phosphatase (Cronin et al. 2003; Newman et al. 2003). sEH was found to act as a phosphatase, though without high specificity. For example, sEH was not mediated by common phosphatase inhibitors including sodium orthovanadate (Newman et al. 2003). However, sEH did effectively metabolize a number of hydroxy lipid phosphates. The connection of phosphatase activity to the N-terminal domain was confirmed with both a plant form of sEH lacking the N-terminal domain and a mutant N-terminal domain form of sEH (Cronin et al. 2003). In both of these models, phosphatase activity of the enzyme was eliminated. In addition, sEH inhibitors used to block epoxide conversion had no effect on phosphatase activity. sEH function related to EET conversion is attributed to the C-terminal domain, which is homologous to haloalkane dehydrogenase (Cronin et al. 2003).

PAGE 36

23 These studies indicate that sEH may play an important physiological function through its phosphatase activity. While evidence into this line of research is sparse, it is conceivable that the number of polymorphisms in sEH across species and strains within species may generate differences in phosphatase activity and thus a novel role for this enzyme. Summary Hypertension is a complex disease controlled by a number of organs including the brain. While our understanding of the central regulation of blood pressure has a substantial base involving connections between specific nuclei in the hypothalamus and brainstem to the spinal cord, key mechanisms involved in the genetic basis of hypertension have not been elucidated. In order to fully understand this disease in the hopes of preventing and combating its progression, it is essential to identify genes and their pathways underlying the dysregulation of blood pressure. Using gene profiling involving microarray analysis of the hypothalamus and brainstem, sEH was found to be overexpressed in the SHR compared to the WKY rat brain. sEH is an enzyme that converts vasoactive EETs to their relatively inactive diol forms. Expressed in a variety of tissues, sEH has been implicated in the peripheral control of hypertension due to its increased expression in the hypertensive state and the resulting decrease in blood pressure following IP delivery of an sEH inhibitor. In addition, sEH polymorphisms are now being associated with cardiovascular disorders. Thus, sEH and its link to hypertension are well-characterized in the periphery. However, little is known about the role of this enzyme in the brain. Given the previous studies of sEH and hypertension coupled with its dramatic overexpression in the brain of the SHR, we hypothesized that sEH is involved in the

PAGE 37

24 central regulation of hypertension. In order to address this hypothesis, our aims were as follows: 1. Determine if central sEH expression is increased in the hypertensive state. These studies outlined in Chapter 2 focus on the validation of gene profiling data as well as whether this increased sEH expression is a cause or consequence of hypertension. 2. What is the physiological effect of inhibiting sEH in the brain? Chapter 3 discusses central sEH inhibitor studies in both SHR and WKY rats and the resulting blood pressure, heart rate, and baroreceptor reflex changes. 3. Does the pressor action of central Ang II function through NAD(P)H oxidase? As discussed earlier, the RAS plays a major role in the central regulation of blood pressure. In addition, ROS continues to emerge as a necessary component of this regulation. These studies in Chapter 4 address this question with central administration of NAD(P)H oxidase formation blockers and Ang II and resulting blood pressure changes. This role of ROS in the brain forms the basis of the central mechanism of sEH discussed in Chapter 5. 4. What is the central sEH mechanism that results in blood pressure and heart rate changes? Chapter 5 outlines experiments incorporating EET mediators, ROS production antagonists, and sympathetic blockers in order to elucidate the mechanism by which central sEH inhibition increases blood pressure. 5. Determine if sEH overexpression in the brain alters blood pressure and heart rate. These studies in Chapter 6 use the lentivirus to overexpress the sEH gene in the PVN of SHR and WKY rats. Blood pressure and heart rate are recorded daily and mechanisms underlying sEH control are studied using sEH inhibitors and EET agonists. Taken together, these aims dissect the role of sEH on the central regulation of blood pressure. The results of these experiments invoke intriguing questions into the specific effect of EETs in the brain and how this effect is regulated in the hypertensive and normotensive state. Overall, these studies provide further insight into the central regulation of blood pressure and propose a novel role of EETs in the brain.

PAGE 38

25 Figure 1-1 Major pathways of the RAS

PAGE 39

26 Figure 1-2 Major pathways of ROS production and metabolism

PAGE 40

27 Figure 1-3 Scatter plot of gene expression in the SHR and WKY hypothalamus and brainstem. Each point represents the average measurement for a gene. Dotted lines segregate genes with a two-fold expression change between SHR and WKY samples. sEH, indicated by the black arrow, is significantly upregulated in the SHR.

PAGE 41

28 Figure 1-4 Arachidonic acid metabolism

PAGE 42

29 Figure 1-5 Tissue-specific functions of EETs

PAGE 43

30 Figure 1-6 Cellular membrane actions of EETs

PAGE 44

CHAPTER 2 INCREASED SEH EXPRESSION IN SHR VS. WKY RAT BRAIN: IN VITRO AND IN VIVO ANALYSIS Introduction The brain is an essential component of the mechanisms controlling blood pressure. As previously discussed, specific nuclei of brain regions including the hypothalamus and brainstem function in the central regulation of blood pressure (Dampney 1994). Given the relative importance of the brain in establishing and maintaining hypertension coupled with the inadequacy of our knowledge of the mechanisms underlying this influence, it is imperative to study genes with discordant expression in the hypertensive state. By elucidating the roles of these genes in the brain, we better understand the mechanisms involved in the establishment of hypertension and therefore have more power with which to prevent and even reverse this disease. Chapter 1 discussed gene profiling findings that sEH had the most disproportionate mRNA levels in hypothalamus-brainstem samples of the male SHR compared to the male WKY rat. High sEH expression in the kidney also has been identified in hypertensive animal models (Imig et al. 2002; Yu et al. 2000a). In addition, deletion of the EPHX2 gene encoding sEH decreased the systolic blood pressure of male mice (Sinal et al. 2000b). These studies raise several questions regarding sEH expression. First, given the ubiquitous nature of this enzyme, is sEH overexpression in hypertensive models generalized and therefore not confined to renal action? What are the sEH expression levels in other cardiovascular-relevant tissues including the brain? Second, are 31

PAGE 45

32 differences in brain sEH expression the result of hypertension, or are they independent of blood pressure changes? The increased sEH mRNA levels in the SHR brain from microarray analysis must first be verified, given the unpredictability of microarray significance. Therefore, the first part of Aim I is to use real-time RT-PCR and Western blot analysis to measure sEH levels in the brain areas of SHR and WKY rats. The hypothesis is that both RNA and protein levels of the hypothalamus and brainstem are increased in the SHR compared to the WKY rat. The second part of Aim II is to determine if central sEH expression is independent of blood pressure changes. First, if sEH expression is increased in the hypertensive state, is that increase present from birth, or do the expression levels change with development? If the expression levels remain constant, then sEH expression cannot be a consequence of hypertension. Conversely, if the levels change, then sEH expression may be sensitive to changes in blood pressure. This question is important in understanding the role of sEH in the development of hypertension. To address this issue, neuronal cultures were prepared from one-day-old SHR and WKY rat pups. The hypothesis was that sEH overexpression was present from birth and not an effect of high blood pressure. The question of whether sEH expression is dependent on blood pressure changes was next addressed in the adult SHR. In contrast to measuring sEH expression prior to the development of hypertension, this experiment measured sEH expression following blood pressure normalization with losartan, a potent pharmacological AT 1 R blocker (Carr and Prisant 1996). We hypothesized that normalizing blood pressure in the SHR would

PAGE 46

33 not affect sEH protein levels in the brain, indicating that sEH expression is not dependent on blood pressure changes. The following studies thus address two facets of sEH expression. First, they determine whether the sEH data from the microarray studies do in fact translate to a change in sEH expression. Second, they answer whether sEH expression is driven by changes in blood pressure. Taken together, these experiments define central sEH expression in the SHR and WKY rat. Materials and Methods Animals Male SHR and WKY rats, weighing 220-250g at the beginning of the study, were ordered from Charles River Laboratories (Wilmington, Mass). Rats were housed individually and kept on 12:12 light:dark cycle in a climate-controlled room. Rat chow (Harlan Tekland, Madison, WI) and water were provided ad libitum. Number of animals per group are described in Results. All animal protocols were approved by the Institutional Animal Care and Use Committee of the University of Florida. Immunohistochemistry Rats were anesthetized with inhaled isofluorane (5%) and perfused transcardially with saline followed by 4% paraformaldehyde (PFA). SHR brains were post-fixed in PFA and saturated in 20% sucrose solution. 10-20 M sections were cut using a cryostat and mounted on poly-L-lysine-coated slides; the Rat Brian Atlas (Paxinos & Watson 4 th Ed 1998) was used as a reference. Sections were blocked in 2% bovine serum albumin (Sigma-Aldrich, St. Louis MO) dissolved in Tris-buffered saline with Tween (TBS-T, 0.1M Tris-HCl, 0.9% NaCl, 0.1% Tween) for three hours. Sections were then incubated with anti-sEH rabbit antibody overnight (1:500), a kind gift from Dr. Bruce Hammock,

PAGE 47

34 University of California Davis, followed by anti-rabbit biotinylated (1:200) for two hours and 10g/ml Avidin-FITC for one hour (Amersham Biosciences, Buckinghamshire, England). The sections were double-stained with either neuronal-specific (NeuN, 1:10, Amersham Biosciences) or glial-specific antibody [glial fibrillary acidic protein (GFAP), 1:10, a kind gift from Dr. Gerard Shaw, University of Florida] to detect cellular distribution of sEH. sEH localization was detected with fluorescent microscopy. Real-Time RT-PCR The RNAqueous-4PCR kit was used to isolate DNA-free RNA from tissue samples (Ambion, Austin TX). One-step real-time RT-PCR was performed on 50ng RNA per sample. Briefly, samples were combined with sEH-specific primers and probe (900nM forward: 5-GATTCTCATCAAGTGGCTGAAGAC-3; 900nM reverse: 3-GGACACGCCACTGGCTAAAT-5) and probe (250nM: 5-CCAGAACCCATCGGTGACCTCCAA-3) and TaqMan One-Step RT-PCR Master Mix and Multiscribe as described by the company (Applied Biosystems, Foster City CA). Primers and probe to 18S were used as an internal control. Reactions were carried out in the ABI PRISM 7000 sequence detector, and the standard curve method was used to calculate the threshold cycle (C T ) for target amplification. The input amounts were then calculated from the C T and standard curve and normalized using the 18S input amounts. Western Blot Analysis Total cell lysate (TCL) was isolated according to the companys research applications instructions (Santa Cruz Biotechnology Inc, Santa Cruz CA). Twenty g protein from either neuronal cultures or brain tissue were run on a 10% SDS-PAGE gel and transferred onto a nitrocellulose membrane. Following three hours of blocking with

PAGE 48

35 5% milk in TBS-T, the membrane was probed with the sEH rabbit-anti mouse antibody (1:3000 in 1% milk/TBS-T) overnight. Specificity of this antibody has been previously established (Sinal et al. 2000a; Yu et al. 2000b). The membrane was rinsed 3 times and washed for 20 min in TBS-T and then incubated with anti-rabbit IgG HRP-conjugated secondary antibody (1:3000) for 1 hour. Following final washes, the membrane was incubated with Western Lightning Chemiluminescence Plus reagent for 1 min and then exposed to film to visualize the bands (Perkin Elmer, Wellesley, MA). Neuronal Cells in Primary Culture Primary neuronal cultures (90% neurons, 10% glia) from the hypothalamus and brainstem of one-day-old SHR and WKY rats were prepared as previously described (Fleegal and Sumners 2003; Raizada et al. 1995; Sunn et al. 2002). The cells were cultured grown twelve days in Dulbeccos Modified Eagles Media (DMEM) + 10% horse serum at 37C, 10% CO 2 in 100 mm dishes. Three dishes were used per experimental group. Losartan Treatment of SHRs to Normalize Blood Pressure Losartan (10mg/kg/day) was delivered in the drinking water to male SHR (n=6) after determining the basal drinking rate to be 32 ml water/day. Six SHRs were kept on regular drinking water as control. The water bottles containing losartan were covered with aluminum foil to address the light sensitivity of the drug. Water intake and body weight were monitored daily one week prior to and up to one month following the start of losartan treatment. One rat in the control group was eliminated from the study due to its inability to develop high blood pressure. Systolic blood pressure was recorded using the tail cuff method three and four weeks after the start of losartan treatment. At the end of

PAGE 49

36 the experiment, protein and mRNA was isolated from the hypothalamus, brainstem, and cortex of the rats. Statistical Analysis All data are expressed as mean standard error (SE). The number of animals or samples in each group is described in the Results below. Comparisons between experimental groups were analyzed using either one-way ANOVA (SPSS) or Students T test (Stat View). Differences between means within groups were assessed with the Newman-Keuls analysis. Significance was set at a confidence level at or above 95% and is denoted by in each figure. Results Cellular Localization of sEH Immunohistochemical analysis revealed that sEH is localized to both neurons and glia throughout the SHR brain (n=3). Neurons were double-stained with both NeuN (red) and sEH antibody (green), and glial cells were double stained with both sEH antibody (green) and GFAP (red), as shown in Figure 2-1. Co-staining was identified by the yellow overlapping fluorescence detected using confocal microscopy. sEH was detected in all areas of the midbrain and brainstem sectioned. Control sections treated only with secondary and tertiary antibodies did not fluoresce at the intensity used for the confocal analysis, thus indicating the fluorescence was due to sEH antibody rather than background fluorescence. Fluorescence from the sEH antibody was localized to the cytoplasm and neuronal projections of the cell. No sEH was detected in the nucleus. This result corresponds with the nature of this protein, which is a cytoplasmic protein. The GFAP antibody was also localized to the cytoplasm rather than the nucleus, and overlapping fluorescence was observed in this area.

PAGE 50

37 sEH Expression in the SHR Profiling with microarray technology previously identified profoundly increased sEH mRNA levels in the brain of the SHR compared with its WKY normotensive control. Thus, the first objective was to determine if this result corresponded with RNA and protein levels measured by real-time RT-PCR and Western blot analysis, respectively. Figure 2-2 outlines the results of real-time RT-PCR using hypothalamus and brainstem isolated from four male SHR and WKY rats. Samples within each rat strain were combined; therefore, it is impossible to say with any certainty that there were differences. White and black bars represent sEH mRNA levels to normalized to 18S levels of WKY rat and SHR, respectively. sEH mRNA levels in the SHR were three-fold higher hypothalamus and six-fold higher in the brainstem compared to WKY rats. sEH protein expression was also increased in the SHR hypothalamus and brainstem. Figure 2-3 depicts a representative radiograph (A) and quantitation of sEH protein levels normalized to -actin (n=4/group) (B). In TCL isolated from the hypothalamus, relative sEH:-actin protein ratios in SHR and WKY rats were 0.52+/0.14 OD/mm 2 and 0.12+/-0.02 OD/mm 2 respectively. In the brainstem samples, the ratio was 0.60+/-0.14 OD/mm 2 in the SHR and 0.13+/-0.03 OD/mm 2 in the WKY rats. sEH protein levels were measured with Western blot analysis using the same sEH antibody source used in the peripheral studies. White and black bars represent WKY rat and SHR, respectively. sEH was barely detectable in WKY rats while they were dramatically increased in the SHR. In vitro Validation with Neuronal Cells in Primary Culture Primary co-cultures from hypothalamus-brainstem of WKY and SHR have been used in the past to elucidate cellular and molecular mechanisms of physiological

PAGE 51

38 dysregulation in neural control of hypertension (Sun et al. 2003b; Yang et al. 2004). These cultures were used to determine if sEH overexpression in these hypertensive animals is present prior to the establishment of high blood pressure. Western blot analysis demonstrated a four-fold increase in sEH protein levels in neuronal cultures of SHR vs. WKY rats, indicating that sEH overexpression is present from birth in the SHR (Figure 2-4). The ratio of sEH to -actin protein was 0.34+/-0.15 OD/mm 2 in the SHR and 0.08+/-0.04 OD/mm 2 in the WKY rats (n=4/group). Panel (A) is a representative radiograph highlighting the sEH and -actin protein bands. Panel (B) is the graphical representation of sEH protein levels normalized to -actin from the four sets of neuronal cultures. sEH Expression Following Blood Pressure Normalization Delivery of losartan (10mg/kg/day) into the drinking water resulted in a significant decrease in systolic blood pressure in the SHR one month following the initiation of losartan treatment. Three weeks after the start of the study, systolic blood pressure was 33 mmHg lower in the rats treated with losartan [181.48+/-5.11 mmHg SHR (n=5), 148.40+/-1.71 mmHg SHR + losartan (n=6)]. This gap widened to a decrease in systolic blood pressure by 38 mmHg (173.84+/-4.40 mmHg SHR, 136.28+/-2.05 mmHg SHR + losartan) one month following the start of losartan treatment (Figure 2-5). Body weights were not significantly different between groups. At the end of the study, brains were dissected and protein isolated from losartan-treated and control rats. Western blot analysis revealed no significant change in the ratio of sEH to -actin expression in the hypothalamus between the losartan-treated (0.530+/-0.078 OD/mm 2 ) and control rats (0.739+/-0.246 OD/mm 2 ) (Figure 2-6). Similarly, the

PAGE 52

39 ratio of sEH to -actin expression was 0.863+/-0.026 OD/mm 2 and 0.840+/-0.066 OD/mm 2 in the brainstem of the losartan-treated and control-treated SHRs, respectively. White and black bars represent losartan-treated and control samples, respectively. Thus, sEH expression in the SHR was not affected by blood pressure depression using an AT 1 R antagonist delivered orally. Discussion This study was the first to measure and compare central sEH expression between hypertensive and normotensive animal models. Both sEH mRNA and protein levels were elevated in the hypothalamus and brainstem of SHR compared to WKY rats. This overexpression was independent of blood pressure changes because (i) sEH overexpression existed in neuronal cultures from prehypertensive rats and (ii) normalization of blood pressure with losartan did not alter sEH expression levels. These expression studies validate the gene profiling data, are parallel to the expression findings in peripheral tissue and provide a foundation on which to study sEH in the central control of hypertension (Imig et al. 2002; Yu et al. 2000a). Immunohistochemical studies established that sEH is expressed in both neurons and glial cells of one-day-old SHR and WKY rats. In contrast, CYP and EETs have been mainly localized to astrocytes and endothelial cells surrounding the cerebral vasculature (Alkayed et al. 1997; Gebremedhin et al. 1992; Medhora et al. 2001; Shivachar et al. 1995). Thus, the role of sEH in the brain may involve divergent roles including sympathetic nerve activation through neuronal pathways or control of cerebral blood flow. The role of central sEH in relation to blood pressure likely stems from neuronal control given two sets of data. First, sEH was overexpressed in neuronal cultures of one

PAGE 53

40 day-old SHRs. Second, sEH expression does not differ in glial cultures of SHR and WKY rats (data not shown). In the brain areas studied, sEH protein and mRNA levels were significantly increased in the SHR compared to the WKY rat. This result correlates to the peripheral studies that showed an increase in sEH expression in the kidney and liver of SHR and Ang II-induced hypertensive models (Imig et al. 2002; Yu et al. 2000a). Thus, in all tissue areas studied, sEH is more abundant in the Charles River SHR compared to the WKY rat. This result therefore proves that sEH overexpression is not limited to the renal and hepatic systems of the SHR but is in fact present in other cardiovascularly-relevant areas. This was the first study to measure sEH expression patterns in non-adult animal models. sEH was highly expressed in neuronal cultures from one-day-old SHR compared to WKY rats. This result indicates that sEH expression patterns exist from birth and are not affected by the onset of hypertension. However, these results alone do not prove that increased sEH expression in the brain is the cause of any change in blood pressure. Future studies in which either central sEH is blocked during development in a hypertensive strain or overexpressed in the brain of normotensive strain would serve to answer this question. The conclusion that central sEH expression is independent of systemic blood pressure changes was also supported by the normalization of blood pressure experiment. Chronic delivery of losartan into the drinking water had no effect on the sEH levels in either the hypothalamus or the brainstem. This result suggests that depression of blood pressure in the SHR does not alter sEH expression. Losartan is a potent AT 1 R blocker

PAGE 54

41 that is often used to evaluate the role of RAS (Carr and Prisant 1996). The decrease in systolic blood pressure by almost 40 mmHg following its oral delivery highlights the essential role RAS plays in blood pressure regulation. However, this decrease in blood pressure was not accompanied by changes in sEH expression. Several caveats regarding this experiment must be addressed. First, sEH expression was only measured at one time point, three weeks following the start of losartan delivery. Therefore, one cannot discount expression changes prior to or following this time point. For example, perhaps sEH expression was affected during the initial drop in blood pressure and then recovered by means of feedback mechanisms after three weeks. This result would indicate that sEH expression might have a role in the RAS regulation of blood pressure. Alternately, sEH expression may be affected after four weeks of treatment or longer due to delayed mechanisms. If this postulation were true, then sEH expression would be dependent on blood pressure changes. Another possibility is that while sEH expression may not change following blood pressure normalization, either the enzymes activity or the affinity of the product for its receptor may be affected. Regardless of expression levels, if the enzymatic activity changes, then the role of sEH following blood pressure changes must be reassessed. sEH activity is generally determined by HPLC analysis to compare the levels of EETs and DHETs (Yu et al. 2000a). This analysis should be performed in the future in order to confirm that sEH is independent of blood pressure changes. Finally, further studies incorporating different means of altering blood pressure should be performed since blood pressure normalization does not follow only one mechanism. In this experiment, losartan was delivered via the drinking water; therefore,

PAGE 55

42 the blood pressure was normalized by blocking peripheral AT 1 R that results in a decrease in total peripheral resistance. While central sEH expression was not affected by this method, it may have changed had the losartan been delivered to the brain, thus decreasing sympathetic nerve activity. To verify that the sEH expression is independent of blood pressure depression, other antihypertensive agents including diuretics should be incorporated. Alternately, sEH gene regulation may be constitutively active in the SHR and therefore other hypertensive models should be incorporated. Similarly, sEH expression may only be activated with blood pressure stimulation rather than depression. While we can conclude that decreasing blood pressure via oral delivery of losartan does not alter central sEH expression, this result does not conclusively prove that central sEH is independent of any change in blood pressure. Collectively, these studies reveal that central sEH expression is higher in the SHR compared to the WKY rats. In addition, these results suggest that central sEH expression is independent of blood pressure changes. Given the dichotomy of central sEH expression in the SHR and WKY rat, what effect, if any, do these expression changes have on the central control of blood pressure? Does sEH overexpression in the brain have a role in hypertension? To begin to answer these questions, Chapter 3 outlines central sEH inhibition studies to determine whether pharmacological blockade of sEH action in the brain results in a change in blood pressure.

PAGE 56

43 Figure 2-1 Cellular localization of sEH in the brain. Following perfusion, SHR rat brains sections (20M) from the midbrain were prepared for immunohistochemical analysis of sEH and its localization to neurons and glial cells. sEH Antibody is detected by green fluorescence, while the red fluorescence detects either neurons (upper panel) or glia (lower panel). Yellow fluoresence marks the overlap between sEH Antibody and cell type-specific Antibody. All images were taken using confocal microscopy.

PAGE 57

44 Figure 2-2 sEH mRNA levels in SHR and WKY brain regions. RNA was isolated from hypothalamus and brainstem regions of SHR and WKY rat brains (n=4/combined in each group). Real-time RT-PCR incorporating sEH-specific primers and probe was used to measure sEH cDNA levels in samples from these extracted tissues. Data were normalized with primers and probe to 18S and are presented as arbitrary units (AU). White and black bars represent WKY and SHR samples, respectively. Reprinted with permission from The FASEB Journal.

PAGE 58

45 Figure 2-3 sEH protein expression in SHR and WKY brain regions. Protein was isolated from hypothalamus and brainstem regions of SHR and WKY rat brains (n=4/combined in each group). Western blot analysis was used to measure sEH protein levels in from 40g total cell lysate. (A) Representative radiograph of sEH and -actin. (B) Data were normalized with -actin. White and black bars represent WKY and SHR samples, respectively. Data are represented as mean+/-SEM. significantly different in SHR and WKY rat (p<0.05). Reprinted with permission from The FASEB Journal.

PAGE 59

46 Figure 2-4 sEH protein expression in neuronal cultures. Total cell lysate was isolated from hypothalamus and brainstem co-cultures from one-day-old SHR and WKY rats. (A) Representative radiograph of sEH and -actin. (B) Quantitation of sEH protein normalized with -actin protein band. Data are represented as mean+/-SEM. significantly different in SHR vs. WKY samples (p<0.05, n=4/group). Reprinted with permission from The FASEB Journal.

PAGE 60

47 Figure 2-5 Effect of chronic losartan delivery on SBP in the SHR. Losartan (10mg/kg/day) was delivered orally to male SHRs. SHRs only receiving water were used as control. SBP was recorded using tail cuff recordings. Data are represented as mean+/-SEM. *significantly different between groups (p<0.05, n=6)

PAGE 61

48 Figure 2-6 Effect of chronic losartan delivery on central sEH expression. Total cell lysate was isolated from brainstem and hypothalamus, and Western blot analysis performed as described in Methods to compare sEH protein levels. sEH expression was normalized with -actin and presented graphically. White and black bars represent losartan and control treatments, respectively. Data are represented as mean+/-SEM (p<0.05, n=6).

PAGE 62

CHAPTER 3 CENTRAL SEH INHIBITION INCREASES BLOOD PRESSURE AND HEART RATE IN THE SHR Introduction Pharmacological sEH inhibitors delivered IP to the SHR led to a decrease in blood pressure (Yu et al. 2000a). This depressor effect is postulated to involve the accumulation of vasodilatory EETs. What is the effect of central sEH inhibition on blood pressure? Chapter 2 revealed an sEH overexpression in the hypothalamus and brainstem of the SHR. These results correlated with increased renal and hepatic sEH expression in hypertensive models (Imig et al. 2002; Yu et al. 2000a). Given the similarity of expression patterns in the different tissues, does sEH also yield a pressor response in the brain? Prior to embarking on these studies, it is necessary to understand the action and limitations of the currently available sEH inhibitors. Pharmacological agents used as sEH inhibitors act as competitive inhibitors by forming hydrogen bonds and salt bridges with the active site of sEH. These compounds have evolved both in their potency and versatility of use. The first round of inhibitors were tight-binding with K(I) values in the nanomolar range; however, limitations hampered the extended use of these compounds (Morisseau et al. 1999). First, the compounds had a high crystal lattice energy that translated to an elevated melting point. Second, they were not water-soluble and therefore were not easily dissolved in agents that could be applied for use in vivo or in vitro. 49

PAGE 63

50 The major sEH inhibitor used in published animal studies is N,N-dicyclohexylurea (DCU), a 1,3-disubstituted urea that is formed by hydrolysis dicyclohexylcarbodiimide (Morisseau et al. 2002). DCU specifically inhibits sEH and has no effect on mEH, CYP or any other tested compounds related to the structure of sEH. DCU and related compounds were determined to be effective sEH inhibitors because of hydrophobic groups on either side of the urea (Morisseau et al. 1999). In physiological studies, DCU was delivered to the SHR via IP injection, and blood pressure was recorded using photoelectric tail cuff. DCU delivery decreased urinary excretion of 14,15-DHET by 40%, indicating the functionality of this inhibitor. sEH inhibition resulted in a decrease in systolic blood pressure 12+/-2 mmHg after six hours (Yu et al. 2000a). This time lapse of blood pressure effect may be due to the kinetics of the drug as well as its processing by the liver. This study provided the first pharmacological evidence linking sEH to blood pressure control. While DCU is effective in its blockage of sEH function, it is limited by its solubility in water. Thus, a new generation of soluble, potent sEH inhibitors was synthesized. One main structural change underlying these improvements was substituting a hydrophobic side group with a polar functional group arranged in an alkyl chain (Kim et al. 2004). Adamantyl urea dodecanoic acid (AUDA) is one such second-generation sEH inhibitor. It is disubstituted with an adamantyl group on one end and an eleven-membered carbon chain on the other. It was formulated and characterized by Bruce Hammocks research group at University of California, Davis. This pharmacological inhibitor has an IC 50 of 18+/-1 nM with mouse sEH (Morisseau et al.

PAGE 64

51 2002). In comparison, DCU has a less potent IC 50 of 81.8+/-0.7 nM with mouse sEH. AUDA is therefore a promising candidate as an sEH inhibitor. Overall, pharmacological sEH inhibitors have evolved in their potency and specificity. We chose to use these inhibitors in vivo as blockers of sEH activity. The following experiments outline physiological measurements following the central delivery of either DCU or AUDA. Given the sEH expression patterns in the brain mimics that of the periphery, we hypothesized that ICV delivery of sEH inhibitors would lead to a decrease in blood pressure in the SHR. Materials and Methods Animals Statistical Analysis The above Methods are described in Chapter 2 ICV Cannulation Rats were anaesthetized with inhaled isofluorane (3%) in all surgical procedures. A stereotaxic frame was used to position a twenty-two-gauge guide cannula (PlasticsOne, Roanoke VA) into the right lateral ventricle (AP: 1.3mm, ML: 1.5mm, 4.5mm below skull) of male SHR and WKY rats. The cannula was secured to the skull with dental resin assisted by 3 3/32 screws secured in the skull. Appropriate drugs (1-2l) were injected into the right lateral ventricle of unrestrained rats using a 28 gauge internal cannula, 4.5mm. Rats were allowed to recover for one week following all surgeries. Abdominal Aorta Cannulation A radiotelemetric pressure transducer (Data Sciences International, Arden Hills MN) consisting of a fluid-filled catheter attached to a PA-C40 transmitter was implanted into the abdominal aorta. The aorta was clamped proximally and the catheter inserted

PAGE 65

52 caudal to the left renal artery and secured with medical adhesive. Prior to suturing the abdomen, the transducer was checked for proper placement using a radio to transmit the sound oscillations from pressure changes in the aorta. Rats were anaesthetized with inhaled isofluorane (3%) during surgery and allowed to recover one week following the surgical procedure. Blood Pressure and Heart Rate Recordings Blood pressure and heart rate were recorded using the implanted radiotelemetry transducers. For each dataset acquisition, the rat cages were positioned on receivers that collected signals from the implanted transducers. These signals were then transmitted to an adapter with an ambient pressure monitor that relayed the signals to the DataQuest 3.1 Acquisition program (DataSciences International, Arden Hills MN). The rats were allowed to acclimate to their new cage position for at least one hour before basal measurements were recorded. During data collection, blood pressure (systolic, mean and diastolic), heart rate and activity were recorded every minute for an average of ten seconds at 500Hz. Data were acquired and transferred to Microsoft Excel for graphical analysis. In vivo Drug Delivery sEH inhibitors were delivered via the ICV cannula into the right lateral ventricle of unrestained rats. A 4.5 mm injector containing the inhibitor was inserted and secured into the cannula. The injector was attached to a 5l Hamilton syringe via 0.38 mm polethylene tubing 120 cm in length (Becton Dickinson Sparks, MD). sEH inhibitors DCU and AUDA (0.8-60ng, 2l volume) were a kind gift from Dr. Bruce Hammock, University of California, Davis. DCU and AUDA were dissolved in 10% DMSO/90%

PAGE 66

53 artificial cerebrospinal fluid (aCSF: 133mM NaCl, 3.4mM KCl, 1.3mM CaCl 2 1.2mM MgCl 2 6mM NaH 2 PO 4 32mM NaHCO 3 ) and 100% aCSF, respectively. These inhibitors as well as their vehicle controls were delivered as a single bolus to singly-housed, unrestrained SHR and WKY rats. Results Effect of sEH Inhibitor DCU on Blood Pressure and Heart Rate Figure 3-1 outlines the physiological response to sEH inhibition. Figures 3-1A,B are representative recordings of blood pressure (A) and heart rate (B) in the SHR (red) and the WKY rat (blue). The x-axis is time related to DCU injection in hours. Figures 3-1C,D are bar graphs of peak blood pressure (C) and heart rate (D) responses to DCU, expressed as mean +/SEM. WKY rat In the WKY rat, heart rate increased from 342.4+/-7.6 bpm with vehicle delivery to 393.1+/-19.0 bpm following 90ng DCU (Figure 3-1D). There was no significant change in blood pressure in the WKY rat (113.78+/-3.03 mmHg CSF, 120.34+/-1.96 mmHg DCU, n=4). The increase in heart rate began within one hour following injection and normalized after two hours. SHR Central delivery of sEH inhibitors resulted in an increased blood pressure and heart rate in the SHR. DCU (90ng) injected into the right lateral ventricle increased blood pressure from 153.0+/-7.8 mmHg to 184.5+/-5.3 mmHg and increased heart rate from 339.6+/-15.3 bpm to 433.5+/-11.5 bpm (n=4) (Figure 3-1C,D). The increase in blood pressure and heart rate initiated within one hour of injection and peaked at three to four

PAGE 67

54 hours after injection. Blood pressure and heart rate were normalized within seven hours following injection. Effect of sEH Inhibitor AUDA on Blood Pressure and Heart Rate The results from ICV injection with DCU indicate that heart rate is increased in both the SHR and WKY rat following sEH inhibition. Blood pressure, however, was increased only in the SHR. No pressor responses were detected in the WKY rat. In order to verify these results, we used a second sEH inhibitor AUDA that later became available from Dr. Bruce Hammock at University of California Davis. As previously discussed, AUDA is more potent and has increased water solubility, thereby making it a better pharmacological agent for testing the physiological effects of sEH inhibition. Dose response ICV administration of AUDA, a potent sEH inhibitor, caused a dose-dependent increase in both blood pressure and heart rate in the SHR. Figure 3-2 is a graphical representation of the change in blood pressure following delivery of either 0.8ng or 7.5ng AUDA. Artificial cerebrospinal fluid was used as the control. Either concentration of AUDA elicited only modest increases in blood pressure in the WKY rats [23.61+/-2.90 mmHg 0.8ng AUDA (n=5), 12.49+/-3.72 mmHg 7.5ng AUDA (n=4)]; however, the 0.8ng AUDA dose was the only delivery that yielded significance (Figure 3-2). The alternate doses did not yield blood pressure increases that significantly differed from that of aCSF injection (13.74+/-1.82 mmHg, n=4). In the SHR, a significant increase of 25+/-0.9 mmHg in blood pressure was seen with as low as 0.8ng AUDA, and a dose of 7.5ng AUDA increased blood pressure by 31.8+/-3.9ng AUDA (n=3).

PAGE 68

55 WKY rat Given this initial dose response, 15ng AUDA was used in the remaining studies in order to measure the maximum physiological effects of sEH inhibition. Figures 3-3A,B depict representative blood pressure (A) and heart rate (B) recordings prior to and following ICV delivery of 15ng AUDA. Quantitation of blood pressure and heart rate recordings are charted in Figures 3-3D,E. ICV delivery of 15ng AUDA did not significantly change blood pressure in the WKY rat (106.52+/-2.40 mmHg basal change, 115.91+/-2.30 mmHg AUDA, n=6). Alternately, heart rate increased from 311.60+/-9.22 bpm to 358.06+/-7.73 bpm, a change of 46+/-12 bpm following AUDA injection (Figure 3-3). SHR Figures 3-3A,C depict representative blood pressure (A) and heart rate (C) recordings prior to and following ICV delivery of 15ng AUDA. Quantitation of blood pressure and heart rate recordings are charted in Figures 3-3D,E. Central delivery of 15ng AUDA resulted in a change in blood pressure from 148.04+/-1.18 mmHg to 180.48+/-0.25 mmHg, an increase of 32 mmHg (n=6). In addition, heart rate increased from 334.44+/-2.52 bpm to 388.24+/-0.80 bpm, a change of 54 bpm (Figures 3-3). This increase began to express after thirty minutes, reached maximal levels in three to four hours and returned to basal levels in seven hours. Discussion These studies are the first to determine the physiological effects of inhibiting sEH action in the brain. Central sEH inhibition resulted in an increase in both blood pressure and heart rate in the already hypertensive SHR. While heart rate increased in the WKY rat, blood pressure did not dramatically change following ICV delivery of sEH inhibitors.

PAGE 69

56 These results were opposite from the hypothesized decrease in blood pressure and from the depressor effect of IP delivery of DCU to the SHR. Given the whole-body overexpression of sEH in different hypertensive models, why is the physiological effect of sEH inhibition in the brain opposite from that in the periphery? The understanding of how sEH in the periphery affects blood pressure is limited. Explanations are based on the enzymes conversion of vasodilatory EETs to relatively inactive DHETs. The major function of EETs is to increase the open-state probability of BK(Ca) channels in vascular smooth muscle cells (Harder et al. 1995; Li and Campbell 1997). sEH depletes the stores of EETs, thereby leading to vasoconstriction in the vasculature. This hypothesis is supported by increased sEH expression in both the SHR and Ang II-induced models of hypertension (Imig et al. 2002; Yu et al. 2000a). Translation of this hypothesis to the central role of sEH, however, is complex. sEH may function to deplete stores of EETs surrounding the cerebral arteries, leading to constriction and decreased cerebral blood flow. However, while decreased cerebral blood flow is highly implicated in stroke, its direct regulation on blood pressure is not clear. In addition, sEH is found in neurons; therefore, its potential role in sympathetic activation cannot be discounted. Thus, while sEH expression patterns are the same in the brain and the periphery, the mechanism underlying sEH influence on blood pressure is not. One important question is whether ICV delivery of DCU and AUDA is an effective means to inhibit sEH. DCU (3mg/kg, IP) was previously used in physiological studies and effectively decreased 14,15-DHET urinary excretion by 65% (Yu et al. 2000a). Thus, this pharmacological inhibitor injected IP acts on tissues to inhibit the activity of

PAGE 70

57 this enzyme. However, the tissue-specific effect of this delivery was not known, nor do we know what percentage of DCU was taken up and converted by the liver. In addition, transfer efficiency of this drug to the brain is not known. This concern of sEH inhibition effectiveness in these central studies is first addressed by the use of two inhibitors rather than only one. Both have been found to inhibit sEH activity and not other members of this family of inhibitors such as mEH. In addition, AUDA is more potent than DCU, the inhibitor used in the previous studies. One caveat of this current study, however, was that the sEH activity was not measured. Measurements of EETs and DHETs by HPLC analysis must be incorporated into future studies to conclusively state that DCU and AUDA delivery to the lateral ventricle attenuates sEH activity in the brain. Cardiovascularly-relevant brain regions should be individually analyzed in order to ascertain which regions ICV delivery of these pharmacological agents are targeted. Only by meticulous analysis of sEH inhibition in specific brain nuclei can we conclude what areas are involved in this pressor response. One interesting observation was the discrepancy of blood pressure and heart rate effects between the SHR and WKY rat. The lack of blood pressure response coupled with an attenuated heart rate response in magnitude and duration in the WKY rat compared to the SHR suggests differential central pathways between these two strains. Given the low endogenous level of sEH in the brain of the WKY rat, it logically follows that the sEH inhibitor would have a limited supply of enzyme on which to act compared to the hypertensive rat. sEH inhibition in these two strains may act through the same pathway but yield different results due to endogenous sEH expression. Alternately, since

PAGE 71

58 the SHR is known for its dysregulation of blood pressure control, one of these central pathways unique to the SHR or hypertension itself may involve sEH. These inhibitor studies suggest that the overexpression of sEH in the SHR brain may be a compensatory outcome of this hypertensive strain. We know that increased sEH expression has not normalized the blood pressure in the SHR; however, inhibition of this enzyme increases the blood pressure. Thus, without the increased sEH expression in the brain, blood pressure in the SHR would be even higher. This idea cannot be supported on an individual basis, given the increased sEH expression in neuronal cultures from one-day-old SHR pups. This hypothesis instead is rooted in a proposed evolutionary development of the SHR over generations. sEH overexpression in the brain may have been selected for during reproduction due to increased embryo viability. Alternately, whole-body sEH overexpression may have stemmed from random mutations that collectively result in an increased blood pressure. Thus while the brain function of sEH attenuates blood pressure, this beneficial effect is masked by the increased pressor response from alternate pathways. Finally, ICV delivery of sEH inhibitors may not be a comprehensive look at sEH in the brain. The cerebral vasculature selectively targets certain brain regions, and injection into the right lateral ventricle will likely target areas immediately surrounding the site of injection. It is necessary as discussed above to measure the physiological effects of sEH inhibition in various brain regions in order to elucidate its role in the central control of blood pressure. The question, however, is how central sEH inhibition increases blood pressure and heart rate. These studies conclude that pharmacological sEH inhibitors delivered to the lateral ventricle results in an increase in blood pressure and heart rate in the SHR. It is

PAGE 72

59 essential to elucidate the mechanisms underlying this blood pressure effect stemming from the brain. Do these effects also include the conversion of EETs, the main substrate identified for sEH? Or does this enzyme act through a different pathway unique to the brain? The answers to these questions will be undertaken by experiments discussed in the next two chapters incorporating known regulators of blood pressure control in the brain.

PAGE 73

60 Figure 3-1 Effect of ICV DCU delivery on blood pressure and heart rate. DCU was injected into the lateral ventricle of SHR and WKY rats. Representative tracings of blood pressure (A) and heart rate (B) in SHR and WKY rats. Quantitation of blood pressure (C) and heart rate (D) following DCU or aCSF injection. These values represent the peak time of blood pressure response over a ten-minute period. The first and second arrows represent the point of injection of aCSF or DCU, respectively. Data are expressed mean +/-SEM. represents significance between groups (p<0.05, n=4). 1

PAGE 74

61 Figure 3-2 Dose response of ICV delivery of AUDA to SHR and WKY rats. aCSF, 0.8ng and 7.5ng AUDA were delivered to SHR and WKY rats. Blood pressure was recorded using radiotelemetry. Mean change in blood pressure was plotted; error bars represent SEM. significantly different from aCSF response (n=4, p<0.05).

PAGE 75

62 Figure 3-3 Effect of central AUDA on blood pressure and heart rate. 15ng AUDA was delivered ICV, and radiotelemetry was used to record blood pressure and heart rate. (A) MAP of SHR (red) and WKY rats (blue). (B,C) Representative HR of WKY rats and SHRs, respectively. Quantitaton of MAP (D) and HR (E). White and black bars represent basal and AUDA-induced levels, respectively, as means +/SEM. significantly different from basal (p<0.05, n=6). Reprinted with permission from The FASEB Journal.

PAGE 76

CHAPTER 4 ROLE OF ROS IN ANG II-INDUCED REGULATION OF BLOOD PRESSURE Introduction The role of the brain in hypertension remains to be fully elucidated. Chapter 1 outlined the major RAS pathways and evidence linking Ang II to the central control of blood pressure. RAS members are localized to a number of cardiovascularly-relevant brain areas including the PVN and SON in the hypothalamus and the RVLM and NTS in the brainstem (Bastos et al. 1997; Mangiapane and Simpson 1980; Muratani et al. 1993; Tanaka et al. 2001). An overactive RAS in these areas leads to an increase in blood pressure due to sympathetic nerve activation. Thus, while the RAS was initially identified as systemic, the brain RAS is an excellent example of cardiovascular control localized to one organ. The binding of Ang II to the AT 1 R induces the most significant pressor response of the RAS members (Helin et al. 1997). Overwhelming electrophysiological and pharmacological evidence indicates that the binding of Ang II to the AT 1 R stimulates sympathoexcitatory neurons that in turn signal to the IML to induce blood pressure (Reid 1992). Specifically, Ang II increases neuronal firing rate by activating calcium channels and inhibiting the delayed rectifier potassium current (Sun et al. 2003a; Zhu et al. 1997). These changes in firing rate are prevented by losartan. Thus activation of catecholaminergic neurons by Ang II is through its binding to the AT 1 R. Although the overall pressor effect of central Ang II is established, the mechanisms underlying this activation are complex and not well understood. An emerging set of 63

PAGE 77

64 regulators in this pathway is the ROS. As previously discussed in Chapter 1, ROS results in a dysregulation of a number of physiological pathways and has been linked to a multitude of diseases including cancer. Hypertension is no exception. Striking evidence has linked an overproduction of ROS to an increase in blood pressure Recently, studies have focused on the role of ROS in the central control of hypertension (Zimmerman and Davisson 2004; Zimmerman et al. 2002). Treatment of primary cultures from the lamina terminalis with Ang II resulted in an increase in superoxide, thereby linking Ang II action to ROS production (Zimmerman et al. 2002). Gene therapy strategies also have defined the overall effect of ROS members on blood pressure, though the underlying mechanisms are not understood. Ang II-induced blood pressure was prevented in mice centrally injected with Adenovirus containing either mitochondrial or cytoplasmic SOD (Zimmerman et al. 2002). Adenovirus was also used to inhibit NAD(P)H oxidase activator Rac1 production in the CVOs. NAD(P)H oxidase is a key enzyme involved in the formation of free radicals from oxygen. Again, the blood pressure and dipsogenic responses to Ang II were prevented (Zimmerman and Davisson 2004). This evidence indicates ROS production is involved in the Ang II-induced blood pressure responses. While these studies provide a basis of ROS-RAS interaction, it is necessary to elucidate key ROS members and provide further insight into the mechanisms behind this interaction. Given the emerging evidence that ROS is linked to the central action of Ang II, do the Ang II-induced pressor and dipsogenic actions require ROS member NAD(P)H oxidase specifically? To answer this question, we used NAD(P)H oxidase formation blocker gp91ds-tat, a compound discussed in Chapter 1, whose high specificity

PAGE 78

65 distinguishes the action of NAD(P)H oxidase from other ROS members. This study provides a comprehensive analysis of the overall central effect of NAD(P)H oxidase on Ang II action. We hypothesized that pretreatment of the brain with gp91ds-tat would prevent the ICV Ang II-induced pressor and dipsogenic responses in the SHR and WKY rat. Methods Animals ICV Cannulation Abdominal Aorta Cannulation Statistical Analysis A description of the above Methods is found in Chapter 2. In vivo Drug Delivery All drugs were delivered via the ICV cannula into the right lateral ventricle of unrestained rats. The drug solutions were delivered using an injector 4.5mm in length that was secured in the ICV cannula. The injector was attached to 0.38mm polyethylene tubing 120 cm in length (Becton Dickinson, Sparks, MD) with a 5l Hamilton syringe attached to the other end of the tubing. All injections were given to unrestrained, singly-housed rats. When testing the mechanism of Ang II requiring two drugs, the first drug was injected one hour prior to the second, and the dummy cannula was replaced following injection. 30ng Ang II dissolved in CSF was delivered to the right lateral ventricle (1l injection) using a 5l Hamilton syringe with fitted tubing + injector. gp91ds-tat and its scrambled peptide used as a control (200-800ng each, 2l, dissolved in CSF) were

PAGE 79

66 synthesized by the Temple University Protein Synthesis Core facility (Philadelphia, PA) and used to inhibit the action of NAD(P)H oxidase (Rey et al. 2001a; Rey et al. 2001b). Dipsogenic Response Water intake of WKY rats (n=3) following ICV delivery of Ang II was measured using sterile graduated glass pipets fitted with metal sipper tubes. The pipets were filled with water from the rats sterile water bottles. The pipets replaced the water bottles thirty minutes prior to the first injection. Water level in milliliters was recorded thirty minutes prior to, at injection time, and thirty minutes post Ang II injection. Drinking was calculated as the basal water level minus the water level thirty minutes following the Ang II injection. Rats remained singly-housed and were not restrained during the experiment. Results Angiotensin II Pressor Response Figure 4-1 depicts the changes in blood pressure and heart rate following ICV Ang II delivery in the SHR and WKY rat. ICV delivery of 30ng Ang II to conscious, free-moving WKY rats (n=5) resulted in an increase in blood pressure from 102.81+/-3.36 mmHg to 146.90+/-1.87 mmHg, a change of 44 mmHg (Figure 4-1C). Heart rate increased 44 bpm, from 320.13+/-7.37 bpm to 364.22+/-25.39 bpm (Figure 4-1D). Figure 4-1A shows representative blood pressure and heart rate recordings surrounding Ang II delivery to the WKY rat. The central Ang II response began within two minutes following injection, and maximum response occurred by ten minutes. Blood pressure and heart rate were normalized one hour post injection. Central delivery of Ang II (30ng) to the SHRs (n=3) also resulted in a pressor response. Blood pressure increased from 148.61+/-1.09 mmHg to 191.36+/-6.14 mmHg following Ang II treatment, a change of 43 mmHg (Figure 4-1C). Heart rate increased

PAGE 80

67 from 310.15+/-15.39 bpm to 432.93+/-9.64 bpm, an increase of 123 bpm (Figure 4-1D). Representative recordings of blood pressure and heart rate of the SHR are shown in Figure 4-1B. gp91ds-tat Prevents Ang II-Induced Blood Pressure gp91ds-tat was delivered ICV to the lateral ventricle, and radiotelemetry was used to measure BP and HR responses. Central administration of this NAD(P)H oxidase formation blocker prior to Ang II delivery yielded no change in blood pressure or heart rate in both the SHR and WKY rat. Pretreatment with gp91ds-tat one hour prior to ICV delivery of Ang II attenuated the Ang II-induced increases in blood pressure and heart rate in both rat strains (Figure 4-2). WKY rat Blood pressure and heart rate did not significantly change from basal levels (108.86+/-1.83 mmHg and 312.62+/-5.89 bpm, respectively) thirty minutes following ICV delivery of 800ng gp91ds-tat (106.81+/-3.72 mmHg and 329.54+/-8.11 bpm, respectively). Central delivery of 800ng gp91ds-tat one hour prior to ICV delivery of Ang II attenuated the Ang II-induced blood pressure by 67% in the WKY rat (146.90+/-1.87mmHg Ang II, 123.55+/-3.75 mmHg gp91ds-tat + Ang II) (Figure 4-2C). Pretreatment with 200ng gp91ds-tat did not significantly prevent the Ang II-induced pressor response. In addition, 800ng gp91ds-tat did not prevent the heart rate increase following Ang II delivery (364.22+/-25.39 bpm for Ang II, 358.84+/-24.15 bpm for gp91ds-tat+Ang II) (Figure 4-2D). SHR Blood pressure increased slightly from basal levels (154.22+/-5.65 mmHg) thirty minutes following ICV delivery of 200ng gp91ds-tat (167.58+/-3.62 mmHg). Heart rate

PAGE 81

68 increased from 325.04+/-8.32 bpm to 375.02+/-13.07 bpm. Figure 4-3 outlines the blood pressure and heart rate recordings and averages following deliveries of gp91ds-tat and Ang II. Central delivery of 200ng gp91ds-tat one hour prior to ICV delivery of Ang II attenuated the Ang II-induced peak blood pressure response by 67% in the SHR as well (Ang II 191.36+/-6.14 mmHg Ang II, 168.22+/-5.10 mmHg gp91ds-tat + Ang II) (Figure 4-3C). Pretreatment with gp91ds-tat prevented the heart rate increase following Ang II delivery by 58% (Ang II 432.93+/-9.64 bpm Ang II, 376.98+/-11.79 bpm gp91ds-tat + Ang II) (Figure 4-3D). Thus, pretreatment with gp91ds-tat resulted in an attenuation of blood pressure increase induced by central Ang II delivery in both the SHR and WKY rat. In contrast, a scrambled form of the peptide did not prevent the Ang II-induced blood pressure in a WKY rat (135.16 mmHg Ang II, 137.26 mmHg scrambled + Ang II), indicating the gp91ds-tat peptide was specific in its blockade of NAD(P)H oxidase. gp91ds-tat Prevents Ang II-Induced Drinking Next we determined if the dipsogenic responses of ICV Ang II administration involve the ROS signaling pathway. Figure 4-4 is a graphical representation of the water intake of the WKY rats following either Ang II treatment alone or central delivery of Ang II following gp91ds-tat pretreatment (n=3). Delivery of Ang II into the lateral ventricle resulted in 8.8+/-0.5 ml water intake within thirty minutes following injection. Drinking began within two minutes of ICV delivery. Pretreatment with 800ng gp91ds-tat, however, resulted in water intake of only 2.6+/-1.4 ml thirty minutes following Ang II injection, thereby attenuating the Ang II dipsogenic response by 70% (Figure 4-4).

PAGE 82

69 Discussion These results support the hypothesis that brain Ang II increases blood pressure and heart rate through a ROS-mediated pathway. Specifically, this study establishes that blocking NAD(P)H oxidase in the brain prevents the pressor and dipsogenic actions of Ang II. This response was observed both in the hypertensive SHR and in the normotensive WKY rat. The scrambled form of the peptide did not affect Ang II-induced blood pressure; therefore, gp91ds-tat was specific in its action. gp91ds-tat alone had no effect on blood pressure or heart rate, indicating that these basal physiological mechanisms do not involve NAD(P)H oxidase. This work complements previous published studies involving the link between central Ang II action and ROS in mice. Adenovirus encoding SOD delivered ICV also prevented Ang II-induced blood pressure (Zimmerman et al. 2002). One caveat of that study, however, was the sole use of SOD to inhibit ROS accumulation. While SOD is an important component of ROS conversion, it does not discriminate whether Ang II acts upstream of superoxide formation. gp91ds-tat, however, is a highly specific blocker of NAD(P)H oxidase formation, thereby useful for analysis upstream of superoxide in Ang II action (Rey et al. 2001b). Its use in this study therefore confirms the role of ROS, specifically NAD(P)H oxidase, in Ang II-induced pressor and dipsogenic responses. These studies were the first to measure the affect of NAD(P)H oxidase blockade on central Ang II pressor response in both hypertensive and normotensive models. The comparison of WKY rat to SHR response is critical in understanding the role of ROS in Ang II action. First, the blood pressure response between the two models was the same. This result was unexpected given the characterized heightened pressor response in the SHR (Wright et al. 1986). This discrepancy may be due to the large dose of Ang II

PAGE 83

70 (30ng), yielding a potential maximum response in both strains. Pretreatment with gp91ds-tat prevented the Ang II pressor effect by 67% in both the SHR and WKY rat. Therefore, the influence of NAD(P)H oxidase on the Ang II-induced blood pressure is not dependent on the basal blood pressure. However, while the heart rate response was attenuated 58% in the SHR with gap91ds-tat pretreatment, no change was measured in the WKY rat. This discrepancy is likely due to the differences in Ang II-induced heart rate between the two models. In these studies, Ang II-induced heart rate in the SHR was three times that of the WKY rat, which was only transiently increased bpm. Pretreatment with gp91ds-tat in the SHR attenuated the heart rate response to the same level following ICV Ang II delivery in the WKY rat. It is therefore likely that this 40 bpm change in heart rate is independent of NAD(P)H oxidase signaling. One caveat of this study is while it determined the overall central link of NAD(P)H oxidase to Ang II, it did not extrapolate specific nuclei involved, nor did it address cellular mechanisms underlying this central ROS-RAS control. The AT 1 R has been localized to brain nuclei including the PVN, RVLM, and NTS, where activation through Ang II binding elicits sympathetic nerve activation and therefore an increase in pressure (Bastos et al. 1997; Mangiapane and Simpson 1980; Muratani et al. 1993; Tanaka et al. 2001). Thus, it is necessary to further characterize the role of NAD(P)H oxidase on an individual nuclei basis. Future studies should address this question in order to more completely elucidate the mechanism of Ang II-ROS action. Signaling of AT 1 R and NAD(P)H oxidase has begun to be elucidated. Most studies in this regard have focused on the peripheral Ang II and ROS, but the mechanisms may indeed apply to the brain as well. In summary, AT 1 R stimulation activates PKC and

PAGE 84

71 therefore Rac, a subunit needed to activate NAD(P)H oxidase (Brandes 2003; Gregg et al. 2003). Functional NAD(P)H oxidase can therefore convert oxygen to hazardous H 2 O 2 thus increasing ROS production. This increased ROS is theorized to increase sympathetic nerve activity, though this mechanism is unknown. The electrophysiological basis of the role of ROS in central Ang II pressor response was recently elucidated by post-doctoral fellow Dr. Cheng-wen Sun of our research group. Dr. Sun used both ROS inhibitors and generators in conjunction with Ang II and measured firing rate and the delayed rectifier potassium current (I Kv ). Both Tempol and gp91ds-tat attenuated the Ang II-induced neuronal firing rate by 70% and 50%, respectively. Alternately, ROS generator Xanthine-Xanthine oxidase increased firing rate above basal levels, indicating that ROS functions independently of extracellular Ang II stimulation. In addition, the inhibition of I Kv by Ang II was blocked by the concomitant treatment with gp91ds-tat. These findings indicate that ROS is involved in the Ang II-mediated increase in neuronal activity. In order to confirm these findings, specific channel involvement and kinetics need to be examined. This study therefore provides a cellular basis for the pressor and dipsogenic responses generated from the in vivo studies. It also suggests the role of ROS in central control of hypertension acts through neuronal activation. Given that ROS continues to emerge as an important regulator in several disease states coupled with this evidence linking NAD(P)H oxidase to Ang II function in the central control of blood pressure, are endogenous levels of ROS activity elevated in human hypertension? If there is an increase in ROS production, can this dysregulation be corrected by either SOD mimetics or NAD(P)H oxidase blockers in order to diminish the

PAGE 85

72 accumulation of superoxides? These questions must be addressed in future studies in the hopes of reversing the hypertensive state. In summary, the pressor and dipsogenic actions of central Ang II are mediated by ROS action. Specifically, ROS member NAD(P)H oxidase was implicated in this mechanism. Both in vivo and in vitro data support the regulation of central Ang II pressor action by ROS. These results concur and expand on previous studies linking ROS to Ang II in the brain. While the specific mechanism by which ROS increases neuronal firing rate remains to be elucidated, this study provides a solid foundation on which to study the involvement of NAD(P)H oxidase in the central control of blood pressure. This essential requirement of ROS in central pressor control invites thought as to what other mechanisms ROS involved in the brain regulate blood pressure. For instance, is ROS production necessary for the central action of sEH inhibition described in Chapter 3? Given the wide range of responsibilities of ROS, it is indeed plausible that ROS production underlies all the major central blood pressure regulators. In theory, these brain mechanisms contributing to blood pressure control may converge at the ROS production level. Chapter 5 will outline and discuss data related to the mechanism underlying blood pressure and heart rate increases following central sEH inhibition.

PAGE 86

73 Figure 4-1 Effect of central Ang II on blood pressure and heart rate. 30ng Ang II was delivered ICV to SHR and WKY rats. Blood pressure and heart rate were recorded using radiotelemetry (see Methods). Bars represent peak increases over 10 minutes. Representative recordings of WKY (A) and SHR (B). Red and blue lines indicate HR and MAP, respectively. Arrows represent Ang II injection. (C,D) Quantitation of MAP and HR, respectively. White and black bars represent mean +/SEM of basal and Ang II measurements, respectively (p<0.05, n=5/WKY, n=3/SHR).

PAGE 87

74 Figure 4-2 Effect of gp91ds-tat on Ang II-induced BP response in the WKY rat. 800ng gp91ds-tat was injected ICV one hour prior to Ang II. Representative recordings of MAP (A) and HR (B). Arrows represent point of drug delivery. Quantitation of MAP (C) and HR (D). Bars represent means +/-SEM; significantly different between groups (p<0.05, n=5).

PAGE 88

75 Figure 4-3 Effect of gp91ds-tat on Ang II-induced BP response in the SHR. 200ng gp91ds-tat was injected ICV one hour prior to Ang II. Representative recordings of MAP (A) and HR (B). Arrows represent points of drug delivery. Quantitation of MAP (C) and HR (D). Bars represent means +/-SEM; significantly different between groups (p<0.05, n=3).

PAGE 89

76 Figure 4-4 Dipsogenic responses of ICV gp91ds-tat and Ang II. Water intake following Ang II injection with and without 800ng gp91ds-tat pretreatment was measured. Bars represent water intake means +/SEM (p<0.05, n=3).

PAGE 90

CHAPTER 5 MECHANISM OF CENTRAL SEH INHIBITION ON BLOOD PRESSURE REGULATION Introduction sEH action in the brain is emerging as critical in blood pressure regulation. Chapter 3 established that central sEH inhibition results in an increase in blood pressure and heart rate in the SHR model of hypertension. In addition, this inhibition yielded an increase in heart rate in the WKY rat. Taken together, these results suggest a role for sEH in the central control of blood pressure. Essentially, though, how does central sEH inhibition result in an increase in blood pressure and heart rate in the SHR? This chapter seeks to elucidate the mechanism underlying this physiological response. The pressor effects of central sEH inhibition are opposite from the depressor response following IP delivery of DCU to the SHR and therefore suggest an alternate pathway of sEH action in the brain. Peripheral sEH functions as a regulator of vasoactivity by converting vasodilatory EETs to their less active diol forms (Yu et al. 2000a). Decreased vasodilation in smooth muscle cells of the arterial walls leads to increased probability of contractility, which results in an increase in blood pressure. While this proposed vasoactive mechanism of sEH in the periphery coincides with its increased expression in hypertension, the effect of central sEH inhibition likely diverges from this pathway. The question is in what way? Is the action of sEH inhibition related to a known pathway of central control of blood pressure? We sought to answer these 77

PAGE 91

78 questions through a series of experiments designed to elucidate the pathway of central sEH control of blood pressure. The first goal is to extrapolate the overall physiological mechanism behind the increase in blood pressure and heart rate following central sEH inhibition in the SHR. As previously discussed, the SHR is characterized by several dysregulatory pathways. One is the decreased baroreceptor reflex described in Chapter 1 (Hayashi et al. 1988). Another is the increased sympathetic nerve activity that results in an increase in blood pressure (Biaggioni 2003). Given that the SHR is predisposed to these pathways, we hypothesized that AUDA-induced blood pressure and heart rate changes in the SHR involved baroreceptor reflex dysregulation and sympathetic nerve activation. The second goal is to elucidate the cellular and signaling mechanisms involved in the AUDA-induced pressor response in the SHR. This undertaking is complex and likely to involve years if not decades of study. However, the start of this discovery must begin with what we know of sEH action, its conversion of EETs. Does the action of central sEH inhibition involve the accumulation of its substrate, the EETs? Peripheral studies have focused on this branch of the arachidonic acid pathway as the powerhouse behind sEH cardiovascular effects. However, sEH was originally identified as a converter of xenobiotic material foreign to the organism (Grant et al. 1993). In fact, several substrates have already been identified for sEH in addition to its well-known role in EET metabolism (Sinal et al. 2000b). Alternately, sEH itself may function to regulate channel kinetics leading to changes in firing rate patterns or even regulate neurotransmitters such as Ang II or vasopressin. Based on the primary role of sEH as an enzyme involved in the

PAGE 92

79 epoxygenase branch of arachidonic acid conversion, however, we hypothesized that sEH inhibition leads to an increase in blood pressure due to EET accumulation in the brain. Aside from the question whether the sEH substrate EETs are involved in its central action on blood pressure, it is important to begin to understand how this inhibition leads to an increase in blood pressure. Is there a connection of sEH to known regulators of central blood pressure control such as Ang II or another sympathetic activator? Chapter 2 presented evidence that sEH expression increases in the hypothalamus following ICV delivery of Ang II. Chapter 4 further analyzed the role of brain Ang II signaling by incorporating the NAD(P)H oxidase inhibitor gp91ds-tat. These studies linked central Ang II action to ROS member NAD(P)H oxidase. ROS has also been linked to epoxygenase member CYP 2C9 (Fleming et al. 2001b). Given that ROS activity in cardiovascular control, both peripheral and central, continues to emerge as a strong regulator, we hypothesized that the blood pressure effects stemming from sEH inhibition were mediated by NAD(P)H oxidase. Finally, what cell type in the brain is responsible for the pressor response following central sEH inhibition? Previous studies have localized both CYP and EETs mainly to astrocytes, though CYP has also been found in the cerebral vasculature as well as dopaminergic neurons. Our studies discussed in Chapter 2 localized sEH to both neurons and glia. Therefore all brain cell types are potential targets for the action of sEH inhibition. However, overwhelming evidence reveals neurons as the main regulator in the central control of blood pressure. For example, increased neuronal firing rate from the RVLM and NTS to the IML result in an increase in sympathetic activation and hence

PAGE 93

80 increased blood pressure. The following studies seek to identify key mediators and pathways in the increase in blood pressure following sEH inhibition in the SHR brain. Methods Animals ICV Cannulation Abdominal Aorta Cannulation Blood Pressure and Heart Rate Recordings Statistical Analysis The above Methods are described in Chapters 2 and 3 In vivo Drug Delivery All drugs were delivered as bolus injections via the ICV cannula into the right lateral ventricle of unrestained rats as described in Chapter 3. When testing the mechanism of sEH inhibition requiring two drugs, the first drug was injected one hour prior to the second, and the dummy cannula was replaced following injection. MS-PPOH (680ng, 2l, dissolved in CSF), a kind gift from Dr. John Falck, University of Texas Southwestern Medical Center, was used to block the formation of EETs (Brand-Schieber et al. 2000b). 11-nonyloxy-undec-8-enoic acid (11-NODA, 100ng, 1l, dissolved in CSF), an EET agonist, was also provided by Dr. Falck. gp91ds-tat and its scrambled peptide used as a control (100ng each, 2l, dissolved in CSF) were synthesized by the Temple University Protein Synthesis Core facility (Philadelphia, PA) and used to inhibit the action of NAD(P)H oxidase (Rey et al. 2001a; Rey et al. 2001b). Evaluation of Spontaneous Baroreceptor Reflex Gain To evaluate baroreceptor reflex function, an index of gain was determined from spontaneous changes in systolic blood pressure and pulse interval using a time-series

PAGE 94

81 method for the rat, as described (Oosting et al. 1997; Waki et al. 2003). This method correlates to traditional pharmacological methods for measuring the baroreceptor reflex. However, because this method does not distinguish between an increase in blood pressure and heart rate either by a decrease in the baroreceptor reflex or by the pharmacological agent itself, this measurement is assumed to be an estimate of spontaneous baroreceptor reflex gain. To calculate this index of baroreceptor reflex gain, spontaneous ramps of systolic blood pressure changes (at least four beats) were extracted from the moving average data. The data was collected at a frequency of 500 Hz. Measurements of systolic blood pressure and pulse interval ramps were made at delays of three to five beats based on previous findings (Oosting et al. 1997). Pulse interval was compared to systolic blood pressure during these delays to calculate the spontaneous baroreceptor reflex gain. Only positive slope values were used to avoid contaminating baroreceptor reflex data with non-baroreceptor-mediated changes in pulse interval. This analysis was completed by Dr. Hidefumi Waki, Department of Physiology, Bristol University, England. Analysis of Heart Rate Variability Heart rate variability was analyzed using a fast Fourier transformation (FFT). For each ten-minute recording period, the beat-to-beat pulse interval data were converted into data points every 100 ms using a spline interpolation. Power spectral density was then computed using FFT algorithm and averaged. It is generally accepted that the high frequency (HF) component of heart rate variability is mediated by cardiac parasympathetic tone (Pagani et al. 1986a; Pagani et al. 1986b). This analysis was completed by Dr. Hidefumi Waki, Department of Physiology, Bristol University, England.

PAGE 95

82 Neuronal Firing Recording Spontaneous action potentials were recorded with the whole-cell voltage clamp configuration in current clamp mode. Neurons cultured from hypothalamus were bathed in Tyrodess solution containing (in mM): 140 NaCl, 5.4 KCl, 2.0 CaCl 2 2.0 MgCl 2 0.3 NaH 2 PO 4 10 HEPES, and 10 dextrose, pH adjust to 7.4 with NaOH. The patch electrodes (resistances from 3-4 MOhms) were filled with an internal pipette solution containing (in mM): 140 KCl, 4 MgCl 2 4 ATP, 0.1 guanosine 5-triphosphate, 10 dextrose, and 10 HEPES, pH adjusted to 7.2 with KOH. The resting membrane potential was defined as the potential within a 1 s time period during which there were no spontaneously firing action potentials. Neuronal firing rate was measured as the number fully developed action potentials (depolarization beyond 0 mV) per second (Hz). This study was completed by Dr Chen-wen Sun of our research group. Results Waveform Analysis of Baroreceptor Parameters Because of the concomitant increase in blood pressure and heart rate in the SHR following sEH inhibition, it was hypothesized that central AUDA delivery impaired the ability of the baroreceptors to regulate physiological changes. In order to test this hypothesis, spontaneous baroreceptor reflex gain and cardiac vagal tone were measured using waveform analysis in response to sEH inhibition. Index of spontaneous baroreceptor reflex gain Analysis of waveform telemetry data revealed a 56+/-5% decrease in the estimate of spontaneous baroreceptor reflex gain (p<0.05) following sEH inhibition in the SHR. Specifically, the index of baroreceptor reflex gain decreased from a basal level of 0.82+/-0.06 ms/mmHg to 0.36+/-0.04 ms/mmHg at the peak of the pressor response from sEH

PAGE 96

83 inhibition (Figure 5-1A). In the WKY rat, the index of baroreceptor reflex gain was 1.09+/-0.11 at basal levels and 1.13+/-0.08 three to four hours after ICV delivery of 15ng AUDA. Thus, no significant change in the baroreceptor reflex gain index was measured in the WKY rat. In comparing basal levels of the two strains, the index of the baroreceptor reflex gain of the WKY rat was 33% higher compared to the SHR, though this difference was not significant. High frequency analysis of pulse interval Given the decrease in the index of baroreceptor reflex gain in the SHR following central sEH inhibition, high frequency analysis of pulse interval was then analyzed to determine if this component was also involved in this concomitant increase in blood pressure and heart rate. This measurement correlates to the level of cardiac vagal tone. In the SHR, this cardiac vagal tone indicator measurement decreased from 16.68+/-2.55 ms to 10.39+/-0.28 ms at the peak response of sEH inhibition (Figure 5-1B). This result translated to a 33+/-8% decrease in heart rate analysis of pulse interval following ICV AUDA administration in the SHR. In contrast, no significant changes were observed in the WKY rats (13.91+/-0.84 ms basal, 13.74+/-0.95 ms 15ng AUDA). These data demonstrate that increases in blood pressure and heart rate are consistent with a decrease in baroreceptor reflex functions in the SHR. AUDA Regulation of Sympathetic Nerve Activity Regulation of sympathetic nerve activity is one of the major mediators of the central control of blood pressure. Given the high impact of this system plus its neuronal origin that corresponded with previous sEH expression studies, atenolol, a 1R antagonist, was used to test whether the effects of sEH inhibition were related to sympathetic nerve activity. 1mg/kg atenolol was delivered IV following 15ng AUDA

PAGE 97

84 ICV delivery to two SHRs. The results from this preliminary study are shown in Figure 5-2. Atenolol delivery completely prevented the increase in blood pressure increase following central AUDA administration (34.54+/-7.23 mmHg AUDA, 0.69+/-3.73 mmHg atenolol + AUDA, n=2). No statistical analysis could be completed due to the low number of animals in this study. These data indicate that AUDA-induced increase in blood pressure functions through sympathetic nerve activity. Increased EETs Linked to Increase in BP and HR The first step in deducing the mechanism underlying sEH inhibition-induced blood pressure was to examine the role of EETs, the main physiological substrate of sEH. Since sEH converts EETs to DHETs, inhibiting the enzyme results in the accumulation of EETs. Thus, we hypothesized that EETs may be the vital in this central control of blood pressure. MS-PPOH This hypothesis was tested initially with the use of MS-PPOH, an inhibitor of the epoxygenase pathway that generates EETs and related PUFA epoxides (Brand-Schieber et al. 2000a). Figure 5-3 outlines the pressor response to 15ng AUDA with and without pretreatment of MS-PPOH in the SHR. Figures 5-3A,B are representative blood pressure recordings from ICV delivery of AUDA alone (A) and with ICV delivery of MS-PPOH one hour prior to sEH inhibition (B, n=5). Figure 5-3C is a graphical representation of the pressor response resulting from the treatments. While central delivery of AUDA increased blood pressure 38.99+/-4.29mmHg, pretreatment with MS-PPOH attenuated this AUDA-induced increase in blood pressure by 65% in the SHR (14.43+/-8.04 mmHg). However, MS-PPOH alone had no effect on basal blood pressure.

PAGE 98

85 11-NODA While MS-PPOH provided the first evidence that sEH action was through EET production, it was imperative to determine if the action was through EETs specifically or through another product of epoxygenase. Thus, EET agonist 11-NODA (100ng) was delivered ICV in the WKY rat to determine whether EET-specific agonist would have any effect on blood pressure or heart rate (Figure 5-4). This central administration of an EET agonist results in a transient increase in blood pressure (blue) and heart rate (red) in the WKY rat (Figure 5-4, n=6). This increase was biphasic for blood pressure increases, each increase lasting only about 10 min. The first peak was recorded just after delivery and the second 15-30 minutes following the first. Blood pressure increased 13.2+/-2.5 mmHg in the first peak and 8.8+/-3.2 mmHg in the second peak (Figure 5-4B). Heart rate increased 61+/-19 bpm (Figure 5-4C). Effects of sEH Inhibition Function through ROS To further examine the mechanism underlying this central pressor response, we examined the role of ROS on sEH-inhibitor-mediated increase in blood pressure in the SHR. Reasoning behind this study was two-fold. First, epoxygenases have been linked to ROS, albeit in the periphery. In addition, Chapter 4 discussed the importance of ROS member NAD(P)H oxidase is in the central control of hypertension. Figure 5-5 outlines the blood pressure and heart rate data from this study (n=3). The top panels are representative blood pressure and heart rate recordings of an SHR treated with AUDA alone (Figures 5-5A,C) and AUDA with gp91ds-tat pretreatment (Figures 5-5B,D). Figure 5-5E is a graphical representation of the peak blood pressure changes showing that while ICV delivery of AUDA resulted in a 39.20+/-3.03 mmHg increase in mean arterial pressure, pretreatment with gp91ds-tat caused the AUDA-induced blood pressure to only

PAGE 99

86 increase 6.10+/-5.78 mmHg, an 85% attenuation. Figure 5-3F is a graphical representation of the peak heart rate changes indicating that AUDA delivery resulted in a 85.66+/-4.99 bpm change, yet pretreatment with gp91ds-tat yielded an AUDA-induced heart rate change of 19.24+/-12.48 bpm, thereby attenuating the heart rate response by 77%. In contrast, gp91ds-tat alone had no effect on blood pressure and heart rate. These results indicate that ROS member NAD(P)H oxidase is involved in the sEH inhibitor-induced increase in blood pressure and heart rate. Discussion These series of studies succeeded in beginning to elucidate the complex signaling involved in the central sEH-mediated blood pressure control. Two important findings can be extrapolated from these results. First, the pressor effects stemming from central sEH inhibition are linked to the increase in its substrate, the EETs. Second, the mechanism leading to the increase in blood pressure involves ROS, specifically NAD(P)H oxidase. These two conclusions, taken together, form the foundation of how sEH and EETs function in the brain to elicit blood pressure and heart rate effects. EET studies involving formation blockers as well as agonists strongly suggest that this central pathway involves the sEH substrate EETs. Pretreatment with MS-PPOH prevented sEH increases in blood pressure in the SHR, though alone this compound had no effect on blood pressure. This lack of blood pressure response may be explained by the high sEH expression in the SHR that would prevent any basal effects from the EETs While this result was good evidence that EETs were involved, the non-specificity of MS-PPOH to EETs still questioned whether EETs were the main regulator. For example, since MS-PPOH inhibits epoxygenase action, it blocks the formation of all epoxygenase products (Brand-Schieber et al. 2000b). Therefore, EET agonists were delivered ICV to

PAGE 100

87 determine whether increasing the agents themselves resulted in a change in blood pressure. ICV delivery of the agonists resulted in a biphasic increase in blood pressure as well as an increase in heart rate in the WKY rat, indicating these sEH substrates are indeed the potentiators of sEH inhibitor pressor effects. The reason behind the biphasic increase in pressure is unknown at this time, but may be related to differences in immediate EET activity on the cerebral microcirculation and later effects involving neuronal activation pathways in cardiovascular-relevant brain areas. Thus, the role of central EETs appears to be distinct from that of its peripheral expression, which is characterized by its vasodilatory properties that are associated with a decrease in blood pressure. These results strongly indicate that the effects of central sEH inhibition involve the accumulation of its substrate. We further elucidated the central sEH pathway through studies involving oxidative stress. The mechanism linking central sEH inhibition to the increase in blood pressure and heart rate appears to function through ROS (Fleming 2001; Fleming et al. 2001a). gp91ds-tat, an NAD(P)H oxidase blocker, was used to elucidate the ROS involvement. Central delivery prevented AUDA-induced increase in blood pressure and heart rate in the SHR. gp91ds-tat also prevented the increase in neuronal firing rate induced by sEH inhibitors in vitro. As previously discussed, ROS had been linked to the epoxygenase pathway; however, this is the first link of the NAD(P)H oxidase arm of ROS to EETs and sEH. One major question is what cell type is involved in stimulating blood pressure following central sEH inhibition. sEH is localized to both neurons and glia, yet its substrate is primarily localized to astrocytes. In order to begin to answer this question,

PAGE 101

88 Electrophysiological studies were performed by post-doctoral fellow Dr. Cheng-wen Sun. The top two panels of Figure 5-6A are representative neuronal firing rate recordings with and without AUDA delivered to the culture media. Delivery of 0.4mg/ml AUDA resulted in a two-fold increase in neuronal firing rate in the SHR neurons (Figure 5-6B). Next, gp91ds-tat was added to the cultures in conjunction with AUDA to determine if the role of ROS observed in vivo is related to neuronal firing rate regulation. Figure 5-6A shows representative tracings of firing rate following AUDA treatment, gp91ds-tat + AUDA or AUDA + scrambled tat peptide. Figure 5-6B is a graphical representation of neuronal firing of these different treatments. AUDA-induced increase was attenuated 75% by pretreatment with 5M gp91ds-ta. Taken together, these observations provide cellular insight into the effects of sEH and NAD(P)H oxidase on neuronal activity in the SHR. These electrophysiological studies therefore supported the role of neurons in the central pressor action of sEH. The increased neuronal firing rate with AUDA treatment coupled with its attenuation in the presence of gp91ds-tat indicates effects from sEH inhibition are through neuronal targeting. However, these studies do not discount the role of glial or endothelial cells in sEH central control (Medhora et al. 2001). These cultures are 80% neurons; therefore, the other 20% of cells may be essential in providing EETs for sEH action. In order to resolve this issue, sEH and EETs in the glia should be blocked to determine if sEH inhibition still results in a pressor response. This targeted disruption can be accomplished with the use of GFAP promoters coupled with either an antisense or ribonuclease interference strategy in the brain.

PAGE 102

89 We propose that an increase in EETs by inhibition of sEH leads to an increase in ROS in the brain and hence an increase in blood pressure. An alternate possibility is that ROS acts upstream and actually stimulates EETs which therefore leads to an increase in blood pressure. This possibility cannot be excluded since the experiments presented here showed only a relationship between sEH inhibition and ROS. In order to resolve this issue, gp91ds-tat should be delivered prior to EET agonist delivery. If pretreatment with ROS inhibitors prevents the actions of the EET agonists, then ROS most likely acts downstream of EETs in the central control of hypertension. If, however, EET agonists still exert a pressor effect with effective ROS inhibition, then EETs are likely to act downstream of ROS, and the proposed mechanism needs to be readjusted. At this point, we hypothesize that ROS acts downstream of EETs given the direct involvement of brain ROS to blood pressure control that has been elucidated over the past decade. Because ROS seems to be a common denominator in several systems regulating hypertension, it is likely that several factors including members of the epoxygenase pathway function to regulate the production of ROS in the brain. The first two studies in this series addressed the overall mechanism underlying blood pressure effects in the SHR following sEH inhibition. Waveform analysis revealed that the baroreceptor reflex was decreased in the SHR, providing an explanation for the concomitant increase in blood pressure and heart rate. The SHR is known to be less efficient with its control of heart rate regulation, and this result further recognizes its dysfunction. The WKY rat had no change in baroreceptor reflex, thus explaining why blood pressure is increased only in the SHR.

PAGE 103

90 The second finding related to the overall mechanism of sEH inhibition was that atenolol blocked the effects of AUDA, suggesting involvement of sympathetic nerve activating. While this study cannot be statistically analyzed since only two rats were involved in the study, it provides a starting base on which to study sympathetic activation in future studies. Sympathetic activation is a major regulator of the brains control of blood pressure and is involved in the majority of these central pathways including the RAS (Dampney 1994; Di Nicolantonio et al. 1982). Given the activation of sympathetic nerve activity by dopaminergic neurons, this study points to neurons as the mediators of central sEH inhibition action. Taken together, these studies provide a critical look into the function and mechanism of central sEH. However, discrepancies between expression data and inhibitor data invite a more comprehensive analysis of sEH in specific brain regions. In order to fully elucidate the role of sEH in the central control of hypertension, it is important to determine what effect overexpressing the gene will have on blood pressure and heart rate. Chapter 6 discusses studies on gene therapy utilizing a viral vector to deliver sEH to cardiovascularly-relevant nuclei in the brain of hypertensive and normotensive rats.

PAGE 104

91 Figure 5-1 Effect of central AUDA delivery on baroreceptor parameters. 15ng AUDA was injected into the lateral ventricle of SHR and WKY rats. (A) Baroreceptor reflex gain was measured as described in Methods and is expressed as ms/mmHg. (B) HF analysis of PI, bars represent mean +/SEM (see Methods). significantly different between basal and AUDA treatments (p<0.05, n=6). Reprinted with permission from The FASEB Journal.

PAGE 105

92 Figure 5-2 Effect of atenolol on AUDA-induced blood pressure. 1mg/kg atenolol was delivered IV to the SHR following ICV delivery of 15ng AUDA. Blood pressure was recorded using radiotelemetry. Bars represent changes in mean arterial pressure in mmHg (n=2).

PAGE 106

93 Figure 5-3 Effect of MS-PPOH on AUDA-induced blood pressure. SHRs were pretreated with ICV MS-PPOH one hour prior to AUDA injection. BP was monitored using radiotelemetry. (A) Representative MAP recording following AUDA injection, (B) Representative MAP recording following MS-PPOH + AUDA injections, x-axis is time in minutes. Arrows represent point of injection. (C) Quantitation of blood pressure data, mean +/SEM. significantly different between groups (p<0.05, n=5). Reprinted with permission from The FASEB Journal.

PAGE 107

94 Figure 5-4 Effect of EET agonist on BP and HR in the WKY rat. 11-NODA was injected into the lateral ventricle, and BP and HR was recorded using radiotelemetry (see Methods). Representative recordings of BP and HR (A); x-axis represents time pre and post-injection. (B,C) Quantitation of BP and HR in the WKY rats, mean +/SEM. significantly different between treatments (p<0.05, n=6).

PAGE 108

95 Figure 5-5 Effect of ROS inhibition on AUDA-induced BP and HR response in the SHR. NAD(P)H oxidase activity blocker gp91ds-tat was injected ICV one hour prior to AUDA delivery. Representative recordings of BP (A,B) and HR (C,D). (A,C) AUDA treatment alone. (B,D) gp91ds-tat + AUDA treatment. Arrows represent points of injection. (E,F) Quantitation of BP and HR as mean +/-SEM. significantly different between groups (p<0.05, n=3). Reprinted with permission from The FASEB Journal.

PAGE 109

96 Figure 5-6 Effect of AUDA and gp91ds-tat on neuronal firing rate. (A) Action potential recordings of neurons +/treatment. (B) Quantitation of firing rate, mean+/-SEM. significantly different from control. significantly different from AUDA (p<0.05). This figure was used with permission from Dr. Chengwen Sun, University of Florida and reprinted with permission from The FASEB Journal.

PAGE 110

CHAPTER 6 EFFECT OF SEH OVEREXPRESSION IN THE PVN OF SHR AND WKY RATS Introduction Central sEH inhibition resulted in an increase in blood pressure and heart rate in the SHR, an effect opposite from that in the periphery. Additional sEH inhibitor studies indicate that central pressor action of EETs involves ROS production and sympathetic nerve activation, thereby providing a novel role for EETs in the brain. Thus far, these studies into the central role of sEH on cardiovascular function have utilized pharmacological agents delivered to the lateral ventricle to inhibit the action of sEH. These results, however, cannot distinguish the role of central sEH in distinct nuclei. This chapter examines the effect of sEH overexpression in the PVN on blood pressure and heart rate in the SHR and WKY rat. Chapter 1 discussed the complex pathways involved in the central control of blood pressure. Specific brain areas elicit different effects; for example, activation of the RVLM and CVLM yields a pressor and depressor effect, respectively, yet both nuclei are located in the brainstem (Guertzenstein and Silver 1974). Similarly, the effects of the sEH inhibitors injected into the lateral ventricle are a culmination of the responses of each brain nucleus exposed to DCU and AUDA. In order to comprehensively understand the role of sEH in the brain, it is imperative to examine its blood pressure effects when localized to distinct cardiovasculary-relevant brain nuclei. The PVN, located in the hypothalamus, is one such nucleus whose neuronal activation stimulates sympathetic nerve activity and affects blood pressure. While the 97

PAGE 111

98 complete mechanism of this activation is not fully understood, we know that it involves neuronal projections from the PVN to the IML in the spinal column either directly or via the RVLM in the brainstem (de Wardener 2001; Strack et al. 1989). Stimulation of the PVN produces a pressor response, while denervation of this nucleus depresses blood pressure (Dampney 1994; Harland et al. 1989). Thus, the PVN provides an intriguing start point to elucidate the role of sEH in specific brain nuclei. Given the increased expression of sEH in hypertensive models, it is logical to measure the physiological effects of overexpression in normotensive models as well as further overexpression in hypertensive models. Overexpression of a gene can be accomplished by several methods, including using gene therapy to deliver the gene of interest. Both viral and nonviral vectors can be used to accomplish this gene therapy, each with its own advantages and disadvantages. Naked DNA, a nonviral vector, is noted for its safety; however, it has low efficiency due to its low rate of transduction and limited expression time (Wivel and Wilson 1998). Similarly, liposomes are safe due to its lack of pathogenicity, but its expression is also low because it does not integrate into the genome (Aoki et al. 1997; Morishita et al. 2000; Raizada et al. 2000). Both nonviral methods have been used for gene transfer, though low efficiency has limited their success in trials. Viral vector-mediated delivery is an appealing choice for gene transfer because of their natural ability to efficiently infect different cell types. Theoretically, they are a useful alternative in in vivo studies. Viruses are extremely diverse, each with different advantages and disadvantages based on efficiency, limitations to transduction of non-dividing cells, as well as gene insert size limitations. Therefore, when choosing a gene

PAGE 112

99 delivery vector, it is essential to consider the target cell type, timeframe of genetic action, and gene size. Many clinical trials involving gene therapy have used the adenovirus, a family of viruses that includes members that causes the common cold. Adenovirus is an attractive choice because (i) large quantities can be produced with high efficiency; (ii) it is able to infect nondividing cells; and (iii) it results in long-term expression of the gene (Lu et al. 1998; Raizada et al. 2000). In addition, it has a wide tissue distribution and effectively diffuses from the site of injection. However, two recent clinical trials involving adenovirus resulted in adverse effects and even one death, highlighting the potential dangers of both the immunological response as well as an unknown site of integration (Amalfitano and Parks 2002; Reid et al. 2002). The adeno-associated virus, in contrast, is not immunogenic and integrates into a particular chromosome. Unfortunately, the virus has a small capacity for the gene insert and is difficult to produce on a large scale (Flotte and Carter 1995). The final major class of viral vectors is the retrovirus, a RNA virus that reverse transcribes into DNA. The retrovirus can hold a large gene insert and is able to be produced on a large scale but has an unknown site of integration (Raizada et al. 2000; Raizada et al. 1999). A subset of the retrovirus known as the lentivirus was chosen as the viral vector for the sEH overexpression studies. The lentiviral vector is a modified form of the human immunodeficiency virus type 1 (HIV-1). While the wild-type virus encodes nine genes, the genes not essential to its vector function are eliminated in this modified virus, thereby only housing four of the original nine genes. These remaining genes are known as cis-acting sequences because they are only recognized by viral proteins (Buchschacher and Wong-Staal 2000). Because safety needs be ensured with this type of virus, viral production is accomplished

PAGE 113

100 only when the genes, individually prepared, are combined. Due to the removal of half of the viral genome, the virus only replicates one time and therefore does not infect again, further ensuring its safety. Lentivirus was selected as the viral vector of choice for five reasons. First, it is able to infect nondividing cells, a requirement when studying neurons (Naldini et al. 1996; Verma and Somia 1997). Second, the vector can house a large transgene up to 18 kb. While sEH is only ~1.7 kb, future studies may include additional regulatory genes that can easily be cloned into the vector. Third, the vector allows long-term expression of the sEH gene, thereby determining a true progression of sEH action. Fourth, brain injections of lentivirus revealed it did not diffuse widely from the point of injection, making it an attractive candidate for targeting specific brain nuclei. Finally, the large-scale production of the lentiviral vector was optimized in our laboratory (Coleman et al. 2003), and this vector has been used and characterized in other cardiovascular studies by members of this research group (Metcalfe et al. 2004). Thus, the lentiviral vector was ideal for the overexpression of the sEH gene. The lentiviral vector used in these experiments is outlined in Figure 6-1. It, along with all retroviruses, encodes three common genes, gag, pol, and env (Coleman et al. 2003). Within the virus, gag encodes the core proteins; pol encodes the replication enzymes, and env encodes the envelope glycoprotein. Gag and Pol proteins are initially fused together and then cleaved to yield individual functional proteins including the viral body (from Gag), reverse transcriptase and other proteases (from Pol). The translated envelope proteins function to target specific cell types based on the env gene. As shown in Figure 6-1, this lentiviral vector contains vesicular stomatitis virus G-protein (VSV-G),

PAGE 114

101 which functions both to infect a wide array of cells as well as to aid in the production of large-scale high-titer virus (Naldini et al. 1996; Yee et al. 1994). The long terminal repeat (LTR) sites flank the genes transcribed following viral infection. The lentiviral vector contains several genes that distinguish it from other retroviruses, including rev and tat. The Rev protein functions in concert with the Rev-responsive element to guide the movement of the viral RNA to the cytoplasm from the nucleus (Lesnik et al. 2002). The Tat protein functions in increasing efficient gene production (Roebuck and Saifuddin 1999). This protein has been isolated and used in other studies as a stand-alone efficiency regulator in various transduction pathways. For example, the NAD(P)H oxidase blocker used in Chapters 4 and 5 was fused to tat in order to increase efficiency. The lentiviral vector contains the human elongation factor 1 (EF1) promoter to efficiently induce gene delivery (Zaiss et al. 2002). In summary, this lentiviral vector can easily incorporate a gene of interest and provides a safe, effective, long-term expression of the gene. The lentiviral vector is ideal for delivering the sEH gene to specific brain nuclei. The following studies outline the construction and testing of the lentiviral vector encoding the sEH gene (lenti-sEH) followed by its delivery in vivo. Blood pressure and heart rate were then measured in SHR and WKY rats overexpressing the sEH gene in the PVN.

PAGE 115

102 Methods Animals ICV Cannulation Abdominal Aorta Cannulation Western Blot Analysis The above Methods are described in Chapters 2 and 3 Transformation of pCR 2.1 sEH cDNA into competent cells The mouse sEH cDNA cloned into the pCR 2.1-TOPO plasmid (Invitrogen, Carlsbad, CA) was a kind gift from Dr. Curt Sigmund at the University of Iowa. The plasmid contained resistance genes to both Kanamycin and Ampicillin. The plasmid was transformed into the competent cell line TOP10 (Invitrogen, Carlsbad, CA) in order to amplify the plasmid. TOP10 cells (1x10 9 cfu/g tube) were thawed on ice. The pCR 2.1 sEH cDNA plasmid (20l) was added to the cells, and the tube was incubated on ice for 30 min. The cells were then heat-shocked at 42C for 90 seconds and then placed on ice for 2 minutes. SOC (800l) was then added, and the cells were agitated at 225 rpm at 37C for one hour. The transformation was then plated on LB+Kanamycin plates overnight at 37C. Resulting colonies were grown up in 2 ml superbroth+Kanamycin at 37C, 225 rpm. The media was cloudy with the bacterial growth, and the DNA was then extracted using DNA miniprep. DNA miniprep The bacteria were pelleted at maximum speed in the microcentrifuge for 15 seconds and resuspended in 100 l GTE solution containing 100g/ml RNase. NaOH/SDS (200l) solution was added, vortexed, and left at room temperature for 2 minutes. Cold potassium-acetate solution (150l) was added and inverted. The solution was centrifuged

PAGE 116

103 at maximum speed for 15 minutes, 4C. The supernatant was added to 800l 95% EtOH, and the DNA was pelleted for 10 minutes, 4C. The DNA was air-dried and suspended in Tris-EDTA buffer, pH 7.5. Large-scale Lentiviral Production Transfection Cultured human embryonic kidney (HEK293FT, Invitrogen) cells were split into 27 T-75 flasks coated with poly-d-lysine, 1x10^7 cells/flask. Once the cells were approximantely 90% confluent, they were transfected with the lenti-sEH or lenti-neo complex that was comprised of the following per flask: Serum-free media 400l pHP 7.10g pTYF-sEH or pTYF-neo 3.50g VSV-G 2.80g Tat 0.60g Superfect 28l 10% fetal bovine serum (FBS) media 5.50ml The above reagents (minus the 10% FBS media) were mixed in a polystyrene tube to prevent any DNA from adhering to the walls and incubated at room temperature for 10 minutes. The mixture was then added to the 10% FBS media (Invitrogen), and incubated at 37C for 5 minutes. The transfection media was then used to replace the old media, and the flasks were incubated at 37C for six hours. The media was then replaced with fresh 5.5 ml 10% FBS media and incubated again for 24 hours. First virus collection

PAGE 117

104 Thirty hours following transfection, the media was collected into four 50ml conical tubes and centrifuged at 2000xg for 10 minutes. Fresh media was added to the flasks. The media was then filtered through a PES 45m filter (Nalge Nunc, Rochester NY) to further remove debris. The filtrate was stored on ice overnight to be processed with the second collection. The next morning, the filtrate was added to two Centricon-80 ultrafiltration columns (Millipore, Billerica MA) and spun at 2000xg for one hour. This concentrate was collected by inverting it into the collection cup and spinning again at 990xg for 2 minutes at 4C. Second virus collection Forty-eight hours following transfection, the media was collected into 4 50ml conical tubes and centrifuged at 2000xg for 10 minutes. The media was then filtered through a PES 45m (Nalge Nunc) filter to further remove debris. The concentrate from the first collection was used to spike the second collection, and the two were mixed. Aliquots (30 ml) were added to four chilled SW28 rotor tubes containing 220l 60% iodixanol (Optiprep, Axis-Shield, UK). The collection was centrifuged at 20,000xg for 2.5 hours at 4C using the SW-28 swinging-bucket rotor (Beckman Coulter, Fullerton CA). Following centrifugation, the top media layer was removed to the same height distance as the iodixanol height. The contents in the four tubes were then mixed and combined into 3 ml conical tubes (Beckman Coulter). The volume was brought up to 3.5ml with CSF. The virus was then centrifuged at 8100xg for 48 hours at 4C using a SW-50.1 swinging-bucket rotor (Beckman Coulter). The supernatant was then removed and the pellet was resuspended in 20l CSF. The virus was aliquoted (1-2l each per tube) and stored at -80C.

PAGE 118

105 Infection of COS-7 cells with lenti-sEH To determine whether the transfection was successful, COS-7 cells derived from African green monkey kidney (a kind gift from Dr. Peter Sayeski, University of Florida) were infected with the viral preparations, and the cells were analyzed for sEH expression. COS-7 cells were chosen as the in vitro vehicle because of their very low endogenous levels of sEH protein. COS-7 cells were plated at 1x10 5 cells/well in six-well plates. Cells were infected with either lenti-sEH, lenti-neo (control), or lenti-GFP (visual control). Virus was delivered at a multiplicity of infection (MOI) of either 1 or 10. For cells infected with virus with an MOI of 1, 10l unconcentrated virus (1x10 Tu/ml) was added to each well; 100l unconcentrated virus was added to achieve an MOI equal to ten. Twelve wells were used for each treatment of lenti-sEH or lenti-neo in order to extract substantial amounts of protein for Western blot analysis of sEH protein (see Chapter 2 for protocol). In contrast, four wells were used for each treatment condition of lenti-GFP since these cells were used for fluorescence detection and not for protein extraction. Cytoplasmic Isolation for HPLC Analysis COS-7 cells in six-well plates were washed twice with phosphate-buffered saline (PBS ), removed from the well with rubber policemen and pelleted at 1500 rpm for 15 min. PBS (100l) + protease inhibitor solution was added to each tube and the contents homogenized. The samples were centrifuged at 100,000xg for 60 min and the supernatant collected for DHET analysis by HPLC as previously described (Brand-Schieber et al. 2000b).

PAGE 119

106 Radiotelemetry Recordings Blood pressure and heart rate were recorded using the implanted radiotelemetry transducers. For each dataset acquisition, the rat cages were positioned on receivers that collected signals from the implanted transducers. These signals were then transmitted to an adapter with an ambient pressure monitor that relayed the signals to the DataQuest 3.1 Acquisition program (DataSciences International, Arden Hills MN). The rats were allowed to acclimate to their new position for at least one hour before basal measurements were recorded. For basal measurements, blood pressure and heart rate were recorded for (four) days prior to virus injection. Daily recordings were taken between 3 and 4pm and averaged for analysis. During data collection, blood pressure (systolic, mean and diastolic), heart rate and activity were recorded every minute for an average of ten seconds at 500Hz. Data was acquiesced and transferred to Microsoft Excel for graphical analysis. PVN Coordinate Determination Coordinates to inject into the PVN were determined for both SHR and WKY rats weighing 250-270g. Initial coordinates were taken from studies done by Drs. Beverly Falcon (AP: -1.6mm, ML: +/-0.5mm, 7.3mm from dura) and Jorge Vazquez (AP: -1.3mm, ML: +/-0.5mm, 8.3 from skull) in our research group using SHRs weighing 180-220g and >250g, respectively (unpublished data). SHR and WKY rats were injected at the higher weight in the current study in order to complete the abdominal aorta cannulation approximately ten days prior to the PVN injection. This time frame allowed for a one-week recovery time from surgery as well as basal blood pressure and heart rate measurements. To determine the coordinates, 500nl dye was injected bilaterally using a 5l Hamilton syringe mounted on the stereotaxic frame. The dye was delivered over 8

PAGE 120

107 10 minutes, and ten minutes elapsed following the injection before the syringe was removed. The rats were sacrificed and the brain sectioned at 20m using a cryostat. Dye location was determined by comparing the stained localization to nuclei markers from the Rat Brain Atlas (Paxinos & Watson 4 th Ed 1998). Coordinates were adjusted accordingly and the process repeated until reproducible injections into the PVN were generated with dye. These coordinates were then used for subsequent studies using the viral delivery of the sEH gene. Immunohistochemistry Rats were anesthetized with inhaled isofluorane (5%) and perfused transcardially with saline followed by 4% paraformaldehyde (PFA). SHR brains were post-fixed in PFA and saturated in 20% sucrose solution. 20 M sections were cut using a cryostat and mounted on poly-L-lysine-coated slides; the Rat Brian Atlas (Paxinos & Watson 4 th Ed 1998) was used as a reference. Slides were rinsed with TBS and then washed in 0.3% hydrogen peroxide/methanol for twenty minutes to block endogenous peroxides. Sections were blocked with 2% BSA in TBS-T for three hours. Sections were incubated overnight with anti-sEH rabbit antibody (1:500) in 1% BSA, a kind gift from Dr. Bruce Hammock, University of California Davis, followed by anti-rabbit biotinylated (1:200) for two hours and streptavidin-HRP (1:100) for one hour (Amersham Biosciences, Buckinghamshire, England). sEH protein was visualized using 3,3'-diaminobenzidine (DAB) substrate in peroxide solution (Fisher Scientific, Fairlawn NJ). Between each incubation, the sections were washed three times in TBS, five minutes each. Following DAB treatment for one minute, the sections were rinsed in increasing concentrations of

PAGE 121

108 ethanol and finally xylene before a coverslip was mounted using Permount (Fisher Scientific). PVN Injection of lenti-sEH Male SHR and WKY rats, 250-270g (Charles River Laboratories), were used in bilateral PVN injections. Pre-determined PVN coordinates were AP: -1.3mm, ML: +/-0.5mm, 7.9mm from dura for SHR and AP: -1.2mm, ML: +/-0.5mm, 7.8mm from dura for WKY rats. Ten days following abdominal aorta cannulation, rats were injected bilaterally with 5x10 5 TU of lentivirus per injection. Half of the rats received lenti-neo (n=4/WKY, n=5/SHR) as control and half received lenti-sEH (n=4/WKY, n=4/SHR). The right lateral ventricle of the rats was cannulated for future drug delivery, and the rats were allowed to recover for one week. At the end of the study, the brain was prepared for immunohistochemical analysis of sEH in order to determine injection position and sEH localization following viral delivery (see Chapter 2 Methods for protocol). In vivo Drug Delivery All drugs were delivered via the ICV cannula into the right lateral ventricle of unrestained rats. sEH inhibitor AUDA (15ng, 2l volume) dissolved in CSF was used to compare the effect of central sEH inhibition between the rats injected with control and sEH virus. 11-nonyloxy-undec-8-enoic acid (11-NODA, 100ng, 1l, dissolved in CSF), an EET agonist, was provided by Dr. Falck. Statistical Analysis All data are expressed as mean standard error of the mean (SEM). The number of animals or samples in each group is described in the Results below. The effects of lenti-sEH delivery in the PVN were analyzed using two-way repeated measures ANOVA

PAGE 122

109 (SigmaStat, kindly provided by Dr. Charles Wood, University of Florida). The two factors individually analyzed in one dimension were time and group. In the remaining experiments, comparisons between experimental groups were analyzed using either one-way ANOVA (SPSS) or Students T test (Stat View). Differences between means within groups were assessed with the Newman-Keuls analysis. Significance was set at a confidence level at or above 95% and is denoted by in each figure. Results Infection of COS-7 cells with lenti-sEH Three days after infection of COS-7 cells with lenti-GFP, green fluorescence was detected, indicating a successful transfection and subsequent infection. Given the positive result of the GFP infection, protein was isolated from cells containing either sEH or control virus. Western blot analysis revealed sEH expression in cells infected with the lenti-sEH virus and no detectable sEH expression in cells infected with lenti-neo (Figure 6-2). Functionality of Lenti-sEH While sEH overexpression was clearly detected using Western blot analysis, it was imperative to verify the functionality of this enzyme. Cytoplasmic fractions were isolated from lenti-sEH or lenti-neo-infected COS-7 cells to measure DHET levels, the product of EETs under sEH regulation. HPLC analysis by Dr. Michal Scwartzman, New York Medical College, revealed 11,12-DHET levels increased from 0.03 nmol/mg to 3.26 nmol/mg and 14,15-DHET levels increased from 0.41 nmol/mg to 4.95 nmol/mg in the lenti-sEH (red) compared to lenti-neo-infected cells (blue, Figure 6-3). This analysis was only done in one group of COS-7 cell cultures and therefore cannot be analyzed for

PAGE 123

110 statistical significance. However, the substantial increase in DHETs in lenti-sEH-infected cells indicates that lenti-sEH infection results in sEH functionality in vitro. sEH Overexpression in WKY PVN WKY rats (250-270g) were injected with either lenti-sEH (red) or lenti-neo (blue) into the PVN. Blood pressure (Figure 6-4A) and heart rate (Figure 6-4B) were recorded daily from 3-4pm prior to and following brain injections. Two-way repeated measures ANOVA was used to analyze blood pressure and heart rate. Figure 6-4 shows that blood pressure was not significantly different between the two groups. From two to forty days post injection, rats injected with lenti-neo and lenti-sEH had average blood pressures of 105.6 mmHg and 102.2 mmHg, respectively, with a standard error of least square means of 1.7 mmHg. In the same time period, rats injected with lenti-neo and lenti-sEH had average heart rates of 317.3 bpm and 311.9 bpm, respectively, with a standard error of least squares means of 2.2 mmHg. The test for normality failed for these data sets. However, heart rate was 6 bpm lower in lenti-sEH compared to lenti-neo-injected animals (310.7 bpm versus 304.3 bpm, respectively, LS means = 1.7bpm) from twenty to forty days post injection. Collectively in both groups, blood pressure increased and heart rate decreased following viral delivery. AUDA delivery 15ng ICV AUDA delivery resulted in similar increases in heart rate in both the lenti-sEH and lenti-neo-injected groups (Figure 6-5). Heart rate increased from 321.69+/-8.93 bpm to 414.52+/-9.39 bpm in the lenti-sEH rats and from 323.33+/-8.21 bpm to 435.87+/-9.72 bpm in the lenti-neo-infected rats.

PAGE 124

111 EET agonist delivery 100ng 11-NODA was delivered ICV, and blood pressure and heart rate were recorded using radiotelemetry. In contrast to the biphasic peak from 11-NODA delivery in control rats, lenti-sEH-injected rats had no second pressor peak (Figure 6-6). For the first peak, blood pressure peaked at 118.85+/-2.70 mmHg in lenti-sEH rats (n=4) and 121.41+/-2.3 mmHg in lenti-neo rats(n=3). For the second peak, blood pressure peaked at 114.44+/-5.78 mmHg in lenti-neo rats and returned to basal levels (100.23+/-3.29 mmHg) in the lenti-sEH rats. Heart rate peaked at 379.99+/-5.98 bpm in lenti-sEH rats and 392.91+/-3.76 bpm in lenti-neo rats. Thus, the first pressor peak as well as the heart rate were not significantly different between the two groups. Localization of viral delivery Immunohistochemistry using the sEH antibody and visualized with DAB substrate was used to detect viral delivery of lenti-sEH in 10m brain slices. Figure 6-7 shows images from the PVN region of the four WKY rats injected with lenti-sEH and their relative positions from Rat Brain Atlas images (Paxinos & Watson, 4 th Ed 1998). sEH expression was localized bilaterally to the PVN in all rats, as detected by antibody staining as indicated by the circular region of brown color. The images were captured under visual field with 10x power and photographed with a Nikon Coolpix 990 digital camera mounted on the Leica microscope. sEH Overexpression in SHR PVN SHRs (250-270g) were injected with either lenti-sEH or lenti-neo into the PVN. Blood pressure and heart rate were recorded daily from 3-4pm prior to and following brain injections. Two-way repeated measures ANOVA was used to analyze blood pressure and heart rate. Figure 6-8 shows that neither blood pressure nor heart rate was

PAGE 125

112 significantly different between the two groups. From two to fourteen days post injection, rats injected with lenti-neo and lenti-sEH had average blood pressures of 146.40+/-4.27 mmHg and 146.78+/-4.77 mmHg, respectively. In the same time period, rats injected with lenti-neo and lenti-sEH had average heart rates of 340.30+/-7.33 bpm and 346.99+/-8.19 bpm, respectively. The test for normality failed for these data sets. Collectively in both groups, blood pressure and heart rate increased following viral delivery. Discussion Overexpression of sEH using the lentiviral vector has proven to be successful both in vitro and in vivo. COS-7 cells infected with lenti-sEH had dramatic overexpression of sEH as demonstrated by Western blot analysis. Thus, this gene therapy method was able to successfully infect the cells and lead to a translation of the gene insert into its respective protein. More importantly, the functionality of this protein was verified through HPLC analysis of COS-7 cells infected with lenti-sEH. The lentiviral vector used to deliver sEH is indeed functional and successfully infects cells in vitro. The pertinent question, however, was how does this sEH overexpression in cardiovascular-relevant brain nuclei affect blood pressure and heart rate? sEH gene therapy to the WKY rat resulted in only a 6 bpm decrease in heart rate twenty to forty days post injection, as compared to delivery with lenti-neo. In the SHR, no changes in blood pressure or heart rate were detected following lenti-sEH delivery up to two weeks post-injection. Changes in SHR blood pressure and heart rate will continue to be monitored and compared to the WKY rat. At this point, however, the sEH overexpression in the PVN exerts minimal control in the central control of blood pressure.

PAGE 126

113 It is important to discuss why the lenti-sEH-infected WKY rats had no change in blood pressure and only a small decrease in heart rate. Several possibilities can be addressed. First, the gene delivery coordinates to individual rats may not have targeted the PVN. However, immunohistochemistry of sEH in brain sections of the WKY rats following the study shows the sEH expression in the PVN of the four rats infected with lenti-sEH. Given the importance of correct localization, it is essential in all gene therapy studies to verify injection site, including at the end of the current SHR PVN study. Second, the blood pressure and heart rate may have already been at the minimum physiological level. Since the WKY rats are normotensive, they have little to no cardiovascular problems, including those involving increased heart rate. Because there is no endogenous elevated heart rate to combat, increasing sEH may not be able to lower heart rate further than basal levels. Another possibility that may work in conjunction with the second point is that WKY rats do not have the same pathway invoked in the SHR through which EETs function. We know that ROS, found to be associated with the actions of sEH inhibition, is elevated in the SHR. In the WKY rat, however, EETs may not be at the same level to induce ROS, or ROS members may not be as widely available. Thus, increasing sEH, which decreases EETs, would not affect pathophysiologies associated with ROS. One piece of evidence against this suggestion, however, is that heart rate does increase in the WKY rat with central sEH inhibition, albeit not as dramatically as in the SHR. Therefore, this pathway must be intact to some degree in order to allow for the increase in heart rate. sEH overexpression in the PVN had no effect of blood pressure or heart rate in the SHR. These results suggest several underlying possibilities. First, the high endogenous

PAGE 127

114 sEH levels in the SHR may be in excess of the EETs, indicating that EETs are the rate-limiting step in this conversion. Thus overexpressing the protein would not affect physiology since the SHR would already be converting the maximum level of EETs in the PVN. Second, sEH itself may not be essential in central blood pressure regulation. While the inhibitor studies clearly identified the epoxygenase branch of arachidonic acid conversion in blood pressure changes, these effects may be due to CYP function or EETs. While sEH is definitely a strong regulator of EET availability, perhaps alternate pathways mask its influence. In addition, because the sEH activity was not measured in vivo following sEH inhibition, we cannot conclusively state that ICV delivery of sEH inhibitors solely targeted sEH. Activity of sEH using HPLC analysis of DHETs should be incorporated into future gene therapy studies. To address these first two explanations, EETs should be targeted to the PVN, either by overexpression or depletion. This analysis of substrate function would determine the importance of the PVN in epoxygenase-mediated blood pressure. Third, sEH may not act through the PVN to influence blood pressure and heart rate. Though the PVN is an important regulator of cardiovascular function, it is in the company with several other brain nuclei that must be examined for sEH function. Indeed, Dr. Julian Paton, our collaborator in Bristol, England, has recently used lenti-sEH to overexpress the gene in the RVLM. Surprisingly, blood pressure increased in the SHR from 136 mmHg to 151 mmHg two weeks following viral delivery, an unexpected result. This finding corresponds with the action of sEH in the peripheral vasculature but disputes the pressor effect of ICV delivery of the sEH inhibitors. This discrepancy in the brain is likely due to differences between targeting specific nuclei and diverse brain area delivery

PAGE 128

115 with ICV injection. In order to resolve this contradiction, AUDA should be delivered to specific brain nuclei including the RVLM to further elucidate the role of sEH in different brain areas. These different results following gene therapy to the PVN and RVLM, though, support the hypothesis that sEH has diverse functions in different brain nuclei. One question that remains unanswered is the pattern of heart rate and blood pressure changes following viral injections in specific brain nuclei. In both control and sEH viral injections into the WKY PVN, heart rate decreased and blood pressure increased. In the SHR, both factors increased following viral delivery. The trend seen in both viral treatments indicates that the changes in physiological measurements are due to the viral injections or the injection protocol itself. This was the first study to inject lentivirus into the brain and measure blood pressure and heart rate daily using radiotelemetry; therefore, whether this physiological result is common for the lentiviral injection is not currently known. If this pressor response is indeed reproducible in other gene therapy studies, then it is necessary to determine the cause prior to considering this strategy in a therapeutic manner. Differences between strains may be due to an intrinsic dampened baroreceptor reflex in the SHR. More studies are needed to define this pressor response following central lentiviral delivery in each strain. While sEH overexpression in the PVN of SHR and WKY rats had little effect on the cardiovascular parameters measured, this work provides a solid basis for future analysis of sEH function in different brain nuclei. The functionality of the lentivirus coupled with its high titer and ability to incorporate specific promoters makes it ideal for studying gene function in the brain. Using this approach, the central role of sEH on cardiovascular function can be mapped clearly in different models of hypertension.

PAGE 129

116 Figure 6-1 Lentiviral vector

PAGE 130

117 Figure 6-2 sEH protein expression in lenti-sEH-infected COS-7 cells. COS-7 cells were infected with 1x10 5 or 1x10 6 TU lenti-sEH or lenti-neo. After 3 days, protein was extracted from the cells (see Methods), and Western blot analysis was performed to detect sEH protein levels. Representative radiograph is shown above. Bands represent sEH Ab detection, with the TU listed below each band. The first two bands are infected with lenti-sEH, and the last two are infected with lenti-neo.

PAGE 131

118 Figure 6-3 DHET measurements using HPLC analysis. DHET levels were measured in COS-7 cells infected with either lenti-sEH or lenti-neo. DHET regioisomers were measured as described in Methods by Dr. Michal Schwartzman, New York Medical College.

PAGE 132

119 Figure 6-4 Blood pressure and heart rate recordings following lenti-sEH and lenti-neo delivery to the WKY rat PVN. Blood pressure and heart rate were recorded using radiotelemetry prior to and following PVN bilateral injections of the 5x10 5 TU lentivirus. X-axis represents days post injection. (A) Mean arterial pressure; (B) Heart rate. Data are mean +/SEM (p<0.05, n=4).

PAGE 133

120 Figure 6-5 Heart rate recordings following AUDA delivery in the lenti-sEH-infected WKY rat. Heart rate was recorded using radiotelemetry prior to and following 15ng AUDA delivery ICV (n=4 lenti-sEH, n=3 lenti-neo). The graph is quantitation of heart rate changes. Data are mean +/SEM, p<0.05.

PAGE 134

121 Figure 6-6 Blood pressure and heart rate recordings following EET agonist delivery in the lenti-sEH-infected WKY rat. Blood pressure and heart rate were recorded prior to and following 11-NODA delivery ICV (n=4 lenti-sEH, n=3 lenti-neo). X-axis represents time, and arrows represent point of drug delivery. (A) Representative blood pressure recording; (B) Representative heart rate recording; (C) quantitation of blood pressure changes. Black and gray bars represent first and second blood pressure peaks, respectively. Data are mean +/SEM, p<0.05.

PAGE 135

122 Figure 6-7 Localization of lenti-sEH delivered to the PVN of WKY rats

PAGE 136

123 Figure 6-8 Blood pressure and heart rate recordings following lenti-sEH (n=4) and lenti-neo (n=5) delivery to the SHR PVN. Blood pressure and heart rate were recorded using radiotelemetry prior to and following PVN bilateral injection of 5x10 5 TU lentivirus. X-axis represents days post-injection. (A) Mean arterial pressure; (B) Heart rate. Data are mean +/SEM, p<0.05

PAGE 137

CHAPTER 7 CONCLUSIONS AND FUTURE DIRECTIONS What began as a single gene identified from a microarray experiment emerged as an in-depth study of the cardiovascular effects of sEH in the brain. While sEH expression in the SHR brain is elevated, central sEH inhibition resulted in further increases in blood pressure and heart rate through the accumulation of EETs. This pressor effect is mediated by central ROS and functions through sympathetic nerve activation (Figure 7-1). Gene therapy was used to elucidate brain nuclei-specific effects of sEH overexpression. Lentiviral-mediated delivery of the sEH gene to the PVN had no effect on either blood pressure or heart rate in the SHR and only a minimal decrease in heart rate in the WKY rat. Collectively, these studies provide compelling evidence that sEH is a novel regulator of the central control of hypertension, though its effects may not be mediated through the PVN. These results stimulate a number of questions and plans for future analysis of central sEH function, as discussed in the following sections. sEH Overexpression in Alternate Brain Nuclei Mapping the mechanism of central sEH and EET regulation of blood pressure will be an extensive project. Initial gene therapy studies found that the PVN has minimal influence in the central role of sEH. However, the same experimental methods applied to the RVLM resulted in an increase in blood pressure in the SHR, as deduced by Dr. Julian Patons research group at the University of Bristol, England. These findings are the foundation for future brain-nuclei directed studies of sEH. Other cardiovascularly-relevant nuclei that should be targeted include the NTS and the SON. Effects of this 124

PAGE 138

125 overexpression should be compared between nuclei as well as between hypertensive and normotensive strains. In addition, it is critical to deliver sEH inhibitors and EET agonists directly to these nuclei via cannulae in order to extrapolate their specific effects. Given the wide array of neuronal projections between these areas, we hypothesize that sEH overexpression will have diverse effects in different areas, following the same results already observed in the PVN and RVLM. It will be interesting to study further any nuclei whose sEH overexpression yields a decrease in blood pressure or heart rate, thus supporting the increased pressor response resulting from ICV delivery of sEH inhibitors. The lentiviral vector is ideal for nuclei-specific delivery given its minimal distribution following central injection as well as the ease of incorporating promoters to target sEH to specific cell types. sEH Expression sEH expression is higher in the SHR brain compared to its normotensive control. This result correlates to sEH overexpression in the kidney and liver, indicating a whole-body induction of this enzyme in the SHR (Sinal et al. 2000b; Yu et al. 2000a). However, prior to definitely linking the central sEH to hypertension, it is necessary to determine the expression levels in other models of hypertension. Does sEH expression play a role in the induction or progression of hypertentension, or is it unique to the SHR? Peripheral studies have indicated an increase in sEH protein levels in the Ang II infusion model (Imig et al. 2002). However, these protein levels were highly variable between rats and therefore do not provide conclusive evidence for the link of sEH to hypertension in general. Future studies into central sEH expression should include the Ang II infusion model as well as strains outside RAS manipulation including Dahl salt sensitive rats and the two kidney, one clip model of hypertension. These models incorporate

PAGE 139

126 pharmacological, dietary, and surgical manipulation methods that will further elucidate the role of this enzyme. ROS-Mediated Pathway of EET Function sEH inhibition-induced effects were attenuated by blocking the formation of either EETs or ROS. From these results, we postulate that EETs increase the production of ROS; however, it is possible that ROS itself is upstream of EET function and controls the regulation of EETs. Inhibiting ROS and then adding EET agonists to the brain should address this question. If the ROS inhibition blocks the effects of EET activation, then ROS is downstream of EET action. If, however, EET agonists still result in increasing blood pressure and heart rate, then ROS is likely to be upstream of the EETs, indicating that EETs cause a pressor response through an alternate pathway than hypothesized. More focus should then turn to whether ROS effects in other tissues function though EET accumulation. This is an important next question that will provide further insight into the pathway of sEH regulation of blood pressure and heart rate control in the brain. Validation of Baroreceptor Reflex Findings Waveform analysis of AUDA delivery to the brain indicated a decrease in the spontaneous baroreceptor reflex gain in the SHR. This analysis employed the use of a time-series extrapolation from spontaneous changes in heart rat that was developed in 1997 (Oosting et al. 1997). While the methods are attractive in their elimination of response to pharmacological agents, debate exits as to their accuracy. Thus, in order to verify that concomitant increases in blood pressure and heart rate in the SHR are due to a dampening of the baroreceptor reflex gain, vasoactive agents such as phenylephrine (pressor) or nitroprusside (depressor) should be injected and the reflex measured as in traditional methods.

PAGE 140

127 Role of sEH in Glial and Endothelial Cells Conflict exists over the cell-specific actions of sEH and EETs. Previous studies, both peripheral and central, highlight the production of EETs in endothelial cells and its vasodilatory action in vascular smooth muscle cells (Harder et al. 1995; Li and Campbell 1997). Indeed, even in the brain, EETs are localized to endothelial and glial cells, though one study did locate CYP 2D19 in dopaminergic neurons (Medhora et al. 2001; Thompson et al. 2000). However, our studies found that sEH inhibition increased neuronal firing rate in cultures from one-day-old SHR pups. In addition, while the EF1 promoter used in lenti-sEH overexpression infects most cells, it seems to preferentially target neurons when delivered to the brain (Coleman et al. 2003). While our results suggest sEH is involved in neuronal activation, we cannot discount the role of other cell types in the brain. In order to determine the cell type-specific effects involved with sEH and EET action, it is necessary to incorporate GFAP promoters to target glial cells. Overexpression of sEH or blockade of EETs specifically in the glia will further answer this question of what cell types are involved in sEH action. The pathway may involve multiple cell types as does EET action in the vasculature. For example, EETs produced in the glia may transport to the neurons where they are either converted by sEH or elicit neuronal activation through a ROS-dependent pathway. Alternately, ICV delivery of sEH inhibitors may function to decrease EET stores in the cerebral vasculature and lead to changes in cerebral blood flow. Signaling from these changes to the overall

PAGE 141

128 vasculature may elicit pressor effects, though possible mechanisms behind this postulation are not known. Role of Central Epoxygenases We propose that sEH inhibition elicits its pressor effects through accumulation of the EETs. However, while EET formation blocker and EET agonist data support this idea, the role of epoxygenases the central control of blood pressure also must be determined. Epoxygenases are a subset of CYP that function to convert arachidonic acid to EETs. Given the connection of ROS to epoxygenases in the coronary artery and the role of ROS in central sEH-mediated physiological effects, these enzymes should not be overlooked as mediators in the regulation of blood pressure. Perhaps their expression or activity is altered in the hypertensive state. Many epoxygenase isoforms exist, though relatively few have been identified in the brain. This discrepancy may be due to enzyme specificity or to the lack of sufficient analysis in the brain. Collectively, inhibiting central epoxygenases may have attractive therapeutic potential. If EETs do indeed function in certain brain areas to increase blood pressure in the hypertensive state, then blocking their formation may prevent this progression. While MS-PPOH did not have any depressor effects on basal blood pressure, this result stemmed from ICV delivery of the drug. Direct inhibition of epoxygenase in brain areas may have beneficial effects on blood pressure and heart rate in hypertensive subjects. Effect of sEH Manipulation in Female Rats All the current studies used male rats to evaluate the effects of central sEH. However, it is essential to determine the effect of brain sEH on the blood pressure and heart rate in females as well. The only study incorporating females was the generation of transgenic mice lacking the sEH gene (Sinal et al. 2000b). In these animals, no change in

PAGE 142

129 physiological parameters was observed in the females, whose blood pressure was lower than that of the males. In essence, the effect of sEH knockout in the males was to feminize their systolic blood pressure. However, these studies do not address brain-specific sEH actions and their gender differences. Does central sEH inhibition in female SHRs also result in an increase in blood pressure and heart rate? If not, can these differences be explained by hormonal regulation? Do females have similar endogenous sEH expression levels compared to the males? The importance of these studies is two-part. First, female responses are not homogeneous to those of males, so the role of an enzyme studied in one gender cannot be automatically applied to another. In order to comprehensively study sEH, it must be analyzed in both males and females. Second, potential differences in central sEH effects between genders would further elucidate mechanisms underlying the control of this enzyme. This comparison between genders may reveal sEH and EET pathways not otherwise discerned by the study of only males. Implications of Central sEH in Human Hypertension The pinnacle question is what role, if any, sEH has in the human control of hypertension. As previously discussed, sEH polymorphisms have been identified in humans (Przybyla-Zawislak et al. 2003; Saito et al. 2001; Sandberg et al. 2000; Sato et al. 2004). Polymorphisms localized to members of the African American community correlated with an increase in coronary artery calcification (Fornage et al. 2004). Little research has been done in the brain, except one study that found no correlation of sEH polymorphisms to the incidence of Parkinsons disease (Farin et al. 2001). Given the increase in blood pressure and heart rate following sEH inhibition it is important to examine potential similarities between these models and the human state of hypertension.

PAGE 143

130 If sEH is indeed linked to the hypertensive state, then pharmacological agents already used in animal research may be modified for effective use in clinical trials. This finding may be a novel way to treat hypertension or tachycardia in a subset of the population that has sEH SNPs and thus an underactive function of the enzyme. One question that must be addressed, however, is what effect sEH agonists would have on the periphery, given the opposite effects of sEH compared to the brain. Our studies have set the basis for sEH overexpression in the brain, but it remains to be seen whether this overexpression not directed at the brain would have adverse side effects. The products of the epoxygenase pathway of arachidonic acid in the brain have been shown, for the first time, to elicit blood pressure and heart rate responses in the hypertensive rat. This mechanism involves sympathetic activation as well as ROS production, two established mediators of pressor response. These studies could not have been completed without sEH reagents including antibodies, inhibitors, and substrate agonists that were kindly provided by multiple researchers. Future studies will undertake linking and establishing brain-specific sEH effects, determining the roles of alternate members of the epoxygenase pathway, and translating these findings to polymorphisms identified in humans. Together, this work will continue to elucidate the role of central sEH in blood pressure regulation.

PAGE 144

131 Figure 7-1 Proposed mechanism of brain sEH function in the central control of blood pressure

PAGE 145

LIST OF REFERENCES Alkayed NJ, Birks EK, Narayanan J, Petrie KA, Kohler-Cabot AE, and Harder DR: Role of P-450 arachidonic acid epoxygenase in the response of cerebral blood flow to glutamate in rats. Stroke 28: 1066-72, 1997 Allen AM: Inhibition of the hypothalamic paraventricular nucleus in spontaneously hypertensive rats dramatically reduces sympathetic vasomotor tone. Hypertension 39: 275-80, 2002 Allen AM, Zhuo J, and Mendelsohn FA: Localization and function of angiotensin AT1 receptors. Am J Hypertens 13: 31S-38S, 2000 Amalfitano A and Parks RJ: Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr Gene Ther 2: 111-33, 2002 Andreatta SH, Averill DB, Santos RA, and Ferrario CM: The ventrolateral medulla. A new site of action of the renin-angiotensin system. Hypertension 11: I163-6, 1988 Aoki M, Morishita R, Muraishi A, Moriguchi A, Sugimoto T, Maeda K, Dzau V J, Kaneda Y, Higaki J, and Ogihara T: Efficient in vivo gene transfer into the heart in the rat myocardial infarction model using the HVJ (Hemagglutinating Virus of Japan)--liposome method. J Mol Cell Cardiol 29: 949-59, 1997 Arand M, Wagner H, and Oesch F: Asp333, Asp495, and His523 form the catalytic triad of rat soluble epoxide hydrolase. J Biol Chem 271: 4223-9, 1996 Bastos R, Menani J V, Saad WA, Renzi A, Silveira JE, and Camargo LA: Ventromedial hypothalamus lesions increase the dipsogenic responses and reduce the pressor responses to median preoptic area activation. Physiol Behav 62: 311-6, 1997 Becker LB: New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 61: 461-70, 2004 Biaggioni I: Sympathetic control of the circulation in hypertension: lessons from autonomic disorders. Curr Opin Nephrol Hypertens 12: 175-80, 2003 Borhan B, Mebrahtu T, Nazarian S, Kurth MJ, and Hammock BD: Improved radiolabeled substrates for soluble epoxide hydrolase. Anal Biochem 231: 188-200, 1995 132

PAGE 146

133 Brandes RP: Role of NADPH oxidases in the control of vascular gene expression. Antioxid Redox Signal 5: 803-11, 2003 Brand-Schieber E, Falck JF, and Schwartzman M: Selective inhibition of arachidonic acid epoxidation in vivo. J Physiol Pharmacol 51: 655-72, 2000b Buchschacher GL, Jr. and Wong-Staal F: Development of lentiviral vectors for gene therapy for human diseases. Blood 95: 2499-504, 2000 Campbell WB, Deeter C, Gauthier KM, Ingraham RH, Falck JR, and Li PL: 14,15-Dihydroxyeicosatrienoic acid relaxes bovine coronary arteries by activation of K(Ca) channels. Am J Physiol Heart Circ Physiol 282: H1656-64, 2002 Campbell WB, Gebremedhin D, Pratt PF, and Harder DR: Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78: 415-23, 1996 Carr AA. and Prisant LM: Losartan: first of a new class of angiotensin antagonists for the management of hypertension. J Clin Pharmacol 36: 3-12, 1996 Chan JY, Wang LL, Wu KL, and Chan SH: Reduced functional expression and molecular synthesis of inducible nitric oxide synthase in rostral ventrolateral medulla of spontaneously hypertensive rats. Circulation 104: 1676-81, 2001 Chappell MC, Modrall JG, Diz DI, and Ferrario CM: Novel aspects of the renal renin-angiotensin system: angiotensin-(1-7), ACE2 and blood pressure regulation. Contrib Nephrol 143: 77-89, 2004 Coleman JE, Huentelman MJ, Kasparov S, Metcalfe BL, Paton JF, Katovich MJ, Semple-Rowland SL, and Raizada MK: Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics 12: 221-8, 2003 Colombari E, Sato MA, Cravo SL, Bergamaschi CT, Campos RR, Jr, and Lopes OU: Role of the medulla oblongata in hypertension. Hypertension 38: 549-54, 2001 Croft KD, McGiff JC, Sanchez-Mendoza A, and Carroll MA: Angiotensin II releases 20-HETE from rat renal microvessels. Am J Physiol Renal Physiol 279: F544-51, 2000 Cronin A, Mowbray S, Durk H, Homburg S, Fleming I, Fisslthaler B, Oesch F, and Arand M: The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase. Proc Natl Acad Sci U S A 100: 1552-7, 2003 Dampney RA: Functional organization of central pathways regulating the cardiovascular system. Physiol Rev 74: 323-64, 1994

PAGE 147

134 Dampney RA, Fontes MA, Hirooka Y, Horiuchi J, Potts PD, and Tagawa T: Role of angiotensin II receptors in the regulation of vasomotor neurons in the ventrolateral medulla. Clin Exp Pharmacol Physiol 29: 467-72, 2002 de Wardener HE: The hypothalamus and hypertension. Physiol Rev 81: 1599-658, 2001 Di Nicolantonio R, Mendelsohn FA, Hutchinson JS, Takata Y, and Doyle AE: Dissociation of dipsogenic and pressor responses to chronic central angiotensin II in rats. Am J Physiol 242: R498-504, 1982 Fang X, Kaduce TL, Weintraub NL, Harmon S, Teesch LM, Morisseau C, Thompson DA, Hammock BD, and Spector AA: Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem 276: 14867-74, 2001 Farin FM, Janssen P, Quigley S, Abbott D, Hassett C, Smith-Weller T, Franklin GM, Swanson PD, Longstreth WT, Jr, Omiecinski CJ, and Checkoway H: Genetic polymorphisms of microsomal and soluble epoxide hydrolase and the risk of Parkinson's disease. Pharmacogenetics 11: 703-8, 2001 Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R: Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401: 493-7, 1999 Fleegal MA and Sumners C: Drinking behavior elicited by central injection of angiotensin II: roles for protein kinase C and Ca2+/calmodulin-dependent protein kinase II. Am J Physiol Regul Integr Comp Physiol 285: R632-40, 2003 Fleming I: Cytochrome p450 and vascular homeostasis. Circ Res 89: 753-62, 2001 Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP, and Busse R: Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res, pp. 44-51, 2001a Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B., Dehghani F, Brandes RP, and Busse R: Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88: 44-51, 2001b Flotte TR. and Carter BJ: Adeno-associated virus vectors for gene therapy. Gene Ther 2: 357-62, 1995 Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, and Wong ND: Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109: 335-9, 2004

PAGE 148

135 Fornage M, Hinojos CA, Nurowska BW, Boerwinkle E, Hammock BD, Morisseau CH, and Doris PA: Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 40: 485-90, 2002 Gebremedhin D, Ma YH, Falck JR, Roman RJ, VanRollins M, and Harder DR: Mechanism of action of cerebral epoxyeicosatrienoic acids on cerebral arterial smooth muscle. Am J Physiol 263: H519-25, 1992 Gomez RE, Cannata MA, Milner TA, Anwar M, Reis DJ, and Ruggiero DA: Vasopressinergic mechanisms in the nucleus reticularis lateralis in blood pressure control. Brain Res 604: 90-105, 1993 Grant DF, Storms DH, and Hammock BD: Molecular cloning and expression of murine liver soluble epoxide hydrolase. J Biol Chem 268: 17628-33, 1993 Gregg D, Rauscher FM, and Goldschmidt-Clermont PJ: Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. Am J Physiol Cell Physiol 285: C723-34, 2003 Guertzenstein PG and Silver A: Fall in blood pressure produced from discrete regions of the ventral surface of the medulla by glycine and lesions. J Physiol 242: 489-503, 1974 Hanna IR, Taniyama Y, Szocs K, Rocic P, and Griendling KK: NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxid Redox Signal 4: 899-914, 2002 Harder DR, Campbell WB, and Roman RJ: Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J Vasc Res 32: 79-92, 1995 Harland D, Gardiner SM, and Bennett T: Paraventricular nucleus injections of noradrenaline: cardiovascular effects in conscious Long-Evans and Brattleboro rats. Brain Res 496: 14-24, 1989 Hayashi J, Takeda K, Kawasaki S, Nakamura Y, Oguro M, Nakata T, Tanabe S, Lee LC, Sasaki S, and Nakagawa M: Central attenuation of baroreflex by angiotensin II in normotensive and spontaneously hypertensive rats. Am J Hypertens 1: 15S-22S, 1988 Helin K, Stoll M, Meffert S, Stroth U, and Unger T: The role of angiotensin receptors in cardiovascular diseases. Ann Med 29: 23-9, 1997 Imig JD, Zhao X, Capdevila JH, Morisseau C, and Hammock BD: Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39: 690-4, 2002

PAGE 149

136 Kannan H and Yamashita H: Connections of neurons in the region of the nucleus tractus solitarius with the hypothalamic paraventricular nucleus: their possible involvement in neural control of the cardiovascular system in rats. Brain Res 329: 205-12, 1985 Kim IH, Morisseau C, Watanabe T, and Hammock BD: Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem 47: 2110-22, 2004 Kishi T, Hirooka Y, Ito K, Sakai K, Shimokawa H, and Takeshita A: Cardiovascular effects of overexpression of endothelial nitric oxide synthase in the rostral ventrolateral medulla in stroke-prone spontaneously hypertensive rats. Hypertension 39: 264-8, 2002 Lee HC, Lu T, Weintraub NL, VanRollins M, Spector AA, and Shibata EF: Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes. J Physiol 519 Pt 1: 153-68, 1999 Lesnik EA, Sampath R, and Ecker DJ.: Rev response elements (RRE) in lentiviruses: an RNAMotif algorithm-based strategy for RRE prediction. Med Res Rev 22: 617-36, 2002 Li PL and Campbell WB: Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res 80: 877-84, 1997 Lindpaintner K: What can the molecular genetics of hypertensive rats teach us about the genetics of hypertension in humans? Curr Opin Nephrol Hypertens 3: 30-8, 1994 Louis WJ and Howes LG: Genealogy of the spontaneously hypertensive rat and Wistar-Kyoto rat strains: implications for studies of inherited hypertension. J Cardiovasc Pharmacol 16 Suppl 7: S1-5, 1990 Lu D, Yang H, and Raizada MK: Attenuation of ANG II actions by adenovirus delivery of AT1 receptor antisense in neurons and SMC. Am J Physiol 274: H719-27, 1998 Lu T, Hoshi T, Weintraub NL, Spector AA, and Lee HC: Activation of ATP-sensitive K(+) channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes. J Physiol 537: 811-27, 2001 Maeda M, Krieger AJ, Nakai M, and Sapru HN: Chemical stimulation of the rostral ventrolateral medullary pressor area decreases cerebral blood flow in anesthetized rats. Brain Res 563: 261-9, 1991 Malpas SC: What sets the long-term level of sympathetic nerve activity: is there a role for arterial baroreceptors? Am J Physiol Regul Integr Comp Physiol 286: R1-R12, 2004

PAGE 150

137 Mangiapane ML and Simpson JB: Subfornical organ: forebrain site of pressor and dipsogenic action of angiotensin II. Am J Physiol 239: R382-9, 1980 Medhora M, Narayanan J, and Harder D: Dual regulation of the cerebral microvasculature by epoxyeicosatrienoic acids. Trends Cardiovasc Med 11: 38-42, 2001 Metcalfe BL, Huentelman MJ, Parilak LD, Taylor DG, Katovich MJ, Knot HJ, Sumners C, and Raizada MK: Prevention of Cardiac Hypertrophy by Angiotensin II Type 2 Receptor Gene Transfer. Hypertension, 2004 Morishita R, Gibbons GH, Kaneda Y, Ogihara T, and Dzau VJ: Systemic administration of HVJ viral coat-liposome complex containing human insulin vector decreases glucose level in diabetic mouse: A model of gene therapy. Biochem Biophys Res Commun 273: 666-74, 2000 Morisseau C, Goodrow MH, Dowdy D, Zheng J, Greene JF, Sanborn JR, and Hammock BD: Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci U S A 96: 8849-54, 1999 Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, and Hammock BD: Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 63: 1599-608, 2002 Muratani H, Ferrario CM, and Averill DB: Ventrolateral medulla in spontaneously hypertensive rats: role of angiotensin II. Am J Physiol 264: R388-95, 1993 Muratani H, Teruya H, Sesoko S, Takishita S, and Fukiyama K: Brain angiotensin and circulatory control. Clin Exp Pharmacol Physiol 23: 458-64, 1996 Naldini L, Blomer U, Gage FH, Trono D, and Verma IM: Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 93: 11382-8, 1996 Newman JW, Morisseau C, Harris TR, and Hammock BD: The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci U S A 100: 1558-63, 2003 Omata K, Abraham NG, Escalante B, and Schwartzman ML: Age-related changes in renal cytochrome P-450 arachidonic acid metabolism in spontaneously hypertensive rats. Am J Physiol 262: F8-16, 1992 Oosting J, Struijker-Boudier HA, and Janssen BJ: Validation of a continuous baroreceptor reflex sensitivity index calculated from spontaneous fluctuations of blood pressure and pulse interval in rats. J Hypertens 15: 391-9, 1997 Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, Sandrone G, Malfatto G, Dell'Orto S, and Piccaluga E: Power spectral analysis of heart rate

PAGE 151

138 and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res 59: 178-93, 1986a Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, Sandrone G, Malfatto G, Dell'Orto S, Piccaluga E, and et al: Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res, pp. 178-93, 1986b Palkovits M, Mezey E, Skirboll LR, and Hokfelt T: Adrenergic projections from the lower brainstem to the hypothalamic paraventricular nucleus, the lateral hypothalamic area and the central nucleus of the amygdala in rats. J Chem Neuroanat 5: 407-15, 1992 Pan HL: Brain Angiotensin II and Synaptic Transmission. Neuroscientist 10: 422-31, 2004 Pomposiello SI, Carroll MA, Falck JR, and McGiff JC: Epoxyeicosatrienoic acid-mediated renal vasodilation to arachidonic acid is enhanced in SHR. Hypertension 37: 887-93, 2001 Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, Bradbury JA, Enayetallah AE, Zeldin DC, and Grant DF: Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 64: 482-90, 2003 Punnen S, Willette R, Krieger AJ, and Sapru HN: Cardiovascular response to injections of enkephalin in the pressor area of the ventrolateral medulla. Neuropharmacology 23: 939-46, 1984 Raizada MK, Francis SC, Wang H, Gelband CH, Reaves PY, and Katovich MJ: Targeting of the renin-angiotensin system by antisense gene therapy: a possible strategy for the long-term control of hypertension. J Hypertens 18: 353-62, 2000 Raizada MK, Katovich MJ, Wang H, Berecek KH, and Gelband CH: Is antisense gene therapy a step in the right direction in the control of hypertension? Am J Physiol 277: H423-32, 1999 Raizada MK, Lu D, and Sumners C: AT1 receptors and angiotensin actions in the brain and neuronal cultures of normotensive and hypertensive rats. Adv Exp Med Biol, pp. 331-48, 1995 Reid IA: Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 262: E763-78, 1992 Reid T, Warren R, and Kirn D: Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 9: 979-86, 2002

PAGE 152

139 Rey FE, Cifuentes ME, Kiarash A, Quinn MT, and Pagano PJ: Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res, pp. 408-14, 2001a Rey FE, Cifuentes ME, Kiarash A, Quinn MT, and Pagano PJ: Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res 89: 408-14, 2001b Roebuck KA and Saifuddin M: Regulation of HIV-1 transcription. Gene Expr 8: 67-84, 1999 Roman RJ: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82: 131-85, 2002 Rosolowsky M and Campbell WB: Synthesis of hydroxyeicosatetraenoic (HETEs) and epoxyeicosatrienoic acids (EETs) by cultured bovine coronary artery endothelial cells. Biochim Biophys Acta 1299: 267-77, 1996 Saito S, Iida A, Sekine A, Eguchi C, Miura Y, and Nakamura Y: Seventy genetic variations in human microsomal and soluble epoxide hydrolase genes (EPHX1 and EPHX2) in the Japanese population. J Hum Genet 46: 325-9, 2001 Sandberg M, Hassett C, Adman ET, Meijer J, and Omiecinski CJ: Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms. J Biol Chem 275: 28873-81, 2000 Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, Matsuda Y, and Inagami T: Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 351: 230-3, 1991 Sato K, Emi M, Ezura Y, Fujita Y, Takada D, Ishigami T, Umemura S, Xin Y, Wu LL, Larrinaga-Shum S, Stephenson SH, Hunt SC, and Hopkins PN: Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. J Hum Genet 49: 29-34, 2004 Shivachar AC, Willoughby KA, and Ellis EF: Effect of protein kinase C modulators on 14,15-epoxyeicosatrienoic acid incorporation into astroglial phospholipids. J Neurochem 65: 338-46, 1995 Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, and Gonzalez FJ: Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. Vol 275, J Biol Chem Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, and Gonzalez FJ: Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275: 40504-10, 2000b

PAGE 153

140 Spector AA, Fang X, Snyder GD, and Weintraub NL: Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 43: 55-90, 2004 Strack AM, Sawyer WB, Hughes JH, Platt KB, and Loewy AD: A general pattern of CNS innervation of the sympathetic outflow demonstrated by transneuronal pseudorabies viral infections. Brain Res 491: 156-62, 1989 Sumners C, Fleegal MA, and Zhu M: Angiotensin AT1 receptor signalling pathways in neurons. Clin Exp Pharmacol Physiol 29: 483-90, 2002 Sun C, Du J, Raizada MK, and Sumners C: Modulation of delayed rectifier potassium current by angiotensin II in CATH.a cells. Biochem Biophys Res Commun 310: 710-4, 2003a Sun C, Du J, Sumners C, and Raizada MK: PI3-kinase inhibitors abolish the enhanced chronotropic effects of angiotensin II in spontaneously hypertensive rat brain neurons. J Neurophysiol, pp. 3155-60, 2003b Sunn N, Egli M, Burazin TC, Burns P, Colvill L, Davern P, Denton DA, Oldfield BJ, Weisinger RS, Rauch M, Schmid HA, and McKinley MJ: Circulating relaxin acts on subfornical organ neurons to stimulate water drinking in the rat. Proc Natl Acad Sci U S A 99: 1701-6, 2002 Sved AF, Ito S, Madden CJ, Stocker SD, and Yajima Y: Excitatory inputs to the RVLM in the context of the baroreceptor reflex. Ann N Y Acad Sci 940: 247-58, 2001 Tanaka J, Hori K, and Nomura M: Dipsogenic response induced by angiotensinergic pathways from the lateral hypothalamic area to the subfornical organ in rats. Behav Brain Res 118: 111-6, 2001 Thompson CM, Capdevila JH, and Strobel HW: Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid. J Pharmacol Exp Ther 294: 1120-30, 2000 Touyz RM: Reactive oxygen species and angiotensin II signaling in vascular cells -implications in cardiovascular disease. Braz J Med Biol Res 37: 1263-73, 2004 Trippodo NC and Frohlich ED: Similarities of genetic (spontaneous) hypertension. Man and rat. Circ Res 48: 309-19, 1981 Turner AJ, Hiscox JA, and Hooper NM: ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 25: 291-4, 2004 Verma IM and Somia N: Gene therapy -promises, problems and prospects. Nature 389: 239-42, 1997

PAGE 154

141 Waki H, Kasparov S, Wong LF, Murphy D, Shimizu T, and Paton JF: Chronic inhibition of endothelial nitric oxide synthase activity in nucleus tractus solitarii enhances baroreceptor reflex in conscious rats. J Physiol 546: 233-42, 2003 Willette RN, Barcas PP, Krieger AJ, and Sapru HN: Endogenous GABAergic mechanisms in the medulla and the regulation of blood pressure. J Pharmacol Exp Ther 230: 34-9, 1984a Willette RN, Punnen S, Krieger AJ, and Sapru HN: Cardiovascular control by cholinergic mechanisms in the rostral ventrolateral medulla. J Pharmacol Exp Ther 231: 457-63, 1984b Wivel NA and Wilson JM: Methods of gene delivery. Hematol Oncol Clin North Am 12: 483-501, 1998 Wright JW, Sullivan MJ, Quirk WS, Batt CM, and Harding JW: Heightened pressor effect and dipsogenicity to intracerebroventricularly applied angiotensin II and III in spontaneously hypertensive rats. J Hypertens Suppl 4: S408-11, 1986 Yang H, Reaves PY, Katovich MJ, and Raizada MK: Decrease in hypothalamic gamma adducin in rat models of hypertension. Hypertension, pp. 324-8, 2004 Yee JK, Friedmann T, and Burns JC: Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 43 Pt A: 99-112, 1994 Yoshimura K, Hanaoka T, Ohnami S, Kohno T, Liu Y, Yoshida T, Sakamoto H, and Tsugane S: Allele frequencies of single nucleotide polymorphisms (SNPs) in 40 candidate genes for gene-environment studies on cancer: data from population-based Japanese random samples. J Hum Genet 48: 654-8, 2003 Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC, and Kroetz DL: Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87: 992-8, 2000a Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC, and Kroetz DL: Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res, pp. 992-8, 2000b Zaiss AK, Son S, and Chang LJ: RNA 3' readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol 76: 7209-19, 2002 Zanchetti A and Mancia G: Cardiovascular reflexes and hypertension. Hypertension 18: III13-21, 1991 Zeldin DC: Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276: 36059-62, 2001

PAGE 155

142 Zhu M, Neubig RR, Wade SM, Posner P, Gelband CH, and Sumners C: Modulation of K+ and Ca2+ currents in cultured neurons by an angiotensin II type 1a receptor peptide. Am J Physiol 273: C1040-8, 1997 Zimmerman BG, Sybertz EJ, and Wong, P. C.: Interaction between sympathetic and renin-angiotensin system. J Hypertens 2: 581-7, 1984 Zimmerman MC and Davisson RL: Redox signaling in central neural regulation of cardiovascular function. Prog Biophys Mol Biol 84: 125-49, 2004 Zimmerman MC, Lazartigues E, Lang JA, Sinnayah P, Ahmad IM, Spitz DR, and Davisson RL: Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res 91: 1038-45, 2002

PAGE 156

BIOGRAPHICAL SKETCH Kathleen Sellers was born February 3 rd 1978, in Savannah, Georgia. During her primary and secondary educational training, she lived in Gainesville, Florida; Nashville, Tennessee; and Daytona Beach, Florida. Her first taste for research came in 1995 when she attended the Student Science Training Program at the University of Florida. There, she worked on a project entitled Effect of Melatonin on Progesterone Secretion in Hysterectomized Pony Mares. Kathleen earned her bachelors degree in science from Winthrop University in Rock Hill, South Carolina. While attending the university, she worked with both Dr. Dwight Dimaculangan on genetic impulses underlying blackworm regeneration and Dr. Patricia Bossart-Whitacker on pneumocystis carinii cloning. In Summer 2000, Kathleen worked in Dr. Mohan Raizadas laboratory before starting the Interdisciplinary Program in Biomedical Sciences at the University of Florida. She joined the Department of Physiology and Functional Genomics in May 2001 where she continued to work under the guidance of Dr. Raizada to examine to the central role of soluble epoxide hydrolase on blood pressure regulation. She will earn her doctorate in December 2004. 143


Permanent Link: http://ufdc.ufl.edu/UFE0008356/00001

Material Information

Title: Role of Brain Soluble Epoxide Hydrolase in Cardiovascular Function
Physical Description: Mixed Material
Copyright Date: 2008

Record Information

Source Institution: University of Florida
Holding Location: University of Florida
Rights Management: All rights reserved by the source institution and holding location.
System ID: UFE0008356:00001

Permanent Link: http://ufdc.ufl.edu/UFE0008356/00001

Material Information

Title: Role of Brain Soluble Epoxide Hydrolase in Cardiovascular Function
Physical Description: Mixed Material
Copyright Date: 2008

Record Information

Source Institution: University of Florida
Holding Location: University of Florida
Rights Management: All rights reserved by the source institution and holding location.
System ID: UFE0008356:00001


This item has the following downloads:


Full Text












ROLE OF BRAIN SOLUBLE EPOXIDE HYDROLASE IN CARDIOVASCULAR
FUNCTION
















By

KATHLEEN WALWORTH SELLERS


A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL
OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT
OF THE REQUIREMENTS FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY

UNIVERSITY OF FLORIDA


2004

































Copyright 2004

by

Kathleen Walworth Sellers

















This work is dedicated to my family, who has taught me to embrace life with love,
perseverance, and grace.















ACKNOWLEDGMENTS

I could not have completed this work without the assistance from many colleagues

and friends. First and foremost, I would like to thank my mentor, Dr. Mohan Raizada,

who has consistently supported and encouraged me these last several years. It was by

chance that I worked in his research group before starting my graduate program, and I

could not have found a better group with which to work. Dr. Raizada's excitement and

fervor for new ideas have helped shape my appreciation for scientific research and the

pursuit of knowledge.

I also want to acknowledge all of the members of the Raizada research group, past

and present. I am fortunate to work in such a friendly and intellectually-stimulating

environment. Specifically, I want to thank Drs. Beverly Falcon and Matthew

Huentelman, the two graduate students in our research group who both helped me

tremendously. In addition, I would like to thank Drs. Carlos Diez, Cheng-wen Sun, Jorge

Vazquez, Shereeni Veerasingham and Hong Yang for all of their intellectual guidance.

I greatly acknowledge the members of my committee, Drs. Michael Katovich,

Gerard Shaw, Colin Sumners and Charles Wood. Each has provided me with unique

experience and expertise to further my research and career. In addition, I want to thank

all of my teachers throughout my education. Without a solid learning base, I would not

have reached this goal.









Finally, I want to thank all my family and friends who have supported me over the

years. It is they who lift my spirits and keep my sights set high. Each of my loved ones

has a purpose in my life for which I am eternally grateful.
















TABLE OF CONTENTS

page

A C K N O W L E D G M E N T S ................................................................................................. iv

LIST OF FIGURES ............................... ... ...... ... ................. .x

ABSTRACT .............. ..................... .......... .............. xii

CHAPTER

1 IN TR OD U CTION ............................................... .. ......................... ..

Central Regulation of H hypertension .................................. .................... ............... ..
B rain stem .................................................................................. . 2
H ypothalam u s ................................................................................................ 4
B aroreceptor R eflex ......................................... ....... ........ .. ....... .. ..
M echanism s U underlying SN A ......................................... .......................... 5
R enin-angiotensin system ........................................ ......................... 5
R active oxygen species........................................... .......................... 7
Im plications ................................... ................................ ........10
Soluble Epoxide H ydrolase ................................................... ....... .. ............... 11
H history .................. ................ .............................. ................ 11
Epoxyeicosatrenoic Acids ...........................................................................12
V asodilatory properties ........................................ .......................... 12
EETs in the brain ................. .. ............. .. ... ... ..... .. ........ .... 14
A alternate actions of EETs ........................................ ........................ 14
Dihydroxyeicosatrenoic Acids ......................... .... ............... ............... 15
Cytochrom e P-450 ............. .. .... .................. ........ .. .. .......... .. 16
Epoxygenases in the brain................................ ......................... ........ 16
2 0-H E T E ...................................................................... 17
sE H and H hypertension .................................................................... ............... 17
sEH Polym orphism s .................. ............................. .. ...... .. .......... 19
R o d en t .........................................................................19
H u m an ....................................... ............... ................ 2 0
sEH polymorphisms in cardiovascular disease................. ............. .....21
sEH polymorphisms in other disorders ................................................21
Phosphatase Studies.............. .. .................. ..... .. ......22
Sum m ary ................................................. ............ .. ... ................. 23









2 INCREASED SEH EXPRESSION IN SHR VS. WKY RAT BRAIN: IN VITRO
A N D IN VIVO A N A L Y SIS ......... ......... .. .............. .. ......................................... 31

Introduction ......... ........... ..................... .... ......................... 31
M materials and M methods ........................................................................ ..................33
A n im als ...................................................... ................... 3 3
Im m unohistochem i stry .......................................................... ...............33
R eal-T im e R T -P C R ............................. ............................... ............. .... 34
W western B lot A analysis .................................................. ............................. 34
N euronal Cells in Prim ary Culture ................................................................... 35
Losartan Treatment of SHRs to Normalize Blood Pressure..............................35
Statistical A analysis ...................... .................. ................. ...........36
R e su lts .............................. ....... ............................. ........................... 3 6
Cellular Localization of sEH .......................... ..... ............... ..... .......... 36
sEH Expression in the SHR....................... ...................... 37
In vitro Validation with Neuronal Cells in Primary Culture .............................37
sEH Expression Following Blood Pressure Normalization ..............................38
D isc u ssio n .......................................... ....... .................. ................ 3 9

3 CENTRAL SEH INHIBITION INCREASES BLOOD PRESSURE AND HEART
R A T E IN T H E SH R ......... ...... ........... ................. .......................... ..................... 49

Introduction ............... ...... .. .......... ........ .... ........................ 49
M materials and M methods ........................................................................ ..................5 1
A n im als....................................................5 1
Statistical A naly sis ...................... .................. ............................5 1
IC V C an nu nation ......... .................................................. ............ .. ... .... ... ....5 1
A bdom inal A orta Cannulation ........................................ ......................... 51
Blood Pressure and Heart Rate Recordings.............................. ...............52
In vivo Drug D delivery .................. ........................... ........ ... ........ .... 52
R e su lts............................. .................... ..... ............ .. .... .... ....... ............. 5 3
Effect of sEH Inhibitor DCU on Blood Pressure and Heart Rate ......................53
W K Y rat ................................................................................... 53
SH R ................. ..... ..... ... .... ... ... ..... .. ...............53
Effect of sEH Inhibitor AUDA on Blood Pressure and Heart Rate ...................54
Dose response ................................... ........................... ..........54
W K Y rat ............................................ ........................... 55
S H R ........................................................................... 5 5
D iscu ssion ......... .................. .................................... ............................55

4 ROLE OF ROS IN ANG II-INDUCED REGULATION OF BLOOD PRESSURE.63

Intro du action ...................................... ................................................ 6 3
M eth o d s ..............................................................................6 5
A n im als................................. ...................................................... ............... 6 5
IC V C annulation ......... .................................................. .............. ... .... .... .. 65
A bdom inal A orta Cannulation ........................................ ......................... 65









Statistical A analysis ...................... ................ ................. ..... ...... 65
In v iv o D rug D eliv ery .............................................................. .....................6 5
D ipsogenic R esponse............ .... ............................................ .... ............... 66
R results ...............................................................................................66
Angiotensin II Pressor Response..........................................................................66
gp9lds-tat Prevents Ang II-Induced Blood Pressure .....................................67
W K Y rat ........................................... ........................... 67
SH R .................................................. ........ .............. 67
gp91ds-tat Prevents Ang II-Induced Drinking ............................... ...............68
D iscu ssio n ......... .................................... ............................6 9

5 MECHANISM OF CENTRAL SEH INHIBITION ON BLOOD PRESSURE
R E G U L A T IO N ......... ......................................................................... ........ .. ..... .. 77

Introduction ............. ..... ... ............................................................ 77
M eth o d s .............................................................................. 8 0
A n im als................................. ..................................................... ............... 8 0
IC V C annulation ........... .......................................................... ..... ...... ........ 80
A bdom inal A orta Cannulation ........................................ ........................80
Blood Pressure and Heart Rate Recordings.............................. ...............80
Statistical A analysis .......................... ............ ...........................80
In vivo D rug D delivery .............. ......... ........................... ............... .. ..... 80
Evaluation of Spontaneous Baroreceptor Reflex Gain.......................................80
Analysis of Heart Rate Variability .............. ............................................81
N euronal Firing R ecording............................................................. ............... 82
R esults.......................... ...... ................ ............................................82
Waveform Analysis of Baroreceptor Parameters ............................................82
Index of spontaneous baroreceptor reflex gain ...........................................82
High frequency analysis of pulse interval................... ...............................83
AUDA Regulation of Sympathetic Nerve Activity ............................................83
Increased EETs Linked to Increase in BP and HR ................... ................84
M S -P P O H ............................................................................... 8 4
11-N O D A ................................................................................. 85
Effects of sEH Inhibition Function through ROS ..............................................85
D iscu ssio n ......... .................................... ............................8 6

6 EFFECT OF SEH OVEREXPRESSION IN THE PVN OF SHR AND WKY RATS97

In tro d u ctio n .................................................................... ................ 9 7
M e th o d s .......................................................................... 1 0 2
A n im als................................. ................................................... ............... 10 2
IC V C annulation ......... .............................................................. .. .... .. .... .. 102
Abdom inal A orta Cannulation ........................................ ....... ...............102
W western B lot A analysis ........................................ ....... .......................... 102
Transformation of pCR 2.1 sEH cDNA into competent cells.................... 102
DN A m iniprep ................................................ ...... .............. ... 02
Large-scale Lentiviral Production ............................................. ...............103


viii









Infection of COS-7 cells with lenti-sEH ................................. ............... 105
Cytoplasmic Isolation for HPLC Analysis............................................105
R adiotelem etry R ecordings ........................................ .......................... 106
PVN Coordinate D eterm nation ............................................. ............... 106
Im m unohistochem istry .............................................................. ............ ..... 07
PVN Injection of lenti-sEH ...... ............................................................ 108
In vivo D rug D delivery ............................................... ............................ 108
Statistical A naly sis .......................... ...... ................ ............ .. .............. 108
R e su lts .................................. ......... .. .................................................................. 1 0 9
Infection of COS-7 cells with lenti-sEH ................................. ............... 109
Functionality of Lenti-sEH ........................................................... ............... 109
sEH Overexpression in WKY PVN .............. .............................................110
AUDA delivery .................. .................................... ..... .... ........ 110
EE T agonist delivery ............................................................ .... ........... .111
Localization of viral delivery ........... ................................. .................111
sEH Overexpression in SHR PVN ............................................ ..................111
D iscu ssion ................................................................................................ ..... 1 12

7 CONCLUSIONS AND FUTURE DIRECTIONS ................................................124

sEH Overexpression in Alternate Brain Nuclei................................ .................. 124
sE H E expression .............. ........ ................ ................ .................... 12 5
ROS-M ediated Pathway of EET Function .........................................................126
Validation of Baroreceptor Reflex Findings...................... ..... ..............126
Role of sEH in Glial and Endothelial Cells........................................ ............... 127
Role of Central Epoxygenases........................................ 128
Effect of sEH Manipulation in Female Rats..................................................... 128
Implications of Central sEH in Human Hypertension.................... ..................129

LIST OF REFEREN CES ......... ......... ..... ............... ..................................... 132

B IO G R A PH ICA L SK ETCH ......... ................. ...................................... .....................143
















LIST OF FIGURES


Figure pge

1-1 M ajor pathw ays of the RA S ..................................................... ...................25

1-2 Major pathways of ROS production and metabolism...........................................26

1-3 Scatter plot of gene expression in the SHR and WKY hypothalamus and brainstem
..................................................................................................................................2 7

1-4 Arachidonic acid metabolism........................................... 28

1-5 Tissue-specific functions of EETs............................................. ......... ............... 29

1-6 Cellular membrane actions of EETs............................................30

2-1 Cellular localization of sEH in the brain ...................................... ............... 43

2-2 sEH mRNA levels in SHR and WKY brain regions ...........................................44

2-3 sEH protein expression in SHR and WKY brain regions ....................................45

2-4 sEH protein expression in neuronal cultures .................................. .................46

2-5 Effect of chronic losartan delivery on SBP in the SHR ............ .................47

2-6 Effect of chronic losartan delivery on central sEH expression ..........................48

3-1 Effect of ICV DCU delivery on blood pressure and heart rate ...........................60

3-2 Dose response of ICV delivery of AUDA to SHR and WKY rats.........................61

3-3 Effect of central AUDA on blood pressure and heart rate ...................................62

4-1 Effect of central Ang II on blood pressure and heart rate. ....................................73

4-2 Effect of gp91ds-tat on Ang II-induced BP response in the WKY rat .................74

4-3 Effect of gp91ds-tat on Ang II-induced BP response in the SHR ...................75

4-4 Dipsogenic responses of ICV gp9lds-tat and Ang II .....................................76









5-1 Effect of central AUDA delivery on baroreceptor parameters..............................91

5-2 Effect of atenolol on AUDA-induced blood pressure............................................92

5-3 Effect of MS-PPOH on AUDA-induced blood pressure ......................................93

5-4 Effect of EET agonist on BP and HR in the WKY rat...........................................94

5-5 Effect of ROS inhibition on AUDA-induced BP and HR response in the SHR......95

5-6 Effect of AUDA and gp91ds-tat on neuronal firing rate........................................96

6-1 Lentiviral vector ............................................. .................... ......... 116

6-2 sEH protein expression in lenti-sEH-infected COS-7 cells ................................117

6-3 DHET measurements using HPLC analysis............................................... 118

6-4 Blood pressure and heart rate recordings following lenti-sEH and lenti-neo delivery
to th e W K Y rat P V N ................................................................... ..................... 119

6-5 Blood pressure and heart rate recordings following AUDA delivery in the lenti-
sEH -infected W KY rat ...................................................................... ................ 120

6-6 Blood pressure and heart rate recordings following EET agonist delivery in the
lenti-sEH -infected W K Y rat............................................................. ................ 121

6-7 Localization of lenti-sEH delivered to the PVN of WKY rats.............................122

6-8 Blood pressure and heart rate recordings following lenti-sEH and lenti-neo delivery
to the SH R PV N .................. ..................................... .. ........ .... 123















Abstract of Dissertation Presented to the Graduate School
of the University of Florida in Partial Fulfillment of the
Requirements for the Degree of Doctor of Philosophy

ROLE OF BRAIN SOLUBLE EPOXIDE HYDROLASE IN CARDIOVASCULAR
FUNCTION

By

Kathleen Walworth Sellers

December 2004

Chair: Mohan K. Raizada
Major Department: Physiology and Functional Genomics

Recent studies have linked peripheral soluble epoxide hydrolase (sEH) to

hypertensive animal models. However, the role of this enzyme in the central control of

blood pressure has not been elucidated. Thus, the objective was to investigate the

involvement of brain sEH in blood pressure control through expression studies,

pharmacological inhibition, and overexpression of sEH in the brain.

First, sEH expression in the hypothalamus and brainstem, two cardioregulatory

brain areas, was increased in the spontaneously hypertensive rat (SHR) compared to the

Wistar Kyoto (WKY) rat. Second, inhibition of the enzyme by intracerebroventricular

(ICV) delivery of pharmacological agents increased both blood pressure and heart rate in

the SHR, an effect opposite to that following intraperitoneal delivery. This concomitant

increase in blood pressure and heart rate in the SHR was accompanied by a depression of

the baroreceptor reflex gain.









The pathway by which sEH inhibition resulted in an increase in blood pressure and

heart rate functioned through an accumulation of its substrate, epoxyeicosatrienoic acid

(EET). Central delivery of the EETs resulted in an increase in pressor response in the

WKY rat. In addition, P-adrenergic receptor antagonist atenolol blocked the effect of

sEH inhibition, indicating the pathway involves sympathetic activation. Furthermore, the

effects of sEH inhibition were regulated by reactive oxygen species member NAD(P)H

oxidase. This generator of toxic free radicals also mediated the central pressor response

of angiotensin II. These observations suggest that central EETs and sEH inhibition are

involved in increasing blood pressure.

Finally, gene transfer using the lentiviral vector was used to overexpress sEH in

cardiovascular-relevant nuclei. In the WKY rat, heart rate decreased six beats per minute

following sEH overexpression and blood pressure remained unchanged. These studies,

taken together, suggest that an increased expression of sEH is a futile central nervous

system response in protection against hypertension.














CHAPTER 1
INTRODUCTION

Hypertension has long been regarded as a silent killer, a disease that presents few

symptoms but can generate devastating health problems and eventual death. Beginning

as a sustained increase in blood pressure, this disease can lead to end-organ damage

including heart failure. Cardiac output and total peripheral resistance determine blood

pressure. Each component of this equation is influenced by a number of physiological

factors in several organs including the kidney, heart and brain. For example, the heart

regulates its contractility through input from baroreceptors in the carotid sinus and aortic

arch that react to pressure changes (Zanchetti and Mancia 1991). An increased cardiac

contractility results in an increased cardiac output, thereby increasing blood pressure.

Similarly, increasing sodium intake leads to an increase in the body's fluid volume, thus

increasing cardiac output. Total peripheral resistance is ultimately controlled by the

levels of hypertrophy and constriction present in smooth muscle cells that shape how the

blood flows through the vasculature. While these factors define the major influences of

blood pressure, it is necessary to understand the mechanisms underlying these factors in

order to prevent and even reverse this disease.

Central Regulation of Hypertension

The brain continues to emerge as essential in the body's regulation of blood

pressure. For example, when an animal senses a predator, the sympathetic nervous

system increases blood pressure and activates other defense mechanisms to prepare the

animal for a fight or flight response. This response begins when the body senses danger









and transmits this input to the brain to activate the sympathetic nerves that send

projections to the brainstem and spinal column. Preganglionic neurons from these areas

project to postganglionic neurons that in turn project to the heart or blood vessels

(Dampney 1994). Two forms of preganglionic neurons are important in cardiovascular

function, sympathetic preganglionic neurons (SPN) and vagal preganglionic neurons.

Activation of SPN result in an increase in pressor response, while vagal preganglionic

neurons regulate the baroreceptor reflex response that controls heart rate and blood

pressure (Dampney 1994). Thus, signaling from these neurons regulates or controls

cardiac contraction and blood vessel constriction. This autonomic nervous system

signaling therefore regulates both blood pressure and heart rate from information initially

processed from areas in the brain.

In order to elucidate the involvement of the brain in blood pressure regulation via

sympathetic control, it is necessary to identify regions that signal to the SPN. Retrograde

tracers injected into the intermediolateral cell column (IML) have been used to map

afferent neuronal projections. Specifically, transneuronal retrograde tracers incorporating

either herpes or pseudorabies virus have been used recently to push the retrograde tracer

into the cell body, thereby allowing the identification of specific nuclei that signal to the

SPN (Strack et al. 1989). These techniques have identified nuclei in the brainstem,

hypothalamus, caudal ventrolateral pons, and the A5 noradrenergic cell group. Based on

a plethora of data underlying their influence on sympathetic activation, our research

group has chosen to focus on the brainstem and hypothalamus.

Brainstem

The brainstem functions to regulate essential physiological functions including

blood pressure, heart rate and respiration. This brain region houses several specific









nuclei involved with cardiovascular function, including the rostral ventrolateral medulla

(RVLM). The RVLM signals to the SPN, and bilateral denervation of the RVLM results

in a decrease in blood pressure (Guertzenstein and Silver 1974). The RVLM therefore

has influence over the pressor response. The excitatory response of the RVLM is

regulated by several known factors. Excitatory inputs include acetylcholine, angiotensin

II (Ang II), vasopressin, and excitatory amino acids (Andreatta et al. 1988; Dampney

1994; Gomez et al. 1993; Maeda et al. 1991; Willette et al. 1984b). Inhibitory factors

include GABA and opiate receptor activation (Kishi et al. 2002; Punnen et al. 1984;

Willette et al. 1984a).

The important transmission ability of the RVLM is highlighted in work done with

nitric oxide synthase (NOS), a known depressor. First, the inducible form of NOS,

iNOS, is higher in the RVLM of normotensive Wistar Kyoto (WKY) versus

spontaneously hypertensive rats (SHR), indicating a reason for the increased sympathetic

activity in the SHR (Chan et al. 2001). Second, injection of eNOS, the endothelial form,

increased GABA's inhibitory action on RVLM neurons (Kishi et al. 2002). Third,

injections of Ang II into the RVLM increased both sympathetic vasomotor activity as

well as blood pressure (Dampney et al. 2002; Kishi et al. 2002). Finally, gene therapy

using adenovirus encoding eNOS delivered to the RVLM resulted in a decrease in blood

pressure, heart rate and SNA in the WKY rat (Hirooka PBMP 2003). Thus, the RVLM

functions to increase SNA and hence blood pressure through its neuronal projections.

While some of these regulators have been identified, the complete mechanism of the

RVLM in blood pressure control is not yet understood. In order to develop









comprehensive treatments and preventative measures towards the development of

hypertension, it is necessary to elucidate and define this role.

Hypothalamus

The hypothalamus is known for its regulation of body homeostasis and contains

several specific nuclei that are linked to blood pressure regulation. The paraventricular

nucleus (PVN) of the hypothalamus contains both magnocellular and parvocellular

subdivisions, surrounding the third ventricle in an inverted triangular shape. The PVN

has neuronal projections to the IML in the spinal column and also receives and transmits

signals to the RVLM and the nucleus tractus solitarius (NTS) in the brainstem (de

Wardener 2001). In relation to sympathetic control, the PVN can directly innervate the

SPN or send projections to another excitatory nucleus such as the RVLM (Allen 2002).

In fact, the PVN has a large number of catecholaminergic fibers ascending from the

RVLM that release norepinephrine (de Wardener 2001; Palkovits et al. 1992).

Norepinephrine delivery to the PVN increased blood pressure by 30 mmHg, suggesting

that the PVN has direct role on the central control of blood pressure (Harland et al. 1989).

The PVN has a diverse collection of neurons with distinct projections; therefore, its

relation to SPN control is complicated. For example, electrical stimulation of the PVN

has both stimulated and depressed blood pressure (Dampney 1994). Hence, while the

PVN serves as a control unit for SPN action, its overall role is difficult to elucidate.

Research of this key hypothalamic nucleus continues to define its control in brain-

mediated blood pressure.

Baroreceptor Reflex

Apart from the influence of SPN on the pressor response, the baroreceptor reflex

response is also an important component in cardiovascular regulation. Long believed to









function only in the short-term regulation of blood pressure, recent evidence points to the

baroreceptor reflex response as an important regulator of the long-term control of blood

pressure (Malpas 2004). Baroreceptors are found in the aortic arch and the carotid sinus

where they transmit and receive cardiac impulses to the IML and finally the brain. These

impulses stimulate vagal preganglionic neurons that in turn affect heart rate, sympathetic

vasomotor activity and the rate of secretion of vasopressin (Dampney 1994; Sved et al.

2001). Thus, the baroreceptor reflex response functions to control the balance of blood

pressure and heart rate stimulation. The RVLM is a major mediator of the baroreceptor

reflex response (Dampney 1994). For example, baroreceptor activation leads to an

inhibitory effect in the RVLM (Colombari et al. 2001). The PVN has not been

extensively studied in baroreceptor activation control, but studies do suggest it modulates

this action through signaling with the NTS (Kannan and Yamashita 1985). The

baroreceptor reflex response plays an important role in cardiovascular regulation and is

influenced by brain nuclei also involved in SPN control.

Mechanisms Underlying SNA

Renin-angiotensin system

As discussed, firing of neurons from specific nuclei including the PVN and RVLM

to the IML result in an increase in SNA and hence an increase in blood pressure.

Mechanisms controlling these oscillations in firing rate involve a number of hormones,

neurotransmitters and other gene products, many still unknown. One major example of

how these factors in the brain regulate hypertension is the renin-angiotensin system

(RAS).

The brain RAS continues to emerge as a vital regulator of hypertension since its

discovery and characterization more than thirty years ago. Figure 1-1 illustrates the main









pathways and members of the RAS. Classically, angiotensinogen is made in the liver and

then cleaved by renal renin into angiotensin I. Angiotensin I is then converted to Ang II

by angiotensin I converting enzyme (ACE) produced in the lung. Ang II, an eight-

membered peptide, then binds to the Ang II type 1 receptor (ATiR), a G-protein coupled

receptor (Sasaki et al. 1991). This binding results in an increase in blood pressure

through vasoconstriction, increased sympathetic activity and fluid/salt volume regulation.

Ang II functions as both a hormone and as a neurotransmitter in the brain and is also

present in cardiovascular-relevant tissues including the kidney, heart and vasculature.

(Allen et al. 2000).

The initial understanding of the RAS has advanced and become more complex with

new findings. First, the RAS has been identified both systemically and in individual

tissues. Second, novel components have been identified that increase the complexity of

this system. For example, ACE2 converts either Angiotensin I to Angiotensin (1-9) or

Ang II to Angiotensin (1-7) (Turner et al. 2004). In most tissues, Angiotensin (1-7) acts

opposite to that of Ang II (Chappell et al. 2004). These contradictory effects are also

seen when Ang II binds to the AT2R. With each new discovery of the RAS, the pathway

is further elucidated and better understood.

Ang II is a major player in the central regulation of hypertension.

Intracerebroventricular (ICV) delivery of Ang II results in a dramatic increase in both

blood pressure and drinking (Di Nicolantonio et al. 1982). This response begins within

minutes and is only a short-term effect following bolus delivery. Ang II has also been

extensively studied in specific brain nuclei that function in blood pressure and dipsogenic

responses (Pan 2004). For example, Ang II injection to the subfornical organ results in a









profound dipsogenic response, while injection into the PVN, NTS or RVLM leads to a

dramatic increase in blood pressure (Bastos et al. 1997; Mangiapane and Simpson 1980;

Muratani et al. 1993; Tanaka et al. 2001). Taken together, central Ang II binding to the

AT1R in several brain nuclei induces a pressor response.

One ongoing area of study involves the mechanisms underlying this blood pressure

control. Ang II through AT1R stimulation is known to increase neuronal firing rate and

norepinephrine release from sympathoexcitatory neurons, therefore resulting in

sympathetic nerve activation (Sumners et al. 2002; Zimmerman et al. 1984). One

question that remains is what are the steps involved after ATiR stimulation and prior to

sympathetic nerve activation? Recent evidence points to the involvement of reactive

oxygen species (ROS) as a second messenger in the central mediation of RAS.

Reactive oxygen species

ROS has emerged as a major player in a number of disease states, including

cardiovascular disease. ROS members include superoxide (02O-), hydrogen peroxide

(H202), and the hydroxyl radicals. ROS are formed from oxygen converted to superoxide

by enzymes including NAD(P)H oxidase and xanthine oxidase (Figure 1-2). Superoxide

is converted to the hydrogen peroxide using superoxide dismutase (SOD) and then

normally converted to water via either catalase or glutathione peroxidase (Becker 2004).

This pathway is not destructive to cellular function and is the normal progression of

oxygen processing. Oxygen is processed through the mitochondria in order to provide

energy for metabolic functions. During certain disease states and times of physiological

stress, however, hydrogen peroxide can instead be converted to hydroxyl radicals that

lead to cellular injury. Thus, when the ROS outnumbers the available antioxidants,









oxidative stress results (Touyz 2004). This damaging progression is thought to be a

significant factor in a growing number of disease states.

NAD(P)H oxidase, one of the key enzymes in the generation of ROS, was

originally localized in phagocytes (Hanna et al. 2002). It is able to convert oxygen to its

superoxide form by converting NAD(P)H to NAD(P) and donating the released electron.

This conversion rendered it able to defend the host cell against microorganisms. More

recently, though, focus has shifted to the role ofNAD(P)H oxidase in other tissues. This

enzyme was found to be a major source of ROS in cardiovascular tissue, and it has also

been localized to both neurons and glia in the brain (Hanna et al. 2002; Zimmerman and

Davisson 2004). One key difference between NAD(P)H oxidase sources from

phagocytotic or non-phagocytotic cells is that the NAD(P)H oxidase in non-phagocytotic

sources is constitutively active, thus increasing the probability for oxidative stress.

NAD(P)H oxidase is a multimeric enzyme consisting of membranous subunits Gp91ds

and p22 and cytoplasmic subunits p67, p47, p40 and Rac (Hanna et al. 2002). The active

form the enzyme is initiated when p47 is phosphorylated and transports to the membrane

along with the other cytoplasmic subunits and binds with Gp91. Phosphorylation of p47

is driven by protein kinase C (Rey et al. 2001b).

Due to the importance of ROS in a wide array of systems, several inhibitors and

activators have emerged in the field of study. Tempol is a SOD mimetic used in a variety

of studies as an antioxidant, though its specificity is low. Recent studies used an

adenoviral vector to deliver SOD to the brain (Zimmerman et al. 2002). In addition to

SOD manipulation, NAD(P)H oxidase has also been used in therapeutic approaches. A

peptide that competes with the docking portion of gp91 was sequenced to block the









effects ofNAD(P)H oxidase. The tat peptide derived from HIV was included upstream

of the docking sequence in order to facilitate delivery in vivo (Rey et al. 2001b). This

peptide, gp91ds-tat, is a specific, effective blocker of NAD(P)H oxidase both in vitro and

in vivo.

Several studies have implicated ROS in the central Ang II-mediated pathway. ICV

delivery of SOD using adenovirus prevented Ang II-induced increases in blood pressure

and drinking (Zimmerman et al. 2002). In addition, the Ang II-induced decrease in heart

rate was abolished. These results were reproducible using both the mitochondrial and

cytoplasmic forms of SOD. Given the wide range of impact from ICV delivery, studies

were undertaken to elucidate the importance of specific brain nuclei in the ROS-Ang II

connection. Adenovirus encoding a dominant-negative inhibitor ofNAD(P)H oxidase

activator Racl was injected into the circumventricular organs (CVOs) (Zimmerman and

Davisson 2004). CVOs are distinct brain regions in that they lack a blood-brain barrier;

therefore, they are influenced by both the brain and the periphery and serve to pass

information across the two. RAS members are present in several CVOs, and previous

research highlighted the cardiovascular regulatory role of RAS in the CVOs (Muratani et

al. 1996). This adenoviral delivery resulted in preventing the pressor and drinking

responses of Ang II (Zimmerman and Davisson 2004). Thus, ROS involvement in the

Ang II pathway is localized to distinct neurons as well. As a complement to the in vivo

experiments, Ang II treatment of primary lamina terminalis cultures led to an increase in

superoxide, indicating the importance of Ang II on ROS production in vitro (Zimmerman

et al. 2002).









Implications

The central control of blood pressure is regulated by neurotransmitters, hormones

and genetic factors that act to control SNA. While we understand the importance of

specific nuclei in both the hypothalamus and brainstem, the mechanisms underlying this

control have not been fully elucidated. Hypertension is indeed a complex disease whose

establishment and progression cannot be pinpointed to one genetic malfunction. Thus, in

order to understand the genetic basis of hypertension, it is necessary to identify multiple

genes underlying the basis of this disease.

Our research group began the task of identifying genes novel to central blood

pressure regulation by analyzing differences in brain gene mRNA levels between the

SHR and WKY rat, using microarray technology. The SHR was chosen because of

similarities between this genetic strain and human forms of genetic hypertension

(Lindpaintner 1994; Louis and Howes 1990; Trippodo and Frohlich 1981). The

hypothesis was that genes involved in the central regulation of hypertension would have

different gene expression levels between the hypertensive and normotensive state.

However, this genetic profiling cannot in itself distinguish genes whose expression alters

as a consequence of hypertension.

In order to analyze 7000 genes and 1500 ESTs, the Affymetrix U34A Rat

GeneChip was used. Isolated mRNA from the hypothalamus and brainstem was

amplified, fluorescently-labeled, hybridized to the chip, and scanned in order to be

analyzed using GeneSpring software. Figure 1-3 highlights gene expression expressed as

log values in four SHR compared to four WKY samples. Each point represents the

average measurement for an individual gene between the rats in each group. Dotted lines

segregate genes with a two-fold expression change between SHR and WKY rats.









EPHX2, the gene that encodes the soluble epoxide hydrolase (sEH) protein, had the

highest expression discrepancy between the two models. The sEH gene, indicated by the

arrow, was significantly upregulated in the SHR and virtually undetectable in the WKY

rat. This result incited a review of sEH and how it may be related to hypertension. The

following section discusses the history, pathways and actions of sEH and how these

factors may function to regulate blood pressure.

Soluble Epoxide Hydrolase

History

The family of epoxide hydrolases (EH) includes sEH, microsomal EH (mEH),

leukotriene A4 hydrolase, and cholesterol 5,6-oxide hydrolase (Spector et al. 2004). sEH

was first identified as a cohort to mEH, a detoxifying agent to many foreign ingested

agents. The sEH gene was first cloned in 1985, and its dimer structure (two 62-kDa

subunits) was deduced in 1996 (Arand et al. 1996; Grant et al. 1993). A ubiquitous

enzyme, sEH converts arachidonic acid metabolites and linoleic acid epoxides to less

active forms through the addition of water (Zeldin 2001). Figure 1-4 outlines the

placement of sEH in the major pathways of arachidonic acid conversion.

The sEH enzyme can act on several substrates, and initial evidence suggested 1,2-

disubstituted aliphatic epoxides were the ideal substrates for this enzyme. In fact,

radiolabeled forms of this type of compound are used in activity studies of sEH (Borhan

et al. 1995). The active site of sEH has been identified by crystal structure analysis to be

a catalytic triad (Arand et al. 1996). Recently, more research has focused on the

structure-function relationship in sEH. Crystal structure analysis revealed that sEH is a

homodimer made up of two 62.5 kDa units. The two C-terminal domains interact with









each other, while the N-terminal domains have no calculated or observed interactions

with each other (Newman et al. 2003).

Epoxyeicosatrenoic Acids

The most well-studied role of sEH involves its enzymatic conversion of vasoactive

epoxyeicosatrenoic acids (EETs) to dihydroxyeicosatrenoic acids (DHETs). The EETs

are formed from arachidonic acid (AA) through the enzymatic action of cytochrome P-

450 (CYP) epoxygenases (Zeldin 2001). The EETs are divided into four different

regioisomer forms (5,6-, 8,9-, 11,12-, and 14,15-EETs) and are found in a variety of

tissues including brain, kidney, and vasculature (Fang et al. 2001; Spector et al. 2004).

Figure 1-5 outlines the main pathways and tissue locations of EET regioisomers. Most

forms of EETs promote vasodilation, while their DHET metabolites are relatively

inactive.

Vasodilatory properties

EETs in the vasculature have been implicated in blood pressure control due to their

ability to dilate arteries. While EETs are found in a variety of tissue including the brain

and kidney, plasma levels of these epoxygenase products predominate over all other

known sources (Rosolowsky and Campbell 1996). EETs are produced from arachidonic

acid in the endothelium; however, they are secreted from the cells to act on vascular

smooth muscle cells. Evidence suggest that EETs bind to and activate the G-protein

coupled receptor subunit Gs within the smooth muscle cell which then stimulates the

large conductance calcium-activated potassium (BK(Ca)) channel (Harder et al. 1995; Li

and Campbell 1997). Potassium influx into the cell results in hyperpolarization and

therefore dilation of the vascular smooth muscle cell. Thus, increasing EET plasma

levels decreases blood pressure by decreasing total peripheral resistance via vascular









smooth muscle dilation. Figure 1-6 illustrates this vasodilatory action from a cellular

level.

Evidence for this dilation is as follows. First, all regioisomer forms of EETs have

been found to activate BK(Ca) channels in vascular smooth muscle cells (Harder et al.

1995). Second, 11,12- and 14,15-EETs increase the open-state probability of Ca2+-

activated K+ channels in coronary smooth muscle cells (Campbell et al. 1996). Third, all

the regioisomers relax coronary vessels following contraction with thromboxane mimetic

U46619 (Campbell et al. 1996). Fourth, EETs can transiently increase Ca2+ release from

intracellular stores, which also functions to activate BK(Ca) channels (Li and Campbell

1997). While this pathway results in the overall hyperpolarization of the membrane, it is

not necessary for the EET-modulated activation of BK(Ca) channels. Finally, an

increased EET production is associated with hypertensive models, presumably as a

feedback mechanism that cannot overcome the increase in blood pressure (Omata et al.

1992; Pomposiello et al. 2001). Taken together, these studies provide comprehensive

evidence that EETs function to relax the vasculature and thus lead to a decrease in blood

pressure.

This evidence of membrane hyperpolarization has led to high speculation that EETs

function as the elusive endothelial-derived hyperpolarizing factor (EDHF) in the

vasculature. While enormous evidence has implicated nitric oxide as a major player in

relaxing arteries, complete abolition of relaxation cannot be achieved with inhibitors to

NO action alone. The remaining action is termed EDHF, and its identity remains

unknown. While EDHF is likely to be a combination of several factors, the

hyperpolarizing nature of EETs coupled with their high expression in the vasculature has









led to the hypothesis that EETs function as EDHF (Campbell et al. 1996; Fisslthaler et al.

1999).

EETs in the brain

EETs are expressed in astrocytes and endothelial cells in the brain, and evidence

suggests their vasodilatory roles found in the periphery are translated to cerebral blood

flow control in the brain (Medhora et al. 2001). All regioisomer forms of EETs are

expressed in the brain, though astrocytes preferentially intake 8,9-EETs over 14,15-EETs

(Shivachar et al. 1995). In addition, 8,9-EETs were not converted to DHETs in

astrocytes. Whether this result was due to sEH regulation or other conversion

mechanisms is unclear.

EETs from both astrocytes and endothelial cells dilate smooth muscle cells through

activation of the BK(Ca) channels (Gebremedhin et al. 1992). The central result of this

dilation is an increase in cerebral blood flow. While all regioisomers act to dilate the

cerebral arteries, 8,9-EETs and 11,12-EETs are the most potent forms in the brain

(Gebremedhin et al. 1992). Studies that inhibited the CYP-450 epoxygenases in the brain

and thereby prevented the formation of EETs resulted in the reduction of basal cerebral

blood flow by 30% (Alkayed et al. 1997). Thus, central EETs play an integral role in the

maintenance of cerebral blood flow.

Alternate actions of EETs

These four regioisomers of EETs exert different functions dependent on their tissue

location. Vasodilation in the vascular smooth muscle leads to a decrease in blood

pressure via the enlargement of arteries and thus an increase in blood flow, thereby

decreasing total peripheral resistance. A second organ potentially involved in the sEH

regulation of blood pressure is the kidney. Vasodilatory properties of EETs in the renal









vasculature result in changes in renal blood flow and hence changes in water and

electrolyte balance. All regioisomers modulate calcium influx in the vascular smooth

muscle, while 11,12-EET is the predominant form regulating calcium as well as other

studied functions in the endothelium (Spector et al. 2004). In the myocardium, all the

regioisomers inhibit the sodium ion channel, while only the 8,9- and 11,12-EETs activate

the K(ATP) ion channel (Lee et al. 1999; Lu et al. 2001).

EETs can also be converted to different metabolites using enzymes ranging from

COX to CYP co-oxidase (Zeldin 2001). These actions are dependent on the tissue type

and likely the availability of sEH, since treatment with sEH inhibitor N,N'-

dicyclohexyurea (DCU) augments the conversion by these alternate enzymes (Spector et

al. 2004). EETs can also be effectively stored in phospholipids if not immediately

converted by enzymes.

Dihydroxyeicosatrenoic Acids

Studies on the function of DHETs have produced inconsistent results compared to

the role of the EETs. For example, DHETs is generally less potent than the EETs.

Evidence in support of this includes decreases in Ca2+ uptake and relaxation of the

bovine coronary artery compared to the EETs (Campbell et al. 2002). However, DHETs

do activate the BK(Ca) channel of coronary artery myocytes and serve to dilate coronary

arterioles following constriction with endothelin (Spector et al. 2004). While the general

consensus is that the EETs overshadow the DHETs in their action, DHET function cannot

be discounted due to lack of sufficient studies done on these metabolites. Overall,

however, by converting EETs to DHETs, sEH acts to attenuate EET action and promotes

the relative inactivity of DHETs.









Cytochrome P-450

EETs are only one branch of products generated from arachidonic acid. Figure 1-4

illustrates an overview of the pathways stemming from arachidonic acid.

Cyclooxygenase converts AA into a variety of prostaglandins that have been well

characterized in their inflammatory activation role. Prostaglandins have also been

implicated in labor induction and metabolic regulation. The second conversion pathway

uses lipoxygenases that generate hydroxyeicosatrenoic acids (HETEs). HETEs are well

studied in their roles in vascular tissue. HETEs are known to be potent vasoconstrictors

in the kidney and vasculature.

The cyclooxygenase and lipoxygenase branches of arachidonic acid conversion are

therefore stimulating in their roles both in blood pressure control and other essential

physiological regulation. This section will focus, however, on the CYP conversion of

arachidonic acid and what is known and hypothesized about its role in the brain. 20-

HETE, an alternate product of CYP action, is discussed regarding its vasoactive effects

opposite to that of EETs.

Epoxygenases in the brain

Most isoforms are able to convert AA to all regioisomer forms of EETs. Isoforms

in the brain include CYP 2C11, 2C12, 2D18, 2D19, 2C29, 2C38, and 2C39, though more

may be identified in the future (Roman 2002). Interestingly, the studies done to localize

epoxygenase expression in the brain have pinpointed the enzymes to astrocytes. These

studies hypothesize that central epoxygenases have a role in microvascular control. In

contrast, though, CYP 2D19 has been localized to dopaminergic neurons, suggesting that

CYP members are not found exclusively in the glia (Thompson et al. 2000). More









research is needed to elucidate this pathway in conjunction with EET-mediated effects on

cardiovascular control.

20-HETE

Regioisomers of HETEs can also be generated by CYP, specifically co-hydroxylase

of the CYP 4A family. co-hydroxylase converts arachidonic acid to 19-HETE and 20-

HETE. 20-HETE acts as a vasoconstrictor in vessels ranging from the kidney to the

brain. While EETs activate BK(Ca) channels, 20-HETE inhibits these channels, thus

inducing contraction (Croft et al. 2000). Inhibiting 20-HETE results in a decrease in

blood pressure due to the decrease in total peripheral resistance. Levels of both 20-HETE

and CYP 4A are increased in the SHR (Omata et al. 1992). In addition, this

vasoconstrictor is activated by Ang II, further elucidating its role in hypertension (Croft

et al. 2000). Thus, 20-HETE functions are opposite to the vasodilator role reported for

EETs and its overexpression is linked to hypertension. In summary, these arachidonic

acid metabolites from the epoxygenase and co-hydroxylase pathways serve a variety of

functions throughout the body, and these functions are dependent on the converting

enzymes that regulate the activity of these metabolites.

sEH and Hypertension

sEH has been implicated in cardiovascular, renal, and inflammatory biology

functions. Recently, studies have linked sEH to hypertension through both a transgenic

model overexpressing the gene and sEH inhibitor studies in the SHR. sEH-null mice

were generated from offspring of chimeric mice with the disrupted sEH gene (Sinal et al.

2000b). Homologous recombination was used to disrupt the sEH gene in embryonic stem

cells. High performance liquid chromatography (HPLC) revealed that the sEH-null mice

had elevated levels of EETs and decreased levels of DHETs as compared to the wild-type









mice. Blood pressure was measured using tail-cuff and compared between groups. Male

sEH-null mice had decreased systolic blood pressure and did not have an increased blood

pressure in response to salt loading. Female sEH-null mice had no significant change in

systolic blood pressure. Thus, deletion of the sEH gene lowered systolic blood pressure

to that of the female mice.

An important subsequent finding was relative sEH expression in the SHR and

WKY rat from Charles River Laboratories. As previously mentioned, the SHR is a good

animal model to use for hypertension studies based on similarities to the human form of

the disease (Lindpaintner 1994; Louis and Howes 1990; Trippodo and Frohlich 1981).

Using an sEH-specific antibody, researchers found a significant elevation of sEH protein

in the SHR kidney and liver; in fact, it was hardly detectable in the WKY rat (Yu et al.

2000a). Given the overexpression of sEH in the hypertensive model, researchers sought

to determine whether the activity of this enzyme was linked to blood pressure.

The second major paper addressing the sEH control in blood pressure involved the

intraperitoneal (IP) delivery of sEH inhibitor N,N'-dicyclohexylurea (DCU). Treatment

with 3 mg/kg DCU resulted in a 65% decrease in 14,15-DHET and a 30% increase in

14,15-EET (Yu et al. 2000a). As a result, systolic blood pressure decreased by 22 mmHg

in the SHR and had no significant effect in the WKY rat. Thus, pharmacological

inhibition of sEH also results in a decrease of systolic blood pressure in hypertensive

male rats. In summary, both a genetic and a non-genetic method for decreasing sEH in

the periphery led to a decrease in systolic blood pressure and were accompanied by a

decrease in the conversion of EETs to DHETs.









Expression studies for sEH have also included alternate models of high blood

pressure aside from the Charles River source of SHRs (Imig et al. 2002). Peripheral or

central delivery of Ang II results in an increase in blood pressure and consequently

hypertension (Allen et al. 2000; Di Nicolantonio et al. 1982). Ang II was chronically

infused (60 ng/min) using an osmotic minipump, and blood pressure was recorded using

tail cuff (Imig et al. 2002). Following IP injection of the sEH inhibitor N-cyclohexyl-N-

dodecyl urea, systolic blood pressure decreased 30 mmHg in the Sprague-Dawley (SD)

rat. Following sEH inhibition, sEH expression increased two-fold in the kidney.

However, sEH overexpression is not present in all SHR sources. As discussed below, the

Heidelberg (Heid) SHR has a lower sEH expression compared to its normotensive

control. Thus, the importance of sEH overexpression in the peripheral tissues remains to

be established.

sEH Polymorphisms

Rodent

It is important to note that in the Ang II-infusion study, the basal sEH expression in

the SD rats was highly variable, ranging from present to not present. This variable

expression is typical of sEH in SD rats. SD rats are outbred, which increases the

probability of new gene patterns with each new breeding source. Interestingly, sEH has

known polymorphisms found in both rodent models and in humans. As previously

described, the SHR from Charles River has increased sEH expression in both kidney and

liver (Yu et al. 2000a). However, sEH expression in Heid SHR and WKY rats was

opposite-WKY rats have increased sEH expression in the liver and kidney (Fornage et

al. 2002). This finding was accompanied by the identification of a separate sEH allele in

the Heid rat source. The two alleles differ by four single nucleotide polymorphisms









(SNPs). Consequently, the polymorphism identified in the Heid source results in a

blunted sEH activity. Thus, presence of these polymorphisms and reduced activity can

explain the strain source difference in the Western blot analysis results.

Human

Polymorphisms in sEH have also been identified in humans; in fact, most of the

research involving the sEH role in the human focuses on polymorphism and its effects

ranging from sEH activity itself to coronary artery calcification. The human form of sEH

is 73% identical to the mouse form, with 100% similarity in the catalytic triad (Przybyla-

Zawislak et al. 2003). This highly conserved region underlies the importance of the sEH

active site across species. The human sEH gene has been localized to the p arm of

chromosome 8, specifically, 8p21-pl2. The sEH gene is not without differences in its

sequence, however, as highlighted by three separate studies.

Initially, seven SNPs were identified in liver samples from twenty-five human

subjects. Two of these SNPs resulted in amino acid substitutions, while the remaining

five were silent mutations (Sandberg et al. 2000). In the second study, a total of thirty-six

SNPs were identified in forty-eight members of the Japanese population. Five of these

SNPs were found in exons of the gene (Saito et al. 2001; Sato et al. 2004). A third study

resulted in the identification of six SNPs of the gene in a population size of seventy-two.

Three of these polymorphisms had an increased level of epoxide hydrolase activity while

one had decreased activity. The one with decreased activity also had significant

reduction in 14,15-EET hydrolysis. Interestingly, the incidence of sEH polymorphisms

in the sample group studies was higher in the Black population as compared to White or

Asian population (Przybyla-Zawislak et al. 2003).









sEH polymorphisms in cardiovascular disease

This variation in sEH polymorphisms as related to race and disease was further

examined in a recent correlation study. The sEH gene was mapped in 1201 African

American and 1506 White subjects, and groups were separated based on the presence or

absence of the genotypes Gln287/Gln287, Arg287/Gln287, Arg287/Arg287 (Fornage et

al. 2004). The Gln287 polymorphism has been shown to result in a decrease in sEH

activity. The presence of the Gln287 polymorphism was associated with a two-fold

increase in coronary artery calcification in an African American subset of the Black

population (Fornage et al. 2004). This finding suggests that a decrease in sEH activity

and thus an increase in EETs may lead to an increase in coronary artery calcification in

the African American population.

In a separate study involving a family afflicted with familial hypercholesterolemia,

the sEH polymorphism Glu287/Arg was identified (Sato et al. 2004). Results indicated

that patients with one Arg287 allele as well as defects in the LDL receptor gene had

elevated total cholesterol levels as well as plasma triglyceride levels. No positive

correlation was identified in subjects not having defects in the LDL receptor gene. Thus,

it is interesting that these different polymorphisms at the same locus elicit different

effects on sEH activity. More research is needed to elucidate possible mechanisms

underlying this hypothesis and other associations between sEH and cardiovascular

disease.

sEH polymorphisms in other disorders

The Arg287/Gln287 polymorphism was further studied to identify any correlation

between this sEH SNP and Parkinson's disease (Farin et al. 2001). The rationale behind

the study was that a decrease in sEH activity leads to an increase in active epoxide









intermediates, which may generate an increase in oxidative stress, leading to Parkinson's

disease. No significant correlation was measured in Parkinson's patients, indicating a

decrease in sEH activity was not related to Parkinson's disease. However, this study

cannot rule out other sEH roles that may be related to CNS disorders or general oxidative

stress in general. In addition, the general study size could mask a subset of Parkinson's

disease development that may in fact stem from sEH dysregulation. Finally, SNP allele

frequencies were measured in a subset of the Japanese population for future studies on

cancer. The sEH gene was included in this study based on its involvement in conversion

of toxins (Yoshimura et al. 2003). Thus, sEH is being examined in a variety of disorders

and diseases based on its widespread activity and implications. In addition, its ubiquitous

expression and polymorphisms resulting in changes in activity target this as a candidate

gene for regulation of a number of genetic-based problems.

Phosphatase Studies

Two recent PNAS publications focused on the role of sEH as a phosphatase

(Cronin et al. 2003; Newman et al. 2003). sEH was found to act as a phosphatase, though

without high specificity. For example, sEH was not mediated by common phosphatase

inhibitors including sodium orthovanadate (Newman et al. 2003). However, sEH did

effectively metabolize a number of hydroxy lipid phosphates. The connection of

phosphatase activity to the N-terminal domain was confirmed with both a plant form of

sEH lacking the N-terminal domain and a mutant N-terminal domain form of sEH

(Cronin et al. 2003). In both of these models, phosphatase activity of the enzyme was

eliminated. In addition, sEH inhibitors used to block epoxide conversion had no effect on

phosphatase activity. sEH function related to EET conversion is attributed to the C-

terminal domain, which is homologous to haloalkane dehydrogenase (Cronin et al. 2003).









These studies indicate that sEH may play an important physiological function through its

phosphatase activity. While evidence into this line of research is sparse, it is conceivable

that the number of polymorphisms in sEH across species and strains within species may

generate differences in phosphatase activity and thus a novel role for this enzyme.

Summary

Hypertension is a complex disease controlled by a number of organs including the

brain. While our understanding of the central regulation of blood pressure has a

substantial base involving connections between specific nuclei in the hypothalamus and

brainstem to the spinal cord, key mechanisms involved in the genetic basis of

hypertension have not been elucidated. In order to fully understand this disease in the

hopes of preventing and combating its progression, it is essential to identify genes and

their pathways underlying the dysregulation of blood pressure. Using gene profiling

involving microarray analysis of the hypothalamus and brainstem, sEH was found to be

overexpressed in the SHR compared to the WKY rat brain. sEH is an enzyme that

converts vasoactive EETs to their relatively inactive diol forms. Expressed in a variety of

tissues, sEH has been implicated in the peripheral control of hypertension due to its

increased expression in the hypertensive state and the resulting decrease in blood pressure

following IP delivery of an sEH inhibitor. In addition, sEH polymorphisms are now

being associated with cardiovascular disorders. Thus, sEH and its link to hypertension

are well-characterized in the periphery. However, little is known about the role of this

enzyme in the brain.

Given the previous studies of sEH and hypertension coupled with its dramatic

overexpression in the brain of the SHR, we hypothesized that sEH is involved in the









central regulation of hypertension. In order to address this hypothesis, our aims were as

follows:

1. Determine if central sEH expression is increased in the hypertensive state. These
studies outlined in Chapter 2 focus on the validation of gene profiling data as well
as whether this increased sEH expression is a cause or consequence of
hypertension.

2. What is the physiological effect of inhibiting sEH in the brain? Chapter 3 discusses
central sEH inhibitor studies in both SHR and WKY rats and the resulting blood
pressure, heart rate, and baroreceptor reflex changes.

3. Does the pressor action of central Ang II function through NAD(P)H oxidase? As
discussed earlier, the RAS plays a major role in the central regulation of blood
pressure. In addition, ROS continues to emerge as a necessary component of this
regulation. These studies in Chapter 4 address this question with central
administration ofNAD(P)H oxidase formation blockers and Ang II and resulting
blood pressure changes. This role of ROS in the brain forms the basis of the central
mechanism of sEH discussed in Chapter 5.

4. What is the central sEH mechanism that results in blood pressure and heart rate
changes? Chapter 5 outlines experiments incorporating EET mediators, ROS
production antagonists, and sympathetic blockers in order to elucidate the
mechanism by which central sEH inhibition increases blood pressure.

5. Determine if sEH overexpression in the brain alters blood pressure and heart rate.
These studies in Chapter 6 use the lentivirus to overexpress the sEH gene in the
PVN of SHR and WKY rats. Blood pressure and heart rate are recorded daily and
mechanisms underlying sEH control are studied using sEH inhibitors and EET
agonists.

Taken together, these aims dissect the role of sEH on the central regulation of blood

pressure. The results of these experiments invoke intriguing questions into the specific

effect of EETs in the brain and how this effect is regulated in the hypertensive and

normotensive state. Overall, these studies provide further insight into the central

regulation of blood pressure and propose a novel role of EETs in the brain.












Angiotensinogen
SRenin
Angiotensin I
I


NEP IACE2
Angiotensin 1-9
ACEE:

Angiotensin 1-7 4


ACE


Angiotensin II

2J

T AT1R AT2R

Vasoconstriction
SNA
Blood Pressure


Figure 1-1 Major pathways of the RAS











NAD(P)H-NAD(P)+ + H+
Xanthine Oxidase
CYP





SOD




Catalase Fe2+
Glutathione
peroxidase


Figure 1-2 Major pathways of ROS production and metabolism


H20+0


F-P




















41


1000 -
Unchanged
U Downregulated
.p<0.01 Upregulated

1000 10000 100000
WKY



Figure 1-3 Scatter plot of gene expression in the SHR and WKY hypothalamus and
brainstem. Each point represents the average measurement for a gene. Dotted
lines segregate genes with a two-fold expression change between SHR and
WKY samples. sEH, indicated by the black arrow, is significantly
upregulated in the SHR.















s EETs DHETs
e.-, 8,9-, G-8 11. 2-, 14.1 5-EETs) aG-. 8.9-. 11.12-. 14.1 -DIET,
CYP
I Cyclooxygenase
SidroQ a 20-HETE
1 9-HETE

,Y
Cyclooxygenase T
C daoxenase Prostaglandin H2 _- PGD/PGE/PGF

SrPmstacyclin

< Thromboxane
Lipoxygenase
SHETEs Leukotrienes


Figure 1-4 Arachidonic acid metabolism













Brain

IRelax VSMC; increase cerebral blood flow
Activate BK(Ca2+) channels
Distribution: Astrocyes > Endothelial cells > Neurons
Cerebral vessel dilation
Glutamate stimulates production



Heart/Vascuature

-- Relax VSMC
I '. Activate BK(Ca2+) channels
'ii ,Relax precontracted coronary vessels
8,9-, 11 ,12-EETs activate K(ATP) channel
Inhibit Na+channels
Found in endothelium and blood vessels
EDHF role


Kidney

Relax VSMC
Activate BiKCa2+) channels
Increase renal blood flow
EDHF role


Figure 1-5 Tissue-specific functions of EETs











Endothelial cell


VSMC


SMembrane Hyperpolarization
$ VSMC Contraction


Ca2+


Figure 1-6 Cellular membrane actions of EETs


AA- p E



EETs














CHAPTER 2
INCREASED SEH EXPRESSION IN SHR VS. WKY RAT BRAIN:
IN VITRO AND IN VIVO ANALYSIS

Introduction

The brain is an essential component of the mechanisms controlling blood pressure.

As previously discussed, specific nuclei of brain regions including the hypothalamus and

brainstem function in the central regulation of blood pressure (Dampney 1994). Given

the relative importance of the brain in establishing and maintaining hypertension coupled

with the inadequacy of our knowledge of the mechanisms underlying this influence, it is

imperative to study genes with discordant expression in the hypertensive state. By

elucidating the roles of these genes in the brain, we better understand the mechanisms

involved in the establishment of hypertension and therefore have more power with which

to prevent and even reverse this disease.

Chapter 1 discussed gene profiling findings that sEH had the most disproportionate

mRNA levels in hypothalamus-brainstem samples of the male SHR compared to the male

WKY rat. High sEH expression in the kidney also has been identified in hypertensive

animal models (Imig et al. 2002; Yu et al. 2000a). In addition, deletion of the EPHX2

gene encoding sEH decreased the systolic blood pressure of male mice (Sinal et al.

2000b). These studies raise several questions regarding sEH expression. First, given the

ubiquitous nature of this enzyme, is sEH overexpression in hypertensive models

generalized and therefore not confined to renal action? What are the sEH expression

levels in other cardiovascular-relevant tissues including the brain? Second, are









differences in brain sEH expression the result of hypertension, or are they independent of

blood pressure changes?

The increased sEH mRNA levels in the SHR brain from microarray analysis must

first be verified, given the unpredictability of microarray significance. Therefore, the

first part of Aim I is to use real-time RT-PCR and Western blot analysis to measure sEH

levels in the brain areas of SHR and WKY rats. The hypothesis is that both RNA and

protein levels of the hypothalamus and brainstem are increased in the SHR compared to

the WKY rat.

The second part of Aim II is to determine if central sEH expression is independent

of blood pressure changes. First, if sEH expression is increased in the hypertensive state,

is that increase present from birth, or do the expression levels change with development?

If the expression levels remain constant, then sEH expression cannot be a consequence of

hypertension. Conversely, if the levels change, then sEH expression may be sensitive to

changes in blood pressure. This question is important in understanding the role of sEH in

the development of hypertension. To address this issue, neuronal cultures were prepared

from one-day-old SHR and WKY rat pups. The hypothesis was that sEH overexpression

was present from birth and not an effect of high blood pressure.

The question of whether sEH expression is dependent on blood pressure changes

was next addressed in the adult SHR. In contrast to measuring sEH expression prior to

the development of hypertension, this experiment measured sEH expression following

blood pressure normalization with losartan, a potent pharmacological AT1R blocker (Carr

and Prisant 1996). We hypothesized that normalizing blood pressure in the SHR would









not affect sEH protein levels in the brain, indicating that sEH expression is not dependent

on blood pressure changes.

The following studies thus address two facets of sEH expression. First, they

determine whether the sEH data from the microarray studies do in fact translate to a

change in sEH expression. Second, they answer whether sEH expression is driven by

changes in blood pressure. Taken together, these experiments define central sEH

expression in the SHR and WKY rat.

Materials and Methods

Animals

Male SHR and WKY rats, weighing 220-250g at the beginning of the study, were

ordered from Charles River Laboratories (Wilmington, Mass). Rats were housed

individually and kept on 12:12 light:dark cycle in a climate-controlled room. Rat chow

(Harlan Tekland, Madison, WI) and water were provided ad libitum. Number of animals

per group are described in Results. All animal protocols were approved by the

Institutional Animal Care and Use Committee of the University of Florida.

Immunohistochemistry

Rats were anesthetized with inhaled isofluorane (5%) and perfused transcardially

with saline followed by 4% paraformaldehyde (PFA). SHR brains were post-fixed in

PFA and saturated in 20% sucrose solution. 10-20 [tM sections were cut using a cryostat

and mounted on poly-L-lysine-coated slides; the Rat Brian Atlas (Paxinos & Watson 4th

Ed 1998) was used as a reference. Sections were blocked in 2% bovine serum albumin

(Sigma-Aldrich, St. Louis MO) dissolved in Tris-buffered saline with Tween (TBS-T,

0.1M Tris-HC1, 0.9% NaC1, 0.1% Tween) for three hours. Sections were then incubated

with anti-sEH rabbit antibody overnight (1:500), a kind gift from Dr. Bruce Hammock,









University of California Davis, followed by anti-rabbit biotinylated (1:200) for two hours

and 10tlg/ml Avidin-FITC for one hour (Amersham Biosciences, Buckinghamshire,

England). The sections were double-stained with either neuronal-specific (NeuN, 1:10,

Amersham Biosciences) or glial-specific antibody gliall fibrillary acidic protein (GFAP),

1:10, a kind gift from Dr. Gerard Shaw, University of Florida] to detect cellular

distribution of sEH. sEH localization was detected with fluorescent microscopy.

Real-Time RT-PCR

The RNAqueous-4PCR kit was used to isolate DNA-free RNA from tissue samples

(Ambion, Austin TX). One-step real-time RT-PCR was performed on 50ng RNA per

sample. Briefly, samples were combined with sEH-specific primers and probe (900nM

forward: 5'-GATTCTCATCAAGTGGCTGAAGAC-3'; 900nM reverse: 3'-

GGACACGCCACTGGCTAAAT-5') and probe (250nM: 5'-

CCAGAACCCATCGGTGACCTCCAA-3') and TaqMan One-Step RT-PCR Master Mix

and Multiscribe as described by the company (Applied Biosystems, Foster City CA).

Primers and probe to 18S were used as an internal control. Reactions were carried out in

the ABI PRISM 7000 sequence detector, and the standard curve method was used to

calculate the threshold cycle (CT) for target amplification. The input amounts were then

calculated from the CT and standard curve and normalized using the 18S input amounts.

Western Blot Analysis

Total cell lysate (TCL) was isolated according to the company's research

applications instructions (Santa Cruz Biotechnology Inc, Santa Cruz CA). Twenty |tg

protein from either neuronal cultures or brain tissue were run on a 10% SDS-PAGE gel

and transferred onto a nitrocellulose membrane. Following three hours of blocking with









5% milk in TBS-T, the membrane was probed with the sEH rabbit-anti mouse antibody

(1:3000 in 1% milk/TBS-T) overnight. Specificity of this antibody has been previously

established (Sinal et al. 2000a; Yu et al. 2000b). The membrane was rinsed 3 times and

washed for 20 min in TBS-T and then incubated with anti-rabbit IgG HRP-conjugated

secondary antibody (1:3000) for 1 hour. Following final washes, the membrane was

incubated with Western Lightning Chemiluminescence Plus reagent for 1 min and then

exposed to film to visualize the bands (Perkin Elmer, Wellesley, MA).

Neuronal Cells in Primary Culture

Primary neuronal cultures (90% neurons, 10% glia) from the hypothalamus and

brainstem of one-day-old SHR and WKY rats were prepared as previously described

(Fleegal and Sumners 2003; Raizada et al. 1995; Sunn et al. 2002). The cells were

cultured grown twelve days in Dulbecco's Modified Eagle's Media (DMEM) + 10%

horse serum at 370C, 10% CO2 in 100 mm dishes. Three dishes were used per

experimental group.

Losartan Treatment of SHRs to Normalize Blood Pressure

Losartan (10mg/kg/day) was delivered in the drinking water to male SHR (n=6)

after determining the basal drinking rate to be 32 ml water/day. Six SHRs were kept on

regular drinking water as control. The water bottles containing losartan were covered

with aluminum foil to address the light sensitivity of the drug. Water intake and body

weight were monitored daily one week prior to and up to one month following the start of

losartan treatment. One rat in the control group was eliminated from the study due to its

inability to develop high blood pressure. Systolic blood pressure was recorded using the

tail cuff method three and four weeks after the start of losartan treatment. At the end of









the experiment, protein and mRNA was isolated from the hypothalamus, brainstem, and

cortex of the rats.

Statistical Analysis

All data are expressed as mean + standard error (SE). The number of animals or

samples in each group is described in the Results below. Comparisons between

experimental groups were analyzed using either one-way ANOVA (SPSS) or Student's T

test (Stat View). Differences between means within groups were assessed with the

Newman-Keuls analysis. Significance was set at a confidence level at or above 95% and

is denoted by in each figure.

Results

Cellular Localization of sEH

Immunohistochemical analysis revealed that sEH is localized to both neurons and

glia throughout the SHR brain (n=3). Neurons were double-stained with both NeuN (red)

and sEH antibody (green), and glial cells were double stained with both sEH antibody

(green) and GFAP (red), as shown in Figure 2-1. Co-staining was identified by the

yellow overlapping fluorescence detected using confocal microscopy. sEH was detected

in all areas of the midbrain and brainstem sectioned. Control sections treated only with

secondary and tertiary antibodies did not fluoresce at the intensity used for the confocal

analysis, thus indicating the fluorescence was due to sEH antibody rather than

background fluorescence. Fluorescence from the sEH antibody was localized to the

cytoplasm and neuronal projections of the cell. No sEH was detected in the nucleus.

This result corresponds with the nature of this protein, which is a cytoplasmic protein.

The GFAP antibody was also localized to the cytoplasm rather than the nucleus, and

overlapping fluorescence was observed in this area.









sEH Expression in the SHR

Profiling with microarray technology previously identified profoundly increased

sEH mRNA levels in the brain of the SHR compared with its WKY normotensive

control. Thus, the first objective was to determine if this result corresponded with RNA

and protein levels measured by real-time RT-PCR and Western blot analysis,

respectively. Figure 2-2 outlines the results of real-time RT-PCR using hypothalamus

and brainstem isolated from four male SHR and WKY rats. Samples within each rat

strain were combined; therefore, it is impossible to say with any certainty that there were

differences. White and black bars represent sEH mRNA levels to normalized to 18S

levels of WKY rat and SHR, respectively. sEH mRNA levels in the SHR were three-fold

higher hypothalamus and six-fold higher in the brainstem compared to WKY rats.

sEH protein expression was also increased in the SHR hypothalamus and

brainstem. Figure 2-3 depicts a representative radiograph (A) and quantitation of sEH

protein levels normalized to P-actin (n=4/group) (B). In TCL isolated from the

hypothalamus, relative sEH:P-actin protein ratios in SHR and WKY rats were 0.52+/0.14

OD/mm2 and 0.12+/-0.02 OD/mm2, respectively. In the brainstem samples, the ratio was

0.60+/-0.14 OD/mm2 in the SHR and 0.13+/-0.03 OD/mm2 in the WKY rats. sEH

protein levels were measured with Western blot analysis using the same sEH antibody

source used in the peripheral studies. White and black bars represent WKY rat and SHR,

respectively. sEH was barely detectable in WKY rats while they were dramatically

increased in the SHR.

In vitro Validation with Neuronal Cells in Primary Culture

Primary co-cultures from hypothalamus-brainstem of WKY and SHR have been

used in the past to elucidate cellular and molecular mechanisms of physiological









dysregulation in neural control of hypertension (Sun et al. 2003b; Yang et al. 2004).

These cultures were used to determine if sEH overexpression in these hypertensive

animals is present prior to the establishment of high blood pressure. Western blot

analysis demonstrated a four-fold increase in sEH protein levels in neuronal cultures of

SHR vs. WKY rats, indicating that sEH overexpression is present from birth in the SHR

(Figure 2-4). The ratio of sEH to p-actin protein was 0.34+/-0.15 OD/mm2 in the SHR

and 0.08+/-0.04 OD/mm2 in the WKY rats (n=4/group). Panel (A) is a representative

radiograph highlighting the sEH and P-actin protein bands. Panel (B) is the graphical

representation of sEH protein levels normalized to P-actin from the four sets of neuronal

cultures.

sEH Expression Following Blood Pressure Normalization

Delivery of losartan (10mg/kg/day) into the drinking water resulted in a significant

decrease in systolic blood pressure in the SHR one month following the initiation of

losartan treatment. Three weeks after the start of the study, systolic blood pressure was

33 mmHg lower in the rats treated with losartan [181.48+/-5.11 mmHg SHR (n=5),

148.40+/-1.71 mmHg SHR + losartan (n=6)]. This gap widened to a decrease in systolic

blood pressure by 38 mmHg (173.84+/-4.40 mmHg SHR, 136.28+/-2.05 mmHg SHR +

losartan) one month following the start of losartan treatment (Figure 2-5). Body weights

were not significantly different between groups.

At the end of the study, brains were dissected and protein isolated from losartan-

treated and control rats. Western blot analysis revealed no significant change in the ratio

of sEH to p-actin expression in the hypothalamus between the losartan-treated (0.530+/-

0.078 OD/mm2) and control rats (0.739+/-0.246 OD/mm2) (Figure 2-6). Similarly, the









ratio of sEH to p-actin expression was 0.863+/-0.026 OD/mm2 and 0.840+/-0.066

OD/mm2 in the brainstem of the losartan-treated and control-treated SHRs, respectively.

White and black bars represent losartan-treated and control samples, respectively. Thus,

sEH expression in the SHR was not affected by blood pressure depression using an AT1R

antagonist delivered orally.

Discussion

This study was the first to measure and compare central sEH expression between

hypertensive and normotensive animal models. Both sEH mRNA and protein levels were

elevated in the hypothalamus and brainstem of SHR compared to WKY rats. This

overexpression was independent of blood pressure changes because (i) sEH

overexpression existed in neuronal cultures from prehypertensive rats and (ii)

normalization of blood pressure with losartan did not alter sEH expression levels. These

expression studies validate the gene profiling data, are parallel to the expression findings

in peripheral tissue and provide a foundation on which to study sEH in the central control

of hypertension (Imig et al. 2002; Yu et al. 2000a).

Immunohistochemical studies established that sEH is expressed in both neurons

and glial cells of one-day-old SHR and WKY rats. In contrast, CYP and EETs have been

mainly localized to astrocytes and endothelial cells surrounding the cerebral vasculature

(Alkayed et al. 1997; Gebremedhin et al. 1992; Medhora et al. 2001; Shivachar et al.

1995). Thus, the role of sEH in the brain may involve divergent roles including

sympathetic nerve activation through neuronal pathways or control of cerebral blood

flow. The role of central sEH in relation to blood pressure likely stems from neuronal

control given two sets of data. First, sEH was overexpressed in neuronal cultures of one-









day-old SHRs. Second, sEH expression does not differ in glial cultures of SHR and

WKY rats (data not shown).

In the brain areas studied, sEH protein and mRNA levels were significantly

increased in the SHR compared to the WKY rat. This result correlates to the peripheral

studies that showed an increase in sEH expression in the kidney and liver of SHR and

Ang II-induced hypertensive models (Imig et al. 2002; Yu et al. 2000a). Thus, in all

tissue areas studied, sEH is more abundant in the Charles River SHR compared to the

WKY rat. This result therefore proves that sEH overexpression is not limited to the renal

and hepatic systems of the SHR but is in fact present in other cardiovascularly-relevant

areas.

This was the first study to measure sEH expression patterns in non-adult animal

models. sEH was highly expressed in neuronal cultures from one-day-old SHR

compared to WKY rats. This result indicates that sEH expression patterns exist from

birth and are not affected by the onset of hypertension. However, these results alone do

not prove that increased sEH expression in the brain is the cause of any change in blood

pressure. Future studies in which either central sEH is blocked during development in a

hypertensive strain or overexpressed in the brain of normotensive strain would serve to

answer this question.

The conclusion that central sEH expression is independent of systemic blood

pressure changes was also supported by the normalization of blood pressure experiment.

Chronic delivery of losartan into the drinking water had no effect on the sEH levels in

either the hypothalamus or the brainstem. This result suggests that depression of blood

pressure in the SHR does not alter sEH expression. Losartan is a potent AT1R blocker









that is often used to evaluate the role ofRAS (Carr and Prisant 1996). The decrease in

systolic blood pressure by almost 40 mmHg following its oral delivery highlights the

essential role RAS plays in blood pressure regulation. However, this decrease in blood

pressure was not accompanied by changes in sEH expression.

Several caveats regarding this experiment must be addressed. First, sEH

expression was only measured at one time point, three weeks following the start of

losartan delivery. Therefore, one cannot discount expression changes prior to or

following this time point. For example, perhaps sEH expression was affected during the

initial drop in blood pressure and then recovered by means of feedback mechanisms after

three weeks. This result would indicate that sEH expression might have a role in the

RAS regulation of blood pressure. Alternately, sEH expression may be affected after

four weeks of treatment or longer due to delayed mechanisms. If this postulation were

true, then sEH expression would be dependent on blood pressure changes.

Another possibility is that while sEH expression may not change following blood

pressure normalization, either the enzyme's activity or the affinity of the product for its

receptor may be affected. Regardless of expression levels, if the enzymatic activity

changes, then the role of sEH following blood pressure changes must be reassessed. sEH

activity is generally determined by HPLC analysis to compare the levels of EETs and

DHETs (Yu et al. 2000a). This analysis should be performed in the future in order to

confirm that sEH is independent of blood pressure changes.

Finally, further studies incorporating different means of altering blood pressure

should be performed since blood pressure normalization does not follow only one

mechanism. In this experiment, losartan was delivered via the drinking water; therefore,









the blood pressure was normalized by blocking peripheral AT1R that results in a decrease

in total peripheral resistance. While central sEH expression was not affected by this

method, it may have changed had the losartan been delivered to the brain, thus decreasing

sympathetic nerve activity. To verify that the sEH expression is independent of blood

pressure depression, other antihypertensive agents including diuretics should be

incorporated. Alternately, sEH gene regulation may be constitutively active in the SHR

and therefore other hypertensive models should be incorporated. Similarly, sEH

expression may only be activated with blood pressure stimulation rather than depression.

While we can conclude that decreasing blood pressure via oral delivery of losartan does

not alter central sEH expression, this result does not conclusively prove that central sEH

is independent of any change in blood pressure.

Collectively, these studies reveal that central sEH expression is higher in the SHR

compared to the WKY rats. In addition, these results suggest that central sEH expression

is independent of blood pressure changes. Given the dichotomy of central sEH

expression in the SHR and WKY rat, what effect, if any, do these expression changes

have on the central control of blood pressure? Does sEH overexpression in the brain

have a role in hypertension? To begin to answer these questions, Chapter 3 outlines

central sEH inhibition studies to determine whether pharmacological blockade of sEH

action in the brain results in a change in blood pressure.











NuEn Ab (Rodamine)


Neuron


sFH Ah + IFAP Ah


sEH Ab (FITC)


GFAP Ab (Rodamine)


Figure 2-1 Cellular localization of sEH in the brain. Following perfusion, SHR rat brains
sections (20[LM) from the midbrain were prepared for immunohistochemical
analysis of sEH and its localization to neurons and glial cells. sEH Antibody
is detected by green fluorescence, while the red fluorescence detects either
neurons (upper panel) or glia (lower panel). Yellow fluoresence marks the
overlap between sEH Antibody and cell type-specific Antibody. All images
were taken using confocal microscopy.


Glia


Fr-H Ah rIl-rrl










1.2

1

0.8

S0.6

0.4

0.2


-- WKY
SHR


Bninstem


Figure 2-2 sEH mRNA levels in SHR and WKY brain regions. RNA was isolated from
hypothalamus and brainstem regions of SHR and WKY rat brains
(n=4/combined in each group). Real-time RT-PCR incorporating sEH-
specific primers and probe was used to measure sEH cDNA levels in samples
from these extracted tissues. Data were normalized with primers and probe to
18S and are presented as arbitrary units (AU). White and black bars represent
WKY and SHR samples, respectively. Reprinted with permission from The
FASEB Journal.


Hqpdhdamisr










A.
62 kDa m 4- sEH

42 kDa p-actin

WKY SHR WKY SHR
Hypothalamus Brainstem
B WKY
0.8 B. SHR

S 0.6 -







Hypothalamus Brainstem


Figure 2-3 sEH protein expression in SHR and WKY brain regions. Protein was isolated
from hypothalamus and brainstem regions of SHR and WKY rat brains
(n=4/combined in each group). Western blot analysis was used to measure
sEH protein levels in from 40jtg total cell lysate. (A) Representative
radiograph of sEH and P-actin. (B) Data were normalized with P-actin.
White and black bars represent WKY and SHR samples, respectively. Data
are represented as mean+/-SEM. significantly different in SHR and WKY
rat (p<0.05). Reprinted with permission from The FASEB Journal.









A.
62 kDa dl-sEH


42 kDa


0.6 -


0.4-

0.2-

0-


*-P-actin


WKY SHR
Neurons


B.


WKY


SHR


Figure 2-4 sEH protein expression in neuronal cultures. Total cell lysate was isolated
from hypothalamus and brainstem co-cultures from one-day-old SHR and
WKY rats. (A) Representative radiograph of sEH and P-actin. (B)
Quantitation of sEH protein normalized with P-actin protein band. Data are
represented as mean+/-SEM. significantly different in SHR vs. WKY
samples (p<0.05, n=4/group). Reprinted with permission from The FASEB
Journal.


I I










190.0 -

180.0 -

170.0 -

"- 160.0 -
I
E 150.0 -

IL 140.0 -

130.0 -

120.0 -

110.0 -

100.0
SHR+Los SHR



Figure 2-5 Effect of chronic losartan delivery on SBP in the SHR. Losartan
(10mg/kg/day) was delivered orally to male SHRs. SHRs only receiving water
were used as control. SBP was recorded using tail cuff recordings. Data are
represented as mean+/-SEM. *significantly different between groups (p<0.05,
n=6)









EI LLosartan
-ontrol


Erainstem I-xthdamanijs


Figure 2-6 Effect of chronic losartan delivery on central sEH expression. Total cell
lysate was isolated from brainstem and hypothalamus, and Western blot
analysis performed as described in Methods to compare sEH protein levels.
sEH expression was normalized with P-actin and presented graphically.
White and black bars represent losartan and control treatments, respectively.
Data are represented as mean+/-SEM (p<0.05, n=6).


Q015 -
c 1-

~o5s














CHAPTER 3
CENTRAL SEH INHIBITION INCREASES BLOOD PRESSURE AND
HEART RATE IN THE SHR

Introduction

Pharmacological sEH inhibitors delivered IP to the SHR led to a decrease in blood

pressure (Yu et al. 2000a). This depressor effect is postulated to involve the

accumulation of vasodilatory EETs. What is the effect of central sEH inhibition on blood

pressure? Chapter 2 revealed an sEH overexpression in the hypothalamus and brainstem

of the SHR. These results correlated with increased renal and hepatic sEH expression in

hypertensive models (Imig et al. 2002; Yu et al. 2000a). Given the similarity of

expression patterns in the different tissues, does sEH also yield a pressor response in the

brain? Prior to embarking on these studies, it is necessary to understand the action and

limitations of the currently available sEH inhibitors.

Pharmacological agents used as sEH inhibitors act as competitive inhibitors by

forming hydrogen bonds and salt bridges with the active site of sEH. These compounds

have evolved both in their potency and versatility of use. The first round of inhibitors

were tight-binding with K(I) values in the nanomolar range; however, limitations

hampered the extended use of these compounds (Morisseau et al. 1999). First, the

compounds had a high crystal lattice energy that translated to an elevated melting point.

Second, they were not water-soluble and therefore were not easily dissolved in agents

that could be applied for use in vivo or in vitro.









The major sEH inhibitor used in published animal studies is N,N-dicyclohexylurea

(DCU), a 1,3-disubstituted urea that is formed by hydrolysis dicyclohexylcarbodiimide

(Morisseau et al. 2002). DCU specifically inhibits sEH and has no effect on mEH, CYP

or any other tested compounds related to the structure of sEH. DCU and related

compounds were determined to be effective sEH inhibitors because of hydrophobic

groups on either side of the urea (Morisseau et al. 1999). In physiological studies, DCU

was delivered to the SHR via IP injection, and blood pressure was recorded using

photoelectric tail cuff. DCU delivery decreased urinary excretion of 14,15-DHET by

40%, indicating the functionality of this inhibitor. sEH inhibition resulted in a decrease

in systolic blood pressure 12+/-2 mmHg after six hours (Yu et al. 2000a). This time

lapse of blood pressure effect may be due to the kinetics of the drug as well as its

processing by the liver. This study provided the first pharmacological evidence linking

sEH to blood pressure control.

While DCU is effective in its blockage of sEH function, it is limited by its

solubility in water. Thus, a new generation of soluble, potent sEH inhibitors was

synthesized. One main structural change underlying these improvements was

substituting a hydrophobic side group with a polar functional group arranged in an alkyl

chain (Kim et al. 2004). Adamantyl urea dodecanoic acid (AUDA) is one such second-

generation sEH inhibitor. It is disubstituted with an adamantyl group on one end and an

eleven-membered carbon chain on the other. It was formulated and characterized by

Bruce Hammock's research group at University of California, Davis. This

pharmacological inhibitor has an IC5o of 18+/-1 nM with mouse sEH (Morisseau et al.









2002). In comparison, DCU has a less potent IC5o of 81.8+/-0.7 nM with mouse sEH.

AUDA is therefore a promising candidate as an sEH inhibitor.

Overall, pharmacological sEH inhibitors have evolved in their potency and

specificity. We chose to use these inhibitors in vivo as blockers of sEH activity. The

following experiments outline physiological measurements following the central delivery

of either DCU or AUDA. Given the sEH expression patterns in the brain mimics that of

the periphery, we hypothesized that ICV delivery of sEH inhibitors would lead to a

decrease in blood pressure in the SHR.

Materials and Methods

Animals

Statistical Analysis

The above Methods are described in Chapter 2

ICV Cannulation

Rats were anaesthetized with inhaled isofluorane (3%) in all surgical procedures.

A stereotaxic frame was used to position a twenty-two-gauge guide cannula (PlasticsOne,

Roanoke VA) into the right lateral ventricle (AP: 1.3mm, ML: 1.5mm, 4.5mm below

skull) of male SHR and WKY rats. The cannula was secured to the skull with dental

resin assisted by 3 3/32 screws secured in the skull. Appropriate drugs (1-2[tl) were

injected into the right lateral ventricle of unrestrained rats using a 28 gauge internal

cannula, 4.5mm. Rats were allowed to recover for one week following all surgeries.

Abdominal Aorta Cannulation

A radiotelemetric pressure transducer (Data Sciences International, Arden Hills

MN) consisting of a fluid-filled catheter attached to a PA-C40 transmitter was implanted

into the abdominal aorta. The aorta was clamped proximally and the catheter inserted









caudal to the left renal artery and secured with medical adhesive. Prior to suturing the

abdomen, the transducer was checked for proper placement using a radio to transmit the

sound oscillations from pressure changes in the aorta. Rats were anaesthetized with

inhaled isofluorane (3%) during surgery and allowed to recover one week following the

surgical procedure.

Blood Pressure and Heart Rate Recordings

Blood pressure and heart rate were recorded using the implanted radiotelemetry

transducers. For each dataset acquisition, the rat cages were positioned on receivers that

collected signals from the implanted transducers. These signals were then transmitted to

an adapter with an ambient pressure monitor that relayed the signals to the DataQuest 3.1

Acquisition program (DataSciences International, Arden Hills MN). The rats were

allowed to acclimate to their new cage position for at least one hour before basal

measurements were recorded. During data collection, blood pressure (systolic, mean and

diastolic), heart rate and activity were recorded every minute for an average of ten

seconds at 500Hz. Data were acquired and transferred to Microsoft Excel for graphical

analysis.

In vivo Drug Delivery

sEH inhibitors were delivered via the ICV cannula into the right lateral ventricle of

unrestained rats. A 4.5 mm injector containing the inhibitor was inserted and secured

into the cannula. The injector was attached to a 5[tl Hamilton syringe via 0.38 mm

polethylene tubing 120 cm in length (Becton Dickinson, Sparks, MD). sEH inhibitors

DCU and AUDA (0.8-60ng, 2[l volume) were a kind gift from Dr. Bruce Hammock,

University of California, Davis. DCU and AUDA were dissolved in 10% DMSO/90%









artificial cerebrospinal fluid (aCSF: 133mM NaC1, 3.4mM KC1, 1.3mM CaC12, 1.2mM

MgC12, 6mM NaH2PO4, 32mM NaHCO3) and 100% aCSF, respectively. These

inhibitors as well as their vehicle controls were delivered as a single bolus to singly-

housed, unrestrained SHR and WKY rats.

Results

Effect of sEH Inhibitor DCU on Blood Pressure and Heart Rate

Figure 3-1 outlines the physiological response to sEH inhibition. Figures 3-1A,B

are representative recordings of blood pressure (A) and heart rate (B) in the SHR (red)

and the WKY rat (blue). The x-axis is time related to DCU injection in hours. Figures 3-

1C,D are bar graphs of peak blood pressure (C) and heart rate (D) responses to DCU,

expressed as mean +/- SEM.

WKY rat

In the WKY rat, heart rate increased from 342.4+/-7.6 bpm with vehicle delivery to

393.1+/-19.0 bpm following 90ng DCU (Figure 3-1D). There was no significant change

in blood pressure in the WKY rat (113.78+/-3.03 mmHg aCSF, 120.34+/-1.96 mmHg

DCU, n=4). The increase in heart rate began within one hour following injection and

normalized after two hours.

SHR

Central delivery of sEH inhibitors resulted in an increased blood pressure and heart

rate in the SHR. DCU (90ng) injected into the right lateral ventricle increased blood

pressure from 153.0+/-7.8 mmHg to 184.5+/-5.3 mmHg and increased heart rate from

339.6+/-15.3 bpm to 433.5+/-11.5 bpm (n=4) (Figure 3-1C,D). The increase in blood

pressure and heart rate initiated within one hour of injection and peaked at three to four









hours after injection. Blood pressure and heart rate were normalized within seven hours

following injection.

Effect of sEH Inhibitor AUDA on Blood Pressure and Heart Rate

The results from ICV injection with DCU indicate that heart rate is increased in

both the SHR and WKY rat following sEH inhibition. Blood pressure, however, was

increased only in the SHR. No pressor responses were detected in the WKY rat. In order

to verify these results, we used a second sEH inhibitor AUDA that later became available

from Dr. Bruce Hammock at University of California Davis. As previously discussed,

AUDA is more potent and has increased water solubility, thereby making it a better

pharmacological agent for testing the physiological effects of sEH inhibition.

Dose response

ICV administration of AUDA, a potent sEH inhibitor, caused a dose-dependent

increase in both blood pressure and heart rate in the SHR. Figure 3-2 is a graphical

representation of the change in blood pressure following delivery of either 0.8ng or 7.5ng

AUDA. Artificial cerebrospinal fluid was used as the control. Either concentration of

AUDA elicited only modest increases in blood pressure in the WKY rats [23.61+/-2.90

mmHg 0.8ng AUDA (n=5), 12.49+/-3.72 mmHg 7.5ng AUDA (n=4)]; however, the

0.8ng AUDA dose was the only delivery that yielded significance (Figure 3-2). The

alternate doses did not yield blood pressure increases that significantly differed from that

of aCSF injection (13.74+/-1.82 mmHg, n=4). In the SHR, a significant increase of 25+/-

0.9 mmHg in blood pressure was seen with as low as 0.8ng AUDA, and a dose of 7.5ng

AUDA increased blood pressure by 31.8+/-3.9ng AUDA (n=3).









WKY rat

Given this initial dose response, 15ng AUDA was used in the remaining studies in

order to measure the maximum physiological effects of sEH inhibition. Figures 3-3A,B

depict representative blood pressure (A) and heart rate (B) recordings prior to and

following ICV delivery of 15ng AUDA. Quantitation of blood pressure and heart rate

recordings are charted in Figures 3-3D,E. ICV delivery of 15ng AUDA did not

significantly change blood pressure in the WKY rat (106.52+/-2.40 mmHg basal change,

115.91+/-2.30 mmHg AUDA, n=6). Alternately, heart rate increased from 311.60+/-9.22

bpm to 358.06+/-7.73 bpm, a change of 46+/-12 bpm following AUDA injection (Figure

3-3).

SHR

Figures 3-3A,C depict representative blood pressure (A) and heart rate (C)

recordings prior to and following ICV delivery of 15ng AUDA. Quantitation of blood

pressure and heart rate recordings are charted in Figures 3-3D,E. Central delivery of

15ng AUDA resulted in a change in blood pressure from 148.04+/-1.18 mmHg to

180.48+/-0.25 mmHg, an increase of 32 mmHg (n=6). In addition, heart rate increased

from 334.44+/-2.52 bpm to 388.24+/-0.80 bpm, a change of 54 bpm (Figures 3-3). This

increase began to express after thirty minutes, reached maximal levels in three to four

hours and returned to basal levels in seven hours.

Discussion

These studies are the first to determine the physiological effects of inhibiting sEH

action in the brain. Central sEH inhibition resulted in an increase in both blood pressure

and heart rate in the already hypertensive SHR. While heart rate increased in the WKY

rat, blood pressure did not dramatically change following ICV delivery of sEH inhibitors.









These results were opposite from the hypothesized decrease in blood pressure and from

the depressor effect of IP delivery of DCU to the SHR. Given the whole-body

overexpression of sEH in different hypertensive models, why is the physiological effect

of sEH inhibition in the brain opposite from that in the periphery?

The understanding of how sEH in the periphery affects blood pressure is limited.

Explanations are based on the enzyme's conversion of vasodilatory EETs to relatively

inactive DHETs. The major function of EETs is to increase the open-state probability of

BK(Ca) channels in vascular smooth muscle cells (Harder et al. 1995; Li and Campbell

1997). sEH depletes the stores of EETs, thereby leading to vasoconstriction in the

vasculature. This hypothesis is supported by increased sEH expression in both the SHR

and Ang II-induced models of hypertension (Imig et al. 2002; Yu et al. 2000a).

Translation of this hypothesis to the central role of sEH, however, is complex. sEH may

function to deplete stores of EETs surrounding the cerebral arteries, leading to

constriction and decreased cerebral blood flow. However, while decreased cerebral

blood flow is highly implicated in stroke, its direct regulation on blood pressure is not

clear. In addition, sEH is found in neurons; therefore, its potential role in sympathetic

activation cannot be discounted. Thus, while sEH expression patterns are the same in the

brain and the periphery, the mechanism underlying sEH influence on blood pressure is

not.

One important question is whether ICV delivery of DCU and AUDA is an effective

means to inhibit sEH. DCU (3mg/kg, IP) was previously used in physiological studies

and effectively decreased 14,15-DHET urinary excretion by 65% (Yu et al. 2000a).

Thus, this pharmacological inhibitor injected IP acts on tissues to inhibit the activity of









this enzyme. However, the tissue-specific effect of this delivery was not known, nor do

we know what percentage of DCU was taken up and converted by the liver. In addition,

transfer efficiency of this drug to the brain is not known. This concern of sEH inhibition

effectiveness in these central studies is first addressed by the use of two inhibitors rather

than only one. Both have been found to inhibit sEH activity and not other members of

this family of inhibitors such as mEH. In addition, AUDA is more potent than DCU, the

inhibitor used in the previous studies. One caveat of this current study, however, was that

the sEH activity was not measured. Measurements of EETs and DHETs by HPLC

analysis must be incorporated into future studies to conclusively state that DCU and

AUDA delivery to the lateral ventricle attenuates sEH activity in the brain.

Cardiovascularly-relevant brain regions should be individually analyzed in order to

ascertain which regions ICV delivery of these pharmacological agents are targeted. Only

by meticulous analysis of sEH inhibition in specific brain nuclei can we conclude what

areas are involved in this pressor response.

One interesting observation was the discrepancy of blood pressure and heart rate

effects between the SHR and WKY rat. The lack of blood pressure response coupled

with an attenuated heart rate response in magnitude and duration in the WKY rat

compared to the SHR suggests differential central pathways between these two strains.

Given the low endogenous level of sEH in the brain of the WKY rat, it logically follows

that the sEH inhibitor would have a limited supply of enzyme on which to act compared

to the hypertensive rat. sEH inhibition in these two strains may act through the same

pathway but yield different results due to endogenous sEH expression. Alternately, since









the SHR is known for its dysregulation of blood pressure control, one of these central

pathways unique to the SHR or hypertension itself may involve sEH.

These inhibitor studies suggest that the overexpression of sEH in the SHR brain

may be a compensatory outcome of this hypertensive strain. We know that increased

sEH expression has not normalized the blood pressure in the SHR; however, inhibition of

this enzyme increases the blood pressure. Thus, without the increased sEH expression in

the brain, blood pressure in the SHR would be even higher. This idea cannot be

supported on an individual basis, given the increased sEH expression in neuronal cultures

from one-day-old SHR pups. This hypothesis instead is rooted in a proposed

evolutionary development of the SHR over generations. sEH overexpression in the brain

may have been selected for during reproduction due to increased embryo viability.

Alternately, whole-body sEH overexpression may have stemmed from random mutations

that collectively result in an increased blood pressure. Thus while the brain function of

sEH attenuates blood pressure, this beneficial effect is masked by the increased pressor

response from alternate pathways. Finally, ICV delivery of sEH inhibitors may not be a

comprehensive look at sEH in the brain. The cerebral vasculature selectively targets

certain brain regions, and injection into the right lateral ventricle will likely target areas

immediately surrounding the site of injection. It is necessary as discussed above to

measure the physiological effects of sEH inhibition in various brain regions in order to

elucidate its role in the central control of blood pressure.

The question, however, is how central sEH inhibition increases blood pressure and

heart rate. These studies conclude that pharmacological sEH inhibitors delivered to the

lateral ventricle results in an increase in blood pressure and heart rate in the SHR. It is






59


essential to elucidate the mechanisms underlying this blood pressure effect stemming

from the brain. Do these effects also include the conversion of EETs, the main substrate

identified for sEH? Or does this enzyme act through a different pathway unique to the

brain? The answers to these questions will be undertaken by experiments discussed in

the next two chapters incorporating known regulators of blood pressure control in the

brain.










A 225
2 SHR
75-M WKY







B 1 2 3








0 15 25 3 48

C l" D






SCSF Dc CSFC DCU
CS COC DCL C$F DCU



Figure 3-1 Effect of ICV DCU delivery on blood pressure and heart rate. DCU was
injected into the lateral ventricle of SHR and WKY rats. Representative tracings
of blood pressure (A) and heart rate (B) in SHR and WKY rats. Quantitation of
blood pressure (C) and heart rate (D) following DCU or aCSF injection. These
values represent the peak time of blood pressure response over a ten-minute
period. The first and second arrows represent the point of injection of aCSF or
DCU, respectively. Data are expressed mean +/-SEM. represents significance
between groups (p<0.05, n=4).






61


Uit
I 60
E *

C. 40
30

2 20


d0

WKY SHR


* CSF n 0.8ng AUDA m 7.5ng AUDA


Figure 3-2 Dose response of ICV delivery of AUDA to SHR and WKY rats. aCSF,
0.8ng and 7.5ng AUDA were delivered to SHR and WKY rats. Blood
pressure was recorded using radiotelemetry. Mean change in blood pressure
was plotted; error bars represent SEM. significantly different from aCSF
response (n=4, p<0.05).












2 "00 -
I


100 -

50 -

500
450 -

I 30-
wulf -


I 5HR
-= ..Y


5 35 85 135 185 235 285



1 46444


- I F I P I 18 P I i I
-15 35 85 135 185 235 285


930-
500 -

400-

300-


200 I I I I I 1 !1
-15 36 85 135
D. tnjnt

IE 1 ]75g 400
15050
001 2 250

WKY SHR


1835
E.


235


WKY
WKY


I I
285


r- Basal
m II~f


SHR


Figure 3-3 Effect of central AUDA on blood pressure and heart rate. 15ng AUDA
was delivered ICV, and radiotelemetry was used to record blood pressure and
heart rate. (A) MAP of SHR (red) and WKY rats (blue). (B,C) Representative
HR of WKY rats and SHRs, respectively. Quantitaton of MAP (D) and HR (E).
White and black bars represent basal and AUDA-induced levels, respectively, as
means +/- SEM. significantly different from basal (p<0.05, n=6). Reprinted
with permission from The FASEB Journal.


w,


~sjrs3"",,--J"














CHAPTER 4
ROLE OF ROS IN ANG II-INDUCED REGULATION OF BLOOD PRESSURE

Introduction

The role of the brain in hypertension remains to be fully elucidated. Chapter 1

outlined the major RAS pathways and evidence linking Ang II to the central control of

blood pressure. RAS members are localized to a number of cardiovascularly-relevant

brain areas including the PVN and SON in the hypothalamus and the RVLM and NTS in

the brainstem (Bastos et al. 1997; Mangiapane and Simpson 1980; Muratani et al. 1993;

Tanaka et al. 2001). An overactive RAS in these areas leads to an increase in blood

pressure due to sympathetic nerve activation. Thus, while the RAS was initially

identified as systemic, the brain RAS is an excellent example of cardiovascular control

localized to one organ.

The binding of Ang II to the AT1R induces the most significant pressor response of

the RAS members (Helin et al. 1997). Overwhelming electrophysiological and

pharmacological evidence indicates that the binding of Ang II to the AT1R stimulates

sympathoexcitatory neurons that in turn signal to the IML to induce blood pressure (Reid

1992). Specifically, Ang II increases neuronal firing rate by activating calcium channels

and inhibiting the delayed rectifier potassium current (Sun et al. 2003a; Zhu et al. 1997).

These changes in firing rate are prevented by losartan. Thus activation of

catecholaminergic neurons by Ang II is through its binding to the ATiR.

Although the overall pressor effect of central Ang II is established, the mechanisms

underlying this activation are complex and not well understood. An emerging set of









regulators in this pathway is the ROS. As previously discussed in Chapter 1, ROS results

in a dysregulation of a number of physiological pathways and has been linked to a

multitude of diseases including cancer. Hypertension is no exception. Striking evidence

has linked an overproduction of ROS to an increase in blood pressure Recently, studies

have focused on the role of ROS in the central control of hypertension (Zimmerman and

Davisson 2004; Zimmerman et al. 2002).

Treatment of primary cultures from the lamina terminalis with Ang II resulted in an

increase in superoxide, thereby linking Ang II action to ROS production (Zimmerman et

al. 2002). Gene therapy strategies also have defined the overall effect of ROS members

on blood pressure, though the underlying mechanisms are not understood. Ang II-

induced blood pressure was prevented in mice centrally injected with Adenovirus

containing either mitochondrial or cytoplasmic SOD (Zimmerman et al. 2002).

Adenovirus was also used to inhibit NAD(P)H oxidase activator Racl production in the

CVOs. NAD(P)H oxidase is a key enzyme involved in the formation of free radicals

from oxygen. Again, the blood pressure and dipsogenic responses to Ang II were

prevented (Zimmerman and Davisson 2004). This evidence indicates ROS production is

involved in the Ang II-induced blood pressure responses.

While these studies provide a basis of ROS-RAS interaction, it is necessary to

elucidate key ROS members and provide further insight into the mechanisms behind this

interaction. Given the emerging evidence that ROS is linked to the central action of Ang

II, do the Ang II-induced pressor and dipsogenic actions require ROS member NAD(P)H

oxidase specifically? To answer this question, we used NAD(P)H oxidase formation

blocker gp91ds-tat, a compound discussed in Chapter 1, whose high specificity









distinguishes the action ofNAD(P)H oxidase from other ROS members. This study

provides a comprehensive analysis of the overall central effect of NAD(P)H oxidase on

Ang II action. We hypothesized that pretreatment of the brain with gp91ds-tat would

prevent the ICV Ang II-induced pressor and dipsogenic responses in the SHR and WKY

rat.

Methods

Animals

ICV Cannulation

Abdominal Aorta Cannulation

Statistical Analysis

A description of the above Methods is found in Chapter 2.

In vivo Drug Delivery

All drugs were delivered via the ICV cannula into the right lateral ventricle of

unrestained rats. The drug solutions were delivered using an injector 4.5mm in length

that was secured in the ICV cannula. The injector was attached to 0.38mm polyethylene

tubing 120 cm in length (Becton Dickinson, Sparks, MD) with a 5[l Hamilton syringe

attached to the other end of the tubing. All injections were given to unrestrained, singly-

housed rats.

When testing the mechanism of Ang II requiring two drugs, the first drug was

injected one hour prior to the second, and the dummy cannula was replaced following

injection. 30ng Ang II dissolved in uCSF was delivered to the right lateral ventricle (11l

injection) using a 5[l Hamilton syringe with fitted tubing + injector. gp9lds-tat and its

scrambled peptide used as a control (200-800ng each, 21tl, dissolved in uCSF) were









synthesized by the Temple University Protein Synthesis Core facility (Philadelphia, PA)

and used to inhibit the action of NAD(P)H oxidase (Rey et al. 2001a; Rey et al. 2001b).

Dipsogenic Response

Water intake of WKY rats (n=3) following ICV delivery of Ang II was measured

using sterile graduated glass pipets fitted with metal sipper tubes. The pipets were filled

with water from the rats' sterile water bottles. The pipets replaced the water bottles thirty

minutes prior to the first injection. Water level in milliliters was recorded thirty minutes

prior to, at injection time, and thirty minutes post Ang II injection. Drinking was

calculated as the basal water level minus the water level thirty minutes following the Ang

II injection. Rats remained singly-housed and were not restrained during the experiment.

Results

Angiotensin II Pressor Response

Figure 4-1 depicts the changes in blood pressure and heart rate following ICV Ang

II delivery in the SHR and WKY rat. ICV delivery of 30ng Ang II to conscious, free-

moving WKY rats (n=5) resulted in an increase in blood pressure from 102.81+/-3.36

mmHg to 146.90+/-1.87 mmHg, a change of 44 mmHg (Figure 4-1C). Heart rate

increased 44 bpm, from 320.13+/-7.37 bpm to 364.22+/-25.39 bpm (Figure 4-1D).

Figure 4-1A shows representative blood pressure and heart rate recordings surrounding

Ang II delivery to the WKY rat. The central Ang II response began within two minutes

following injection, and maximum response occurred by ten minutes. Blood pressure and

heart rate were normalized one hour post injection.

Central delivery of Ang II (30ng) to the SHRs (n=3) also resulted in a pressor

response. Blood pressure increased from 148.61+/-1.09 mmHg to 191.36+/-6.14 mmHg

following Ang II treatment, a change of 43 mmHg (Figure 4-1C). Heart rate increased









from 310.15+/-15.39 bpm to 432.93+/-9.64 bpm, an increase of 123 bpm (Figure 4-1D).

Representative recordings of blood pressure and heart rate of the SHR are shown in

Figure 4-1B.

gp9lds-tat Prevents Ang II-Induced Blood Pressure

gp91ds-tat was delivered ICV to the lateral ventricle, and radiotelemetry was used

to measure BP and HR responses. Central administration of this NAD(P)H oxidase

formation blocker prior to Ang II delivery yielded no change in blood pressure or heart

rate in both the SHR and WKY rat. Pretreatment with gp9lds-tat one hour prior to ICV

delivery of Ang II attenuated the Ang II-induced increases in blood pressure and heart

rate in both rat strains (Figure 4-2).

WKY rat

Blood pressure and heart rate did not significantly change from basal levels

(108.86+/-1.83 mmHg and 312.62+/-5.89 bpm, respectively) thirty minutes following

ICV delivery of 800ng gp9lds-tat (106.81+/-3.72 mmHg and 329.54+/-8.11 bpm,

respectively). Central delivery of 800ng gp9lds-tat one hour prior to ICV delivery of

Ang II attenuated the Ang II-induced blood pressure by 67% in the WKY rat (146.90+/-

1.87mmHg Ang II, 123.55+/-3.75 mmHg gp91ds-tat + Ang II) (Figure 4-2C).

Pretreatment with 200ng gp91ds-tat did not significantly prevent the Ang II-induced

pressor response. In addition, 800ng gp9lds-tat did not prevent the heart rate increase

following Ang II delivery (364.22+/-25.39 bpm for Ang II, 358.84+/-24.15 bpm for

gp91ds-tat+Ang II) (Figure 4-2D).

SHR

Blood pressure increased slightly from basal levels (154.22+/-5.65 mmHg) thirty

minutes following ICV delivery of 200ng gp91ds-tat (167.58+/-3.62 mmHg). Heart rate









increased from 325.04+/-8.32 bpm to 375.02+/-13.07 bpm. Figure 4-3 outlines the blood

pressure and heart rate recordings and averages following deliveries of gp9lds-tat and

Ang II. Central delivery of 200ng gp91ds-tat one hour prior to ICV delivery of Ang II

attenuated the Ang II-induced peak blood pressure response by 67% in the SHR as well

(Ang II 191.36+/-6.14 mmHg Ang II, 168.22+/-5.10 mmHg gp9lds-tat + Ang II) (Figure

4-3C). Pretreatment with gp9lds-tat prevented the heart rate increase following Ang II

delivery by 58% (Ang II 432.93+/-9.64 bpm Ang II, 376.98+/-11.79 bpm gp9lds-tat +

Ang II) (Figure 4-3D).

Thus, pretreatment with gp91ds-tat resulted in an attenuation of blood pressure

increase induced by central Ang II delivery in both the SHR and WKY rat. In contrast, a

scrambled form of the peptide did not prevent the Ang II-induced blood pressure in a

WKY rat (135.16 mmHg Ang II, 137.26 mmHg scrambled + Ang II), indicating the

gp91ds-tat peptide was specific in its blockade of NAD(P)H oxidase.

gp9lds-tat Prevents Ang II-Induced Drinking

Next we determined if the dipsogenic responses of ICV Ang II administration

involve the ROS signaling pathway. Figure 4-4 is a graphical representation of the water

intake of the WKY rats following either Ang II treatment alone or central delivery of Ang

II following gp9lds-tat pretreatment (n=3). Delivery of Ang II into the lateral ventricle

resulted in 8.8+/-0.5 ml water intake within thirty minutes following injection. Drinking

began within two minutes of ICV delivery. Pretreatment with 800ng gp9lds-tat,

however, resulted in water intake of only 2.6+/-1.4 ml thirty minutes following Ang II

injection, thereby attenuating the Ang II dipsogenic response by 70% (Figure 4-4).









Discussion

These results support the hypothesis that brain Ang II increases blood pressure and

heart rate through a ROS-mediated pathway. Specifically, this study establishes that

blocking NAD(P)H oxidase in the brain prevents the pressor and dipsogenic actions of

Ang II. This response was observed both in the hypertensive SHR and in the

normotensive WKY rat. The scrambled form of the peptide did not affect Ang II-induced

blood pressure; therefore, gp91ds-tat was specific in its action. gp91ds-tat alone had no

effect on blood pressure or heart rate, indicating that these basal physiological

mechanisms do not involve NAD(P)H oxidase.

This work complements previous published studies involving the link between

central Ang II action and ROS in mice. Adenovirus encoding SOD delivered ICV also

prevented Ang II-induced blood pressure (Zimmerman et al. 2002). One caveat of that

study, however, was the sole use of SOD to inhibit ROS accumulation. While SOD is an

important component of ROS conversion, it does not discriminate whether Ang II acts

upstream of superoxide formation. gp9lds-tat, however, is a highly specific blocker of

NAD(P)H oxidase formation, thereby useful for analysis upstream of superoxide in Ang

II action (Rey et al. 2001b). Its use in this study therefore confirms the role of ROS,

specifically NAD(P)H oxidase, in Ang II-induced pressor and dipsogenic responses.

These studies were the first to measure the affect ofNAD(P)H oxidase blockade on

central Ang II pressor response in both hypertensive and normotensive models. The

comparison of WKY rat to SHR response is critical in understanding the role of ROS in

Ang II action. First, the blood pressure response between the two models was the same.

This result was unexpected given the characterized heightened pressor response in the

SHR (Wright et al. 1986). This discrepancy may be due to the large dose of Ang II









(30ng), yielding a potential maximum response in both strains. Pretreatment with

gp91ds-tat prevented the Ang II pressor effect by 67% in both the SHR and WKY rat.

Therefore, the influence ofNAD(P)H oxidase on the Ang II-induced blood pressure is

not dependent on the basal blood pressure. However, while the heart rate response was

attenuated 58% in the SHR with gap9lds-tat pretreatment, no change was measured in

the WKY rat. This discrepancy is likely due to the differences in Ang II-induced heart

rate between the two models. In these studies, Ang II-induced heart rate in the SHR was

three times that of the WKY rat, which was only transiently increased -bpm.

Pretreatment with gp91ds-tat in the SHR attenuated the heart rate response to the same

level following ICV Ang II delivery in the WKY rat. It is therefore likely that this 40

bpm change in heart rate is independent ofNAD(P)H oxidase signaling.

One caveat of this study is while it determined the overall central link of NAD(P)H

oxidase to Ang II, it did not extrapolate specific nuclei involved, nor did it address

cellular mechanisms underlying this central ROS-RAS control. The AT1R has been

localized to brain nuclei including the PVN, RVLM, and NTS, where activation through

Ang II binding elicits sympathetic nerve activation and therefore an increase in pressure

(Bastos et al. 1997; Mangiapane and Simpson 1980; Muratani et al. 1993; Tanaka et al.

2001). Thus, it is necessary to further characterize the role ofNAD(P)H oxidase on an

individual nuclei basis. Future studies should address this question in order to more

completely elucidate the mechanism of Ang II-ROS action.

Signaling of AT1R and NAD(P)H oxidase has begun to be elucidated. Most studies

in this regard have focused on the peripheral Ang II and ROS, but the mechanisms may

indeed apply to the brain as well. In summary, ATiR stimulation activates PKC and









therefore Rac, a subunit needed to activate NAD(P)H oxidase (Brandes 2003; Gregg et

al. 2003). Functional NAD(P)H oxidase can therefore convert oxygen to hazardous

H202, thus increasing ROS production. This increased ROS is theorized to increase

sympathetic nerve activity, though this mechanism is unknown.

The electrophysiological basis of the role of ROS in central Ang II pressor response

was recently elucidated by post-doctoral fellow Dr. Cheng-wen Sun of our research

group. Dr. Sun used both ROS inhibitors and generators in conjunction with Ang II and

measured firing rate and the delayed rectifier potassium current (IKv). Both Tempol and

gp91ds-tat attenuated the Ang II-induced neuronal firing rate by 70% and 50%,

respectively. Alternately, ROS generator Xanthine-Xanthine oxidase increased firing

rate above basal levels, indicating that ROS functions independently of extracellular Ang

II stimulation. In addition, the inhibition of IKv by Ang II was blocked by the

concomitant treatment with gp91ds-tat. These findings indicate that ROS is involved in

the Ang II-mediated increase in neuronal activity. In order to confirm these findings,

specific channel involvement and kinetics need to be examined. This study therefore

provides a cellular basis for the pressor and dipsogenic responses generated from the in

vivo studies. It also suggests the role of ROS in central control of hypertension acts

through neuronal activation.

Given that ROS continues to emerge as an important regulator in several disease

states coupled with this evidence linking NAD(P)H oxidase to Ang II function in the

central control of blood pressure, are endogenous levels of ROS activity elevated in

human hypertension? If there is an increase in ROS production, can this dysregulation be

corrected by either SOD mimetics or NAD(P)H oxidase blockers in order to diminish the









accumulation of superoxides? These questions must be addressed in future studies in the

hopes of reversing the hypertensive state.

In summary, the pressor and dipsogenic actions of central Ang II are mediated by

ROS action. Specifically, ROS member NAD(P)H oxidase was implicated in this

mechanism. Both in vivo and in vitro data support the regulation of central Ang II

pressor action by ROS. These results concur and expand on previous studies linking

ROS to Ang II in the brain. While the specific mechanism by which ROS increases

neuronal firing rate remains to be elucidated, this study provides a solid foundation on

which to study the involvement of NAD(P)H oxidase in the central control of blood

pressure.

This essential requirement of ROS in central pressor control invites thought as to

what other mechanisms ROS involved in the brain regulate blood pressure. For instance,

is ROS production necessary for the central action of sEH inhibition described in Chapter

3? Given the wide range of responsibilities of ROS, it is indeed plausible that ROS

production underlies all the major central blood pressure regulators. In theory, these

brain mechanisms contributing to blood pressure control may converge at the ROS

production level. Chapter 5 will outline and discuss data related to the mechanism

underlying blood pressure and heart rate increases following central sEH inhibition.






73


A 00 M BP
S- -HR


II I


t tl00

M 15 .5 5 15 25 35 45 55
B
300- 5 0




2 150 2 (4

100 r r r r 1 100 Basal
-15 -5 5 16 26 36 46 56
n C o i Ang II

Cr 400

.o 100

MV SMR KYH S HR

Figure 4-1 Effect of central Ang II on blood pressure and heart rate. 30ng Ang II was
delivered ICV to SHR and WKY rats. Blood pressure and heart rate were
recorded using radiotelemetry (see Methods). Bars represent peak increases
over 10 minutes. Representative recordings of WKY (A) and SHR (B). Red
and blue lines indicate HR and MAP, respectively. Arrows represent Ang II
injection. (C,D) Quantitation of MAP and HR, respectively. White and black
bars represent mean +/- SEM of basal and Ang II measurements, respectively
(p<0.05, n=5/WKY, n=3/SHR).






74



A 175
155-
S135
I. 115


75 -
-75 -55 -35 -15 5 25 45
B
500


e 300
1 200

-75 -55 -35 -15 5 25 45
C Mnutes
C D




5 i 1 ,

,W ,gt I *



Figure 4-2 Effect of gp91ds-tat on Ang II-induced BP response in the WKY rat. 800ng
gp91ds-tat was injected ICV one hour prior to Ang II. Representative
recordings of MAP (A) and HR (B). Arrows represent point of drug delivery.
Quantitation of MAP (C) and HR (D). Bars represent means +/-SEM; *
significantly different between groups (p<0.05, n=5).




















t t


-70 -50 -30 -10


10 30


^H^^ "^at <
t t


I II I I l I I 1 I I I I Il I I I


-70 -50 -30 -10
Timre (irn)


gp1 ids.1ngll


E
L200
: 150 -
S100 -
O 50
AI
0


10 30


*1


Angil


Figure 4-3 Effect of gp91ds-tat on Ang II-induced BP response in the SHR. 200ng
gp9lds-tat was injected ICV one hour prior to Ang II. Representative
recordings of MAP (A) and HR (B). Arrows represent points of drug
delivery. Quantitation of MAP (C) and HR (D). Bars represent means +/-
SEM; significantly different between groups (p<0.05, n=3).


250 -


- 200 -
E
E 150-

100 -

50


500


230


100-


I I P1


OC-

l 60 -


U









10-
8-
6-
4-
2-
0-


30ng Ang II


800ng gp91ds-tat +
Angll 30 min


Figure 4-4 Dipsogenic responses of ICV gp91ds-tat and Ang II. Water intake following
Ang II injection with and without 800ng gp9lds-tat pretreatment was
measured. Bars represent water intake means +/- SEM (p<0.05, n=3).


Tt














CHAPTER 5
MECHANISM OF CENTRAL SEH INHIBITION ON
BLOOD PRESSURE REGULATION

Introduction

sEH action in the brain is emerging as critical in blood pressure regulation.

Chapter 3 established that central sEH inhibition results in an increase in blood pressure

and heart rate in the SHR model of hypertension. In addition, this inhibition yielded an

increase in heart rate in the WKY rat. Taken together, these results suggest a role for

sEH in the central control of blood pressure. Essentially, though, how does central sEH

inhibition result in an increase in blood pressure and heart rate in the SHR? This chapter

seeks to elucidate the mechanism underlying this physiological response.

The pressor effects of central sEH inhibition are opposite from the depressor

response following IP delivery of DCU to the SHR and therefore suggest an alternate

pathway of sEH action in the brain. Peripheral sEH functions as a regulator of

vasoactivity by converting vasodilatory EETs to their less active diol forms (Yu et al.

2000a). Decreased vasodilation in smooth muscle cells of the arterial walls leads to

increased probability of contractility, which results in an increase in blood pressure.

While this proposed vasoactive mechanism of sEH in the periphery coincides with its

increased expression in hypertension, the effect of central sEH inhibition likely diverges

from this pathway. The question is in what way? Is the action of sEH inhibition related

to a known pathway of central control of blood pressure? We sought to answer these









questions through a series of experiments designed to elucidate the pathway of central

sEH control of blood pressure.

The first goal is to extrapolate the overall physiological mechanism behind the

increase in blood pressure and heart rate following central sEH inhibition in the SHR. As

previously discussed, the SHR is characterized by several dysregulatory pathways. One

is the decreased baroreceptor reflex described in Chapter 1 (Hayashi et al. 1988).

Another is the increased sympathetic nerve activity that results in an increase in blood

pressure (Biaggioni 2003). Given that the SHR is predisposed to these pathways, we

hypothesized that AUDA-induced blood pressure and heart rate changes in the SHR

involved baroreceptor reflex dysregulation and sympathetic nerve activation.

The second goal is to elucidate the cellular and signaling mechanisms involved in

the AUDA-induced pressor response in the SHR. This undertaking is complex and likely

to involve years if not decades of study. However, the start of this discovery must begin

with what we know of sEH action, its conversion of EETs. Does the action of central

sEH inhibition involve the accumulation of its substrate, the EETs? Peripheral studies

have focused on this branch of the arachidonic acid pathway as the powerhouse behind

sEH cardiovascular effects. However, sEH was originally identified as a converter of

xenobiotic material foreign to the organism (Grant et al. 1993). In fact, several substrates

have already been identified for sEH in addition to its well-known role in EET

metabolism (Sinal et al. 2000b). Alternately, sEH itself may function to regulate channel

kinetics leading to changes in firing rate patterns or even regulate neurotransmitters such

as Ang II or vasopressin. Based on the primary role of sEH as an enzyme involved in the









epoxygenase branch of arachidonic acid conversion, however, we hypothesized that sEH

inhibition leads to an increase in blood pressure due to EET accumulation in the brain.

Aside from the question whether the sEH substrate EETs are involved in its central

action on blood pressure, it is important to begin to understand how this inhibition leads

to an increase in blood pressure. Is there a connection of sEH to known regulators of

central blood pressure control such as Ang II or another sympathetic activator? Chapter 2

presented evidence that sEH expression increases in the hypothalamus following ICV

delivery of Ang II. Chapter 4 further analyzed the role of brain Ang II signaling by

incorporating the NAD(P)H oxidase inhibitor gp91ds-tat. These studies linked central

Ang II action to ROS member NAD(P)H oxidase. ROS has also been linked to

epoxygenase member CYP 2C9 (Fleming et al. 2001b). Given that ROS activity in

cardiovascular control, both peripheral and central, continues to emerge as a strong

regulator, we hypothesized that the blood pressure effects stemming from sEH inhibition

were mediated by NAD(P)H oxidase.

Finally, what cell type in the brain is responsible for the pressor response following

central sEH inhibition? Previous studies have localized both CYP and EETs mainly to

astrocytes, though CYP has also been found in the cerebral vasculature as well as

dopaminergic neurons. Our studies discussed in Chapter 2 localized sEH to both neurons

and glia. Therefore all brain cell types are potential targets for the action of sEH

inhibition. However, overwhelming evidence reveals neurons as the main regulator in

the central control of blood pressure. For example, increased neuronal firing rate from

the RVLM and NTS to the IML result in an increase in sympathetic activation and hence









increased blood pressure. The following studies seek to identify key mediators and

pathways in the increase in blood pressure following sEH inhibition in the SHR brain.

Methods

Animals

ICV Cannulation

Abdominal Aorta Cannulation

Blood Pressure and Heart Rate Recordings

Statistical Analysis

The above Methods are described in Chapters 2 and 3

In vivo Drug Delivery

All drugs were delivered as bolus injections via the ICV cannula into the right

lateral ventricle of unrestained rats as described in Chapter 3. When testing the

mechanism of sEH inhibition requiring two drugs, the first drug was injected one hour

prior to the second, and the dummy cannula was replaced following injection. MS-PPOH

(680ng, 21tl, dissolved in uCSF), a kind gift from Dr. John Falck, University of Texas

Southwestern Medical Center, was used to block the formation of EETs (Brand-Schieber

et al. 2000b). 11-nonyloxy-undec-8-enoic acid (11-NODA, 100ng, ICjl, dissolved in

uCSF), an EET agonist, was also provided by Dr. Falck. gp9lds-tat and its scrambled

peptide used as a control (100ng each, 21tl, dissolved in uCSF) were synthesized by the

Temple University Protein Synthesis Core facility (Philadelphia, PA) and used to inhibit

the action of NAD(P)H oxidase (Rey et al. 2001a; Rey et al. 2001b).

Evaluation of Spontaneous Baroreceptor Reflex Gain

To evaluate baroreceptor reflex function, an index of gain was determined from

spontaneous changes in systolic blood pressure and pulse interval using a time-series









method for the rat, as described (Oosting et al. 1997; Waki et al. 2003). This method

correlates to traditional pharmacological methods for measuring the baroreceptor reflex.

However, because this method does not distinguish between an increase in blood pressure

and heart rate either by a decrease in the baroreceptor reflex or by the pharmacological

agent itself, this measurement is assumed to be an estimate of spontaneous baroreceptor

reflex gain. To calculate this index of baroreceptor reflex gain, spontaneous ramps of

systolic blood pressure changes (at least four beats) were extracted from the moving

average data. The data was collected at a frequency of 500 Hz. Measurements of

systolic blood pressure and pulse interval ramps were made at delays of three to five

beats based on previous findings (Oosting et al. 1997). Pulse interval was compared to

systolic blood pressure during these delays to calculate the spontaneous baroreceptor

reflex gain. Only positive slope values were used to avoid contaminating baroreceptor

reflex data with non-baroreceptor-mediated changes in pulse interval. This analysis was

completed by Dr. Hidefumi Waki, Department of Physiology, Bristol University,

England.

Analysis of Heart Rate Variability

Heart rate variability was analyzed using a fast Fourier transformation (FFT). For each

ten-minute recording period, the beat-to-beat pulse interval data were converted into data

points every 100 ms using a spline interpolation. Power spectral density was then

computed using FFT algorithm and averaged. It is generally accepted that the high

frequency (HF) component of heart rate variability is mediated by cardiac

parasympathetic tone (Pagani et al. 1986a; Pagani et al. 1986b). This analysis was

completed by Dr. Hidefumi Waki, Department of Physiology, Bristol University,

England.









Neuronal Firing Recording

Spontaneous action potentials were recorded with the whole-cell voltage clamp

configuration in current clamp mode. Neurons cultured from hypothalamus were bathed

in Tyrodes's solution containing (in mM): 140 NaC1, 5.4 KC1, 2.0 CaC12, 2.0 MgC12, 0.3

NaH2PO4, 10 HEPES, and 10 dextrose, pH adjust to 7.4 with NaOH. The patch

electrodes (resistances from 3-4 MOhms) were filled with an internal pipette solution

containing (in mM): 140 KC1, 4 MgCl2, 4 ATP, 0.1 guanosine 5'-triphosphate, 10

dextrose, and 10 HEPES, pH adjusted to 7.2 with KOH. The resting membrane potential

was defined as the potential within a 1 s time period during which there were no

spontaneously firing action potentials. Neuronal firing rate was measured as the number

fully developed action potentials depolarizationn beyond 0 mV) per second (Hz). This

study was completed by Dr Chen-wen Sun of our research group.

Results

Waveform Analysis of Baroreceptor Parameters

Because of the concomitant increase in blood pressure and heart rate in the SHR

following sEH inhibition, it was hypothesized that central AUDA delivery impaired the

ability of the baroreceptors to regulate physiological changes. In order to test this

hypothesis, spontaneous baroreceptor reflex gain and cardiac vagal tone were measured

using waveform analysis in response to sEH inhibition.

Index of spontaneous baroreceptor reflex gain

Analysis of waveform telemetry data revealed a 56+/-5% decrease in the estimate

of spontaneous baroreceptor reflex gain (p<0.05) following sEH inhibition in the SHR.

Specifically, the index of baroreceptor reflex gain decreased from a basal level of 0.82+/-

0.06 ms/mmHg to 0.36+/-0.04 ms/mmHg at the peak of the pressor response from sEH









inhibition (Figure 5-1A). In the WKY rat, the index ofbaroreceptor reflex gain was

1.09+/-0.11 at basal levels and 1.13+/-0.08 three to four hours after ICV delivery of 15ng

AUDA. Thus, no significant change in the baroreceptor reflex gain index was measured

in the WKY rat. In comparing basal levels of the two strains, the index of the

baroreceptor reflex gain of the WKY rat was 33% higher compared to the SHR, though

this difference was not significant.

High frequency analysis of pulse interval

Given the decrease in the index of baroreceptor reflex gain in the SHR following

central sEH inhibition, high frequency analysis of pulse interval was then analyzed to

determine if this component was also involved in this concomitant increase in blood

pressure and heart rate. This measurement correlates to the level of cardiac vagal tone.

In the SHR, this cardiac vagal tone indicator measurement decreased from 16.68+/-2.55

ms to 10.39+/-0.28 ms at the peak response of sEH inhibition (Figure 5-1B). This result

translated to a 33+/-8% decrease in heart rate analysis of pulse interval following ICV

AUDA administration in the SHR. In contrast, no significant changes were observed in

the WKY rats (13.91+/-0.84 ms basal, 13.74+/-0.95 ms 15ng AUDA). These data

demonstrate that increases in blood pressure and heart rate are consistent with a decrease

in baroreceptor reflex functions in the SHR.

AUDA Regulation of Sympathetic Nerve Activity

Regulation of sympathetic nerve activity is one of the major mediators of the

central control of blood pressure. Given the high impact of this system plus its neuronal

origin that corresponded with previous sEH expression studies, atenolol, a P31R

antagonist, was used to test whether the effects of sEH inhibition were related to

sympathetic nerve activity. Img/kg atenolol was delivered IV following 15ng AUDA









ICV delivery to two SHRs. The results from this preliminary study are shown in Figure

5-2. Atenolol delivery completely prevented the increase in blood pressure increase

following central AUDA administration (34.54+/-7.23 mmHg AUDA, 0.69+/-3.73

mmHg atenolol + AUDA, n=2). No statistical analysis could be completed due to the

low number of animals in this study. These data indicate that AUDA-induced increase in

blood pressure functions through sympathetic nerve activity.

Increased EETs Linked to Increase in BP and HR

The first step in deducing the mechanism underlying sEH inhibition-induced

blood pressure was to examine the role of EETs, the main physiological substrate of sEH.

Since sEH converts EETs to DHETs, inhibiting the enzyme results in the accumulation of

EETs. Thus, we hypothesized that EETs may be the vital in this central control of blood

pressure.

MS-PPOH

This hypothesis was tested initially with the use of MS-PPOH, an inhibitor of the

epoxygenase pathway that generates EETs and related PUFA epoxides (Brand-Schieber

et al. 2000a). Figure 5-3 outlines the pressor response to 15ng AUDA with and without

pretreatment of MS-PPOH in the SHR. Figures 5-3A,B are representative blood pressure

recordings from ICV delivery of AUDA alone (A) and with ICV delivery of MS-PPOH

one hour prior to sEH inhibition (B, n=5). Figure 5-3C is a graphical representation of

the pressor response resulting from the treatments. While central delivery of AUDA

increased blood pressure 38.99+/-4.29mmHg, pretreatment with MS-PPOH attenuated

this AUDA-induced increase in blood pressure by 65% in the SHR (14.43+/-8.04

mmHg). However, MS-PPOH alone had no effect on basal blood pressure.









11-NODA

While MS-PPOH provided the first evidence that sEH action was through EET

production, it was imperative to determine if the action was through EETs specifically or

through another product of epoxygenase. Thus, EET agonist 11-NODA (100ng) was

delivered ICV in the WKY rat to determine whether EET-specific agonist would have

any effect on blood pressure or heart rate (Figure 5-4). This central administration of an

EET agonist results in a transient increase in blood pressure (blue) and heart rate (red) in

the WKY rat (Figure 5-4, n=6). This increase was biphasic for blood pressure increases,

each increase lasting only about 10 min. The first peak was recorded just after delivery

and the second 15-30 minutes following the first. Blood pressure increased 13.2+/-2.5

mmHg in the first peak and 8.8+/-3.2 mmHg in the second peak (Figure 5-4B). Heart

rate increased 61+/-19 bpm (Figure 5-4C).

Effects of sEH Inhibition Function through ROS

To further examine the mechanism underlying this central pressor response, we

examined the role of ROS on sEH-inhibitor-mediated increase in blood pressure in the

SHR. Reasoning behind this study was two-fold. First, epoxygenases have been linked

to ROS, albeit in the periphery. In addition, Chapter 4 discussed the importance of ROS

member NAD(P)H oxidase is in the central control of hypertension. Figure 5-5 outlines

the blood pressure and heart rate data from this study (n=3). The top panels are

representative blood pressure and heart rate recordings of an SHR treated with AUDA

alone (Figures 5-5A,C) and AUDA with gp9lds-tat pretreatment (Figures 5-5B,D).

Figure 5-5E is a graphical representation of the peak blood pressure changes showing that

while ICV delivery of AUDA resulted in a 39.20+/-3.03 mmHg increase in mean arterial

pressure, pretreatment with gp91ds-tat caused the AUDA-induced blood pressure to only









increase 6.10+/-5.78 mmHg, an 85% attenuation. Figure 5-3F is a graphical

representation of the peak heart rate changes indicating that AUDA delivery resulted in a

85.66+/-4.99 bpm change, yet pretreatment with gp91ds-tat yielded an AUDA-induced

heart rate change of 19.24+/-12.48 bpm, thereby attenuating the heart rate response by

77%. In contrast, gp91ds-tat alone had no effect on blood pressure and heart rate. These

results indicate that ROS member NAD(P)H oxidase is involved in the sEH inhibitor-

induced increase in blood pressure and heart rate.

Discussion

These series of studies succeeded in beginning to elucidate the complex signaling

involved in the central sEH-mediated blood pressure control. Two important findings

can be extrapolated from these results. First, the pressor effects stemming from central

sEH inhibition are linked to the increase in its substrate, the EETs. Second, the

mechanism leading to the increase in blood pressure involves ROS, specifically

NAD(P)H oxidase. These two conclusions, taken together, form the foundation of how

sEH and EETs function in the brain to elicit blood pressure and heart rate effects.

EET studies involving formation blockers as well as agonists strongly suggest that

this central pathway involves the sEH substrate EETs. Pretreatment with MS-PPOH

prevented sEH increases in blood pressure in the SHR, though alone this compound had

no effect on blood pressure. This lack of blood pressure response may be explained by

the high sEH expression in the SHR that would prevent any basal effects from the EETs

While this result was good evidence that EETs were involved, the non-specificity of MS-

PPOH to EETs still questioned whether EETs were the main regulator. For example,

since MS-PPOH inhibits epoxygenase action, it blocks the formation of all epoxygenase

products (Brand-Schieber et al. 2000b). Therefore, EET agonists were delivered ICV to









determine whether increasing the agents themselves resulted in a change in blood

pressure. ICV delivery of the agonists resulted in a biphasic increase in blood pressure as

well as an increase in heart rate in the WKY rat, indicating these sEH substrates are

indeed the potentiators of sEH inhibitor pressor effects. The reason behind the biphasic

increase in pressure is unknown at this time, but may be related to differences in

immediate EET activity on the cerebral microcirculation and later effects involving

neuronal activation pathways in cardiovascular-relevant brain areas. Thus, the role of

central EETs appears to be distinct from that of its peripheral expression, which is

characterized by its vasodilatory properties that are associated with a decrease in blood

pressure. These results strongly indicate that the effects of central sEH inhibition involve

the accumulation of its substrate.

We further elucidated the central sEH pathway through studies involving oxidative

stress. The mechanism linking central sEH inhibition to the increase in blood pressure

and heart rate appears to function through ROS (Fleming 2001; Fleming et al. 2001a).

gp91ds-tat, an NAD(P)H oxidase blocker, was used to elucidate the ROS involvement.

Central delivery prevented AUDA-induced increase in blood pressure and heart rate in

the SHR. gp91ds-tat also prevented the increase in neuronal firing rate induced by sEH

inhibitors in vitro. As previously discussed, ROS had been linked to the epoxygenase

pathway; however, this is the first link of the NAD(P)H oxidase arm of ROS to EETs and

sEH.

One major question is what cell type is involved in stimulating blood pressure

following central sEH inhibition. sEH is localized to both neurons and glia, yet its

substrate is primarily localized to astrocytes. In order to begin to answer this question,